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Introduction 
 
Over the last century, preoperative imaging has been of major importance for pre -operative 
planning of surgical procedures. At the end of the nineteenth century, Wilhelm Conrad Rontgen 
created the x-ray Radiograph for which he received the Nobel Prize in 1901. Not long thereafter, 
Franz Konig was the first to describe tumour imaging when he reported the detection of a 
sarcoma of the tibia. Imaging modalities further evolved with the development of the 
computerized tomography in 1972 by Hounsfiels who received the Nobel Price in 1979 and with 
magnetic resonance imaging in 1973. Both of major importance for the field of cancer imaging. 
Since then, many developments have been made including PET and SPECT (Beaney, 1984; 
Jaszczak and Coleman, 1985). In clinical practice, the various non-invasive imaging modalities 
including ultrasonography, x-ray, CT, MRI, positron emission tomography and singlephoton- 
emission computed tomography enable early detection, staging, and treatment evaluation of 
cancer.   
 
Although many preoperative imaging modalities are currently available, during surgery the 
surgeon is only incidentally assisted by intraoperative imaging modalities such as ultrasonography 
and x-ray fluoroscopy for further analysis of tissue (Flum et al., 2003; Leen et al., 2006). 
Presently, surgeons mostly discriminate healthy tissue from cancerous tissue by means of visual 
inspection and palpation, and subsequently resect the tumour with an adequate tumour-free 
margin. High percentages of non-radical tumour resections have been described in clinically 
(based on vision and palpation) radical resected tumours (McMahon et al., 2003). To illustrate, 
local recurrence after curative primary surgery of cancer in the oral cavity has been reported to be 
22% (Rusthoven et al., 2010). Postoperative radiotherapy is therefore usually administered to 
prevent local recurrence. However, despite such radiotherapy following treatment of tongue 
tumours, many patients have been observed to redevelop tumours locally (Brown et al., 2007; 
Rusthoven et al., 2010). The inability to adequately detect the tumour border could be of 
importance in the high rate of non-radical resections. Therefore, intraoperative imaging may 
promise an improvement of radical resections of tumours, thus increasing patients’ survival rates. 
Fluorescence imaging is a highly potential imaging modality that provides the surgeon with 
necessary real-time information and could therefore have major impact in future surgical 
oncology. Although fluorescence imaging gained some interest in the early twentieth century, this 
technology was not further developed due to the absence of necessary knowledge and technical 
support at that time. With the advent of knowledge and technical support in the 1980s, optical 
imaging regained interest. Exciting research became available because optical imaging made it 
possible to image processes at molecular level in real time. Several wavelengths were used but 
particularly, the advantages of the use of near-infrared light (NIR 700-900 nm, Figure 1), that is 
 
the closest in wavelength to visible light were important for the potential use of fluorescence 
intra-operatively (Patterson et al 1989).  
 
Figure 1; Illustrating the ‘NIR window,’ delimiting on the one 
side by the increasing absorbance of blood and on the other side 
by the increasing absorbance of water. Reproduced from Chance 
B. (1998) Near-infrared images using continuous, phase-
modulated, and pulsed light with quantitation of blood and blood 
oxygenation. Annals of the New York Academy of Sciences 838: 
29–45. 
 
 
 
NIR light appeared to be much less absorbed and thus penetrate tissue much deeper than visible 
light or light above 900 nm. Furthermore, lower autofluorescence was observed using NIR light 
compared to that with visible light where autofluorescence hampered a good contrast (Frangioni 
2003). Finally, for an adequate intra-operative implementation it was of importance not to alter 
the regular surgical field. As the human eye is not sensitive to NIR fluorescent light the surgical 
field remains unstained. On the other hand, it raised the challenge of developing NIR 
fluorescence camera systems. When imaging modalities became available, acquisition time in the 
millisecond range was possible, enabling real-time imaging. Altogether this paved the way for the 
development of real-time intra-operative fluorescence imaging (Vahrmeijer et al. 2013).  
 
In practice, NIR fluorescent contrast agents are administered intravenously, topically or 
intraparenchymally. During surgery the contrast agent is visualized using a NIR fluorescence 
camera system (Figure 2). For intraoperative imaging purposes that do not require a specific 
molecular target, such as in sentinel lymph node (SLN) mapping or vascular imaging, a single 
contrast agent (fluorophore) can be used. Indocyanine green (ICG) and methylene blue are 
currently the only NIR fluorophores registered by the Food and Drug Administration (FDA) or 
the European Medicines Agency (EMA). Although ICG has been used since 1950, initially it was 
primary used in hepatic function diagnostics and cardiology. But, as soon as intra-operative 
imaging systems became available many clinical trials on SLN mapping were undertaken 
(Schaafsma et al. 2011). In contrast to SLN or vascular imaging, in tumour imaging mainly 
specific molecular targets are used. In this, a contrast agent is conjugated to a targeting moiety 
that targets one of the hallmarks of cancer. In the past decade many research has been devoted to 
find the optimal probe that offers the ultimate tumour-to-background ratio (TBR). Whether a 
probe adequately detects a tumour cell intra-operatively depends on many variables. 
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Figure 2; The mechanics of NIR fluorescence imaging. A NIR fluorescent contrast agent is administered 
intravenously, topically, or intraparenchymally. During surgery, the agent is visualized using a NIR fluorescence 
imaging system of the desired form factor, i.e., above the surgical field for open surgery or encased within a fiberscope 
for minimally-invasive and robotic surgery (open surgery form factor shown). All systems must have adequate NIR 
excitation light, collection optics and filtration, and a camera sensitive to NIR fluorescence emission light. An optimal 
imaging system includes simultaneous visible (i.e., white) light illumination of the surgical field, which can be merged 
with NIR fluorescence images. The surgeon display can be one of several forms factors including a standard computer 
monitor, goggles, or a wall projector (monitor form factor shown). Current imaging systems operate at a sufficient 
working distance that enables the surgeon to operate and illuminates a sizable surgical field. 
 
 
Target 
The growing insight in cancer is increasingly pointing toward multifactorial processes[1, 2].  In 
2000, Hanahan and Weinberg (2000) reported six essential alterations in cell physiology that 
collectively dictate malignant growth. In 2011 the hallmarks were revised and two emerging 
hallmarks and enabling characteristics were added. Preclinically, many targeting moieties of these 
hallmarks have been explored in the past decennium (Keereweer et al. 2011). Nonetheless, cancer 
targeting with high sensitivity and specificity remains challenging, mostly because of a great 
extent of intra- and intertumoral heterogeneity (Gerlinger et al., 2012; Marusyk et al., 2012). 
Hence, the search for a universal tumour-specific target remains to be ongoing.  
 
  
 
Probe efficiency 
The efficiency of agents to specifically target a single tumour cell is essential when distinguishing 
tumour cells from healthy tissue. Several factors influence the ability of the probe to reach its 
target. A first important factor in probe efficiency that has a large influence on the TBR is the 
number of receptors or epitopes per cell (Gioux et al., 2010). On average, a cancer cell expresses 
103–104 surface receptors to which the NIR fluorescent probe can bind (Frangioni, 2008; 
Hilderbrand and Weissleder, 2010). High expression of the antigen allows more fluorophores to 
accumulate, resulting in higher concentrations and signal (Thurber et al., 2010). Also, the process 
of endocytosis can amplify the fluorescence signal, partly depending on the tumour size (Gioux 
et al., 2010; Kovar et al., 2009). In larger tumours, TBRs ranging from 3 to 12 are often reported. 
However, smaller tumours often have much higher ratios due to more efficient diffusion and 
endocytosis (Thurber et al., 2010). Secondly, probe concentrations in the tumour ranging from 
picomolar to low nanomolar levels are required to generate sufficient TBR for image-guided 
surgery (Gioux et al., 2010). The dose of the probe is highly important to obtain an adequate 
TBR. With saturating doses the extent of antibody uptake is dependent on antigen expression 
levels. Nonetheless, at subsaturating doses, it is mostly the delivery which hampers the 
fluorescent signal (Thurber and Weissleder, 2011). A third factor in probe efficiency is the 
biodistribution of the probe. Although in fact an intrinsic property of the probe, the 
biodistribution has great influence on detection thresholds and the TBR. An adequate 
vascularization of the tumour is indispensable for probe delivery. Tumours exceeding the size of 
1 mm are in need of their own vascularization to supply oxygen and nutrients (Naumov et al., 
2006). However, tumours smaller than 1 mm usually have inadequate vascularization which 
hampers the delivery of probes. Once the probe is nearby tumour tissue, the wall of a blood 
vessel serves as a barrier between tumour cells and the intravascular environment. Most tumours 
induce disorganized and abnormal neovascularization, resulting in leaky blood vessels. In 
addition, lymphatic drainage architecture of the tumour is disordered. This results in enhanced 
permeability and retention (EPR effect), a universal effect of tumours that causes passive passage 
over endothelium and accumulation of the probe in the interstitium of tumour tissue (Fang et al., 
2011). After the extracellular matrix is traversed, the probe needs sufficient time to interact with 
the target for binding to occur and the unbounded probe to be cleared from the circulation (Fang 
et al., 2011; Frangioni, 2003). Clearance from circulation occurs through the liver and/or kidneys 
via excretion into bile/feces and urine, respectively. The best time of optimal imaging with low 
background signal present is greatly dependent on clearance route and clearance rate (Gioux et 
al., 2010). 
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Fluorescent Dye 
The chemical properties of the probe, consisting of a targeting moiety and fluorophore, form an 
alternative important cluster of factors in fluorescence imaging abilities. In principle, a 
fluorophore should not alter the biodistribution and efficiency of the targeting moiety. The 
fluorophore’s high fluorescent signal at the site of interest is subject to several criteria: 
wavelength, quantum yield (QY), photobleaching, clearance, nonspecificity, solubility, and 
toxicity. First, as mentioned earlier, the most efficient wavelength for clinical applications is the 
NIR region. In this region, the influence of autofluorescence is limited, and due to diminished 
absorption, maximum penetration depth is achieved. An extensively used chemical structure to 
achieve absorption and emission in the NIR region is the polymethine backbone (e.g., used in 
ICG and Cy5) (Gioux et al., 2010). The second criterion is the QY. The efficiency of the 
fluorescence process is determined by the QY of the fluorophore that is defined as the ratio of 
the number of photons emitted divided by the number of photons absorbed. When every 
absorbed photon results in a photon emitted, maximum QY is obtained. Heptamethine dyes 
(emission 800 nm) generally have a serum QY between 10% and 20% (Gioux et al., 2010). Third, 
photobleaching refers to the permanent loss of the ability to fluoresce due to photochemical 
damage. Photobleaching can occur when a dye-specific photobleaching threshold is reached. 
Rapid photobleaching restrains the use of a higher fluence rate that potentially can improve the 
TBR (Frangioni, 2003). The ideal fluorescent dye should further be cleared rapidly, preferentially 
through renal clearance and should not bind to any proteins. Nonspecific background binding of 
the dye to proteins, cellular membranes, and extracellular matrix materials will increase 
background fluorescence and degrade the TBR (Kairdolf et al., 2008). Moreover, a high uptake 
of a fluorescent dye in the liver will result in contamination of the gastrointestinal tract and 
decrease the ability to detect primary tumours or metastases in this area. Therefore, rapid renal 
clearance is preferential. Recently, Choi et al. found that rapid clearance by the kidneys and low 
background binding was achieved when fluorescent dyes had a neutral surface charge, were 
geometrically balanced and polyionic (Choi et al., 2011). Finally, for practical use, a fluorescent 
dye has to be soluble and nontoxic. When a fluorophore meets all these criteria, the targeting 
moiety will account for the greater part of the efficiency of the probe. 
 
Camera 
In order to be used inside an operation room, high fundamental requirements are set for the NIR 
image-guided camera system. The camera system has to comply with current standard surgical 
procedures and (logistic) protocols, as well as provide sufficient freedom of motion for the 
surgeon. Also, transillumination and light-conducting liquid media cannot be used 
intraoperatively with the current state of the art technology. Gioux et al. (2010) offer a 
comprehensive overview of requirements and limitations of an intraoperative imaging system, 
 
including the required field of view, the fluorescence excitation light source, the NIR excitation 
fluence rate, simultaneous imaging of color ‘white light’ video, and collection optics and cameras. 
For lesions located at the surface, the detection threshold is a function of TBR and magnification 
(Thurber et al., 2010). In order to accommodate various surgical applications, a field of view of 
10–20 cm (4–8 in.) is required (Gioux et al., 2010). However, in order to increase the detection 
threshold, as well as for surgical resection of small tumour volumes and avoidance of thin nerves, 
adjustable field of view by either zoom or fixed magnification lensing is necessary (Gioux et al., 
2010). 
 
Autofluorescence 
Fluorescence imaging is based on the concept of signal-to-background ratio, which is usually 
called tumour-to-background ratio (TBR) in the case of cancer imaging. For the targeted cancer 
cells to be detected, the tumour-specific signal must be significantly discriminated from the 
nonspecific surrounding signal. However, cells contain endogenous fluorophores which fluoresce 
when excited with light of the appropriate wavelength. Autofluorescence refers to this intrinsic 
fluorescence of the tissue that induces a nonspecific background signal (Keereweer et al., 2011). 
When autofluorescence is high, the TBR is decreased, which hampers the identification of 
fluorescence signals with lower intensity. In the visible light region, autofluorescence is the main 
limiting factor of most in vivo optical imaging applications. Although the use of invisible NIR 
light solves a great deal of this problem, NIR autofluorescence signals still occur and may vary 
between different tissues (Frangioni, 2003). Therefore, the influence of autofluorescence on the 
TBR is an important determinant of detection thresholds in optical imaging. The effect of 
autofluorescence can be reduced by separating the signal of the targeted fluorophores from the 
background signal during optical imaging in vivo. Two methods are used to achieve such 
disjunction of signals, namely, by unmixing the fluorescence spectrum (i.e., ‘spectral unmixing’) 
of each fluorophore or by imaging the lifetime of a fluorophore (Akers et al., 2008; Mansfield, 
2010). These are useful techniques when distinguishing a specific signal, for example, a molecular 
event, or highlighting a signal against background autofluorescence. 
 
Optical properties 
Although optical properties of the imaged tissue have significant influence on the acquired 
fluorescent light intensity, the influence of these properties is often unappreciated in optical 
image-guided cancer surgery. Light must travel through tissue to reach a fluorescent contrast 
agent. The degree in which such photons actually reach the target depends on the tissue’s 
absorption and scattering properties, which both become more hindering factors with increasing 
light penetration depth (Frangioni, 2003)(Figure 3). After excitation, the photon emitted by the 
fluorophore is subject to the same influences once more as they travel back to the surface.  
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including the required field of view, the fluorescence excitation light source, the NIR excitation 
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adjustable field of view by either zoom or fixed magnification lensing is necessary (Gioux et al., 
2010). 
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cells to be detected, the tumour-specific signal must be significantly discriminated from the 
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fluorescence of the tissue that induces a nonspecific background signal (Keereweer et al., 2011). 
When autofluorescence is high, the TBR is decreased, which hampers the identification of 
fluorescence signals with lower intensity. In the visible light region, autofluorescence is the main 
limiting factor of most in vivo optical imaging applications. Although the use of invisible NIR 
light solves a great deal of this problem, NIR autofluorescence signals still occur and may vary 
between different tissues (Frangioni, 2003). Therefore, the influence of autofluorescence on the 
TBR is an important determinant of detection thresholds in optical imaging. The effect of 
autofluorescence can be reduced by separating the signal of the targeted fluorophores from the 
background signal during optical imaging in vivo. Two methods are used to achieve such 
disjunction of signals, namely, by unmixing the fluorescence spectrum (i.e., ‘spectral unmixing’) 
of each fluorophore or by imaging the lifetime of a fluorophore (Akers et al., 2008; Mansfield, 
2010). These are useful techniques when distinguishing a specific signal, for example, a molecular 
event, or highlighting a signal against background autofluorescence. 
 
Optical properties 
Although optical properties of the imaged tissue have significant influence on the acquired 
fluorescent light intensity, the influence of these properties is often unappreciated in optical 
image-guided cancer surgery. Light must travel through tissue to reach a fluorescent contrast 
agent. The degree in which such photons actually reach the target depends on the tissue’s 
absorption and scattering properties, which both become more hindering factors with increasing 
light penetration depth (Frangioni, 2003)(Figure 3). After excitation, the photon emitted by the 
fluorophore is subject to the same influences once more as they travel back to the surface.  
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Figure 3; Light propagation through the tissues. Light traveling through tissue will undergo reflection, scattering, and 
absorption.. 
 
 
In this manner, fluorescence intensity is modulated by the tissue optical properties of absorption, 
scattering, and tissue penetration depth, which are important to consider when quantification of 
the signal is required (Themelis et al., 2009). The NIR range is the most suitable range for clinical 
applications due to deep penetration of light into tissue. Despite this advantageous quality of 
NIR light, it is still subject to absorption and scattering. Absorption denotes that photons 
traveling through tissue can be absorbed by intrinsic components of that tissue. The main light 
absorbers in tissue, responsible for the minimal cumulative absorbance of NIR fluorescence, are 
oxyhemoglobin, deoxyhemoglobin, water, and lipids (Chance, 1998). However, the most 
important contributor to absorbance of NIR wavelengths in regular tissues (containing 8% blood 
volume and 29% lipid content) is hemoglobin, as it accounts for 39–64% of the total light 
absorbance (Frangioni, 2003). This explains why fluorescent signals in organs or tissues with high 
blood volumes, such as the liver (Hutteman et al., 2011), highly vascularized tumours, or tumour 
cells that co-opt host vessels (Holash et al., 1999), may appear lower than surrounding, less-
absorbing tissue (even if they contain larger amounts of contrast agent compared to the 
surrounding tissue) (Themelis et al., 2009). This shows how absorption may prove an important 
confounder of TBR and how it results in a lower detection threshold. Another challenge to the 
use of NIR light in optical imaging is posed by scattering. Due to refractive index mismatches 
between tissue components the direction of a photon will vary during its journey through tissue. 
This phenomenon is known as scattering. Although a single scatter event may not have a large 
effect on photon direction by itself, the cumulative effect of multiple consecutive scatter events 
may result in a significant photon deflection. In tissues, this effect can have a 100- to a 1000-fold 
higher distortion of the fluorescence signal than absorption. However, despite the probability of 
such a change in direction, forward movement of the photon is most likely to occur 
 
(Ntziachristos, 2010). Scatter and absorption coefficients vary between locations and tissues due 
to the different components within the heterogeneous tissue. Intratumour heterogeneity could 
even induce different TBRs between the same population of tumours (Marusyk et al., 2012). The 
net effect of scattering and absorption on fluorescence imaging depends on the exact optical 
properties of the tissue under scrutiny. 
 
Effects on light at greater penetration depths 
Both absorption and scattering are important influences on the assessment of detection 
thresholds of the NIR-fluorescent signal. The influence of these effects on the fluorescence 
signal will be greater when tissue depth increases. Using visible light, penetration depth is limited 
to a few millimeters due to light absorption by biological chromophores (Keereweer et al., 2011). 
With light emitted in the NIR spectrum, penetration depth of higher wavelengths is increased to 
over a centimeter (Frangioni, 2008; Hilderbrand and Weissleder, 2010; Weissleder and Pittet, 
2008). Although the absorption and scattering of light varies significantly between tissues, in 
general, fluorescence intensity has a strong nonlinear dependence on the depth of the 
fluorescence activity (Frangioni, 2003; Themelis et al., 2009; Thurber et al., 2010). A clear 
correlation has been demonstrated between increased penetration depth, increased scattering, 
and decreased fluorescence signal (Pleijhuis et al., 2011). Hence, superficial lesions will appear 
brighter than an identical lesion that is located deeper in the tissue.  
 
Despite the aforementioned challenges in probe development and limitations of fluorescence-
guided surgery due to optical properties, clinical application is still very appealing. During 
surgery, tumours can be explored after resection and the remaining surroundings can be scanned 
for residual tumour cells, indicating irradical margins. When an area is found with persisting 
fluorescence signal, this can subsequently be excised until no signal is detected any longer, similar 
to the technique of Mohs’ surgery (Mohs, 1957). Nevertheless, although in the future even a 
single cell can be imaged on the surface, optical properties will probably hamper detection of 
cancer cells situated under the surface. This may require the need of adjuvant therapy. Further, 
high-risk pathological characteristics could justify adjuvant therapy. In these selected cases, intra-
operative photodynamic therapy (PDT) could be of great value after fluorescence-guided surgery.  
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Adjuvant targeted photodynamic therapy  
In PDT, photosensitizers are used that produce cytotoxic reactive oxygen species after excitation 
by light with a specific wavelength. As a result, cancer cells are killed by apoptosis and/or 
necrosis, and tumour microvasculature is obliterated (Agostinis et al. 2011; Castano et al. 2006). 
Specific damage of the tissue of interest is obtained by local illumination. Furthermore, the very 
short half-life of cytotoxic reactive oxygen species ensures that damage only occurs in the 
immediate vicinity of its formation. Although conventional adjuvant treatments (i.e., 
radiotherapy, chemotherapy, or a combination) can induce immunosuppression, PDT-induced 
immunogenic cell death induces a local inflammatory reaction and stimulates the host immune 
system (Castano et al. 2006). In addition, formation of a tumour specific immune response (e.g., 
production of tumour-specific cytotoxic T-cells) offers opportunities to treat distant metastases 
(Castano et al. 2006). Compared to other adjuvant therapeutic modalities, PDT has the potential 
to induce low toxicity in normal tissue, produce negligible systemic effects, and reduce acute and 
long-term morbidity (Agostinis et al. 2011). Furthermore, PDT does not compromise future 
treatment options for patients with residual or recurrent disease and can be repeated with 
perpetual efficacy. Wavelength-specific excitation of photosensitizers could technically be 
performed using the same imaging systems as those used for optical image-guided surgery, 
emphasizing its practical advantages as an adjuvant therapeutic modality in the surgical theatre. In 
order to fully exploit the advantages of both modalities, a tumour-specific NIR fluorescent 
photosensitizer is required (Bugaj, 2011). A tumour-specific photosensitizer has the potential to 
be much more efficient and cause less damage to surrounding normal tissue than a non-specific 
photosensitizer (Bugaj, 2011). The increasing amount of photosensitizer that is expected to 
accumulate in the tissue of interest ensures that less light is required to induce a cytotoxic 
reaction. Consequently, even light that penetrates deeper into tissue (>1 cm) will result in specific 
damage of tumour cells that are deeper located. Moreover, such an agent could be used for both 
NIR fluorescence image-guided surgery and adjuvant PDT (i.e., a “theranostic”).  
 
Outline of the thesis 
 
In part I the current modalities of fluorescence-guided surgery and the challenges in optical 
imaging are reviewed. Chapter 2 gives an extensive overview of the preclinical and clinical data 
in fluorescence-guided oncologic surgery to reflect its current status. In particular, it focuses on 
specific targeting of primary tumours by organic fluorescent agents that target the alterations in 
cell physiology in cancer. Data is presented per hallmark of cancer as described by Hannahan and 
Weinberg (2000, 2011) In Chapter 3 the fundamental basic principles of optical imaging are 
studied. Here, the consequences of these principles on FGS and the influence on clinical 
decision-making are discussed in more detail. It illustrates how the technique can be a very 
powerful tool in guiding the surgeon to radical tumour resections, as long as the intrinsic 
limitations of this technique are taken into account.  
 
In Part II, preclinical studies are performed using probes that target two different receptors in 
oncology.  Multiple clinically relevant tumour models are used to validate FGS in primary 
tumours, lymph node metastases and distant metastases. The first target that was explored is the 
epidermal growth factor receptor (EGFR) in chapter 4. The EGFR is a transmembrane 
glycoprotein that is involved in DNA synthesis and cell proliferation and overexpression 
contributes to oncogenesis. Because EGFR is highly overexpressed in oral squamous cell 
carcinomas (OSCC), an orthotopic OSCC of the tongue that metastasises to the cervical lymph 
nodes was used. In this study, a nanobody was conjugated to the fluorophore IRDye-800CW. A 
nanobody is the smallest functional antigen-binding fragment derived from naturally occurring 
heavy-chain-only antibodies. They show very specific binding to their targets and their size 
ensures efficient distribution and tissue penetration, as well as rapid clearance from the body. The 
FLARE NIR fluorescence camera was used for NIR fluorescence imaging. The camera was 
compared to preclinical cameras where measurements are performed in an ultimate environment 
that is created by imaging in a ‘black box’ to shield interfering ambient light. In search for an 
even more universal receptor, the epithelial cell adhesion molecule was evaluated in chapter 5. 
EpCAM is a transmembrane glycoprotein involved in cell-cell interactions and cell-stroma 
adhesion. Its expression is restricted to epithelial cells and is highly up-regulated in virtually all 
epithelial carcinomas. To assess the value of this target in FGS the monoclonal chimeric antibody 
323/A3 was conjugated to the IRDye 800CW.  Four clinically relevant orthotopic tumour 
models, i.e. colorectal cancer, breast cancer, head and neck cancer, and peritonitis carcinomatosa 
were used to evaluate the performance of the anti-EpCAM agent with the clinically validated 
Artemis imaging system. Next, in chapter 6, the performance of the new Artemis camera was 
evaluated preclinically as well as clinically. In this article the Artemis camera was presented in 
literature for the first time. The minimal detectable dose of pure ICG and IRDye 800CW was 
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searched for in vitro.  Subsequently, the lower limit of cells targeted by the EGFR targeting 
nanobody 7D12-800CW was determined. In vivo, the camera was evaluated in two procedures 
namely sentinel lymph node imaging and tumour specific FGS. Two head and neck cancer cell 
lines were used in combination with 7D12-800CW and the minimal size of tumour mass that 
could be visualized was explored. Further, for the first time, clinical evaluation of cancer patients 
using the NIR Artemis camera was described. Fluorescence imaging of ICG was performed in 
three patients with liver metastases.  
 
In part III the focus was on the future of fluorescence-guided surgery. In chapter 7 three major 
challenges in FGS were described and subsequently possible solutions were postulated. The 
challenges in FGS described here comprise imaging tumour heterogeneity, invasive tumour 
strands and dealing with the tissue optical properties. Tissue optical properties ensure that it is 
most unlikely that the last residual tumour cells will be visualized using FGS. Mainly in invasive 
tumour strands this could hamper radical tumour resections. To overcome the hurdle of optical 
properties and detect the last tumour cells, intrinsic fluorescence measurements can be 
performed intra-operatively. It was described how point reflectance and fluorescence 
spectroscopy using fiber optic probes can be used to overcome the effects of tissue optical 
properties and detect residual tumour cells. A second promising solution to detect and treat the 
remaining tumour cells is adjuvant photodynamic therapy. PDT is a promising minimally invasive 
approach that is being used for the local treatment of premalignant and malignant lesions. 
Despite the potential advantages of PDT, collateral damage to normal tissue remains a significant 
side effect, particularly in the treatment of large tumours. Targeted PDT, in which 
photosensitizers (PS) are selectively delivered to the tumour, could greatly enhance the efficacy of 
PDT. In chapter 8, a feasibility study is reported at the pre-clinical level on a recently introduced 
format of targeted PDT which employs nanobodies as targeting agents and a water-soluble PS 
(IRDye700DX) that can be used as fluorescence agent as well. The photosensitizer IRDye700DX 
was conjugated to the EGFR targeting nanobody 7D12 and the selectivity and phototoxicity was 
explored in an orthotopic head and neck cancer model. In chapter 9, the steps required for 
successful and safe implementation of intraoperative fluorescence imaging in the clinic were 
identified. The major topics on the critical path of implementation were identified and the 
possible actions discussed to overcome them. A main driving conclusion remained that 
intraoperative fluorescence imaging has great clinical potential and that with the community 
working together the clinical implementation of FGS could be substantially accelerated. Finally, 
in chapter 10 the results of the studies in this thesis were summarized followed by a discussion 
on future perspectives of fluorescence-guided therapy in oncology.   
 
 
This thesis demonstrates the use of fluorescence-guided therapy in oncology. First it shows the 
preclinical validation of two different targets and probes for fluorescence-guided surgery, results 
that pave the way towards clinical implementation. Next, the utility of the NIR fluorescence 
Artemis camera is described. Lastly, the first steps are made towards fluorescence theranostics in 
oncology: NIR fluorescence-guided surgery and intra-operative targeted photodynamic therapy.    
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ABSTRACT 
 
 
Imaging is currently used for cancer detection, staging, and treatment evaluation. However, 
during surgery, surgeons rely mostly on visual inspection and palpation. Fluorescence imaging 
could provide the surgeon with necessary real-time information and could therefore revolutionize 
surgical oncology. This chapter gives an extensive overview of the current status of preclinical 
and clinical fluorescence-guided surgery. We will focus on specific targeting of the primary 
tumour by fluorescent agents that take aim of the alterations in cell physiology that denote 
cancer.  
 
4.20.1 Introduction 
 
 
This chapter will give an overview of preclinical and clinical data to reflect the current status of 
fluorescence-guided surgery. We will focus on specific targeting of the primary tumour by 
fluorescent agents that take aim of the alterations in cell physiology that denote cancer, as 
described by Hanahan and Weinberg (2000, 2011). Concretely, we will discuss the preclinical and 
clinical work of non-invasive NIR fluorescence imaging of cancer in relation to these hallmarks. 
Altogether, an extensive overview will be given to provide the knowledge of the current status of 
fluorescence-guided surgery. 
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4.20.4 Tumour Detection Using Organic Fluorescent Probes 
 
Specific targeting of the primary tumour and metastases by fluorescent agents to intraoperatively 
identify the tumour margin is expected to be of great importance in future surgical oncology. 
Different targeting strategies can be used to visualize tumours and subsequently identify their 
margins for radical resection. Preclinically, many targeting moieties have been explored in the 
past decennium. Nonetheless, cancer targeting with high sensitivity and specificity remains 
challenging, mostly because of a great extent of intra- and intertumoral heterogeneity (Gerlinger 
et al., 2012; Marusyk et al., 2012). Hence, the quest for a universal tumour-specific target remains 
to be ongoing. In 2000, Hanahan and Weinberg (2000) reported six essential alterations in cell 
physiology that collectively dictate malignant growth, namely, tissue invasion and metastasis, 
sustained angiogenesis, limitless replicative potential, self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, and evasion of programmed cell death (Keereweer et 
al., 2011a). In the following, the preclinical and clinical work of NIR fluorescence tumour 
imaging will be discussed, based on specific targeting of each of these hallmarks of cancer (see 
also Part I, Chapter 4.05).  
 
 
4.20.4.1 Tumour Imaging: Preclinical Studies 
 
4.20.4.1.1 Tissue invasion and metastasis 
One of the six essential alterations in cell physiology of tumour cells is the capability of tissue 
invasion and metastasis. To escape the limiting nutrients and space available around the primary 
tumour, tumour cells colonize distant tissue in the body. Proteases play a major role in facilitating 
tumour cells to invade adjacent tissue and metastasize to distant sites. Many tumours have 
elevated levels of proteolytic enzymes (Keppler et al., 1996; Kim et al., 1998; Koblinski et al., 
2000). Proteases can be classified by their mechanisms of action: serine, cysteine, threonine, 
aspartate, glutamic acid proteases, and metalloproteases (Yang et al., 2009a). The main focus of 
interest in targeting proteases for NIR fluorescence imaging has been in cathepsins, 
metalloproteases, and the urokinase plasminogen activator. Cysteine cathepsins are involved in 
protein degradation. They are a member of the family of papain-like cysteine proteases and were 
linked to cancer as long as 30 years ago (Sloane et al., 1981). An elevated cathepsin expression 
has been associated with poor prognosis and progression in a number of cancers (Turk et al., 
2012). Moreover, high serum cathepsins have been correlated with metastases (Turk et al., 2012). 
Cathepsin expression is elevated in cancer cells as well as in macrophages and other host cells 
that are located within the tumour microenvironment (Mohamed and Sloane, 2006; Vasiljeva et 
al., 2006). Next to the well-known extracellular function of promoting migration and invasion of 
 
cancer cells, cathepsins play a pro- and antitumorigenic intracellular role in tumour progression 
(Turk et al., 2012). Eleven human cathepsins are known (i.e., cathepsins B, C, F, h, K, L, O, S, V, 
X, and W) of which especially cathepsins B, D, and S are important because of the high 
expression in malignancies. Therefore, these particular cathepsins have been used as targets in 
optical imaging studies. Weissleder et al. (1999) were the first to image protease activity using the 
so-called ‘smart probes’ (Figure 9).  
 
Figure 9 (a) Schematic diagram of probe activation. 
The initial proximity of the fluoro- chrome molecules 
to each other results in signal quenching. (b) NIRF 
image (top) and bright light image (bottom) of 
nonactivated probe (left) and activated probe (right). 
Note the difference in signal intensity between 
enzyme-activated and unactivated probe. (c) 
Chemical structure of repeating graft copolymer 
segment indicating quenching of fluorophore Cy and 
enzymatic degradation site (green arrow). 
Reproduced from Weissleder R, Tung CH, 
Mahmood U, and Bogdanov A Jr. (1999) In vivo 
imaging of tumours with protease-activated near-
infrared fluorescent probes. Nature Biotechnology 
17(4): 375–378. 
 
 
(Further information about ‘smart probes’ can also be found in Part I, Chapter 4.05 and Part III, 
Chapter 4.15) The smart probes are based on multiple self-quenching (i.e., inactivated) 
fluorophores that are located close to each other. Until the probe is dequenched by the protease 
of interest, excited fluorophores will absorb energy from each other that would otherwise result 
in the emission of a photon (Kobayashi et al., 2010). Weissleder et al. (1999) coupled the 
fluorophore Cy5.5 to a synthetic graft copolymer consisting of poly-L-lysine sterically protected 
by multiple methoxypolyethylene glycol (MPEG) side chains. Selective in vivo accumulation of 
probe in a breast and small cell lung tumour was effectuated by the EPR effect (Fang et al., 
2011). Intratumoral dequenching (i.e., activation) of the fluorophores resulted in a 12-fold 
increase in NIR fluorescent signal that allowed for the detection of tumours with submillimetre-
sized diameters. The substrate-based probe was dequenched by a series of cysteine/serine 
proteases, including cathepsins B, H, and L. Shortly after the finding of the smart probe, Bremer 
et al. (2002) reported the use of aforementioned probe to differentiate the cathepsin B expression 
levels of breast cancer cell lines. Considering the presentation of both human and murine 
cathepsin B in this study, Bremer et al. (2005) conducted a second study in which a spontaneous 
breast tumour was used. Again, breast tumours could be detected. Many resembling probes, 
targeting different cathepsins and built around a reporter substrate, have been developed (Abd-
Elgaliel and Tung, 2010; Cruz-Monserrate et al., 2011; Tung et al., 1999). Thereby, tumour-
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specific imaging in pancreatic cancer, pancreatic intraepithelial neoplasia, peripheral lung cancer, 
breast cancer, oral squamous cell carcinoma, and lymph node metastases have been reported 
using the cathepsins B, H, L, and S sensitive and commercially available probe ProSense680 or 
ProSense780 (PerkinElmer, Waltham, Massachusetts) (Eser et al., 2011; Figueiredo et al., 2006; 
Keereweer et al., 2011b, 2012a; von Burstin et al., 2008; Xie et al., 2012). Mieog et al. (2011b) 
determined the accuracy of real-time NIR fluorescence imaging in obtaining tumour-free 
resection margins by using ProSense680 and ProSense780 (Figure 10).  
 
 
Figure 10; (a) In vivo activation of ProSense750 by syngeneic rat model of primary breast cancer: a typical example of 
a spectral unmixed image of an EMR86 tumour-bearing female WAG/Rij rat, acquired 24 h after intravenous 
administration of 10 nmol ProSense750. Shown is the separation of the autofluorescence signal (pseudocolored green) 
and the ProSense750 signal (pseudocolored red; IVIS spectrum). (b) Emission curve plot of the spectrally unmixed 
fluorescence signals from (a) demonstrates matching of the tumour signal (red line) with the predefined ProSense750 
emission curve (blue line), confirming the localization of activated ProSense750 at the tumours. (c) In a dose-
dependent and time-dependent experiment, nine tumor bearing rats (N¼35 tumours) were randomized to three 
ProSense750 dose groups and imaged 24 h (gray bars) and 48 h (open bars) after intravenous administration of 
ProSense750 using the IVIS Spectrum. Bars represent mean_SEM. (d) Scatter plot of fluorescence intensity and 
tumour volume of the 10 nmol dose group imaged 24 h after intravenous administration of ProSense750 (R¼0.934, 
P<0.0001, N¼12 tumours from three rats). Reproduced from Mieog JS, Hutteman M, van der Vorst JR, et al. (2011) 
Image-guided tumour resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast 
cancer. Breast Cancer Research and Treatment 128(3): 679–689. 
 
 
 
 
Complete resection was attained in 17 out of 17 tumours with minimal excision of healthy tissue. 
Next to cathepsins, matrix metalloproteinases (MMPs) are important matrix-degrading 
proteinases involved in organ morphogenesis, wound healing, and embryonic development. 
Similar to the proteases mentioned above, MMPs are overexpressed in many tumours. Over 20 
MMPs are known of which predominantly MMP-2, MMP-9, and MMP-7 are involved in the 
progression of cancer. Their complex role in carcinogenesis includes the stimulation of cancer 
cell growth, angiogenesis, migration, invasion, and metastasis. Like cathepsins, MMPs are 
overexpressed in cancer cells as well as tumour stromal cells (Egeblad and Werb, 2002; Hua et al., 
2011; Overall and Lopez-Otin, 2002). The expression of MMPs correlates with advanced tumour 
stage, increased invasion, metastasis, and poor survival (Egeblad and Werb, 2002).  
 
By modifying the aforementioned cathepsin-sensing probe, Bremer et al. (2001a) were the first to 
image MMP activity using NIR fluorescence imaging in vivo. Although cleavable by other 
MMPs, the peptide substrate was primarily cleaved by MMP-2. The probe allowed identification 
ofMMP-2-positive tumours and the assessment ofMMP-2 activity after treatment with the potent 
MMP inhibitor prinomastat (Bremer et al., 2001a,b). Next to imaging of nonmembrane-bound 
MMPs, Zhu et al. (2011a,b) explored the imaging of membrane-type MMPs (MT-MMP). 
Membrane type-1 matrix metalloproteinase (MMP-14), one of the six MT-MMPs, is highly 
expressed in different cancers (Zhu et al., 2011a). A nonsubstrate MT1-MMP-binding peptide 
was conjugated to the NIR-fluorescent dye Cy5.5 and targeted the high MT1-MMP that 
expressed MDA-MB-435 xenografts. In the line of research with the commercially available 
probes targeting cathepsins, a substrate-based MMP targeting probe, MMPSense680 
(PerkinElmer, Waltham, Massachusetts) was developed and used in NIR fluorescence imaging of 
oncology (Keereweer et al., 2011b, 2012a; Xie et al., 2012). In healthy tissue, the urokinase-type 
plasminogen activator receptor (uPAR) is moderately expressed in variable tissues. Increased 
expression is related to extensive tissue remodelling through the regulation of extracellular 
proteolysis in healthy tissues, as well as in many pathological conditions including cancer, 
inflammation, and infections (Blasi and Sidenius, 2010). The nonproteolytic functions consist of 
the promotion of cell proliferation, spreading, migration, and invasion (Blasi and Sidenius, 2010). 
Although a variety of studies reported the use of radioactive or iron oxide labeled uPA-based 
peptides, reports on targeting uPAR by using a targeting moiety conjugated to a fluorophore are 
relatively rare (Li et al., 2008; Liu et al., 2009; Yang et al., 2009b,c). Law et al. (2004) described the 
development of a selective uPA activatable NIR fluorescence imaging probe in vitro. A 
copolymer of L-lysine and MPEG was used as a backbone for an uPA selective substrate and 
conjugated to Cy5.5 or Cy7. Upon addition of recombinant human uPA to the probe, a 
significant amplification of fluorescence was observed. No amplification was observed using the 
negative control probe or when uPA inhibitors were added. The same probe was used to assess 
the validation in animal models of human colon adenocarcinoma and fibrosarcoma (Hsiao et al., 
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ProSense750 using the IVIS Spectrum. Bars represent mean_SEM. (d) Scatter plot of fluorescence intensity and 
tumour volume of the 10 nmol dose group imaged 24 h after intravenous administration of ProSense750 (R¼0.934, 
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expression is related to extensive tissue remodelling through the regulation of extracellular 
proteolysis in healthy tissues, as well as in many pathological conditions including cancer, 
inflammation, and infections (Blasi and Sidenius, 2010). The nonproteolytic functions consist of 
the promotion of cell proliferation, spreading, migration, and invasion (Blasi and Sidenius, 2010). 
Although a variety of studies reported the use of radioactive or iron oxide labeled uPA-based 
peptides, reports on targeting uPAR by using a targeting moiety conjugated to a fluorophore are 
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development of a selective uPA activatable NIR fluorescence imaging probe in vitro. A 
copolymer of L-lysine and MPEG was used as a backbone for an uPA selective substrate and 
conjugated to Cy5.5 or Cy7. Upon addition of recombinant human uPA to the probe, a 
significant amplification of fluorescence was observed. No amplification was observed using the 
negative control probe or when uPA inhibitors were added. The same probe was used to assess 
the validation in animal models of human colon adenocarcinoma and fibrosarcoma (Hsiao et al., 
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2006). A threefold higher signal intensity was reported, correlating with tumour-associated uPA 
activity. Dullin et al. (2009) published the use of a nonactivatable uPAR antibody conjugated to 
Cy5.5 to visualize breast carcinoma. In contrast to the nonspecific antibody that was used as a 
control, clear visualization of the breast tumour was observed. Next to the substrate-based 
probes described above, fluorescent activity-based probes (ABPs) have been reported (Blum et 
al., 2005, 2007). In contrast to the substrate-based probes, ABPs label target proteases through 
covalent binding (Figure 11). One of the major advantages of using a substrate as a reporter in 
‘smart probes’ is that a single active protease can process many substrates resulting in the 
amplification of fluorescent signal over time. However, such substrates do usually not target a 
specific single protease, making it difficult to determine which particular protease is being imaged 
(Blum et al., 2009). ABPs allow direct biochemical analysis of targets after in vivo imaging and 
enable a direct link to the imaging data. Moreover, due to small molecules, ABPs have shorter 
half-lives and shorter elimination times, resulting in higher contrast images. ABPs targeting 
cathepsins B, L, S, and X have been synthesized and were reported to successfully delineate 
tumours in vivo (Blum et al., 2007; Paulick and Bogyo, 2011; Tedelind et al., 2011; Verdoes et al., 
2012). Blum et al. (2009) compared the substrate-based probes to the ABPs in imaging of MDA-
MB 231 MFP and C2C12ras tumours in vivo. They reported a more rapid and selective uptake of 
ABPs into tumours and a brighter overall signal and suggested that the lack of signal 
amplification for an ABP was compensated by more efficient kinetics and prolonged retention. 
The major advantage of proteases over other targets is the ubiquity of the expression in cancer 
cells which make them very appealing as a universal target for intraoperative NIR fluorescence 
molecular imaging of cancer (Boonstra et al., 2011; Egeblad and Werb, 2002; Mohamed and 
Sloane, 2006). On the other hand, the increased expression of proteases is not limited to tumours 
and the tumour microenvironment but can be found in inflammation and infections. The 
disadvantage of increased expression in inflammation and infections is often disregarded when 
tumour models are used in immune-compromised mice. A second advantage of proteases is the 
overexpression in tumour stromal cells. These are an interesting target to identify the tumour 
invasive border and subsequently resect the tumour in a radical way. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11; (a) Schematic diagram illustrating activation of the ProSense imaging probes by a target protease. The main 
backbone is made up of PEGylated poly-lysine modified with fluorophores that are quenched by close proximity (gray 
stars). Upon cleavage by a protease at free lysine residues, smaller fragments containing the unquenched fluorophore 
(blue stars) are released. (b) Schematic of fluorescent activity-based probes labeling a target protease. In both examples, 
the probe covalently binds in the active site of the protease target forming a permanent bond between the probe and 
the protease. In the top scheme, the probe contains a fluorescent reporter (blue start) that emits fluorescence even in 
the absence of protease. In the bottom scheme, the fluorophore (gray start) on the ABP is quenched by proximity to a 
quenching group (black circle) that is lost upon covalent modification of the target protease. Reproduced from Blum 
G, Weimer RM, Edgington LE, Adams W, and Bogyo M. (2009) Comparative assessment of substrates and activity 
based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One. 4(7): e6374.  
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4.20.4.1.2 Sustained angiogenesis 
An oncogenic event enables tumour cells to evade the immune system and enhance their 
survival. However, further growth of the tumour extending the size of 1 mm needs 
vascularization to supply oxygen and nutrients (Naumov et al., 2006). Hypoxia and nutrient 
deprivation shift the balance of pro- and antiangiogenic factors toward stimulatory angiogenic 
factors (Weis and Cheresh, 2011). Cytokines and growth factors are released in the tumour 
microenvironment allowing new blood vessels to grow by sprouting from preexisting blood 
vessels or by recruitment of endothelial progenitor cells (Avraamides et al., 2008). The defective 
architecture of newly formed blood vessels of most solid tumours ensures an enhanced vascular 
permeability, thereby offering sufficient supply of nutrients and oxygen for rapid growth (Fang et 
al., 2011). The vascular endothelial growth factor (VEGF) and integrins, both key regulators of 
tumour angiogenesis, provide targets to detect sustained angiogenesis of tumours. In addition, an 
interesting target in NIR fluorescence imaging is the enhanced vascular permeability and 
retention. These targets will be discussed separately in the following paragraphs. The VEGF 
represents a critical rate-limiting step in physiological angiogenesis. In physiological angiogenesis, 
VEGF has the ability to promote growth of vascular endothelial cells (ECs), acts as a survival 
factor for ECs, promotes monocyte chemotaxis, and is known as a vascular permeability factor 
(Ferrara et al., 2003). VEGF acts via two related receptor tyrosine kinases and is upregulated in 
many human tumours (Ferrara et al., 2003). In 2006, Backer et al. (2007) conjugated a single-
chain Cys-tagged VEGF to Cy5.5 (scVEGF/Cy) and explored the specific focal uptake into the 
vasculature of tumours and surrounding host tissue. Compared to a functionally inactive control, 
scVEGF/Cy selectively accumulated in the tumour area. The intensity of NIRF images remained 
nearly constant for at least seven days after injection. Three other research groups conjugated 
bevacizumab, a humanized monoclonal antibody that neutralizes all isoforms of the ligand 
VEGF-A, to alexa fluor680, Cy5.5, and IRDye 800CW, respectively (Chang et al., 2008; 
Terwisscha van Scheltinga et al., 2011; Withrow et al., 2008). Detection of head and neck, 
ovarian, prostate, and pancreatic tumours and monitoring of VEGF expression could be 
obtained. 
 
Integrins are a group of structurally related, heterodimeric transmembrane receptors that 
compose of an alfa and a beta subunit (Avraamides et al., 2008). They are involved in signal 
transduction, cell–cell interaction, and adhesion to the extracellular matrix (Hood and Cheresh, 
2002). Twenty-five intregrin heterodimers are known, of which a number has been implicated in 
the regulation of cell growth, survival, and migration during angiogenesis (Avraamides et al., 
2008). Integrins and especially the avb3 integrin are widely expressed in tumour cells and blood 
vessels of many solid tumours, which make them very appealing as a target in NIR fluorescence 
molecular imaging (Robinson and Hodivala-Dilke, 2011). The avb3 integrin expression had been 
 
studied well by using radionuclide imaging when Chen et al. (2004) performed the first NIR 
fluorescence imaging study that targeted avb3 integrin. Cyclic arginine–glycine–aspartate (cRGD) 
was conjugated to Cy5.5 which enabled clear visualization of a subcutaneous glioblastoma 
tumour (Chen et al., 2004; Hsu et al., 2006). Wang et al. (2004) synthesized an integrin avb3-
targeted peptide cyclo (Lys-Arg-Gly-Asp-Phe) conjugated to Cy5.5 or IRDye 800CW and 
reported its accumulation in tumours expressing avb3. Soon after these exciting results, the 
commercial probe IntegriSense680 (PerkinElmer, Waltham, MA) became available. This targeting 
moiety consists of a small peptidomimetic antagonist conjugated to a NIR-fluorescent dye. A 
higher specificity toward avb3 compared to RGD-based probes could be obtained. Moreover, 
IntegriSense was internalized into avb3 positive tumour cells with subsequent slower clearance 
(Keereweer et al., 2012b; Kossodo et al., 2010; Themelis et al., 2011). To extend the blood 
circulation half-life of the small RGD-based probe, Chen et al. (2009) covalently conjugated a 
cyclic peptide, c(RGDyK), and an organic dye (IRDye 800CW or Cy5.5) to HSA. Higher tumour 
accumulation and TBRs were obtained using HSA–RGD–IRDye 800CW in a subcutaneous 
glioblastoma cancer cell line. Attention has to be paid that although the blood circulation time 
will extend, penetration into the tissue might diminish, resulting in the same or an even lower 
TBR. Two new, exciting approaches were reported to improve the specificity and increase the 
TBR. The use of ‘smart probes’ targeting avb3 was introduced by Jin et al. (2007). To improve 
the performance of their cRGD molecule RAFT-c(-RGDfK-)4, they developed a self-quenched 
probe by linking a fluorescence quencher to Cy5 via a disulfide bond. Fluorescence could be 
activated by RGD-mediated cellular internalization and a significant enhancement of fluorescent 
signal was obtained compared to the unquenched molecule. Lee et al. (2011) developed a pH 
activatable probe by conjugating a pH-sensitive cyanine dye to a cRGD peptide targeting avb3 
integrin. The spectra were shifted to the visible region when the pH was above 6. Tumours 
exhibit a lower extracellular pH than normal tissue (Gerweck and Seetharaman, 1996; 
Thistlethwaite et al., 1985). Therefore, an increase in tumour specificity could be obtained using 
this probe. Cell microscopy indicated avb3 integrin facilitated endocytosismediated lysosomal 
accumulation and enhancement of the fluorescent signal. In vivo, similar enhancement of 
fluorescence was observed in an orthotopic breast cancer model. The defective architecture of 
blood vessels and extensive amounts of vascular permeability factors provide most solid tumours 
with an enhanced vascular permeability (Fang et al., 2011). The increased vascular permeability 
ensures macromolecules larger than 40 kDa to leak out from the tumour vasculature. Due to 
ineffective lymphatic drainage and subsequent abnormal fluid transport accumulation of 
thesemolecules in the interstitial space occurs (Fang et al., 2011). This effect and 
pathophysiological nature of tumour vasculature and lymphatic drainage are of essential value for 
anticancer drug design. Keereweer et al. (2012b) explored the EPR effect in NIR fluorescence 
molecular imaging using the nonspecific IRDye 800CW PEG (LI-COR Biosciences, Lincoln, 
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NE). Clear demarcation of an oral squamous cell carcinoma of the tongue could be obtained. 
Angiogenesis is essential for tumour growth and metastasis. The enhanced expression of 
angiogenic-related receptors and release of cytokines and growth factors are of universal 
importance for tumours. The relative ubiquity in this overexpression, as angiogenesis is essential 
for every tumour to grow, makes this hallmark very appealing as a target in NIR fluorescence 
molecular imaging. 
 
4.20.4.1.3 Limitless replicative potential 
The essence of carcinogenesis is the progression of changes in a normal cell that ultimately gains 
the ability of uncontrolled cell division. Three acquired capabilities are necessary to escape the 
normal growth program: growth signal autonomy, insensitivity to antigrowth signals, and 
resistance to apoptosis (Hanahan and Weinberg, 2000, 2011). To persevere the ability of limitless 
cell division, an increased metabolism and rapid DNA synthesis are required. An elevated rate of 
glycolysis and an increased expression of the folate receptor (FR) are two important targets in the 
limitless replicative potential of cancer. PET has become widely clinically available as a tool in 
cancer detection, staging, and monitoring the response after treatment (Gambhir, 2002; Stokkel 
et al., 1998, see also Volume 1). PET enables the imaging and quantification of cellular and 
molecular processes. One of the targets in PET, using the tracer 2-deoxy-2[18F]fluoro-D-glucose 
([18F]FDG), is the increased glucose metabolism in malignant tissue (Rajendran et al., 2004). In 
the 1930s, Warburg et al. (1927) reported the increased glycolysis of malignant tissue compared 
to normal tissue. The increased demand for glucose in malignant tissue is usually associated with 
upregulation of the glucose transporters (GLUT 1 and GLUT 3) and hexokinase (Rajendran et 
al., 2004). The first in vivo study using a 2-deoxyglucose analog coupled to a NIR-fluorescent dye 
was done by Cheng et al. (2006). Encouraged by the GLUT-specific uptake of the recently 
synthesized 2-dexoyglucose analog 2-NBDG (O’Neil et al., 2005) in vitro, they conjugated Cy5.5 
and D-glucosamine (Cy5.5–2DG). Tumour-specific uptake of Cy5.5–2DG was observed in a 
variety of tumours in vitro and in vivo. Nonetheless, the Cy5.5–NHS, used as a control, 
demonstrated the same tumour specificity. In addition, blocking of the GLUT and hexokinase 
pathway showed no decrease in fluorescent signal. Although tumour specific, the NIR-
fluorescent glucose analog did not prove to target the tumour through the GLUT/hexokinase 
pathway. Kovar et al. (2009) conjugated 2-deoxyglucose to the IRDye 800CW (800CW 2-DG). 
Tumour-specific uptake was observed in epithelial and prostate carcinomas in vitro as well as in 
vivo. In contrast to Cheng et al. (2006), specific blocking of IRDye 800CW 2-DG uptake by an 
antibody against the GLUT 1 glucose transporter and by an excess of unlabeled 2-DG was 
reported. Shortly after these results, 800CW 2-DG (LI-COR Biosciences) became commercially 
available and Keereweer et al. (2012a,c) successfully used the probe to visualize an oral squamous 
cell carcinoma of the tongue and cervical lymph node metastases in animal models. Folate is a 
 
generic name for a group of structurally related compounds like folic acid and vitamin B9. It 
plays an important role during one-carbon transfer reactions that are critical to the metabolism of 
nucleic acids and amino acids (Choi and Mason, 2000). The function of folate in DNA synthesis 
and replication, cell division, and growth and survival is of particular importance in rapid dividing 
cells (Choi and Mason, 2000). The high affinity FR is a glycosylphosphatidylinositolanchored 
protein that mediates folate uptake by endocytosis (Henderson, 1990). Four isoforms of the FR 
have been described of which FRa is of particular interest in NIR fluorescence imaging. The FRa 
is highly expressed in nonmucinous tumours of epithelial origin and its expression is restricted in 
normal cells (Parker et al., 2005). Moreover, the affinity of FR for folic acid is high, the excretion 
of folate from receptor negative tissue is fast, and the small size of folate facilitates its efficient 
penetration of solid tumours (Sega and Low, 2008). Numerous studies explored the use of the 
FR to visualize a variety of tumours. Tung et al. (2002) coupled the asymmetric NIR-fluorescent 
compound NIR2 to a amino-derivatized folic acid. The experiments were performed using the 
FR expressing OVCAR3 ovarian cancer cell line and the FR-negative human lung carcinoma 
A549. Competitive inhibition studies using folic acid and NIR2–folate revealed that fluorophore 
attachment did not interfere with binding to the FR. Subsequently, OVCAR3 tumours were 
implanted in the lower abdomen of nude mice. Successful NIR-fluorescent identification of the 
tumour was obtained as early as 1 h after administration of the conjugate and the fluorescent 
signal reached a plateau at 24 h. No enhancement of tumour fluorescence was observed in mice 
after the administration of NIR2 alone (Tung et al., 2002). Moon et al. (2003) used the same 
NIR2–folate probe in FR-positive nasopharyngeal epidermoid carcinomas and reported the 
inhibition of fluorescent signal after administration of unlabeled folate. Next to the fluorescence 
detection of primary tumours, the use of a folate–fluorescein conjugate enabled the visualization 
of metastatic loci of submillimeter size (Kennedy et al., 2003). Considering the undesirable 
optical qualities of fluorescein, two groups explored the conjugation of folate to ICG (Liu et al., 
2010; Milstein et al., 2005). Liu et al. (2010) synthesized a folate–polyethylene glycol (PEG) 
complex conjugated to ICG. Four different cell lines were used and a TBR up to 20 was 
obtained. The limitless replicative potential is a very interesting target in the use of NIR 
fluorescence imaging. Many studies appraised the use of glucose analogs in noninvasive detection 
of tumours using PET imaging. Recently, Tseng et al. (2012) compared the use of NIR-
conjugated 2-deoxyglucose to [18F]FDG and suggested that large bulky fluorophores disrupt the 
facilitated transport and retention of the 2-DG probes. Even though these results do not support 
the use of large fluorophores conjugated to a glucose analog, the general acceptance of tumour 
detection using PET imaging certainly makes increased glycolysis of tumours an interesting 
target. On the other hand, although not ubiquitously expressed, the FR holds as a very promising 
target for NIR molecular imaging. The upregulation in a large variety of epithelial tumours, the 
absence of the FR in most normal tissue, the high affinity of the FR for its ligand, and the small 
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attachment did not interfere with binding to the FR. Subsequently, OVCAR3 tumours were 
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signal reached a plateau at 24 h. No enhancement of tumour fluorescence was observed in mice 
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inhibition of fluorescent signal after administration of unlabeled folate. Next to the fluorescence 
detection of primary tumours, the use of a folate–fluorescein conjugate enabled the visualization 
of metastatic loci of submillimeter size (Kennedy et al., 2003). Considering the undesirable 
optical qualities of fluorescein, two groups explored the conjugation of folate to ICG (Liu et al., 
2010; Milstein et al., 2005). Liu et al. (2010) synthesized a folate–polyethylene glycol (PEG) 
complex conjugated to ICG. Four different cell lines were used and a TBR up to 20 was 
obtained. The limitless replicative potential is a very interesting target in the use of NIR 
fluorescence imaging. Many studies appraised the use of glucose analogs in noninvasive detection 
of tumours using PET imaging. Recently, Tseng et al. (2012) compared the use of NIR-
conjugated 2-deoxyglucose to [18F]FDG and suggested that large bulky fluorophores disrupt the 
facilitated transport and retention of the 2-DG probes. Even though these results do not support 
the use of large fluorophores conjugated to a glucose analog, the general acceptance of tumour 
detection using PET imaging certainly makes increased glycolysis of tumours an interesting 
target. On the other hand, although not ubiquitously expressed, the FR holds as a very promising 
target for NIR molecular imaging. The upregulation in a large variety of epithelial tumours, the 
absence of the FR in most normal tissue, the high affinity of the FR for its ligand, and the small 
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size and subsequent rapid clearance of folate make the FR a promising target in NIR molecular 
imaging (Sega and Low, 2008).  
 
 
4.20.4.1.4 Self-sufficiency in growth signals 
The essence of cancer is the uncontrollable dividing and growth of cells and subsequent invasion 
of nearby tissue. Normal cells are dependent on mitogenic growth signals if the cells want to get 
into an active proliferative state. Tumour cells produce many of their own growth signals which 
reduce their dependence on growth signals from the microenvironment (Hanahan and Weinberg, 
2000, 2011). The tumour cell has three available molecular strategies to acquire independency 
of growth signals from the microenvironment: alteration of extracellular growth signals, 
alteration of transcellular transducers of those signals, or alteration of intracellular circuits that 
translate those signals into action (Hanahan and Weinberg, 2000, 2011). Targets available within 
the hallmark of self-sufficiency in growth signals have been widely explored. The most promising 
tools for target-specific NIR fluorescence molecular imaging are antibody derivatives. Intact 
antibodies can provoke immunogenic reactions. Moreover, slow blood clearance via the liver 
results in high contrast images days after injection. These disadvantages encouraged the quest for 
new antibody derivatives. In this quest, many different antibody fragments have been synthesized 
(Figure 12).  
 
 
Figure 12; Schematic representation of antibody formats. Antibody fragments ranging from Fab fragments to 
nanobodies have been engineered. Reproduced from Romer T, Leonhardt H, and Rothbauer U (2011) Engineering 
antibodies and proteins for molecular in vivo imaging. Current Opinion in Biotechnology 22(6): 882–887. 
 
 
 
 
 
 
 
The ideal antibody derivative should possess a high affinity to their target antigen and an optimal 
blood clearance to create high contrast imaging in a short time. Furthermore, they need to have a 
low immunogenicity and sufficient tissue penetration (Romer et al., 2011). In this paragraph, we 
will discuss the major preclinical work of NIR fluorescence imaging of cancer that has been 
performed targeting the epidermal growth factor receptor (EGFR), the HER2, the mesenchymal 
epithelial transition factor (cMET), and the insulin-like growth factor 1 (IGF1R).  The epidermal 
growth factor (EGF) tyrosine kinase receptor family comprises four receptors: EGFR/ErbB-1, 
HER2/ErbB-2, HER3/ErbB-3, and HER4/ErbB-4. The signalling pathway is involved in cell 
proliferation, survival, adhesion, migration, and differentiation of normal tissue. Activating 
mutants and overexpression contribute to oncogenesis by proliferation, dedifferentiation, 
inhibition of apoptosis, invasiveness, and lack of adhesion dependence (Yarden, 2001). Of the 
four receptors, EGFR and HER2 are of particular interest in NIR fluorescence molecular 
imaging due to the overexpression in many different cancers (Modjtahedi and Dean, 1994). 
Soukos et al. (2001) were one of the first that conjugated a fluorescent dye (Cy5.5) to an anti-
EGFR monoclonal antibody to detect an EGFR positive tumour. They reported a clear 
demarcation of an EGFR positive carcinogenesis model of a hamster’s cheek pouch. The highest 
TBR was reached between four and eight days after injection of the probe. In 2006, the FDA 
approved two monoclonal antibodies raised against the EGFR. Soon, several studies reported the 
conjugation of a fluorescent dye to panitumumab and cetuximab (Barrett et al., 2007; Gleysteen 
et al., 2008; Heath et al., 2012; Koyama et al., 2007; Villaraza et al., 2010). Cetuximab is a 
recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the 
extracellular domain of the human EGFR. It has an approximate molecular weight of 152 kDa 
and is an IgG1 antibody that competitively inhibits endogenous ligand binding (Gleysteen et al., 
2008). Gleysteen et al. (2008) conjugated cetuximab to Cy5.5. Clear demarcation of primary 
tongue tumour and bilateral cervical nodes was demonstrated. In mice-bearing pulmonary 
metastases, stereomicroscopic fluorescence imaging demonstrated a distinct speckled 
fluorescence pattern and histopathological analysis was used to confirm the presence of 
metastases (Gleysteen et al., 2008). Panitumumab on the other hand is a fully humanized IgG2 
monoclonal antibody with an approximate molecular weight of 147 kDa. Unlike cetuximab, it is 
not associated with infusion reactions (Kundu and Nestor, 2012). Heath et al. (2012) validated 
the use of the SPY imaging system to detect micrometastatic head and neck squamous cell 
carcinoma. Panitumumab was conjugated to the IRDye 800CW, and orthotopic tongue tumours 
were clearly delineated from normal tissue. Fluorescence intensity of the primary tumour was 
minimal using nonspecific IgG, and they were able to detect regional lymph node metastasis and 
microscopic areas of disease (Heath et al., 2012). To decrease the blood clearance time and 
improve the penetrating capability, smaller antibody mimetics were developed. The natural ligand 
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recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the 
extracellular domain of the human EGFR. It has an approximate molecular weight of 152 kDa 
and is an IgG1 antibody that competitively inhibits endogenous ligand binding (Gleysteen et al., 
2008). Gleysteen et al. (2008) conjugated cetuximab to Cy5.5. Clear demarcation of primary 
tongue tumour and bilateral cervical nodes was demonstrated. In mice-bearing pulmonary 
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fluorescence pattern and histopathological analysis was used to confirm the presence of 
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improve the penetrating capability, smaller antibody mimetics were developed. The natural ligand 
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for EGFR has an approximate molecular weight of 6 kDa. Several groups used EGF to image 
EGFR expression in vivo (Ke et al., 2003; Keereweer et al., 2012a,c). Although clear demarcation 
of tumours could be achieved, the possible stimulation of the EGFR-mediated pathway is an 
unwanted property for in vivo imaging (Adams et al., 2007). Affibodies are single proteins 
composed of 58 amino acids derived from one of the IgG-binding domains of staphylococcal 
protein A. The high affinity toward their target protein and a molecular weight of approximately 
6 kDa make them appealing antibody mimetics for NIR fluorescence imaging (Gong et al., 2010; 
Qi et al., 2012). Another promising antibody mimetic is the nanobody. Nanobodies are the 
smallest functional antigen-binding fragments of a naturally occurring single-chain antibody 
(Muyldermans et al., 1994). The nanobodies were derived from the fully functional heavy-chain 
antibodies of camels and llamas that contain a single variable domain and two constant domains. 
Like affibodies, they have a low molecular weight of 15 kDa and bind very specifically to their 
targets. Oliveira et al. (2011) tested an anti-EGFR nanobody conjugated to IRDye 800CW 
(7D12-IR) and compared it with cetuximab conjugated to the IRDye 800CW (Figure 13). 7D12–
IR allowed visualization of the tumour 30-min postinjection when no signal above background 
was observed with cetuximab–IR. Quantification of the IR-conjugated proteins in the tumour 
revealed a significantly higher uptake of 7D12–IR compared to cetuximab–IR which could be 
explained by superior penetration and distribution of 7D12–IR (Oliveira et al., 2011). Using a 
phage display method, Jeong et al. (2012) found an EGFR-specific peptide (EGBP) and tested 
three linking groups for the conjugation to Cy5.5. Clear differences were observed between the 
different probes and EGBP–C-Cy5.5 turned out to be the optimized optical imaging agent for 
the detection of EGFR positive U87MG tumours. High TBRs were obtained as early as 30-min 
postinjection. To obtain a more specific fluorescent signal and a higher TBR, Hama et al. (2007) 
explored the target-specific activation of the optical signal. They described a two-step activation 
process. First, EGFR positive tumours were pretargeted with biotinylated cetuximab followed by 
a second agent, a neutravidin–BODIPY-FL fluorescent conjugate. The binding of this conjugate 
to biotinylated cetuximab resulted in a tenfold amplification of the optical fluorescence signal. To 
amplify the tumour-specific fluorescent signal, Ogawa et al. (2009a) took advantage of the 
property of ICG that loses its fluorescence after protein binding. After cell binding and 
internalization, ICG dissociated from panitumumab thus activating fluorescence. This quenching 
NIR probe using panitumumab and ICG successfully visualized the EGFR positive MDA-
MB468 and A431 tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13; In vivo optical molecular imaging. Athymic nude mice bearing A431 human tumour xenografts at both 
hind legs were intravenously injected with 7D12–IR, R2–IR, or cetuximab–IR and imaged under anesthesia at several 
time points postinjection. (a) Images of mice taken with the optical imaging system at 30 min and 24 h postinjection 
(p.i.), in which tumours are indicated with red arrows and kidneys with green arrows. (b) For all of the images 
obtained, regions of interest were drawn around the tumour areas and in normal tissues (exemplified with red and 
black line, respectively), and the corresponding values of average fluoresence radiance (p/s/cm2/sr) were used to 
calculate tumour to normal tissue ratios 002EC. These values are plotted in time postinjection. Reproduced from 
Oliveira S, van Dongen GA, Stigter-van Walsum M, et al. (2011) Rapid visualization of human tumour xenografts 
through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Molecular 
Imaging 2011 11(1): 33–46.  
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The second EGF receptor, HER2 (HER-2/neu, ErbB2), is as widely explored as a target in NIR 
fluorescence imaging as EGFR. Hilger et al. (2004) were one of the first that targeted HER2 
using an anti-HER2 antibody conjugated to a fluorophore. They used the trastuzumab, an 
antibody that was approved by the FDA in 1998, and conjugated the antibody to Cy5.5. Distinct 
fluorescence imaging of the HER2 overexpressing tumour SK-BR-3 could be obtained compared 
to the normal-expressing PE/CA-PJ34 tumours. Several other groups conjugated trastuzumab or 
HER2-specific affibodies to a fluorophore for intraoperative tumour imaging, quantitative 
analysis of HER2 expression, or molecular imaging of drug susceptibility and dosing during 
HER2-targeted therapy (Chernomordik et al., 2010; Gee et al., 2008; Gong et al., 2010; Longmire 
et al., 2009; Terwisscha van Scheltinga et al., 2011). In the quest to higher TBRs and tumour-
specific signal, Ogawa et al. (2009a) used the same quenching technique with ICG used in the 
conjugation to panitumumab to target the HER2. ICG conjugated to trastuzumab clearly 
demarked 3T3/HER2þ tumours. Next, Ogawa et al. (2009b) explored an in vivo targeted 
activatable optical imaging probe based on a fluorophore–quencher pair conjugated to a targeting 
moiety. Trastuzumab was labeled with the TAMRA (fluorophore)–QSY7 (quencher) pair. Upon 
internalization of the probe through the HER2, the probe was dequenched, resulting in high 
fluorescence intensities in the tumour and subsequent high TBRs. One group explored the use of 
NIR fluorescence imaging to, noninvasively, distinguish tumours by their cell surface expression 
profiles (Barrett et al., 2007; Koyama et al., 2007). Mice bearing A431 (overexpressing EGFR), 
NIH3T3/HER2þ (overexpressing HER2), and Balb3T3/DsRed (nonexpression control) 
tumours were injected with a cocktail of optically labeled antibodies: Cy5.5-labeled cetuximab 
and Cy7-labeled trastuzumab. Spectral fluorescence molecular imaging clearly differentiated 
tumours using the cocktail of optically labeled antibodies. cMET is a receptor tyrosine kinase, 
stimulated via its ligand hepatocyte growth factor, also known as scatter factor (HGF/ SF). The 
activation of the signaling pathway results in a number of biological effects in tumour cells 
including scattering, branching morphogenesis, cell motility, invasion, migration, and metastasis 
(Maulik et al., 2002). As cMET has been shown to be overexpressed and mutated in a variety of  
malignancies, it serves as a promising target in NIR fluorescence molecular imaging (Maulik et al., 
2002). By immunizing rabbits with a HGF–cMET complex, Kim et al. (2007) generated a 
monoclonal antibody (SFN68). They screened out an epitopemimicking peptide from a phage 
display of a combinatorial peptide library and conjugated the peptide to the fluorophore Cy5.5 
(cMBP–AOC–Cy5.5). Clear demarcation of the subcutaneous injected U87MG tumour was 
obtained. A coinjection with free peptide resulted in a 35% decrease of florescent intensity. 
Although several studies reported the use of antibodies to target cMET, no further studies have 
been performed using NIR fluorescence imaging (Perk et al., 2008; Towner et al., 2008). The 
insulin-like growth factor signaling system plays a key role in the growth and development of 
several cancers by stimulating cellular proliferation and survival (Pollak, 2004, 2012). The IGF1R 
 
is a tyrosine kinase cell surface receptor that binds either the insulin-like growth factor 1 (IGF1) 
or the insulin-like growth factor 2 (IGF2). Expression of the IGF1R family (IIRF) is seen widely 
in both neoplastic and normal tissue. Although IIRF can be overexpressed in malignant tissues, 
gene amplification that is associated with large increases in receptor number is rare (Pollak, 2012). 
Nonetheless extensive research has been done, including phase III clinical trials, to explore the 
treatment of IGF1R-specific antibodies. Zhang et al. (2009) assessed the use of a humanized 
anti-IGF1R monoclonal antibody (AVE-1642) conjugated to the fluorophore Alexa 680 to detect 
IGF1R expression and its downregulation by antibodies. The IGF1Rtargeted probe was able to 
visualize the tumour and detect the downregulation of IGF1R. The overexpression of growth 
factor receptors in malignancies has been widely studied over the last decades. NIRfluorescent 
probes in many different sizes with a variety of fluorophores have been studied, mainly targeting 
the EGFR family. Although not ubiquitously expressed in malignancies, preclinical results have 
shown that the EGFR family is of great interest in NIR fluorescence imaging in overexpressing 
cancers. cMET, even though not many studies appraised the use of a cMET-targeted antibody 
conjugated to a fluorophore, does look promising as well. IIRF seems to be less attractive due to 
the moderate gene amplification. Nevertheless, more research is needed to explore this target in 
NIR fluorescence imaging of cancer. Although promising results were achieved targeting the self-
sufficiency in growth signals so far, the quest for the most efficient antibody (mimetic) will 
continue. 
 
 
4.20.4.2 Clinical Detection of Tumours 
 
Although considerable preclinical research in NIR fluorescence imaging of tumours has been 
performed in the past decades, clinical studies are still awaited. The main reason holds the lack of 
FDA-approved fluorescent dyes and to a lesser extent the targeting moieties. At the end of 2011, 
the first and to date only tumour-specific in-human study had been published by van Dam et al. 
(2011). They systemically administered folate conjugated to fluorescein isothiocyanate (folate–
FITC) to visualize ovarian cancer. The FRa provides a promising target in epithelial ovarian 
cancer (EOC) as 90–95% of patients with EOC revealed to overexpress the FRa (Markert et al., 
2008). Currently, the overall 5-year survival rate of EOC is 45% and tumour-specific detection 
could aid in improved staging and possibly survival (van Dam et al., 2011). A total of ten patients 
were included of which four patients were diagnosed with a malignant epithelial ovarian tumour, 
one patient with a serous borderline tumour, and five patients with a benign ovarian tumour. 
Fluorescence imaging was done using a real-time multispectral intraoperative fluorescence 
imaging system. Fluorescence was detectable in all patients with a malignant tumour and FRa 
expression. One patient with a malignant tumour did not have any overexpression of FRa and 
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The second EGF receptor, HER2 (HER-2/neu, ErbB2), is as widely explored as a target in NIR 
fluorescence imaging as EGFR. Hilger et al. (2004) were one of the first that targeted HER2 
using an anti-HER2 antibody conjugated to a fluorophore. They used the trastuzumab, an 
antibody that was approved by the FDA in 1998, and conjugated the antibody to Cy5.5. Distinct 
fluorescence imaging of the HER2 overexpressing tumour SK-BR-3 could be obtained compared 
to the normal-expressing PE/CA-PJ34 tumours. Several other groups conjugated trastuzumab or 
HER2-specific affibodies to a fluorophore for intraoperative tumour imaging, quantitative 
analysis of HER2 expression, or molecular imaging of drug susceptibility and dosing during 
HER2-targeted therapy (Chernomordik et al., 2010; Gee et al., 2008; Gong et al., 2010; Longmire 
et al., 2009; Terwisscha van Scheltinga et al., 2011). In the quest to higher TBRs and tumour-
specific signal, Ogawa et al. (2009a) used the same quenching technique with ICG used in the 
conjugation to panitumumab to target the HER2. ICG conjugated to trastuzumab clearly 
demarked 3T3/HER2þ tumours. Next, Ogawa et al. (2009b) explored an in vivo targeted 
activatable optical imaging probe based on a fluorophore–quencher pair conjugated to a targeting 
moiety. Trastuzumab was labeled with the TAMRA (fluorophore)–QSY7 (quencher) pair. Upon 
internalization of the probe through the HER2, the probe was dequenched, resulting in high 
fluorescence intensities in the tumour and subsequent high TBRs. One group explored the use of 
NIR fluorescence imaging to, noninvasively, distinguish tumours by their cell surface expression 
profiles (Barrett et al., 2007; Koyama et al., 2007). Mice bearing A431 (overexpressing EGFR), 
NIH3T3/HER2þ (overexpressing HER2), and Balb3T3/DsRed (nonexpression control) 
tumours were injected with a cocktail of optically labeled antibodies: Cy5.5-labeled cetuximab 
and Cy7-labeled trastuzumab. Spectral fluorescence molecular imaging clearly differentiated 
tumours using the cocktail of optically labeled antibodies. cMET is a receptor tyrosine kinase, 
stimulated via its ligand hepatocyte growth factor, also known as scatter factor (HGF/ SF). The 
activation of the signaling pathway results in a number of biological effects in tumour cells 
including scattering, branching morphogenesis, cell motility, invasion, migration, and metastasis 
(Maulik et al., 2002). As cMET has been shown to be overexpressed and mutated in a variety of  
malignancies, it serves as a promising target in NIR fluorescence molecular imaging (Maulik et al., 
2002). By immunizing rabbits with a HGF–cMET complex, Kim et al. (2007) generated a 
monoclonal antibody (SFN68). They screened out an epitopemimicking peptide from a phage 
display of a combinatorial peptide library and conjugated the peptide to the fluorophore Cy5.5 
(cMBP–AOC–Cy5.5). Clear demarcation of the subcutaneous injected U87MG tumour was 
obtained. A coinjection with free peptide resulted in a 35% decrease of florescent intensity. 
Although several studies reported the use of antibodies to target cMET, no further studies have 
been performed using NIR fluorescence imaging (Perk et al., 2008; Towner et al., 2008). The 
insulin-like growth factor signaling system plays a key role in the growth and development of 
several cancers by stimulating cellular proliferation and survival (Pollak, 2004, 2012). The IGF1R 
 
is a tyrosine kinase cell surface receptor that binds either the insulin-like growth factor 1 (IGF1) 
or the insulin-like growth factor 2 (IGF2). Expression of the IGF1R family (IIRF) is seen widely 
in both neoplastic and normal tissue. Although IIRF can be overexpressed in malignant tissues, 
gene amplification that is associated with large increases in receptor number is rare (Pollak, 2012). 
Nonetheless extensive research has been done, including phase III clinical trials, to explore the 
treatment of IGF1R-specific antibodies. Zhang et al. (2009) assessed the use of a humanized 
anti-IGF1R monoclonal antibody (AVE-1642) conjugated to the fluorophore Alexa 680 to detect 
IGF1R expression and its downregulation by antibodies. The IGF1Rtargeted probe was able to 
visualize the tumour and detect the downregulation of IGF1R. The overexpression of growth 
factor receptors in malignancies has been widely studied over the last decades. NIRfluorescent 
probes in many different sizes with a variety of fluorophores have been studied, mainly targeting 
the EGFR family. Although not ubiquitously expressed in malignancies, preclinical results have 
shown that the EGFR family is of great interest in NIR fluorescence imaging in overexpressing 
cancers. cMET, even though not many studies appraised the use of a cMET-targeted antibody 
conjugated to a fluorophore, does look promising as well. IIRF seems to be less attractive due to 
the moderate gene amplification. Nevertheless, more research is needed to explore this target in 
NIR fluorescence imaging of cancer. Although promising results were achieved targeting the self-
sufficiency in growth signals so far, the quest for the most efficient antibody (mimetic) will 
continue. 
 
 
4.20.4.2 Clinical Detection of Tumours 
 
Although considerable preclinical research in NIR fluorescence imaging of tumours has been 
performed in the past decades, clinical studies are still awaited. The main reason holds the lack of 
FDA-approved fluorescent dyes and to a lesser extent the targeting moieties. At the end of 2011, 
the first and to date only tumour-specific in-human study had been published by van Dam et al. 
(2011). They systemically administered folate conjugated to fluorescein isothiocyanate (folate–
FITC) to visualize ovarian cancer. The FRa provides a promising target in epithelial ovarian 
cancer (EOC) as 90–95% of patients with EOC revealed to overexpress the FRa (Markert et al., 
2008). Currently, the overall 5-year survival rate of EOC is 45% and tumour-specific detection 
could aid in improved staging and possibly survival (van Dam et al., 2011). A total of ten patients 
were included of which four patients were diagnosed with a malignant epithelial ovarian tumour, 
one patient with a serous borderline tumour, and five patients with a benign ovarian tumour. 
Fluorescence imaging was done using a real-time multispectral intraoperative fluorescence 
imaging system. Fluorescence was detectable in all patients with a malignant tumour and FRa 
expression. One patient with a malignant tumour did not have any overexpression of FRa and 
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subsequently no fluorescence could be detected. No fluorescent signal was detected in the 
patients with benign tumours. The fluorescent dye FITC has an excitation wavelength of 495 and 
emits light at 520 nm. These are suboptimal fluorescent properties for clinical use. Nevertheless, 
this study provides the first in-human proof-ofprinciple of intraoperative tumour-specific 
fluorescence imaging for ovarian cancer. Although one study comprised the clinical use of a 
tumourspecific fluorescent probe, several clinical studies reported the use of ICG in the real-time 
NIR fluorescence visualization of hepatobiliary cancer. Intravenously injected ICG is excreted 
exclusively by the liver. Initially, Gotoh et al. (2009) used ICG for intraoperative NIR-fluorescent 
cholangiography. During cholangiography procedures in patients with hepatocellular carcinoma 
(HCC), they discovered that HCCs fluoresced strongly. The hypothesis was that cancerous tissue 
retained intravenously injected ICG through a disorder in biliary excretion. Intraoperative 
visualization of hepatobiliary cancer could be of great value because the intrahepatic recurrence 
rates after resection of CRC metastases range from 11% to 37.5% (Schaafsma et al., 2011b). The 
current procedure comprises preoperative diagnostic imaging with subsequent intraoperative 
ultrasound imaging. However, 3–17% of HCCs and metastases of CRC can be detected only by 
microscopic examination (Ishizawa et al., 2009). Gotoh et al. (2009) included ten patients who 
underwent curative hepatic resection for HCC. All of the primary tumours were identified with a 
NIR fluorescence imaging system and could be removed radically guided by the fluorescent 
signal. In four cases (40%) new HCC nodules were detected that could not be detected by eye, 
palpation, or with intraoperative ultrasonography. Soon afterward, several other studies reported 
the use of ICG in intraoperative NIR fluorescence imaging of hepatobiliary cancer (Harada et al., 
2010; Ishizawa et al., 2009; Uchiyama et al., 2010, 2011). Imaging of ICG has to occur at least 24 
h after injection. In this window, healthy liver parenchyma will wash out ICG and adequate TBRs 
can be obtained. The relatively unfavorable optical properties of the liver allow a limited 
penetration depth of NIR-fluorescent signal (Ishizawa et al., 2009). Ishizawa et al. (2009) 
described three fluorescent patterns on the cut surfaces of the surgical specimens: a total 
fluorescent type, a partial fluorescent type, and a rim fluorescent type. They suggested that, in 
contrast to well-differentiated HCC, poorly differentiated HCC and CRC metastases produce rim 
fluorescence because of biliary excretion disorders in the surrounding noncancerous liver tissue 
that have been compressed by the tumour (Ishizawa et al., 2009). So far, promising results were 
reported using ICG in realtime NIR fluorescence imaging of hepatobiliary cancer. Due to the 
limited penetration depth of fluorescent signal, ultrasound is still required to detect tumours 
located at greater depth. Nevertheless, real-time NIR fluorescence imaging is a promising tool for 
the detection of superficially located tumours of the liver and guidance of their resection. 
 
 
  
 
4.20.4.3 Conclusion and Future Directions 
 
In cancer surgery, radical resection of the tumour is pivotal for the prognosis of the patient. 
Delineation of the tumour border and assessment of the tumour-free margin are essential to 
reach complete resection of the tumour. NIR fluorescence imaging could be of great value in this 
field of oncological surgery. The ideal probe would require the accurate size to penetrate tumour 
tissue and a high affinity for a target that is only expressed in tumours. Finally, excretion should 
be quick enough to rapidly obtain high contrast images. The intra- and intertumoural 
heterogeneity challenges the quest to find the optimal probe (Gerlinger et al., 2012; Marusyk et 
al., 2012). Targeting strategies that target the universal hallmarks of cancer could circumvent the 
difficulty of heterogeneity. Two promising universal hallmarks that have been explored as a 
possible target are tumour angiogenesis and degradation of the extracellular matrix (Keereweer et 
al., 2011b, 2012b). Nonetheless, the intra- and intertumoural heterogeneity could also lead to a 
personal approach of probe selection. Depending on the characteristics of a single tumour, a 
cocktail of probes could be selected to target a tumour in its best way. Recently, some interesting 
targets have been reported. Increased expression of the follicle-stimulating hormone (FSH) 
receptor has been found in tumour blood vessels in a great variety of tumours (Radu et al., 2010). 
The increased expression was found at the periphery of the tumours in a layer of approximately 
10 mm. Since the FSH receptor is only expressed on the granulosa cells of the ovary and sertoli 
cells of the testis in adult humans, high specificity of the probe could be expected. Although the 
pathogenic mechanism of increased FSH receptor expression is yet unknown, the FSH receptor 
holds great promise as a target for NIR fluorescence imaging. Tissue optical properties and 
autofluorescence can have great influence on the final image that is presented to the surgeon. In 
the NIR- fluorescent range, the absorbance is limited compared to visible light. Nevertheless, the 
surgeon needs to be aware of the limitation in depth. With 3 cm of adipose tissue overlying the 
tissue of interest no fluorescent signal will appear. Highly vascularized tissue, containing many 
absorbers, will mask the tissue of interest in a greater extent than overlying tissues that are 
composed of less-absorbing molecules. Moreover, the possible randomization of photons due to 
scattering can result in a decrease in accuracy of probe localization. As NIR fluorescence imaging 
is going toward clinical application, this is essential knowledge for oncological surgeons. 
Enriched by basic knowledge of fluorescence, surgeons will be able to give the accurate 
interpretation of NIR-fluorescent images presented during operation. NIR fluorescence imaging 
can provide the surgeon with real-time imaging of the tumour. When the tumour is located, the 
fluorescent signal can be excised until no signal is detected any longer. Pre- and intraoperative 
diagnosis of small tumours and metastatic nodules remains challenging. As in SLN mapping, the 
use of multimodal tracers that are both radioactive and fluorescent could be of interest to 
overcome these challenges (Azhdarinia et al., 2012). The combination of tracers enables 
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fluorescence imaging for ovarian cancer. Although one study comprised the clinical use of a 
tumourspecific fluorescent probe, several clinical studies reported the use of ICG in the real-time 
NIR fluorescence visualization of hepatobiliary cancer. Intravenously injected ICG is excreted 
exclusively by the liver. Initially, Gotoh et al. (2009) used ICG for intraoperative NIR-fluorescent 
cholangiography. During cholangiography procedures in patients with hepatocellular carcinoma 
(HCC), they discovered that HCCs fluoresced strongly. The hypothesis was that cancerous tissue 
retained intravenously injected ICG through a disorder in biliary excretion. Intraoperative 
visualization of hepatobiliary cancer could be of great value because the intrahepatic recurrence 
rates after resection of CRC metastases range from 11% to 37.5% (Schaafsma et al., 2011b). The 
current procedure comprises preoperative diagnostic imaging with subsequent intraoperative 
ultrasound imaging. However, 3–17% of HCCs and metastases of CRC can be detected only by 
microscopic examination (Ishizawa et al., 2009). Gotoh et al. (2009) included ten patients who 
underwent curative hepatic resection for HCC. All of the primary tumours were identified with a 
NIR fluorescence imaging system and could be removed radically guided by the fluorescent 
signal. In four cases (40%) new HCC nodules were detected that could not be detected by eye, 
palpation, or with intraoperative ultrasonography. Soon afterward, several other studies reported 
the use of ICG in intraoperative NIR fluorescence imaging of hepatobiliary cancer (Harada et al., 
2010; Ishizawa et al., 2009; Uchiyama et al., 2010, 2011). Imaging of ICG has to occur at least 24 
h after injection. In this window, healthy liver parenchyma will wash out ICG and adequate TBRs 
can be obtained. The relatively unfavorable optical properties of the liver allow a limited 
penetration depth of NIR-fluorescent signal (Ishizawa et al., 2009). Ishizawa et al. (2009) 
described three fluorescent patterns on the cut surfaces of the surgical specimens: a total 
fluorescent type, a partial fluorescent type, and a rim fluorescent type. They suggested that, in 
contrast to well-differentiated HCC, poorly differentiated HCC and CRC metastases produce rim 
fluorescence because of biliary excretion disorders in the surrounding noncancerous liver tissue 
that have been compressed by the tumour (Ishizawa et al., 2009). So far, promising results were 
reported using ICG in realtime NIR fluorescence imaging of hepatobiliary cancer. Due to the 
limited penetration depth of fluorescent signal, ultrasound is still required to detect tumours 
located at greater depth. Nevertheless, real-time NIR fluorescence imaging is a promising tool for 
the detection of superficially located tumours of the liver and guidance of their resection. 
 
 
  
 
4.20.4.3 Conclusion and Future Directions 
 
In cancer surgery, radical resection of the tumour is pivotal for the prognosis of the patient. 
Delineation of the tumour border and assessment of the tumour-free margin are essential to 
reach complete resection of the tumour. NIR fluorescence imaging could be of great value in this 
field of oncological surgery. The ideal probe would require the accurate size to penetrate tumour 
tissue and a high affinity for a target that is only expressed in tumours. Finally, excretion should 
be quick enough to rapidly obtain high contrast images. The intra- and intertumoural 
heterogeneity challenges the quest to find the optimal probe (Gerlinger et al., 2012; Marusyk et 
al., 2012). Targeting strategies that target the universal hallmarks of cancer could circumvent the 
difficulty of heterogeneity. Two promising universal hallmarks that have been explored as a 
possible target are tumour angiogenesis and degradation of the extracellular matrix (Keereweer et 
al., 2011b, 2012b). Nonetheless, the intra- and intertumoural heterogeneity could also lead to a 
personal approach of probe selection. Depending on the characteristics of a single tumour, a 
cocktail of probes could be selected to target a tumour in its best way. Recently, some interesting 
targets have been reported. Increased expression of the follicle-stimulating hormone (FSH) 
receptor has been found in tumour blood vessels in a great variety of tumours (Radu et al., 2010). 
The increased expression was found at the periphery of the tumours in a layer of approximately 
10 mm. Since the FSH receptor is only expressed on the granulosa cells of the ovary and sertoli 
cells of the testis in adult humans, high specificity of the probe could be expected. Although the 
pathogenic mechanism of increased FSH receptor expression is yet unknown, the FSH receptor 
holds great promise as a target for NIR fluorescence imaging. Tissue optical properties and 
autofluorescence can have great influence on the final image that is presented to the surgeon. In 
the NIR- fluorescent range, the absorbance is limited compared to visible light. Nevertheless, the 
surgeon needs to be aware of the limitation in depth. With 3 cm of adipose tissue overlying the 
tissue of interest no fluorescent signal will appear. Highly vascularized tissue, containing many 
absorbers, will mask the tissue of interest in a greater extent than overlying tissues that are 
composed of less-absorbing molecules. Moreover, the possible randomization of photons due to 
scattering can result in a decrease in accuracy of probe localization. As NIR fluorescence imaging 
is going toward clinical application, this is essential knowledge for oncological surgeons. 
Enriched by basic knowledge of fluorescence, surgeons will be able to give the accurate 
interpretation of NIR-fluorescent images presented during operation. NIR fluorescence imaging 
can provide the surgeon with real-time imaging of the tumour. When the tumour is located, the 
fluorescent signal can be excised until no signal is detected any longer. Pre- and intraoperative 
diagnosis of small tumours and metastatic nodules remains challenging. As in SLN mapping, the 
use of multimodal tracers that are both radioactive and fluorescent could be of interest to 
overcome these challenges (Azhdarinia et al., 2012). The combination of tracers enables 
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preoperative localization with nuclear imaging, intraoperative detection of tumours using a 
gamma camera and intraoperative visualization, and real-time resection of the tumour with NIR 
fluorescence. The step toward clinical application of tumour-specific NIR fluorescence imaging 
has to be made yet. Although a variety of monoclonal antibodies are in clinical use (e.g., 
cetuximab, panitumumab, trastuzumab), apart from ICG, no organic fluorophores are FDA 
proved yet. The FDA approval will give rise to a major increase in clinical research and will 
answer whether or not and to what extent the prognosis of cancer patients will increase with the 
use of real-time NIR fluorescence imaging. Although we are waiting for the clinical use of 
NIRfluorescent probes, the quest to find efficient probes will continue. Future preclinical studies 
will focus on the exploration of new hallmarks of cancer and the improvement of (dual labeled) 
probes targeting known hallmarks. Clinical research needs to focus on the patients’ benefit of this 
promising modality that gives visibility to the oncological field. 
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ABSTRACT 
 
Purpose 
To provide a clear overview of the various components that play an essential role in the 
conundrum of optical imaging for application in cancer surgery. 
 
Background 
Optical image-guided cancer surgery is a promising technique to adequately determine tumour 
margins by tumour-specific targeting, potentially resulting in complete resection of tumour tissue 
with improved survival. However, identification of the photons coming from the fluorescent 
contrast agent is complicated by autofluorescence, optical tissue properties, and accurate 
fluorescent targeting agents and imaging systems. These factors all have an important influence 
on the image that is presented to the surgeon.  
 
Results 
Considering the clinical consequences at stake, it is a prerequisite to answer the questions that are 
essential for the surgeon. What is optical image-guided surgery and how can it improve patient 
care? What should the oncologic surgeon know about the fundamental principles of optical 
imaging to understand which conclusions can be drawn from the images? And how do the 
limitations influence the clinical decision-making? This manuscript discusses these questions and 
provides a clear overview of the basic principles and practical applications. 
 
Conclusion 
Although there are limitations to the intrinsic capacity of the technique, when practical and 
technical surgical possibilities are considered, optical imaging can be a very powerful 
intraoperative tool in guiding the future oncologic surgeon towards radical resection and optimal 
clinical results. 
  
 
Introduction 
 
For cancer surgery with curative intentions, radical resection (i.e., removal of all cancer cells) is a 
sine qua non. To achieve this, the surgeon has to adequately assess the tumour resection margin 
during the operation. Optical molecular imaging using near-infrared (NIR) fluorescence 
introduces a revolutionary new approach to address this basic challenge in surgical oncology (1–
3). The field of optical imaging emerged in the early 20th century with the observation of 
porphyrin fluorescence in certain tumours, but a lack of fundamental knowledge and suitable 
optical equipment prevented further development at the time (4). The finding that photons in the 
NIR range (650–900 nm) travel through tissue much deeper than photons in the visible light 
range (5) was essential for the advancement of optical imaging toward clinical practice, and 
further development gained momentum over the past decade (1, 6). To use optical imaging for 
visualization of cancer, fluorescent agents are injected that emit light in the NIR range and are 
tumour specific using a variety of targeting strategies (2). Because the human eye is not sensitive 
for light in the NIR region, dedicated camera systems are required to detect the fluorescence 
emission from these molecules (2). With real-time intraoperative fluorescence imaging of tumour 
margins, the technique promises to guide the oncologic surgeon toward optimal radical resection 
and clinical results. Preclinically, optical imaging has been used in tumour identification, image-
guided resection, therapy monitoring, and detection of sentinel lymph nodes. Because  
tumourspecific agents were not yet approved for clinical use, the first clinical studies were 
conducted using nonspecific fluorescent agents that had long been approved for different 
applications and could therefore be used for sentinel lymph node mapping (6, 7). Clinical trials of 
tumour imaging using indocyanine green have been reported in hepatobiliary and colorectal 
cancer (8). Recently, a milestone step was completed when the first-in-human trial using tumour-
specific targeting was reported (9), marking the beginning of a new phase of optical image-guided 
surgery. However, although it is very likely that the technique will deliver an important 
contribution to surgical oncology, this approach has fundamental limitatioins that influence the 
ability to differentiate the targeted tissue from its surroundings. Nowthat the first clinical trial has 
been reported, the group of oncologic surgeons that gets acquainted with the flourishing field of 
optical image-guided surgery is increasing day by day, with clinical consequences at stake. As we 
show in this review, it is essential for the clinician to understand which phenomena occur when 
photons travel through tissues and how these phenomena influence the optical image that is 
acquired. We therefore believe that it is now, more than ever, of paramount importance to 
provide the surgical oncologist a clear overview of the basic principles of optical image-guided 
surgery to be able to understand how these limitations influence the sensitivity of this technique. 
Awareness of these limitations and focusing research on solving these challenges are of utmost 
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importance for proper implementation and evaluation of the clinical value of this new 
technology. 
 
 
The basic principle of fluorescence imaging 
 
The geometric principle of fluorescence imaging is illustrated in Fig. 1A. A light source is 
required that sends out a bundle of light with a specific wavelength that is able to excite the 
fluorophore (i.e., excitation photons). Because the targeted fluorophore is located under the 
tissue surface, this excitation light has to enter and travel through tissue to reach the fluorophore. 
Light entering the tissue is partly influenced by reflection and refraction at the tissue surface. The 
direction of photons that travel through the tissue can be changed due to scattering. In addition, 
photons can be absorbed by various components in the tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1; Geometric and basic principle of fluorescence imaging. A, light of the appropriate excitation wavelength is 
selected using a filter (Fex), which is located between a light source and the tissue. The excitation light travels through 
the tissue and is absorbed by a fluorophore, which subsequently emits light of a different wavelength. A small portion 
of this emitted light will exit the tissue and can be detected with a camera. A filter (Fem) is placed in front of the 
camera, which allows only the emitted light to pass into the camera. B, absorbed light by the fluorophore instigates an 
electron (e) in the ground state toward an electronically excited state. Upon return to the ground state, the fluorophore 
emits a photon. The wavelength of this emitted photon is specific for the fluorophore. Fex, excitation filter; Fem, 
emission filter. 
 
Only when such a component is a fluorophore, which can be either an intrinsic tissue 
component (i.e., autofluorescence) or an injected external fluorescent agent, absorption of a 
photon results in a gain in energy of the fluorophore, which then enters an excited state (Fig. 1B). 
 
The electrons remain in this state for about 10 _8 seconds depending on the molecule, which is 
called the lifetime of the fluorophore. After this phase, the system returns to its ground state and 
emits the photon, which could be heading into all directions (Fig. 1B). The change in energy 
between the absorbed and the emitted photon results in a change in wavelength. This shift of 
shorter wavelengths (higher energy) of the absorption spectrum to longer wavelengths (lower 
energy) of the emitted fluorophores is called the Stokes shift. After excitation of the fluorophore, 
emission photons will also be influenced by scattering and absorption, and the photons that 
reach the tissue surface will subsequently be influenced again by reflection and refraction at the 
surface.  
 
Finally, in a clinical geometry, only part of these photons can eventually be detected by the 
camera system. Although optical imaging is based on the detection of photons, Fig. 2 illustrates 
that the path that photons travel through the imaged tissue is influenced by optical properties of 
the components in the tissue (i.e., absorption and scattering). As a result, fluorescence 
images will display intensities that are strongly influenced by varying absorption properties of the 
tissue and the images may be blurred due to scattering of light. The following paragraphs explain 
in detail how these phenomena influence the acquired image. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2; Light propagation through tissue. Light travelling through tissue is subject to reflection, scattering, and 
absorption. 
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fluorophore (i.e., excitation photons). Because the targeted fluorophore is located under the 
tissue surface, this excitation light has to enter and travel through tissue to reach the fluorophore. 
Light entering the tissue is partly influenced by reflection and refraction at the tissue surface. The 
direction of photons that travel through the tissue can be changed due to scattering. In addition, 
photons can be absorbed by various components in the tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1; Geometric and basic principle of fluorescence imaging. A, light of the appropriate excitation wavelength is 
selected using a filter (Fex), which is located between a light source and the tissue. The excitation light travels through 
the tissue and is absorbed by a fluorophore, which subsequently emits light of a different wavelength. A small portion 
of this emitted light will exit the tissue and can be detected with a camera. A filter (Fem) is placed in front of the 
camera, which allows only the emitted light to pass into the camera. B, absorbed light by the fluorophore instigates an 
electron (e) in the ground state toward an electronically excited state. Upon return to the ground state, the fluorophore 
emits a photon. The wavelength of this emitted photon is specific for the fluorophore. Fex, excitation filter; Fem, 
emission filter. 
 
Only when such a component is a fluorophore, which can be either an intrinsic tissue 
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surface.  
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tissue and the images may be blurred due to scattering of light. The following paragraphs explain 
in detail how these phenomena influence the acquired image. 
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What happens when light travels through tissue? 
 
Absorption 
All tissues contain components that can absorb photons that travel through them. The 
composition of these components varies between different tissue types and organs, but also 
within these tissues, and may vary in time (10). In general, the most relevant absorbers of 
photons are water, lipids, oxyhemoglobin, and deoxyhemoglobin (Fig. 3A) (11). Blood is the 
main absorber in the visible region, and the absorption of light by blood is the highest in the 
blue-green region. This fact can be illustrated by illuminating the human skin with white light. 
Because of the absorption of photons with shorter wavelengths, a reddish reflection returns from 
the skin. In this way, absorbers influence the color of the light that exits imaged tissues. In the 
NIR range, the absorbance per volume of these components is much lower than in other parts of 
the spectrum, allowing for deeper penetration of photons into the tissue (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3; Absorption of light. A, absorption of light by various components varies over the wavelength spectrum, 
resulting in an optimal window for fluorescence imaging in the NIR light region between 650 and 900 nm. Figure 3A is 
reprinted from ref. 11, with permission, from John Wiley & Sons. B, penetration of light range from 0.5 mm to more 
than 10 mm contingent to the wavelength. OxyHb, oxygenated hemoglobin; DeoxyHb, deoxygenated hemoglobin. 
 
Scattering 
Next to absorption of the photon, a change in photon direction can occur, an effect known as 
scattering (Fig. 4). In most parts of the visible and NIR region, scattering events occur much 
more frequently than absorption events. Even though a forward direction of scattering photons 
is most likely to occur in tissues, the accumulation of multiple consecutive scatter events will 
result in a gradual randomization of the propagation direction (i.e., diffuse light, Fig. 4; ref. 12). 
Randomization of the direction of light reduces the signal strength as well as the accuracy of 
determination of the source localization. However, scattering can also have a positive effect on 
the fluorescence signal intensity because of its effect on the excitation light. The photons that 
 
excite the fluorophore follow a similar contorted light path as the emission light. In highly 
scattering tissue, the contorted light path causes retention of photons in that specific area. In 
other words, in a highly scattering medium, the photons bounce around locally for a longer time, 
increasing the chance for a fluorescence event. Consequently, there can be increased fluorescence 
intensity in tissues with more scattering compared with tissues with less scattering (13). The net 
effect of scattering on fluorescence imaging depends on the exact optical properties of the tissue 
at hand.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4; Photons change direction multiple times when traveling through tissue. In the case of forward scatter, a 
photon travels more or less in the same direction before and after the scattering event. In the case of backscatter, the 
photon will end up traveling in the opposite direction after the scattering event. During fluorescence imaging, the 
direction of both the excitation light and the emitted light is randomized due to scattering. Only a small portion of the 
excitation light will reach a fluorophore, and only the camera will capture a small portion of the emitted light. As a 
result, it is often difficult to pinpoint the exact origin of the detected fluorescent signal. 
 
Influence of optical properties on light penetration depth 
Scattering and absorption coefficients vary between locations and tissues due to the different 
components within the heterogeneous tissue. Importantly, the influence of these phenomena on 
the fluorescence signal will be higher when fluorescent light has to emerge from larger tissue 
depths and consequently has to pass more absorbers and scattering events. In the visible light 
region, absorption by biologic chromophores limits the penetration depth to a few millimeters 
with a maximum of 10 millimeters. Because of less absorption and scattering, penetration depth 
is 
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Influence of optical properties on light penetration depth 
Scattering and absorption coefficients vary between locations and tissues due to the different 
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the fluorescence signal will be higher when fluorescent light has to emerge from larger tissue 
depths and consequently has to pass more absorbers and scattering events. In the visible light 
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increased to more than a centimeter in the NIR region (14, 15); however, this measurement 
strongly depends on the type of tissue (refs. 1, 3, 16; Fig. 5). 
 
 
Figure 5; Effect of optical tissue properties during real-time intraoperative optical imaging of liver metastases in  
humans. The consequences of absorption and scattering on the image are essential for understanding the limitations of 
optical image-guided surgery: At the surface, fluorescent agents will appear as a bright and sharply delineated spot. 
However, the target will always be surrounded by a halo of fluorescent light that was directed into the tissue after 
emission, scattered around locally, and emitted from the surface at some distance from the target location. Moreover, 
due to absorption and scattering, an identical fluorescent agent that is located deeper within the tissue will have lower 
signal intensity and will be imaged as an indistinct blob. An example is shown of a liver metastasis that is delineated by 
fluorescence signal (A–C). When a thick layer of greater omentum covers the area of interest, fluorescence signal is not 
detected (D–F). A second liver metastasis is indicated in a different patient (G–I). However, when the liver is flipped 
around and the opposite side is imaged, high absorption of the liver that is saturated with blood results in an indistinct 
fluorescent blob (J–L). 
 
 
 
Reflection and refraction 
As imaging during surgery always focuses on a surface, the mismatch between the indices of 
refraction of tissue and air is unavoidable, resulting in a change in direction of the photons. This 
mismatch in index of refraction causes reflections to occur at the surface. The excitation light will 
be partially reflected from the surface, like the sun on a water surface. When the light is nearly 
perpendicular to the surface of the tissue, the surface reflection is not more than a few percent. 
However, emitted fluorescent light that is generated inside the tissue is diffuse and partly reaches 
the surface under large angles, resulting in complete reflection within the tissue. This internal 
diffuse reflection coefficient at the surface can be in the order of 50%. Consequently, the emitted 
fluorescent light is even more diffuse, and the amount of light that escapes the surface and can 
be detected by the fluorescence camera is further decreased. 
 
 
Fluorescence imaging and autofluorescence 
The goal of fluorescence imaging is to detect a target by its specific fluorescence signal. 
Detection of the fluorescent signal of the targeted fluorophore is hampered because all cells 
contain various endogenous fluorophores that become fluorescent when excited by UV, visible, 
or NIR radiation of suitable wavelength. This intrinsic fluorescence of the tissue induces a 
nonspecific background signal. The number of endogenous fluorophores varies strongly between 
tissue types. Moreover, the autofluorescence can change in time because of bleaching of the 
endogenous fluorophores and because some of the endogenous fluorophores are related to 
metabolism (e.g., NADH, NAD, FAD, and FADH). Because we can see cancerous lesions with 
our eyes, the optical properties of these lesions are changed by definition, and a difference in 
autofluorescence signal compared with the surroundings can be detected. This effect has been 
used for autofluorescence-guided surgery (17). However, due to the aforementioned effects, 
"tumourspecific" autofluorescence signals can vary over time, making it an unreliable target. 
Furthermore, other benign visible changes (e.g., scar formation) also result in a change in 
autofluorescence, limiting the specificity of this technique (18). Most importantly, despite positive 
correlations that have been reported in a number of studies that use autofluorescence to detect 
and remove the tumour (17), it is not clear which biologic aspects are responsible for the change 
in autofluorescence signal in the imaged lesions. Studies to assess these aspects are compromised 
because of artifacts as a result of color changes in cancer tissue (18). The surgeon should 
therefore approach changes in autofluorescence with the same level of uncertainty as visible clues 
of cancerous tissue. If high correlation of autofluorescence and tumour tissue is consistently 
reported, they can be used to aid the surgeon in assessing the tumour margins but should not be 
considered as tumour-specific proof of tumour margins. As a good alternative, a target-specific 
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agent that contains a fluorophore is usually injected intravenously. Now that we understand how 
optical properties can influence the optical path of the photon, we are confronted with a second 
challenge: How can we determine if the photon that we detect has been excited by the targeted 
fluorophore, and not by its surrounding autofluorescent components? For the targeted cancer 
cells to be detected, the signal of the target-specific fluorescence agent must be significantly 
higher than the nonspecific autofluorescence. Although autofluorescence is much lower when 
NIR light is used, the signal-to-background ratio (SBR) must be sufficient to distinguish the 
photons of the target-specific fluorescent agent from the autofluorescence signal. 
 
 
What are the consequences of these effects for fluorescence imaging of cancer? 
 
We have now set the stage for optical imaging in tissues and gained a clear picture of the 
problems that we face when we aim to detect a minimal amount of tumour-specific fluorescence 
agent within this diffuse heterogeneous medium containing absorbers, scatter events, and 
endogenous fluorophores. First, the fluorescence intensity is not only influenced by the 
concentration and fluorescence quantum yield of the fluorescent agent but also by the tissue 
optical properties that are involved. For example, as a result of absorption by blood, fluorescence 
signals in organs with high blood volumes, such as the liver (19) or highly vascularized tumours, 
or in tumour cells that co-opt host vessels (20) may appear lower than surrounding less-
absorbing tissue, even if they contain larger amounts of contrast agent compared with the 
surrounding tissue (21). Similarly, less absorbing lesions (e.g., cysts and lymph nodes) may seem 
brighter in a heterogeneous environment. The variability in absorption and scattering between 
different tissues or even tissue components should be taken into account during the process of 
image-guided surgery. Second, intraoperative camera systems will not only detect the 
fluorescence signal of the fluorescent agent but also the autofluorescence in the scanned region, 
and therefore a sufficient SBR is required. At present, various strategies are being evaluated that 
represent attempts to improve adequate identification and quantification of the targeted photons. 
 
 
Strategies to reduce the influence of absorption and scattering on the image 
 
With the state-of-the-art technological advancements, it remains impossible to determine all 
absorbers and scatter events within a diffuse, inhomogeneous medium. However, calculation 
methods have been developed that try to estimate the perturbation caused by optical tissue 
properties and improve the image by partly correcting for these properties (14). An intraoperative 
fluorescence imaging system has been developed that implements such a correction scheme for 
 
light intensity variation in tissues (21). Improved accuracy was shown within phantoms and 
postmortem tissues, independently of optical property variation in tissues. At a 5-fold change of 
absorption variation within the fluorescent lesions, quantification errors were reduced from 25% 
in uncorrected images to 8% using the correction scheme (21). A second new technology being 
investigated in this field is fluorescence differential path length spectroscopy, which determines 
fluorophore concentration based on the fluorescence intensity corrected for absorption (22). 
This facilitates quantitative concentration measurements even for strong variations in either 
background absorption or scattering. However, currently this method can only be conducted 
using fiber-optic measurement at a single point. An imaging version and subsequent 
intraoperative applications have not been developed yet. Finally, tomographic reconstruction 
techniques (23), Raman spectroscopy (24), and photoacoustic imaging (12, 25) may play 
important roles in the future, although currently they are not suited for real-time imaging in the 
surgical theater. Raman spectroscopy is based on inelastic scattering: the effect on the frequency 
of excitation photons that changes upon interaction with tissue, which is independent of optical 
tissue properties or autofluorescence (24, 26). In surface-enhanced Raman spectroscopy (SERS), 
tumour-specific nanobodies are injected that are able to increase the intrinsically very low Raman 
effect, thereby improving detectability. Promising preclinical results of brain tumour resection 
guided by SERS have been reported (27). In photoacoustic imaging (also referred to as 
optoacoustic imaging), thermoelastic expansion of molecules resulting from laser pulse 
irradiation causes emission of acoustic waves that can be measured by photoacoustic 
spectroscopy. The resolution in photoacoustic imaging is not limited by tissue scattering but by 
the attenuation of acoustic frequencies by tissue (12, 25). This technique improves deep-tissue 
imaging but is less suitable for image-guided surgery. 
 
 
Strategies to distinguish the target-specific fluorescence signal from autofluorescence 
 
Two methods are now under investigation that represent attempts to separate the target-specific 
fluorescence signal from the nonspecific autofluorescence. The first is based on differences in 
the fluorescence spectrum between photons from these two fluorescent sources (i.e., spectral 
unmixing), and the second method exploits differences in the fluorescence lifetime of the 
fluorophores (i.e., lifetime imaging). The concept of spectral unmixing is based on the 
"signature" emission intensity that each fluorophore has at certain wavelengths, providing the 
fluorophore with its own specific emission spectrum (28). Using spectral unmixing, the signal is 
decomposed into a collection of predefined spectra that is used to determine the individual 
contribution of each fluorophore. Using calculation models combined with the fluorophore-
specific emission spectrum as reference (i.e., linear unmixing), the contribution of each 
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fluorophore in a total fluorescent signal can be extracted (29). When spectral signatures of the 
fluorophore of interest and the autofluorescence are known, unmixing these specific fluorescence 
spectra may result in a more accurate SBR. The first-inhuman trial on intraoperative tumour-
specific fluorescence imaging was conducted using a camera system that was based on spectral 
unmixing technology (9, 21). There are, however, fundamental problems with this approach. 
Linear unmixing is based on the assumption that the measured spectrum consists of the sum of 
the fluorescence spectra of all the components in the tissue, that is, linear mixing. As mentioned 
earlier, inhomogeneous optical properties influence the path that photons travel through the 
imaged tissue and therefore not only put their own signatures on the fluorescence spectrum but 
may also do so nonlinearly owing to the inhomogeneous nature of tissue. Furthermore, the 
unmixing procedure is a very complex process that requires all components contributing to the 
spectrum to be known, as well as all of their specific "signature" spectra, which also need to be 
sufficiently distinctive from one another. The second method, fluorescence lifetime imaging, 
distinguishes individual fluorophores by their specific temporal decay after excitation. This 
fluorescence decay (i.e., lifetime) is a fluorophore-specific characteristic that is not influenced by 
the local concentration of fluorophores, the optical path, the local excitation intensity, or the 
local fluorescence detection efficiency. To acquire the characteristic decay curves, a picosecond 
laser pulse is used for excitation and fluorescence is measured as a function of time. On the basis 
of the specific lifetime of the fluorophores, the target-specific fluorescence signal can be 
distinguished from the nonspecific autofluorescence. In addition, the temporal response at which 
photons emerge from the tissue can be measured (i.e., time-domain imaging), which is used to 
estimate the concentration and depth of the fluorescent source. Lifetime imaging requires  
specific conditions in terms of pulsed excitation and data capturing with complex data 
processing, which currently makes it a time consuming technique. Although intraoperative 
lifetime based techniques are being developed at a strong pace and hold promising advantages, it 
will take some time before they can be used in a real-time intraoperative setting where mobility of 
the equipment and speed of data processing and interpretation are of the essence (30). 
 
 
What is required for a target-specific fluorescence image? 
 
So far, we have assumed that the fluorescent agent has been able to specifically target the tissue 
of interest with subsequent colocalization between the fluorescent signal and tumour cells. 
However, to gain a complete insight into the different phenomena that can influence the optical 
image, it is necessary to understand the challenges of tumour-specific targeting. On the basis of 
the hallmarks of cancer (31), a growing variety of tumour-specific targets are available for 
imaging of cancer (2). The efficiency of target-specific agents to reach their intended target is 
 
defined by many variables, including affinity of the agent and abundance of the target receptors 
or epitopes (16). To achieve target-specific fluorescence imaging, the contrast agent has to be 
delivered to the target, requires adequate contact time with the target for binding to occur, and 
has to be retained by the target while nonbound agents are cleared from the circulation (10). It 
has been reported that at saturating doses of the agent, high-affinity antibody uptake is 
dependent on antigen expression levels. However, at subsaturating doses, the signal is generally 
limited by delivery of the agent (32). For the agent to be effectively delivered to the target, many 
barriers in the human body have to be passed. Next to inhibitor proteins present in plasma that 
can non-specifically bind to the agent (1), walls of blood vessels provide a first barrier for drug 
delivery to targeted tumour tissues. In most cases, abnormal neovascularization of the tumour 
occurs [i.e., enhanced permeability and retention (EPR) effect] resulting in leaky tumour blood 
vessels (33). As a result, macromolecular drugs can traverse the endothelium of these leaky blood 
vessels and passively accumulate in the interstitium of tumour tissues (33). However, the EPR 
effect is largely dependent on the size of the agent; larger agents are less efficient in crossing the 
endothelial barrier (34). Tumour growth beyond the size of approximately 1 mm is dependent on 
oxygen and supply of nutrients and therefore requires angiogenesis (35). However, in smaller 
lesions, the angiogenic switch may not have occurred and drug delivery could be hampered due 
to the lack of adequate vascularization. In other cases, tumour cells may grow alongside pre-
existent host vasculature, a process known as vessel co-option (20). In these cases, in which 
angiogenesis-directed targeting may not yet be possible, indirect indicators of tumour growth 
could be useful for tumour detection, even in the earliest stages of carcinogenesis. For example, 
NIR fluorescence agents that detect proteases that are involved immigration of tumour cells and 
degradation of the extracellular matrix can allow for imaging of the invasive tumour front (36–
38), and preneoplastic lesions in Barrett esophagus can be identified by targeting changed 
patterns of lectin binding (39). Once extravascular, two barriers for adequate binding of the agent 
remain. First, the agent has to cross extracellular matrix tissue surrounding the target cells (33). 
At this point, diffusion into the tumour is sometimes impeded by high hydrostatic pressure of 
many solid tumours, preventing homogeneous infiltration of the agent (1). Second, binding of 
the agent to specific epitopes of the cancer cell has to occur, and internalization of the agent can 
further amplify the fluorescence signal (23, 40, 41). Therefore, the cellular basement membrane is 
the third barrier, which can be passed using the transporter system of the cell by receptor-
mediated endocytosis (33). Finally, clearance of non-bound agent from the circulation is required 
to provide sufficient SBRs. This occurs through the liver (i.e., excretion into bile and feces) 
and/or the kidney (i.e., excretion into urine). Both the route of clearance and the clearance rate 
are important determinants for the blood half-life time and consequently the background signal 
and optimal imaging time of contrast agents (40). 
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How relevant is all this for the clinical practice of surgical oncology? 
 
Optical imaging is a complicated process. To adequately interpret the intraoperative fluorescent 
image of the tumour that is presented, the surgeon should comprehend that the target-specific 
fluorescent agent had to get to and stay at the tumour, that part of the signal was reduced and 
distorted by absorbers and scatter events, and that the signal had to be subtracted from its 
autofluorescent surroundings. Considering all these influences that could hamper detection of 
cancer cells that are located under the surface, the additional value of NIR fluorescence imaging 
over conventional surgery could be questioned. After all, after a mere 3 decades of extensive 
research, the fundamental principles of optical imaging still leave room for error, and it currently 
seems that this approach will never be unambiguous. To determine the additional value of 
intraoperative optical imaging, we need to ask ourselves what the fundamental purpose of this 
tool should be for surgical oncology. In essence, the goal of surgery is to remove all cancer cells 
while minimizing damage to surrounding healthy tissues. Considering the small size of a single 
cancer cell or group of cells, the limited target epitopes available for the fluorescent agent and the 
optical tissue properties and autofluorescence, detection of the last cancer cells under a surface 
will not always be possible. Nevertheless, it is very likely that the current technique of optical 
imaging, with its limitations, will offer improvement of the conventional surgical practice to 
successfully treat the patient and could provide a final solution to the conundrum of irradical 
resection. The most obvious reason is that, although there are limitations when considering the 
cellular level, optical imaging allows for a more detailed delineation of the tumour margins than 
the conventional practice of assessment by palpation and visual aspects of the tumour. It was 
repeatedly shown in animal models that tumour margins can be clearly demarcated by optical 
imaging (10, 38, 42). Consequently, the surgeon can resect the tumour based on these images 
with the required tumour-free margin outside the fluorescent tissue. Moreover, in some cases 
that have thin tumour strands that are invisible to the naked eye, a tumourfree margin of up to 
several centimeters is required for local control using conventional surgical practice. Although 
effects of scattering could result in a fluorescent halo of up to several millimeters under certain 
conditions, detection of these tumour strands using optical imaging would still largely reduce the 
need of these large tumour-free margins, resulting in improved postoperative functionality. 
Although yet to be proven in large clinical trials, it is anticipated that this approach will already 
lead to a decrease in the local recurrence rate and improved patient survival and functionality. 
Second, it has been suggested that penetration depth limitations might not be relevant for 
surgical practice because the surgeon will, by definition, bring the area of interest closer to the 
surface during the surgical procedure (34, 43). When, after resection of the tumour mass, an area 
is found with persisting fluorescence signal indicating irradical margins, this could be resected 
subsequently until no more signal is found in a "cut the light-procedure," similar to the technique 
 
of Mohs surgery. Although a similar procedure, optical imaging will be much more efficient than 
Mohs surgery due to real-time acquisition and the fact that intraoperative pathologic evaluation is 
not required. At the surface, the influence of optical properties will be minimized, improving the 
sensitivity even in cases of perineural or perivascular growth, as long as the photons from the 
contrast agent can be differentiated from autofluorescence. Finally, although it is currently 
impossible to completely correct for an unknown variability in optical properties of the tissue, we 
should not forget that a very advanced system is available that has the capability to identify 
distinct tissue components (e.g., blood vessels) during the surgical process: the surgeon him or 
herself. The true additional value of this technique will become clear once the surgical expertise 
to distinguish tissue components becomes incorporated into the interpretation of the images. For 
example, the surgeon would preferably reinvestigate a suspicious region that has no fluorescence 
signal if it is covered by a blood vessel as long as the surgeon realizes that vessels can be highly 
absorbent. Using the knowledge about the tissues at hand, optical image-guided surgery will 
result in a dynamic and flexible process providing the surgeon with valuable additional 
information during the entire operation. This will likely require a learning curve that would 
follow the encouraging example of pioneer work in resection of malignant gliomas using 5-
aminolevulinic acid. Preliminary intraoperative studies in this field provide detailed reports on 
these learning processes (44, 45). These studies showed that photons are highly absorbed by 
blood or cauterized tissue debris after monopolar cautery resection and that suction of these 
layers or rinsing the surface with saline is required for unperturbed assessment of tissue 
fluorescence. Furthermore, necrotic tumour centers accumulated little fluorescence, which was 
not a problem because necrosis could easily be distinguished under white light and therefore did 
not impair fluorescence-guided tumour resection. Tissues were not falsely labeled by fluorescence 
from blood contaminating the tumour cavity, which might have been expected if plasma had 
contained substantial amounts of fluorescent agent. Photobleaching after overexposure was 
minimized with improved development of fluorophores. Finally, the fluorescent source could be 
located by manipulation of the tissues, as illustrated in Fig. 5. The success of this approach has 
led to a randomized controlled multicenter phase III trial showing improved progression-free 
survival in patients with malignant glioma using fluorescence-guided surgery (46).  
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What level of accuracy is required for the routine of surgical practice? 
 
Considering the intraoperative flexibility of a trained surgeon and the practice of exploration of 
the area of interest during surgery, we believe that optical image-guided surgery has the potential 
to greatly reduce the tumour-free safety margin. If a tumour-free margin could be minimized, 
postoperative functional outcome could be drastically improved in many cases where the tumour 
is surrounded by important anatomical structures. This would require tumour imaging with 
optimal sensitivity and specificity of the tumour-specific agent, followed by resection of the 
fluorescent tissue without any excess margin of healthy tissue. It is anticipated that sensitivity and 
specificity of the target-specific agent will be optimized by simultaneously targeting multiple 
tumour characteristics at different wavelengths (42, 47). To adequately assess the fluorescent 
border, high accuracy of the imaging technique is demanded. This would require high-resolution 
images that can be acquired at higher magnifications than the regular macroscopic field of view. 
Although not suitable for intraoperative use, a system that incorporates both macroscopic and 
microscopic imaging has been tested in an experimental setting of cancer detection (23). In the 
macroscopic field of view, the smallest lesion detectable with a highly expressed antigen (e.g., 
several million antigens/cell) was approximately 600 mm, a volume that approaches pixel 
resolution of the macroscopic images (110 mm/pixel). Higher magnification of this tumour 
revealed images down to the single cell level due to higher resolution (23). These results suggest 
that incorporation of zoom function into the intraoperative camera system would improve 
surgical accuracy by using a combination of macroscopic imaging (to survey the tissue and guide 
tumour resection) and microscopic imaging (to verify clean resection margins; ref. 40). However, 
scattering generally determines the sharpness of the in vivo fluorescence image, especially for 
deeply located fluorescent sources, and not the imaging equipment. Furthermore, microsurgical 
or robotic camera systems are only used in some oncological surgical specialties (e.g., 
neurosurgery). Therefore, in daily routine and logistics of surgical practice in most other cases, 
the tremor of the surgical hand will limit removal of the tumour with accuracy smaller than 0.5 
mm. As a result, the accuracy of removing the fluorescent tissue will not only be limited by the 
resolution of optical imaging but also by the practical limitations of the surgical hand. As long as 
microscopic or robotic surgery is not a routine practice, the discussion on the level of resolution 
will lie within the margin of technical surgical possibilities. In analogy to highly accurate 
stereotactic radiotherapy using Cyberknife that has a technical error margin of 0.5 to 2 mm (48), 
it is very likely that this level of accuracy will be sufficient to adequately treat the patient with 
minimal unnecessary loss of functionality. 
 
 
  
 
Challenges for clinical translation 
 
Although a rapidly increasing amount of data is supporting the additional value of optical image-
guided surgery for cancer therapy, challenges remain in translation of the preclinical experimental 
setup into routine clinical practice (2, 6). The technique requires development of tumour-specific 
fluorescence agents and dedicated intraoperative camera systems. Important progress has been 
made over the past few years in both fields, but it is essential to identify the hurdles that are still 
impeding successful clinical translation. An intrinsic limitation of development of fluorescence 
tumour-specific agents is the fact that such drugs are used as diagnostic tools instead of 
therapeutic drugs that require administration over a longer period of time. Development of 
diagnostic drugs is therefore subject to lower financial incentives for pharmaceutical companies. 
The first obvious steps were taken by conjugation of already clinically available tumour-specific 
agents (e.g., cetuximab) to fluorophores (2, 49). Until the technique will become available at a 
large scale, further development of these agents will have to be carried out by non-profit (i.e., 
academic) organizations. Furthermore, dedicated imaging systems will have to become easily 
available for a large group of surgeons to stimulate adoption of the technique. Currently, the 
most advanced systems are still only available in the research setting of clinical trials (7, 9), 
whereas other systems are already commercially available (50, 51). These economic and 
implementation issues are critical for successful adoption of surgical optical imaging. 
 
 
Conclusions 
 
Optical imaging has the potential to revolutionize cancer surgery by real-time fluorescence 
guidance in discriminating between healthy and diseased tissues and identifying vital structures. 
However, absorption, scattering, and autofluorescence are fundamental optical tissue properties 
that influence the images and limit the ability to differentiate the targeted tissue from its 
surroundings. In pursuit of removing all cancer cells by resection of the total tumour-specific 
fluorescence signal, the oncologic surgeon should carefully consider these limitations during the 
process of image-guided cancer surgery. Although there are limitations to the intrinsic capacity of 
the technique, when practical and technical surgical possibilities are considered, optical imaging 
can be a very powerful intraoperative tool in guiding the future oncologic surgeon toward radical 
resection and optimal clinical results. 
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ABSTRACT 
 
Background 
Intraoperative near-infrared (NIR) fluorescence imaging is a technology with high potential to 
provide the surgeon with real-time visualization of tumours during surgery. This study explores 
the feasibility for clinical translation of an epidermal growth factor receptor (EGFR) targeting 
nanobody for intraoperative imaging and resection of orthotopic tongue tumours and cervical 
lymph node metastases.  
 
Methods 
The anti-EGFR nanobody 7D12 and the negative control nanobody R2 were conjugated to the 
NIR fluorophore IRDye800CW (7D12-800CW and R2-800CW). Orthotopic tongue tumours 
were induced in nude mice using the OSC-19-luc2-cGFP cell line. Tumour bearing mice were 
injected with 25μg 7D12-800CW, R2-800CW or 11μg 800CW. Subsequently, other mice were 
injected with 50 μg or 75 μg of 7D12-800CW. The FLARE imaging system and the IVIS 
spectrum were used to identify, delineate and resect the primary tumour and cervical lymph node 
metastases.  
 
Results 
All tumours could be clearly identified using 7D12-800CW. A significantly higher tumour-to-
background ratio (TBR) was observed in mice injected with 7D12-800CW compared to mice 
injected with R2-800CW and 800CW. The highest average TBR (2.00 ± 0.34 and 2.72 ± 0.17 for 
FLARE and IVIS spectrum, respectively) was observed 24 hours after administration of the 
EGFR-specific nanobody. After injection of 75 μg 7D12-800CW cervical lymph node metastases 
could be clearly detected.  
 
Conclusion 
Orthotopic tongue tumours and cervical lymph node metastases in a mouse model were clearly 
identified intraoperatively using a recently developed fluorescent EGFR targeting nanobody. 
Translation of this approach to the clinic would potentially improve the rate of radical surgical 
resections.  
 
Introduction 
 
In oncology, a range of noninvasive imaging modalities, including X-ray, ultrasonography, 
computed tomography (CT) and magnetic resonance imaging (MRI), enable early detection, 
staging, and treatment evaluation of cancer. However, in most cases surgeons still discriminate 
healthy tissue from cancerous tissue by means of visual inspection and palpation during surgery. 
Given the fact that adequate tumour free margins are of paramount importance for patient 
prognosis and outcome, and that irradical resections still frequently occur, novel imaging 
modalities are needed. Despite the primary objective of achieving macroscopic clearance of 1 cm 
in the surgical management of oropharyngeal or oral squamous cell carcinoma (OSCC), the 
presence of tumour positive margins has been reported in 16% of patients.1 Numerous reports 
have indicated that involved margins imply deteriorated prognoses.2 On the other hand, applying 
wider surgical margins will result in functional impairment in most cases.3, 4 Therefore, clearer 
delineation of the tumour during surgery may improve the number of radical resections, thus 
increasing patients’ survival rates while maintaining postoperative functionality. Near-infrared 
(NIR) fluorescence imaging is a novel imaging technique that provides the surgeon with real-time 
visualization of tumours during surgery.5–7 In the NIR region (650 – 800 nm), less absorption of 
light by tissue components allows much deeper penetration of light. Furthermore, lower 
fluorescence from endogenous fluorophores decreases the nonspecific background signal. As the 
human eye is not sensitive to NIR fluorescent light, a specific NIR fluorescence imaging system 
is needed to visualize the fluorescence signal. At the same time, since NIR light is invisible to the 
human eye, it will not alter the surgical field.8 One of the main challenges in intraoperative 
fluorescence imaging lies in the development, validation and clinical introduction of a tumour 
specific agent. Being widely overexpressed in OSCC, the epidermal growth factor receptor 
(EGFR) serves as an interesting target for intraoperative fluorescence imaging.9, 10 The EGFR is a 
transmembrane glycoprotein that is involved in DNA synthesis and cell proliferation. 
Overexpression contributes to oncogenesis by proliferation, dedifferentiation, inhibition of 
apoptosis, invasiveness and lack of adhesion dependence.11 Furthermore, EGFR overexpression 
is often associated with a poor prognosis for patients with OSCC.12 For tumour targeting using 
molecular imaging techniques, antibodies are promising as they can be raised specifically against 
practically any molecular target. Nevertheless, due to their large hydrodynamic diameter, intact 
antibodies accumulate in the liver. Moreover, long halflife in the bloodstream and slow blood 
clearance via the liver results in high contrast images only several days after injection. A very 
appealing alternative is the use of nanobodies.13 Nanobodies are the smallest functional antigen-
binding fragments derived from naturallyoccurring heavy-chain only antibodies.14 They show 
very specific binding to their targets and their size of approximately 15 kDa ensures efficient 
distribution and tissue penetration, as well as rapid clearance from the body.15–17 This study 
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assesses the feasibility of intraoperative fluorescence delineation of orthotopic OSCC and 
microscopic lymph node metastases, using an anti-EGFR nanobody and a clinically available 
fluorescence camera system. For this, the anti-EGFR nanobody 7D12 was conjugated to the 
NIR fluorophore IRDye800CW18, as previously described by Oliveira et al.17. Tumour 
accumulation and specificity of 7D12-800CW was compared to the negative control nanobody 
R2-800CW and to 800CW alone. 
  
 
Material and Methods 
 
 
Cell lines and culture 
Two human cell lines were used. For the animal studies, the metastatic oral squamous cell 
carcinoma (OSCC) line OSC-19 was used. The OSC19 cell line was established in Japan with 
cells from a patient with a well-differentiated squamous cell carcinoma of the tongue that 
metastasized to a cervical lymph node.19 Luc2 luciferase from pGL4.10 plasmid (Promega, 
Madison, WI, USA) was cloned into the multiple cloning site (MCS) of the lentiviral vector 
pCDH-EF1-MCS-T2A-copGFP (Biocat, Heidelberg, Germany) using specific primers with the 
corresponding restriction sites. OSC-19 cells were transduced by self-inactivating lentiviral 
vectors as previously described20 and positive cell clones selected by limit dilution to create a 
stable luciferase 2 (luc2) and green fluorescent protein (GFP) expressing OSC-19-Luc2-copGFP 
cell line. The cells were grown in vitro in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Invitrogen, Carlsbad, CA, USA) containing 4.5 g DGlucose/L, 110 mg sodium pyruvate/L, 580 
mg L-glutamine/L supplemented with 10% fetal bovine serum (FCS; Lonza, Basel, Swiss), 100 
IU/mL penicillin, 100 μg/mL streptomycin (Invitrogen), 1× Minimal Essential Medium (MEM) 
Non-Essential Amino Acids solution and 1× MEM vitamin solution (Invitrogen). The human 
colorectal cancer cell line SW620 was used as an EGFR negative control. This cell line was 
cultured in Leibovitz’s L-15 medium (Invitrogen) containing 300 mg L-glutamine/L 
supplemented with 10% FetalClone II (Hyclone, Logan, UT, USA) 100 IU/mL penicillin, 100 
μg/mL streptomycin (Invitrogen) and 20 mM HEPES (Invitrogen). All cell lines were grown in a 
humidified incubator at 37°C and 5% CO2. Cells were regularly checked for Mycoplasma infection 
by PCR. 
 
Nanobodies and Conjugation to IRDye800CW 
Two nanobodies were used: 7D12 and R2. The EGFR specific nanobody 7D12 binds to the 
ectodomain of the EGFR.18, 21 EGFR specificity of 7D12-800CW in vitro and in vivo was reported 
earlier.17 The nanobody R2 was used as a non-EGFR specific control.22, 23 Both nanobodies have 
a molecular weight of approximately 15 kDa and show similar in vivo biodistribution.17, 18, 24 The 
generation of the nanobodies 7D12 and R2 was described previously.18, 22 Induction of protein 
expression and purification of nanobodies from the periplasmic space of Escherichia coli were 
performed as described by Roovers et al.25 Conjugation of both nanobodies to the NIR 
fluorophore IRDye800CW was performed as described by Oliveira et al.17 Briefly, the 
IRDye800CW N-hydroxysuccinimide ester (LICOR, Lincoln, NE, USA) was added to the 
protein in a 4-fold molar excess and was incubated for two hours at room temperature. Removal 
of the unconjugated fluorophore was accomplished by using two Zeba Spin Desalting columns 
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(Thermo Fisher Scientific, Perbio Science Nederland B.B., Ettenleur, the Netherlands) per 
protein in two sequential steps. The fluorescent nanobodies, i.e. 7D12-800CW and R2-800CW, 
were characterized as previously described17, namely for their conjugation efficiency and these 
parameters were in agreement with previous values, i.e. 0.5 and 1.1, respectively. 
 
EGFR expression 
OSC-19 and SW620 cells were cultured until subconfluence. Cells were detached with trypsin 
and adjusted at 1 × 105 cells/tube in ice cold PBS, 10% FCS (Lonza, Basel, Swiss) and 1% 
sodium azide. The anti-EGFR monoclonal antibody sc-120 alexa fluor 647 (Santa Cruz 
biotechnology, Santa Cruz, CA, USA) or non-specific normal mouse IgG2a alexa fluor 647 
(Santa Cruz) were added and cells were incubated in the dark on ice for 30 minutes. After 
incubation, cells were washed three times in ice cold PBS and resuspended in ice cold PBS, 
containing 10% FCS (Lonza) and 1% sodium azide. Flow cytometry of alexa fluor 647 labeled 
cells was performed using the BD LSR II (BD biosciences, San Jose, CA, USA). EGFR 
expression was estimated as the geometric mean of fluorescence intensity measured in 10.000 
viable cells. The experiment was performed in duplicate. 
 
Binding study 
A binding assay was performed to confirm the specificity of the EGFR binding of 7D12-800CW. 
A black 96-well plate (Greiner bio-one, Frickenhausen, Deutschland) was used in which 20.000 
OSC-19-luc2-cGFP and SW620 cells were seeded per well. After one day, cells were washed with 
binding medium (DMEM supplemented with 25 mM Hepes and 1% BSA, at pH 7.2). 7D12-
800CW (7D12), R2-800CW (R2) and IRDye800CW carboxylate (800CW, LI-COR, Lincoln, NE, 
USA) were added in triplicate in a concentration range of 0 to 50 nM. R2-800CW and 
IRDye800CW carboxylate were used as negative controls. The cells were incubated for 2 hours 
in the dark on a rocker at 4°C and afterwards washed two times with binding medium. Bound 
proteins were directly observed with the Odyssey scanner (LI-COR), scanning at 800 nm. 
Directly after these measurements cells were fixed with 4% paraformaldehyde and incubated with 
TO-PRO-3 (Invitrogen) at 1:5000 for 15 minutes. Again cells were washed twice and the plate 
was imaged using the 700nm channel of the Odyssey (LI-COR) to detect TO-PRO3 
fluorescence. Nucleus staining was performed to correct the fluorescence signal for the amount 
of cells enabling direct comparison of fluorescence signal of both cell lines. 
 
Fluorescence imaging systems 
Real-time fluorescence imaging of primary tumour and lymph node metastases was performed 
using the FLARE imaging system.26 Briefly, This imaging system consists of three wavelength-
isolated light sources: a 400–650 nm light source generating 40.000 lux (white light), a 656–678 
 
nm light source generating 4 mW/cm2 (700 nm) and a 745 – 779 nm light source generating 14 
mW/cm2 (800 nm). The imaging head, attached to a flexible gooseneck arm, enables real-time 
image acquisition from all three cameras. Color, NIR fluorescence and pseudo-colored (lime 
green) merged images are displayed in real time. Next to the FLARE imaging system, the IVIS 
spectrum (Caliper Life Science, Hopkinton, MA, USA) was used to visualize primary tumours 
and metastases. Data analysis of FLARE and IVIS spectrum data was performed using image J 
and the Living Image software from xenogen version 3.2 (Caliper LS) respectively. Multiple regions 
of interest (ROI) were drawn in the tumour and in adjacent normal tissue of the tongue and 
divided by each other to calculate TBRs. 
 
Animal model 
Nude Balb/c female mice (Charles River laboratories, l’Arbresle, France), aged 4 – 6 weeks, were 
housed in individually ventilated cages and provided with food and sterilized water ad libitum. 
Animal experiments were approved by the local animal welfare committee of the Leiden 
University Medical Center. Orthotopic tongue tumours were submucosally induced in the tip of 
the tongue through injection of 40.000 OSC-19-luc2-cGFP cells, diluted in 20 μL phosphate-
buffered saline (PBS). Mice body weight was monitored twice a week and tumour growth was 
monitored twice a week by bioluminescence (BLI) measurements and visual inspection of the 
tongue. BLI signal, being the most sensitive imaging method for the detection of tumour cells27, 
served as an in vivo control for the tumour specific fluorescence of the nanobodies. Imaging 
procedures were performed under isoflurane gas anesthesia. Weight measurements and tongue 
inspections were performed to monitor general health during the experiments. Mice were 
sacrificed by injection of high doses ketamine/xylazine. 
 
Fluorescence measurements 
Twenty days after injection of tumour cells, mice (n = 9) were randomly divided into three 
groups and received a systemic injection of 25 μg 7D12-800CW (1.6 nmol, 64 nmol/kg), 25 μg 
R2-800CW (1.5 nmol, 60 nmol/kg) or 11 μg 800CW carboxylate (1 nmol, 40 nmol/kg, LI-COR). 
For the two nanobodies, a previous study reported 25 μg to be the optimal dose.17 Fluorescent 
images were acquired at 0.5, 1, 2, 4, 8, 24 and 48 hours after injection. For the detection of 
microscopic cervical lymph node metastases two additional concentrations of 50 and 75 μg 
7D12-800CW were injected (n = 4). Mice were sacrificed at 24 hours after injection and 
overlying skin of the cervical region was removed for gross examination. Whole-body 
fluorescence imaging was performed and the tongue and cervical lymph nodes were subsequently 
resected. 
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overlying skin of the cervical region was removed for gross examination. Whole-body 
fluorescence imaging was performed and the tongue and cervical lymph nodes were subsequently 
resected. 
 
  
88 Chapter 4
 
Histology and fluorescence microscopy 
After ex vivo fluorescent measurements, the resected tongues were cut in two. One half was 
frozen on dry ice, the other half fixed in 4% formalin overnight and embedded in paraffin 
blocks. Cervical lymph nodes on both sides were resected. The left lymph node was frozen on 
dry ice, the right lymph node paraffin embedded and fixed in 4% formalin overnight. Tissue was 
sectioned at 10 μm and imaged using the Odyssey (LI-COR). All images were acquired using the 
same settings but the images (i.e. brightness and contrast) of the control probes were altered to 
show any fluorescence and emphasize the difference in localization between specific and non-
specific probes. To confirm the presence of tumour cells, fluorescence microscopy (Nikon 
eclipse e800, Nikon, Amsterdam, the Netherlands) of the GFP fluorescence signal emitted by 
OSC-19-luc2-cGFP cells was performed on frozen tissue slices. Histologic sections were stained 
with standard hematoxylin-eosin stain (HE). As expected, fluorescence of GFP could not be 
detected in paraffin embedded sections. Therefore, the presence of smaller cervical lymph node 
metastases in paraffin sections was confirmed by staining the cervical lymph node sections with 
anti-human wide-spectrum cytokeratin staining (Abcam inc., Cambridge, MA, USA). 
 
Statistical analysis 
For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, IL) was used. 
TBR’s were calculated by dividing the fluorescent signal of the tumour by fluorescent signal of 
surrounding tissue. TBR was reported in mean and standard deviation. To compare TBR 
between dose groups and time points, and to assess the relation between dose and time, a mixed 
model analysis was used. When a significant difference was detected, a one-way ANOVA was 
used to post-test for differences between separate dose groups and/or time points. The one-way 
ANOVA was corrected using the Bonferroni correction. P < 0.05 was considered significant. 
Differences between the FLARE and IVIS imaging systems were tested with an unpaired T-test. 
  
 
Results 
 
In vitro results 
The specificity of the EGFR targeting nanobody for the squamous cell carcinoma of the tongue, 
that metastasizes to cervical lymph nodes, was first validated in vitro. For that purpose, we started 
with the evaluation of the EGFR expression in the OSC-19-luc2-cGFP cell line. Direct staining 
of the cell surface epitope of the EGFR of OSC-19-luc2-cGFP cells caused an increase in 
fluorescence intensity, as shown by a shift to the right through flow cytometry analyses, 
compared to the non-specific antibody (Fig 1A). Next, as a control to the EGFR overexpressing 
OSC-19-luc2-cGFP cell line, we assessed the EGFR expression in the human colon carcinoma 
cell line SW620, a cell line that has no overexpression of the EGFR. In contrast to OSC-19-luc2-
cGFP, the FACS data of this cell line revealed no increase in fluorescence intensity, thus 
confirming the absence of EGFR expression in the SW620 cell line (Fig 1B). Both these cell lines 
were employed to confirm the specificity of the EGFR targeting nanobody 7D12-800CW, which 
was compared to the non-EGFR specific nanobody R2-800CW and to 800CW alone. The 
IRDye800CW-conjugated probes were produced and characterized as described by Oliveira et 
al.17 Consistently, after purification of the conjugates through removal of unconjugated 
fluorophores, a small percentage of the 800CW unconjugated fluorophore (less than 7.5 % of the 
800CW conjugated fraction) was still present (data not shown) and the fluorophore to protein 
molar ratio of 7D12-800CW and R2-800CW after random conjugation was 0.5 and 1.1 
respectively. The cell assay, performed at 4C to prevent internalization and investigate binding 
only, clearly demonstrated an EGFR specific binding of 7D12-800CW in OSC-19-luc2-cGFP 
cells that proved to be concentration dependent (Fig 1C). With R2-800CW and 800CW, although 
slightly concentration dependent, significantly less fluorescence intensity was observed (Fig 1C). 
In the EGFR negative cell line no significant differences in fluorescence intensity between 7D12-
800CW and R2-800CW were observed. Altogether, these results confirm the specificity of 7D12-
800CW for binding to EGFR and show that both the negative control R2-800CW and the 
800CW alone do not associate with these cells (Fig 1C and 1D). 
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with the evaluation of the EGFR expression in the OSC-19-luc2-cGFP cell line. Direct staining 
of the cell surface epitope of the EGFR of OSC-19-luc2-cGFP cells caused an increase in 
fluorescence intensity, as shown by a shift to the right through flow cytometry analyses, 
compared to the non-specific antibody (Fig 1A). Next, as a control to the EGFR overexpressing 
OSC-19-luc2-cGFP cell line, we assessed the EGFR expression in the human colon carcinoma 
cell line SW620, a cell line that has no overexpression of the EGFR. In contrast to OSC-19-luc2-
cGFP, the FACS data of this cell line revealed no increase in fluorescence intensity, thus 
confirming the absence of EGFR expression in the SW620 cell line (Fig 1B). Both these cell lines 
were employed to confirm the specificity of the EGFR targeting nanobody 7D12-800CW, which 
was compared to the non-EGFR specific nanobody R2-800CW and to 800CW alone. The 
IRDye800CW-conjugated probes were produced and characterized as described by Oliveira et 
al.17 Consistently, after purification of the conjugates through removal of unconjugated 
fluorophores, a small percentage of the 800CW unconjugated fluorophore (less than 7.5 % of the 
800CW conjugated fraction) was still present (data not shown) and the fluorophore to protein 
molar ratio of 7D12-800CW and R2-800CW after random conjugation was 0.5 and 1.1 
respectively. The cell assay, performed at 4C to prevent internalization and investigate binding 
only, clearly demonstrated an EGFR specific binding of 7D12-800CW in OSC-19-luc2-cGFP 
cells that proved to be concentration dependent (Fig 1C). With R2-800CW and 800CW, although 
slightly concentration dependent, significantly less fluorescence intensity was observed (Fig 1C). 
In the EGFR negative cell line no significant differences in fluorescence intensity between 7D12-
800CW and R2-800CW were observed. Altogether, these results confirm the specificity of 7D12-
800CW for binding to EGFR and show that both the negative control R2-800CW and the 
800CW alone do not associate with these cells (Fig 1C and 1D). 
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Figure 1. EGFR expression and binding assay 
Flow cytometry was performed using OSC-19-luc2-cGFP and SW620 without antibody (green), with an EGFR  
specific antibody conjugated to alexa fluor 647 (blue) and with an isotype control normal mouse IgG2a conjugated to 
alexa fluor 647 (red). 7D12-800CW binds to human epidermal growth factor receptor expressed on OSC19-luc2-cGFP 
cells. A. The EGFR is highly expressed on the surface of OSC-19-luc2-cGFP cells. B. No expression of EGFR was 
found on the surface of SW620 cells. C. The human EGFR expressing OSC cells and EGFR negative SW620 cells 
were incubated with different concentrations of 7D12-800CW, R2-800CW and 800CW. The ratio of the fluorophore 
bound protein and the fluorescence intensity of TO-PRO-3 was plotted to correct for the amount of cells. Every 
concentration was performed in triplicate. Error bars indicate the standard deviation. D. Images were acquired with the 
Odyssey Scanner (LICOR). OSC and SW620 cells were incubated with 50 nM 7D12, R2 and 800CW. OSC = OSC-19-
luc2-cGFP. 
  
 
Animal model 
Within three weeks after orthotopic inoculation of OSC-19-luc2-cGFP cells in the tip of the 
tongue, all mice developed a primary tongue tumour and cervical lymph node metastases (a 
typical example is shown in Fig 2A), observed during regular visual inspection and confirmed by 
the increase in mean bioluminescence signal (Fig 2B) 
 
 
Figure 2. Tumour growth followed by imaging bioluminescence 
A. Bioluminescent image after injection of OSC-19-luc2-cGFP cells. Primary tongue tumour and lymph node 
metastasis are shown. B. Increase of tumour growth (measured in bioluminescence signal) as a function of time. 
 
In vivo NIR Fluorescence Imaging of primary tumours 
Three weeks after tumour cell inoculation, mice were injected intravenously with 25 μg of 7D12-
800CW, R2-800CW or 11 μg 800CW (for equivalent fluorescence to 7D12-800CW). To assess 
the feasibility of a possible clinical translation, fluorescence images were taken with both the 
preclinical, highly sensitive IVIS spectrum camera as well as with the FLARE intraoperative 
imaging system. As demonstrated in Figure 3A, all tumours of the animals that were injected with 
7D12-800CW could be clearly identified through NIR fluorescence using both imaging 
modalities. No adequate tumour-to-background ratios were observed in the control mice injected 
with R2-800CW or 800CW (Fig 3B), which is in agreement with the results obtained in vitro (Fig 
1).  
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Figure 3. Multimodal in vivo and ex vivo imaging of an orthotopic tongue tumour 
7D12 is specifically taken up in the oral squamous cell carcinoma of the tongue. Mice bearing OSC-19-luc2-cGFP 
human xenografts were intravenously injected with 25μg of 7D12, R2 and 800CW. After 24 hours fluorescent images 
were obtained with the IVIS spectrum and the intraoperative camera system (FLARE). A. In vivo: bioluminescence 
brightfield merge image (left), NIR fluorescence brightfield merge IVIS image of 7D12-800CW (middle) and NIR 
fluorescence color merge FLARE image (right) Ex vivo: GFP brightfield merge image (left), NIR fluorescence 
brightfield merge IVIS image of 7D12-800CW (middle) and NIR fluorescence color merge FLARE image (right) B. In 
vivo: Fluorescent imaging of a tongue tumour 24 hours after administration of 7D12-800CW (left), R2-800CW (middle) 
and 800CW (right). Ex vivo: Fluorescent imaging of a tongue tumour 24 hours after administration of 7D12-800CW 
(left), R2-800CW (middle) and 800CW (right). Images were obtained with the intraoperative camera system (FLARE) 
 
Using the IVIS imaging system, a mixed model showed significant differences in TBRs between 
three study groups and between time points (p < 0.0001 and p < 0.0001, respectively) (Fig 4A). 
Post-testing using a one-way ANOVA showed significant differences between the 7D12-800CW 
and the R2-800CW (p < 0.0001) study groups and between the 7D12-800CW and 800CW (p < 
0.0001) study groups. No significant difference was found between R2-800CW and 800CW (p > 
0.999). The highest TBR (2.72 ± 0.17) was measured at 24 hours after administration of 7D12-
800CW. Using the FLARE imaging system, a mixed model showed significant differences in 
TBRs between the three study groups and between time points (p = 0.041 and p < 0.0001, 
respectively) (Fig 4B). Post-testing using a one-way ANOVA showed significant differences 
between the 7D12-800CW and the R2-800CW study groups (p = 0.05) and between the 7D12-
800CW and 800CW study groups (p = 0.002). No significant difference was found between R2-
800CW and 800CW (p = 0.77). The highest TBR (2.00 ± 0.34) was measured  at 24 hours after 
administration of 7D12-800CW. The highest TBR measured with the IVIS imaging system was 
significantly higher compared to the highest TBR measured with the FLARE imaging system (p 
= 0.03). 
 
 
Figure 4. Intraoperative tumour to background ratios over time 
The tumour to background ratio of 7D12-800CW is significantly higher compared to those of R2-800CW and 800CW. 
Tumour to background ratios were calculated from 0.5 hours to 48 hours after injection. Error bars indicate the 
standard deviation. Tumour to background ratios were plotted for the IVIS-Spectrum (A) and the FLARE imaging 
system (B). 
 
 
Ex vivo fluorescence imaging and histology of primary tumours 
In cryo sections, fluorescent imaging of the GFP that was transduced in the OSC-19 cells 
confirmed the presence of tumour cells in the tongue (Fig 5). After fluorescent imaging (GFP 
and NIR fluorescence), sections were stained with HE. Even sub-millimeter islands of tumour 
cells, confirmed with GFP fluorescence, co-localized with the fluorescence of 7D12-800CW, as 
measured with the Odyssey Scanner (Fig 5). No co-localization was observed in the tongue 
specimens of mice injected with R2-800CW or 800CW, which is in agreement with our 
observations in vivo (Fig 3B). 
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Figure 5. Histology and fluorescence imaging of orthotopic primary tongue tumours 
Shown are hematoxylin and eosin (HE) stainings, HE and GFP fluorescence overlays, HE and NIR fluorescence 
overlays and HE, NIR and GFP fluorescence overlays. In the 7D12-800CW tissue specimen, a clear overlap between 
NIR and GFP (indicating tumour cells) fluorescence was observed. In the R2-800CW and 800CW specimens, no 
overlap between NIR and GFP fluorescence was observed. Brightness and contrast of the images of R2-800CW and 
800CW was altered to show fluorescence and emphasize the localization in tissue. 
  
 
In vivo and ex vivo fluorescence imaging and histology of cervical lymph nodes 
In contrast to the primary tumour, microscopic cervical lymph node metastases were not grossly 
visible. In fact, a dose of 75 μg of 7D12-800CW only gave a weak fluorescence signal through 
the skin using the IVIS, but, importantly, a strong fluorescence with both imaging systems could 
be detected when the skin was removed (Fig 6). This highlights the potential of this imaging 
modality in the intraoperative context. During ex vivo imaging, the fluorescence of GFP that was 
transfected in the OSC-19-luc2-cGFP cells confirmed the presence of cervical lymph node 
metastases in the tissue specimen and could be colocalized to the fluorescent signal of 7D12-
800CW. As expected, due to bleaching and the washing steps, no GFP fluorescence was found in 
the paraffin sections of the cervical lymph nodes. Nevertheless, immunohistochemical analysis, 
using a wide spectrum anti-cytokeratin staining, confirmed the presence of tumour cells. As 
shown in Figure 6, the fluorescence signal of 7D12-800CW co-localizes with the tumour cells in 
the cervical lymph node. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. In vivo, ex vivo and histological fluorescence imaging of cervical lymph nodes 
In vivo: bioluminescence brightfield merge image (left), NIR fluorescence brightfield merge IVIS image of 7D12-
800CW (middle) and NIR fluorescence color merge FLARE image (right) Ex vivo: GFP brightfield merge image (left), 
NIR fluorescence brightfield merge IVIS image of 7D12-800CW (middle) and NIR fluorescence color merge FLARE 
image (right) Histology: Shown are a hematoxylin and eosin (HE) staining combined with a cytokeratin staining (left) 
and NIR fluorescence image (right) of a cervical lymph node of a mice injected with 7D12-800CW. A clear overlap 
between NIR fluorescence and the brown cytokeratin staining (indicating tumour cells) was observed. 
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Discussion 
 
In the present study, the EGFR targeting nanobody conjugated to 800CW was used to delineate 
orthotopic OSCC tumour margins during surgery. After 2 hours post injection tumours could 
already be clearly delineated. The highest TBR was obtained 24 hours after injection. 
Furthermore, a significant difference in TBR was observed between mice injected with 7D12-
800CW, and mice injected with the control nanobodyR2-800CW or with 800CW alone. NIR 
fluorescent optical imaging is an imaging technique with high potential to obtain realtime 
information about the presence, location and dimensions of tumour tissue so that adequate 
tumour free margins can be obtained after resection28–30. Although the first clinical trial has 
recently been performed29, it remains challenging to find a suitable fluorescent probe which can 
be detected with a sensitive NIR-fluorescent imaging system. The first challenge to NIR 
fluorescence imaging is the optimal fluorescent probe. An ideal fluorescent probe should 
distribute well, have a high affinity towards its target and a fast clearance from the bloodstream, 
to allow efficient accumulation at the tumour and rapid acquisition of images with high contrast. 
Furthermore, no accumulation in the liver is desirable and the ability to adequately penetrate the 
tissue of interest is of great importance. The EGFR serves as a very interesting target in head and 
neck cancer as the majority of these cancers overexpress this receptor.10, 31 In a previous study we 
used recombinant human EGFR ligands conjugated to 800CW to target head and neck 
tumours.32 Although  efficient in targeting head and neck tumours, recombinant human EGFR 
ligands can potentially activate this receptor, which promotes its malignant phenotype. In other 
studies, cetuximab conjugated to Cy5.5 and panitumumab conjugated to 800CW are used to 
image head and neck tumours.9,33 Conventional antibodies, however, show slower blood 
clearance (up to several days), higher accumulation in the liver and limited tumour penetration 
compared to nanobodies.17 For these reasons, we have selected a nanobody as our probe for 
this study. Next to the ideal probe, the extent to which a tumour can be visualized during surgery 
is highly depending on the NIR fluorescent imaging system. Gioux et al.34 have reviewed the 
technical requirements for an intraoperative imaging system. To assess the feasibility of 
translating our results into clinical experiments, we used the clinically available FLARE™ 
imaging system. This system is able to adequately detect microscopic disease intraoperatively and 
has proven its clinical use in over 25 clinical trials.26, 35 Using the IVIS spectrum we were able to 
measure bioluminescence and confirm the presence of tumour cells ex vivo, by imaging GFP 
fluorescence of the transfected OSC-19-luc2-cGFP cells. Furthermore, fluorescence 
measurements obtained with the IVIS spectrum, i.e. a closed (‘black box’) preclinical imaging 
system, were compared with the measurements of the clinically available FLARE™ imaging 
system. This comparison showed a significant difference in TBR favoring the IVIS spectrum on 
the optimal imaging time point (24hr post injection). This difference can be explained by the fact 
 
that the IVIS spectrum is, in contrary to the FLARE imaging system, a ‘black box’ imager with 
less daylight interfering and subsequently less background fluorescence. However, since this 
device obviously cannot be used intraoperatively, the FLARE imaging system is an adequate 
alternative as the average TBR was over 2. In previous studies, we used the EGFR targeted 
nanobody 7D12 conjugated to 800CW to image subcutaneous A431 tumour xenografts, which 
have high EGFR expression.17 Undoubtedly, the host microenvironment has great influence on 
tumour biology that affects parameters such as angiogenesis, growth, invasion, metastasis and 
lymphangiogenesis. Therefore, an orthotopic model is clinically a more relevant model with great 
importance to assess the ability of a probe for fluorescence delineation of tumours and its 
possible translation to the clinic. In this study, we successfully tested the potentiality of 
intraoperative fluorescence delineation of orthotopic OSCC and microscopic lymph node 
metastases using a clinically available fluorescence imaging system. Based on these results we 
conclude that clinical translation of 7D12-800CW may be possible, using the FLARE imaging 
system in the intraoperative set-up. A sufficient TBR is required to distinguish tumour from 
normal tissue30 The small molecular weight of 7D12 allows fast detection of the tumour due to 
rapid distribution and fast clearance of unbound molecules. Oliveira et al.17 reported tumour 
detection from 30 minutes after injection onwards. In the present study, using both the FLARE 
and IVIS spectrum, the tumour could be sufficiently detected 2 hours post injection. The use of 
an orthotopic model in the tongue that differs in angiogenesis, lymphangiogenesis and interstitial 
pressure from a subcutaneous A431 tumour, could perhaps explain these variations. 
Nevertheless, the highest average tumour to background ratio (2.72 IVIS spectrum vs 2.0 
FLARE) was obtained 24 hours after injection, which is in agreement with what was previously 
reported in the subcutaneous tumour model.17 Although nanobodies distribute and bind to their 
targets very rapidly, the background signal is relatively high during the first hours. Monovalent 
nanobodies are not efficiently internalized and therefore bound nanobody can un-bind over a 
certain period of time.36 The 7D12-800CW washout from normal tissue occurs faster than the 
release from its receptor in the tumour. As a result the TBR will increase over time until an 
optimal TBR is reached. After that, release of nanobody from its receptor will result in a decrease 
in TBR. A decreased TBR in our study was seen after 48 hours. Cryosections of the tongue 
confirmed the tumour specific fluorescence by colocalization of the fluorescent signal of 7D12-
800CW and the fluorescence of the GFP transfected OSC-19 cells. In the cryosections of mice 
injected with R2-800CW some fluorescence was detected, but there was no colocalization of NIR 
and GFP fluorescence. R2-800CW fluorescence mainly originated from the area surrounding the 
tumour. A possible explanation for the non- EGFR specific presence of R2-800CW could be the 
enhanced permeability and retention that is seen in many tumours.37 Fluorescence could not be 
detected in the cryo sections of tongues of mice injected with 800CW alone. When translating 
7D12-800CW to the clinic, the specific binding of the nanobody to human EGFR could result in 
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higher background fluorescence and therefore lower contrast. Importantly, Oliveira et al.17 
demonstrated the ability of 7D12-800CW to distinguish between different expression levels of 
EGFR in vitro. This implies that 7D12 could differentiate tumour tissue with high EGFR 
expression from normal tissue without overexpression of EGFR. The prognosis of patients with 
head and neck cancer is largely dependent on lymph node involvement.38, 39 A sentinel lymph 
node (SLN) procedure could prevent elective neck dissections that are frequently performed for 
adequate staging and local control. Furthermore, despite the analysis by a trained pathologist, 
(micro) metastases and occult tumour cells in lymph nodes can be missed by standard 
histopathological examination. Limited examination of one lymph node could increase the 
accuracy of staging in head and neck cancer. Recently van der Vorst et al.40 demonstrated the 
feasibility to detect draining lymph nodes in head and neck cancers using the nonspecific 
fluorescent tracer ICG:HSA. The fluorescent tracer however, quickly migrated to lymph nodes 
beyond the SLN. This present study demonstrates the feasibility of specific targeting of cervical 
lymph node metastases. A dose of 75 μg of 7D12-800CW clearly allowed delineation of the 
primary tumour and identification of the cervical lymph node metastases after removal of the 
skin. Histology showed clear co-localization of the NIR fluorescence of 7D12-800CW and the 
cytokeratin staining, that confirmed the presence of tumour cells. Compared to the primary 
tumour however, an increase of nonspecific background signal was observed. Also, the smaller 
the tumour or metastases, the lower the fluorescent signal. Furthermore, the influence of optical 
properties on the light propagation through tissue can result in a blurred delineation of smaller 
tumours. Altogether, these aspects rendered visualization of the metastases slightly difficult, 
which was significantly improved by removal of the skin. Further research is needed to explore 
which is the minimum size of lymph node metastases that can be detected using 7D12-800CW. 
Intraoperative detection of lymph node metastases would be a better alternative to the non-
specific SLN procedure. First, the efficiency of an intraoperative histopathological diagnosis on 
fresh-frozen sections could be increased by examination of the fluorescence positive lymph node. 
Eventually, the procedure might even prevent intraoperative pathologic analysis of fresh-frozen 
tissue sections.  
 
In conclusion, the present study reports a recently developed fluorescent EGFR targeting 
nanobody, which clearly allowed the identification of orthotopic tongue tumours and cervical 
lymph node metastases in a mouse model. These results highlight the potential of this nanobody 
for clinical translation in the context of surgical management of oropharyngeal or OSCC.  
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ABSTRACT 
 
Evaluation of resection margins during cancer surgery can be challenging, often resulting in 
incomplete tumour removal. Fluorescence-guided surgery (FGS) aims to aid the surgeon to 
visualize tumours and resection margins during surgery. FGS relies on a clinically applicable 
imaging system in combination with a specific tumour-targeting contrast agent.  
 
In this study EpCAM (epithelial cell adhesion molecule) is evaluated as target for FGS in 
combination with the novel Artemis imaging system. The NIR fluorophore IRDye800CW was 
conjugated to the well-established EpCAM specific monoclonal antibody 323/A3 and an isotype 
IgG1 as control. The anti-EpCAM/800CW conjugate showed to be stable in serum and showed 
preserved binding capacity as evaluated on EpCAM positive and negative cell lines using flow 
cytometry and cell-based plate assays. Four clinically relevant orthotopic tumour models, i.e. 
colorectal cancer, breast cancer, head and neck cancer, and peritonitis carcinomatosa, were used 
to evaluate the performance of the anti-EpCAM agent with the clinically validated Artemis 
imaging system. The Pearl Impulse small animal imaging system was used as reference. The 
specificity of the NIRF signal was confirmed using bioluminescence imaging and green-
fluorescent protein.  
 
All tumour types could clearly be delineated and resected 72 hours after injection of the imaging 
agent. Millimetre sized tumour nodules were detected that were invisible for the naked eye. 
Fluorescence microscopy demonstrated the distribution and tumour specificity of the anti-
EpCAM agent.  
 
This study shows the potential of an EpCAM specific NIR-fluorescent agent in combination 
with a clinically validated intraoperative imaging system to visualize various tumours during 
surgery.  
  
 
Introduction 
 
Curative intended oncologic surgery aims to completely resect all malignant cells. Discriminating 
tumour from healthy tissue during surgery is therefore of paramount importance [3]. As a 
consequence, clinically complete resected tumours frequently turn out to be pathological 
incompletely removed [4-6]. Therefore, novel intra-operative imaging modalities are needed that 
aid the surgeon in recognizing tumour spread and provide guidance during tumour removal. 
Fluorescence-guided surgery (FGS) is a technique based on near-infrared (NIR) light, which has 
been widely investigated for sentinel lymph node procedures, anastomosis and during 
cholecystectomies [7-9]. The advantage of NIR fluorescent light is the relatively deep tissue 
penetration and the minimal tissue auto fluorescence at these wavelengths. The tissue depth at 
which a fluorophore can be detected is dependent on the fluorophore (dose), tissue optical 
properties and the sensitivity of the imaging device. It has been estimated to be between 3 and 4 
cm in intensified devices[10] and up to 2 cm in others[11]. Further, since NIR fluorescence light 
is invisible for the human eye, there is no alteration of the surgical field [12]. The major 
challenges for the routine introduction of FGS in the clinic comprise the availability of validated 
NIR fluorescence imaging systems in combination with a dedicated tumour-specific NIR 
fluorescence agent [13]. 
 
The first NIR imaging systems for clinical application proved the feasibility of the concept but 
were in fact more proto-types than standard clinical equipment. The next generation NIR 
imaging systems, as used in this study, are more versatile, smaller, cheaper, and more sensitive 
and should meet uniform standards warranting an exponential increase for clinical applications. 
Therefore, presently the biggest challenge for clinical introduction of FGS is the development of 
specific tumour targeting NIR fluorescent agents that comply with these second generation 
imagers. Various established membrane-bound tumour markers are under evaluation as targets 
for (NIR) fluorescence imaging in pre-clinical settings, such as EGFR, HER2/Neu, VEGF(R), 
folate receptor alpha, uPAR and various integrins [14-19]. Although these proteins have been 
successfully targeted in human tumours xenografted in animal models, none of them seems to be 
the universal target suited for the majority of tumour (types) in a clinical setting: These proteins 
are either present on the majority of tumours but only on a low percentage of tumour (stromal) 
cells, like VEGFR and αvβ3 integrin, or they are abundantly present in only a limited percentage 
of tumour (types), like folate receptor, EGFR and HER2. 
 
In this study we evaluate Epithelial Cell Adhesion Molecule (EpCAM) as target for FGS. 
EpCAM is a transmembrane glycoprotein involved in cell-cell interactions and cell-stroma 
adhesion [20]. EpCAM expression is restricted to epithelial cells and is highly up-regulated in 
EpCAM-targeted fluorescence-guided surgery 107
5
 
ABSTRACT 
 
Evaluation of resection margins during cancer surgery can be challenging, often resulting in 
incomplete tumour removal. Fluorescence-guided surgery (FGS) aims to aid the surgeon to 
visualize tumours and resection margins during surgery. FGS relies on a clinically applicable 
imaging system in combination with a specific tumour-targeting contrast agent.  
 
In this study EpCAM (epithelial cell adhesion molecule) is evaluated as target for FGS in 
combination with the novel Artemis imaging system. The NIR fluorophore IRDye800CW was 
conjugated to the well-established EpCAM specific monoclonal antibody 323/A3 and an isotype 
IgG1 as control. The anti-EpCAM/800CW conjugate showed to be stable in serum and showed 
preserved binding capacity as evaluated on EpCAM positive and negative cell lines using flow 
cytometry and cell-based plate assays. Four clinically relevant orthotopic tumour models, i.e. 
colorectal cancer, breast cancer, head and neck cancer, and peritonitis carcinomatosa, were used 
to evaluate the performance of the anti-EpCAM agent with the clinically validated Artemis 
imaging system. The Pearl Impulse small animal imaging system was used as reference. The 
specificity of the NIRF signal was confirmed using bioluminescence imaging and green-
fluorescent protein.  
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virtually all epithelial carcinomas [21, 22]. EpCAM up-regulation is associated with cancer 
progression and EpCAM is found on circulating tumour cells and metastases. EpCAM 
overexpression in cancer cells was found to be 100- to 1000-fold higher compared to expression 
on normal breast cells resulting in 100,000 to 400,000 copies per cell [23]. Compared to an 
established tumour target like EGFR and Her2/Neu this number is only marginally less. But 
overexpression of EGFR and HER2/Neu in primary breast cancer is reported to be 0.8-14% 
and 15-20% respectively, whereas 40-98% of the primary breast tumours show enhanced 
EpCAM levels [22, 24]. For other epithelial cancers these figures are similar or favor the use of 
EpCAM as imaging target even more [22, 25-27]. These findings have led to the development of 
many EpCAM specific antibodies, from which some have been evaluated in phase I, II and III 
immunotherapeutic trials in various cancer types, such as ovarian, gastric and head-and-neck 
cancer [28, 29]. The results of these studies did not meet the high expectations for the 
therapeutic purpose and most of these investigations were aborted. Mild adverse effects like 
nausea, vomiting and elevation of pancreatic enzymes have been reported for therapeutic use, 
but are not expected in single dose imaging studies. The potential of EpCAM targeting has 
recently been re-discovered, as tumour specific imaging was demonstrated for SPECT imaging. A 
monoclonal antibody with medium high affinity for EpCAM, has been labelled with various 
radionuclides and has been extensively evaluated in several xenografted tumour models in mice 
[30, 31]. 
 
In the current study we conjugated the same monoclonal antibody 323/A3 to the clinically 
relevant NIR fluorescent dye IRDye800CW and evaluated this conjugate in tumour models of 
clinically relevant orthotopic colorectal, breast and head-and-neck cancer models. To simulate 
clinical conditions we evaluated the performance of the probe with the recently introduced 
commercially available Artemis imaging system [32] in comparison with the Pearl Impulse small 
animal imaging system, a standard apparatus for use in pre-clinical settings. 
  
 
Material and Methods 
 
Cell lines  
For colorectal, breast and head-and-neck cancer, we selected two cell lines with different tumour 
characteristics (Table 1). Luciferase transfected cells were used to follow orthotopic tumour 
growth by bioluminescence imaging (BLI). MCF-7 and OSC-19 cells were transfected with 
Luciferase 2 and green fluorescent protein as described previously [33]. All cell lines were grown 
in a humidified incubator at 37°C and 5% CO2. Cells were cultured for not more than 10 
passages and regularly checked for Mycoplasma infection by PCR.  
 
EpCAM expression 
EpCAM expression of HT29(-/+)luc2, COLO320, OSC-19-luc2-cGFP, FaDu-luc2, MCF-7-
luc2-cGFP and MDA-MB-231 cells was evaluated by flow cytometry. Cells were cultured until 
90% confluence and detached with trypsin. Viability of the cells was evaluated using trypan blue. 
After adjusting the number of cells to 0.5 x 106 per tube in ice cold phosphate-buffered saline 
(PBS), they were incubated with 0.4 µg/ml 323/A3 anti-EpCAM antibody or isotype control 
MOPC21 for 30 minutes on ice. Then cells were washed three times in ice cold PBS and 
incubated with a goat anti-mouse IgG1-AF488 secondary antibody (Invitrogen, 2.5 µg/ml). The 
cells were washed three times in ice cold PBS and resuspended in 400 µL PBS containing 
propidium iodide to exclude dead cells from the analysis. Flow cytometry was performed using 
the LSRII (BD Biosciences). The experiments were performed in duplicate and EpCAM 
expression was estimated as the geometric mean of fluorescence intensity measured in 10,000 
viable cells. For quantitative determination of EpCAM numbers per cell type the Qifikit (Dako) 
was used. 
 
Antibodies and Conjugation to IRDye 800CW 
EpCAM specific monoclonal chimeric antibody 323/A3 and the IgG1k isotype control 
monoclonal antibody MOPC21 (BioXcell, West Lebanon, USA) were used [34]. Antibody 
323/A3 has a medium high affinity (Kα = 2 x 109 M-1) for EpCAM and is directed against the 
EGF-like domain I epitope on the extracellular domain of the EpCAM molecule, whereas 
MOPC21 has an unknown specificity after testing on human and rodent tissues [35-37]. Both 
antibodies were covalently conjugated to NIR fluorochrome IRDye 800CW (LI-COR, Lincoln, 
NE, USA). λex= 773 nm, λem= 792 nm) using N-hydroxysuccinimide ester chemistry as 
indicated by the manufacturer. Removal of unconjugated fluorophore was accomplished by using 
two Zeba Spin Desalting columns (Thermo Fisher Scientific, Perbio Science Nederland B.B., 
Etten-Leur, The Netherlands) per protein in two sequential steps. For comparison experiments, 
the two conjugates i.e. the EpCAM specific (323/A3-800CW) and control (MOPC21-800CW) 
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were complemented by the chemically inactive carboxylate version of IRDye 800CW, 
representing the fluorescent label without antibody control.  
 
Serum stability 
The stability of 323/A3-800CW in human serum was evaluated using HPLC (Biosep-SEC-s2000, 
Phenomenex, USA). Serum and sodium azide dilution were filtrated through a 0.22 µm filter in a 
15 ml tube. A 24-wells plate (Greiner Bio-one, Germany) was prepared with 0.02% sodium azide 
and serum/probe in a ratio of 1:1 and PBS as control and incubated at 37°C under 5% CO2. At 
4, 24, 48 and 96 hours 20 µl of sample, diluted in 40 µL PBS was evaluated using HPLC in PBS 
at a flow rate of 0,5 ml/min for 60 minutes, detected at 2 channels, 280nm and 780nm. 
 
Cell binding study 
A cell binding assay was performed to confirm the EpCAM specificity of 323/A3-800CW. 
HT29-luc2 (40,000 cells), COLO320 (40,000 cells), OSC-19-luc2-cGFP (25,000 cells), FaDu-luc2 
(35,000 cells), MCF-7-luc2-cGFP (40,000 cells) and MDA-MB-231 cells (40,000 cells) cells were 
seeded in a black 96-well plate (Greiner Bio-one, Germany). At ±90% confluence the cells were 
washed twice with PBS. 323/A3-800CW and MOPC21-800CW were added in a concentration 
range of 0-8 µg/ml and incubated for 1 hour at 37°C. After incubation, the cells were washed 
twice with culture medium without supplements. Bound antibody was imaged with an Odyssey 
scanner (LI-COR), scanning at the 800 nm channel. To correct the fluorescence signal for the 
number of tumour cells per well a cell nucleus staining was performed: The cells were 
fixed/permeabilized with acetone/methanol for 10 minutes, washed with PBS, and incubated 
with TO-PRO-3 (Invitrogen) at 1:1000 for 5 minutes at room temperature. After washing twice 
with PBS, the plate was imaged with the Odyssey scanner at the 700 nm channel to detect TO-
PRO-3 fluorescence. The ratio of the 800 nm and 700 nm fluorescence was plotted. The 
experiments were performed in triplicate.  
 
Animal models  
Nude Balb/c female mice (Charles River laboratories, l’Arbresle, France), aged 4 – 6 weeks, were 
housed in individually ventilated cages and provided with food and sterilized water ad libitum. 
Their general health state was monitored by weight measurements throughout the experiments. 
Tumour growth was monitored longitudinally by visual inspection of the tumours, caliper 
measurements and/or by bioluminescence imaging. Bioluminescence imaging was performed by 
intraperitoneal injecting of 150 mg/kg of D-luciferin solution (SynChem, Inc, Elk Grove Village, 
IL) in PBS, in a total volume of 50 µL. After 10 minutes, mice were imaged with the IVIS 
Spectrum imaging system (PerkinElmer, Waltham, MA, USA). Imaging procedures were 
 
performed under isoflurane gas anaesthesia. The local Animal Welfare Committee of the Leiden 
University Medical Centre approved all animal experiments. 
Colon cancer models: To induce colon tumours, mice were subcutaneously injected at four sites 
with 5 x 105 HT29 cells in 40µL RPMI1640 medium. Tumour growth was followed by calliper 
measurements and after 10 days, when the tumours reached a volume of approximately 75 mm3, 
imaging experiments started. Orthotopic HT29-luc2 tumours were induced as described 
previously[38].  
Breast carcinoma model: To induce orthotopic breast tumours, 2.5 x 105 MCF-7-luc2-cGFP cells 
were inoculated in two contralateral mammary fat pads. Oestrogen pellets (17β-oestradiol, 0.36 
mg/pellet, 60 day release) were implanted subcutaneously. Tumour growth was followed by 
visual inspection and bioluminescence measurements as described above.  
Head-and-neck tumour model: Orthotopic tongue tumours were induced in the tip of the tongue 
through a submucosal injection of 4 x 104 OSC-19-luc2-cGFP cells. When tumours were visible 
and bioluminescence signal ranged between 5 x 109 and 1 x 1010 relative light units (RLU) 
imaging experiments started.  
Peritonitis carcinomatosa: Multiple small MCF-luc2-cGFP tumours were induced in the 
peritoneum by intraperitoneal injection of 2.5 x 105 MCF-luc2-cGFP cells. Tumour growth was 
followed twice a week by bioluminescence as described above. Imaging experiments initiated 
when multiple tumour nodules were formed of various sizes. 
 
NIR fluorescence imaging systems 
Real-time NIR fluorescence imaging and operative resection of the tumours was performed using 
the next generation Artemis imaging system (Quest Medical Imaging, Middenmeer, the 
Netherlands). An earlier iteration of this system was extensively validated[32]. This system has a 
freely moveable handheld camera for simultaneous acquisition of visible light and NIR 
fluorescence. Since the system has been improved such that the camera can be fixed in a stable 
position with an arm, while both camera and arm are covered with a sterile drape. The 
illumination efficiency and homogeneity has been improved with a ring containing eight 
hemispheric illumination lenses centred around a wide field imaging lens for open surgery. 
Illumination is provided by four visible light sources with peaks centred in the blue, cyan, green 
and red and a NIR laser with a peak at 785 nm for fluorescence excitation. Reflected excitation 
light is blocked by a 750-800 nm notch filter. Captured visible and NIR light is split using a prism 
containing a dichroic coating (<785 mm). Visible light additionally passes through a low-pass 
filter (<640 nm) and the NIR emission light is filtered with a high pass filter (>808 nm). 
Exposure times and sensor gains are separately adjustable for both imaging channels. The visible 
light channel, the NIR fluorescence channel and an adjustable overlay of both channels are 
simultaneously presented during the procedures.  
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Next to the Artemis imaging system, the Pearl Impulse small animal imaging system (LI-COR) 
was used as a preclinical reference to visualize tumours and calculate the tumour-to-background 
ratios (TBRs). Data from the Artemis and Pearl imaging systems were analysed using imageJ (W. 
Rasband, Bethesda, Maryland) and the Pearl Cam Software, respectively.  
 
NIR fluorescence measurements 
Subcutaneous HT29 colon tumours were used to confirm in vivo EpCAM specificity of 323/A3-
800CW and to measure fluorescence over time. When the subcutaneous HT29 colon tumours 
were 36 ± 6 mm2, 1 nmol (≈150µg) of 323/A3-800CW (n=3), 1 nmol (≈150µg) MOPC-800CW 
(n=3) or 1 nmol (≈1.1 µg) of 800CW carboxylate was injected intravenously. NIR fluorescence 
signals were measured at 0, 4, 24, 48, 72 and 96 hours after injection using the PEARL small 
animal imaging system and the intraoperative Artemis imaging system after which TBRs were 
calculated. After in vivo confirmation of the EpCAM specificity and establishment of the optimal 
time frame for imaging with the subcutaneous model, the clinically more relevant orthotopic 
MCF-7-luc2-cGFP breast, OSC-19-luc2-cGFP tongue and HT29-luc2 colon tumours were 
evaluated. Hence, 1 nmol of 323/A3-800CW (n=3) or 1 nmol MOPC21-800CW (n=3) was 
intravenously injected in each group. Fluorescence imaging of mice bearing orthotopic tumours 
was performed 72 hours after administration for optimal TBR as determined in the subcutaneous 
HT29 colon carcinoma model. TBRs of orthotopic tumours were measured and tumours were 
resected under NIR fluorescence guidance using the Artemis imaging system. Ex vivo, fluorescent 
measurements of resected tissue were performed on a back table. Tumours were sliced and 
fluorescence measurements were performed on the sections to evaluate the distribution of the 
probe. Resected tumours from the head-and-neck cancer and breast cancer models were assessed 
by BLI imaging and GFP fluorescence imaging (OSC-19-luc2-cGFP and MCF-7-luc2-cGFP, 
IVIS spectrum). The MCF-luc2-cGFP peritonitis carcinomatosa tumour model was used to 
determine the minimal tumour sizes that could be detected by intra-operative fluorescence 
imaging using the EpCAM specific antibody 323/A3-800CW in combination with 2 imaging 
systems. Because an enhanced permeability and retention (EPR) effect in these micrometases is 
not expected as indicated recently by Hall et al.[36] no MOPC21-800CW control was used in this 
model. Mice were anesthetized 72 hours after intravenous injection of 323/A3-800CW (1 nmol, 
n = 3), as described above and fluorescence imaging using the Pearl and Artemis imaging system 
was performed. A midline abdominal incision was made and the abdominal skin was removed. 
Fluorescence imaging of the mice with both imaging systems was performed followed by 
resection of the peritoneum and again fluorescence images were taken. Fluorescence imaging of 
the abdominal area was performed to search for residual intraperitoneal tumour nodules. 
Presence of tumour nodules and tumour specific NIR fluorescence was confirmed by 
bioluminescence imaging and GFP fluorescence imaging, as described before. Receiver Operator 
 
Curve (ROC) analysis was performed for the detection of micrometastases in the peritoneum. 
The overlay of BLI and GFP was used as the ground truth for tumour metastases and the 
ascending TBRs as positive cutoff criteria. The area under the curve (AUC) was computed and 
the sensitivity and specificity rates at the optimal TBR cutoff were found. The signals of NIR 
fluorescence and the overlay with BLI and GFP was confirmed against pathology in the primary 
tumour but not in the micrometastases. Multiple regions of interest were drawn in the tumour 
and in adjacent normal tissue and divided by each other to calculate TBRs. TBRs of 
subcutaneous colon and orthotopic breast tumours were calculated with skin overlying the 
tumour and adjacent normal tissue. Tongue tumours were imaged through an epithelial cell layer 
covering the tumour and normal tissue. For colon tumours the peritoneum was opened. 
 
In vivo competition study 
Three of the six nude Balb/C mice with bilateral orthotopic MCF-7-luc2-cGFP breast tumours 
were pre-injected with unconjugated 323/A3 antibody (1 mg, intraperitoneal, 100 µL). After 48 
hours, all six mice were intravenously injected with 1 nmol 323/A3-800CW. Then, 72 hours after 
injection of 323/A3-800CW fluorescence imaging of all mice was performed using a Pearl 
imaging system. Mice were sacrificed and tumours were collected. Quantification of fluorescence 
was done as described before (Oliveira et al., 2012). In brief, tumours were resected and lysed 
with a TissueLyser II system (Qiagen, Venlo, The Netherlands) using pre-cooled Eppendorf tube 
holders, 5-mm stainless steel beads, and RIPA buffer supplemented with a complete EDTA-free 
mini tablet protease inhibitor cocktail. Homogenates were serially diluted in 96-well plates, in 
parallel with a probe dilution. The fluorescence intensity of both series was detected at 800 nm 
using the Odyssey scanner. The concentration of probe in the homogenates was extrapolated 
from the calibration curves and the concentration values were used to calculate the injected dose 
per gram of tissue (% ID/g) with standard error of the mean (SEM) indicated per group, based 
on the volume of the homogenate and the weight of the tumours. 
 
Histology and NIR fluorescence microscopy 
After ex vivo fluorescence measurements, tumours were snap frozen in isopentane and kept at -
80°C. Tissues were sectioned at 10 µm and fluorescence imaging was performed using the 
Odyssey imager. The presence of OSC-19-luc2-cGFP and MCF-7-luc2-cGFP tumour cells was 
confirmed by fluorescence microscopy (Nikon Eclipse e800). All histologic sections were stained 
with standard haematoxylin-eosin stain (HE) after acetone fixation. To confirm the presence of 
HT29 and HT29-luc2 cells, sections were stained with an anti-human wide-spectrum cytokeratin 
antibody (Abcam inc., Cambridge, MA, USA). Primary antibodies or controls were incubated for 
60 minutes at room temperature. All slides were three times washed with PBS and incubated with 
Envision anti-rabbit (DAKO) for thirty minutes at room temperature. Subsequently, the slides 
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Next to the Artemis imaging system, the Pearl Impulse small animal imaging system (LI-COR) 
was used as a preclinical reference to visualize tumours and calculate the tumour-to-background 
ratios (TBRs). Data from the Artemis and Pearl imaging systems were analysed using imageJ (W. 
Rasband, Bethesda, Maryland) and the Pearl Cam Software, respectively.  
 
NIR fluorescence measurements 
Subcutaneous HT29 colon tumours were used to confirm in vivo EpCAM specificity of 323/A3-
800CW and to measure fluorescence over time. When the subcutaneous HT29 colon tumours 
were 36 ± 6 mm2, 1 nmol (≈150µg) of 323/A3-800CW (n=3), 1 nmol (≈150µg) MOPC-800CW 
(n=3) or 1 nmol (≈1.1 µg) of 800CW carboxylate was injected intravenously. NIR fluorescence 
signals were measured at 0, 4, 24, 48, 72 and 96 hours after injection using the PEARL small 
animal imaging system and the intraoperative Artemis imaging system after which TBRs were 
calculated. After in vivo confirmation of the EpCAM specificity and establishment of the optimal 
time frame for imaging with the subcutaneous model, the clinically more relevant orthotopic 
MCF-7-luc2-cGFP breast, OSC-19-luc2-cGFP tongue and HT29-luc2 colon tumours were 
evaluated. Hence, 1 nmol of 323/A3-800CW (n=3) or 1 nmol MOPC21-800CW (n=3) was 
intravenously injected in each group. Fluorescence imaging of mice bearing orthotopic tumours 
was performed 72 hours after administration for optimal TBR as determined in the subcutaneous 
HT29 colon carcinoma model. TBRs of orthotopic tumours were measured and tumours were 
resected under NIR fluorescence guidance using the Artemis imaging system. Ex vivo, fluorescent 
measurements of resected tissue were performed on a back table. Tumours were sliced and 
fluorescence measurements were performed on the sections to evaluate the distribution of the 
probe. Resected tumours from the head-and-neck cancer and breast cancer models were assessed 
by BLI imaging and GFP fluorescence imaging (OSC-19-luc2-cGFP and MCF-7-luc2-cGFP, 
IVIS spectrum). The MCF-luc2-cGFP peritonitis carcinomatosa tumour model was used to 
determine the minimal tumour sizes that could be detected by intra-operative fluorescence 
imaging using the EpCAM specific antibody 323/A3-800CW in combination with 2 imaging 
systems. Because an enhanced permeability and retention (EPR) effect in these micrometases is 
not expected as indicated recently by Hall et al.[36] no MOPC21-800CW control was used in this 
model. Mice were anesthetized 72 hours after intravenous injection of 323/A3-800CW (1 nmol, 
n = 3), as described above and fluorescence imaging using the Pearl and Artemis imaging system 
was performed. A midline abdominal incision was made and the abdominal skin was removed. 
Fluorescence imaging of the mice with both imaging systems was performed followed by 
resection of the peritoneum and again fluorescence images were taken. Fluorescence imaging of 
the abdominal area was performed to search for residual intraperitoneal tumour nodules. 
Presence of tumour nodules and tumour specific NIR fluorescence was confirmed by 
bioluminescence imaging and GFP fluorescence imaging, as described before. Receiver Operator 
 
Curve (ROC) analysis was performed for the detection of micrometastases in the peritoneum. 
The overlay of BLI and GFP was used as the ground truth for tumour metastases and the 
ascending TBRs as positive cutoff criteria. The area under the curve (AUC) was computed and 
the sensitivity and specificity rates at the optimal TBR cutoff were found. The signals of NIR 
fluorescence and the overlay with BLI and GFP was confirmed against pathology in the primary 
tumour but not in the micrometastases. Multiple regions of interest were drawn in the tumour 
and in adjacent normal tissue and divided by each other to calculate TBRs. TBRs of 
subcutaneous colon and orthotopic breast tumours were calculated with skin overlying the 
tumour and adjacent normal tissue. Tongue tumours were imaged through an epithelial cell layer 
covering the tumour and normal tissue. For colon tumours the peritoneum was opened. 
 
In vivo competition study 
Three of the six nude Balb/C mice with bilateral orthotopic MCF-7-luc2-cGFP breast tumours 
were pre-injected with unconjugated 323/A3 antibody (1 mg, intraperitoneal, 100 µL). After 48 
hours, all six mice were intravenously injected with 1 nmol 323/A3-800CW. Then, 72 hours after 
injection of 323/A3-800CW fluorescence imaging of all mice was performed using a Pearl 
imaging system. Mice were sacrificed and tumours were collected. Quantification of fluorescence 
was done as described before (Oliveira et al., 2012). In brief, tumours were resected and lysed 
with a TissueLyser II system (Qiagen, Venlo, The Netherlands) using pre-cooled Eppendorf tube 
holders, 5-mm stainless steel beads, and RIPA buffer supplemented with a complete EDTA-free 
mini tablet protease inhibitor cocktail. Homogenates were serially diluted in 96-well plates, in 
parallel with a probe dilution. The fluorescence intensity of both series was detected at 800 nm 
using the Odyssey scanner. The concentration of probe in the homogenates was extrapolated 
from the calibration curves and the concentration values were used to calculate the injected dose 
per gram of tissue (% ID/g) with standard error of the mean (SEM) indicated per group, based 
on the volume of the homogenate and the weight of the tumours. 
 
Histology and NIR fluorescence microscopy 
After ex vivo fluorescence measurements, tumours were snap frozen in isopentane and kept at -
80°C. Tissues were sectioned at 10 µm and fluorescence imaging was performed using the 
Odyssey imager. The presence of OSC-19-luc2-cGFP and MCF-7-luc2-cGFP tumour cells was 
confirmed by fluorescence microscopy (Nikon Eclipse e800). All histologic sections were stained 
with standard haematoxylin-eosin stain (HE) after acetone fixation. To confirm the presence of 
HT29 and HT29-luc2 cells, sections were stained with an anti-human wide-spectrum cytokeratin 
antibody (Abcam inc., Cambridge, MA, USA). Primary antibodies or controls were incubated for 
60 minutes at room temperature. All slides were three times washed with PBS and incubated with 
Envision anti-rabbit (DAKO) for thirty minutes at room temperature. Subsequently, the slides 
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were washed with PBS and staining was visualized by using 3,3-diaminobenzidine. Sections were 
counterstained with haematoxylin, dehydrated and mounted with pertex. Frozen OSC-19-luc2-
cGFP and MCF-7-luc2-cGFP tumours were stained with an anti-cGFP staining (Evrogen, 
Moscow, Russia). Sections stained with anti-cGFP were fixated with 4% formalin for 10 minutes.  
After washing with PBS, cells were treated with 0,1% saponin/PBS for 10 minutes and incubated 
with the anti-GFP antibody, diluted in 0,1% saponin/PBS for 60 minutes at room temperature. 
Adjacent sections were fixated with aceton for 10 minutes followed by three washes with PBS 
and stained for cytokeratin as described before.  
 
Statistical analysis 
For statistical analysis, SPSS statistical software package (version 20.0 for Windows, IBM SPSS 
Inc, Chicago, USA) was used. TBRs were calculated by dividing the fluorescent signal of the 
tumour by fluorescent signal of surrounding healthy tissue. TBRs are reported in mean and 
standard deviation. A two-way repeated measurement ANOVA was used to assess the relation 
between TBRs in the dose groups and time points. Furthermore a paired Student’s t-test was 
used to calculate the overall difference between the EpCAM specific and control groups. The 
two-way repeated measurement ANOVA was corrected using the Bonferroni correction. A P-
value equal or lower than 0.05 was considered significant.  
  
 
Results 
 
EpCAM expression on human cancer cell lines 
The colon adenocarcinoma cell line HT29 showed intermediate high expression of EpCAM 
while COLO320 hardly had any EpCAM expression (200,000 versus <1000 EpCAM/cell), see 
Figure 1A). For MCF-7 breast cancer cells similar EpCAM over-expression was observed as for 
HT29, whereas considerably less expression was seen in MDA-MB-231 cells, as described 
previously  (Figure 1B). For head-and-neck cancer cells, the human hypopharyngeal squamous 
cell carcinoma cell line FaDu-luc2 and the oral squamous cell carcinoma cell line OSC-19 showed 
similar intermediate EpCAM expression (Figure 1C). For all cancer cell lines the control antibody 
MOPC21 showed no significant signal. EpCAM expressing cell-lines MCF-7 and OSC-19 were 
transfected with GFP and luciferase and were, next to HT29-luc2 used for further in vivo 
experiments. 
 
Figure 1 - EpCAM expression:  EpCAM overexpression was present in all cell lines except in COLO320 cells. 
Expression of EpCAM was analyzed in human colon (A, HT29-luc2, COLO320), breast (B, MCF-7, MDA-MB231) 
and head & neck (C, OSC-19, FaDu-luc2) cancer. Cells were incubated with an anti-EpCAM antibody (323/A3) or an 
isotype normal mouse IgG (MOPC21). After washing, cells were incubated with fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG antibody. The anti-mouse antibody was solely used as a control (conjugate). 
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were washed with PBS and staining was visualized by using 3,3-diaminobenzidine. Sections were 
counterstained with haematoxylin, dehydrated and mounted with pertex. Frozen OSC-19-luc2-
cGFP and MCF-7-luc2-cGFP tumours were stained with an anti-cGFP staining (Evrogen, 
Moscow, Russia). Sections stained with anti-cGFP were fixated with 4% formalin for 10 minutes.  
After washing with PBS, cells were treated with 0,1% saponin/PBS for 10 minutes and incubated 
with the anti-GFP antibody, diluted in 0,1% saponin/PBS for 60 minutes at room temperature. 
Adjacent sections were fixated with aceton for 10 minutes followed by three washes with PBS 
and stained for cytokeratin as described before.  
 
Statistical analysis 
For statistical analysis, SPSS statistical software package (version 20.0 for Windows, IBM SPSS 
Inc, Chicago, USA) was used. TBRs were calculated by dividing the fluorescent signal of the 
tumour by fluorescent signal of surrounding healthy tissue. TBRs are reported in mean and 
standard deviation. A two-way repeated measurement ANOVA was used to assess the relation 
between TBRs in the dose groups and time points. Furthermore a paired Student’s t-test was 
used to calculate the overall difference between the EpCAM specific and control groups. The 
two-way repeated measurement ANOVA was corrected using the Bonferroni correction. A P-
value equal or lower than 0.05 was considered significant.  
  
 
Results 
 
EpCAM expression on human cancer cell lines 
The colon adenocarcinoma cell line HT29 showed intermediate high expression of EpCAM 
while COLO320 hardly had any EpCAM expression (200,000 versus <1000 EpCAM/cell), see 
Figure 1A). For MCF-7 breast cancer cells similar EpCAM over-expression was observed as for 
HT29, whereas considerably less expression was seen in MDA-MB-231 cells, as described 
previously  (Figure 1B). For head-and-neck cancer cells, the human hypopharyngeal squamous 
cell carcinoma cell line FaDu-luc2 and the oral squamous cell carcinoma cell line OSC-19 showed 
similar intermediate EpCAM expression (Figure 1C). For all cancer cell lines the control antibody 
MOPC21 showed no significant signal. EpCAM expressing cell-lines MCF-7 and OSC-19 were 
transfected with GFP and luciferase and were, next to HT29-luc2 used for further in vivo 
experiments. 
 
Figure 1 - EpCAM expression:  EpCAM overexpression was present in all cell lines except in COLO320 cells. 
Expression of EpCAM was analyzed in human colon (A, HT29-luc2, COLO320), breast (B, MCF-7, MDA-MB231) 
and head & neck (C, OSC-19, FaDu-luc2) cancer. Cells were incubated with an anti-EpCAM antibody (323/A3) or an 
isotype normal mouse IgG (MOPC21). After washing, cells were incubated with fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG antibody. The anti-mouse antibody was solely used as a control (conjugate). 
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Conjugation, characterization and serum stability of 323/A3-800CW 
Both the EpCAM specific (323/A3) and the control antibody (MOPC21) were labelled with 
IRDye 800CW (Figure 2A) in comparable mean dye:antibody ratios of respectively 2.6 ± 0.9 and 
2.8 ± 0.9, as determined spectrophotometrically, according to the protocol of the manufacturer 
of the dye. Plate assays containing both high and low EpCAM expressing cell lines were utilized 
to confirm EpCAM specificity of 323/A3-800CW after conjugation. A significant (p < 0.01) 
difference was observed between 323/A3-800CW and MOPC21-800CW signals on MCF-7, 
HT29, OSC-19 and FaDu cells, but not on the low EpCAM expressing COLO320 and MB- 
 
Figure 2 – Conjugation, serum stability and EpCAM specificity: Conjugation of IRDye 800CW to 323/A3 and 
MOPC21 was done through NHS ester conjugation. A mean labeling ratio of 2.6 ± 0.98 and 2.8 ± 0.99 was obtained 
for 323/A3 and MOPC21 respectively (A). EpCAM specificity of 323/A3 was confirmed after conjugation of IRDye 
800CW on various cell types, corrected for cell number using the 800/700nm ratio (B). Experiments were done in 
human colon (HT29-luc2, COLO320), breast (MCF-7-luc2-cGFP, MDA-MB231) and head & neck (OSC-19-luc2-
cGFP, FaDu-luc2) cancer. Cells were incubated with different concentrations of 323/A3-800CW or an isotype normal 
mouse IgG (MOPC21) conjugated to 800CW. To correct for the number of cells, the ratio of NIR fluorescence and 
the fluorescence intensity of TO-PRO-3 was plotted. 323/A3-800CW showed to be stable in human serum with more 
than 60% of the conjugate still free to bind EpCAM after 96 hours with the remaining 40% aggregated or bound to 
albumin (C). 
 
MDA-231 cells (Figure 2B). The fluorescence intensity of MOPC21-800CW showed a slight 
concentration dependent increase as a result of non-specific binding. The results are in 
accordance to the EpCAM expression found using flow cytometry results of the antibodies 
without 800CW label, as shown in Figure 1. The increase in concentration resulted in a plateau in 
fluorescence intensity in MDA-MB-231, OSC-19 and FaDu cells. A further increase in 
concentration did not increase signal intensity. This phenomenon was not seen in MCF-7 and 
 
HT29 cells, possibly due to the high EpCAM expression. The EpCAM specific conjugate 
showed to be stable in human serum with more than 60% of the conjugate still free to bind 
EpCAM after 96 hours with the remaining 40% aggregated or bound to albumin (Figure 2C).  
 
Intra-operative NIR fluorescence tumour delineation and resection 
In vivo specificity of 323/A3-800CW was shown by competition with unconjugated antibody. 
Pre-injection of 1 mg unconjugated 323/A3, resulted in a decrease of the percentage of injected 
dose per gram of tumour from 3.2±0.9 % ID/g to 1.0±0.1 % ID/g (p< 0.01, n=3 in both 
groups), see figure 3A. 
 
Figure 3 – EpCAM specificity and intra-operative tumour-to-background ratios (TBR’s): Competition with 1 
mg of cold 323/A3 antibody significantly decreased the percentage of injected dose 323/A3-800CW per gram tumour 
(%ID/gram) indicating in vivo tumour specificity (A). After development of subcutaneous HT29-luc2 tumours, 1 nmol 
(150ug) of 323/A3-800CW, MOPC21-800CW and IRDye 800CW was injected intravenously. TBR’s were calculated 
from 4 hours to 120 hours after injection (B). Subsequently, 1 nmol (150ug) 323/A3-800CW and MOPC21-800CW 
was intravenously injected in mice bearing orthotopic colon (HT29-luc2), breast (MCF-7-luc2-cGFP) and tongue 
(OSC-19-luc2-cGFP) tumours (C). TBR’s were calculated 72 hours post injection. TBR’s of EpCAM specific antibody 
323/A3-800CW in colon, breast and head & neck cancer are significantly higher compared to those of the control 
antibody MOPC21-800CW. 
 
The HT29 subcutaneous tumour model was used to assess the feasibility of  intraoperative 
fluorescence delineation using 1 nmol (150ug) intravenous 323/A3-800CW  combined with the 
Artemis imaging system. Tumours could be clearly delineated from 4 hours post injection and an 
increase in TBR was seen with highest values at 72 hours post-injection (5.2 ± 0.7, Figure 3B). 
After 72 hours the TBR slightly decreased. Significant differences in TBR (p< 0.01) between 
EpCAM specific (323/A3-800CW) and non-specific control (MOPC21-800CW) could be 
observed from 24 hours post injection (TBR 3.2 ± 0.1 and 1.7 ± 0.2 respectively). MOPC21-
800CW and IRDye 800CW showed a significantly lower TBR at all time points (p < 0.01). Based 
on the results from the subcutaneous tumour model an optimal incubation time of 72 hours was 
used to evaluate NIR fluorescence in clinically more realistic orthotopic mouse models for colon, 
breast and head-and-neck cancer. After exploration of the tumour, we assessed the feasibility of 
fluorescence-guided resection and chose suitable resection margins with the real-time NIR 
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Conjugation, characterization and serum stability of 323/A3-800CW 
Both the EpCAM specific (323/A3) and the control antibody (MOPC21) were labelled with 
IRDye 800CW (Figure 2A) in comparable mean dye:antibody ratios of respectively 2.6 ± 0.9 and 
2.8 ± 0.9, as determined spectrophotometrically, according to the protocol of the manufacturer 
of the dye. Plate assays containing both high and low EpCAM expressing cell lines were utilized 
to confirm EpCAM specificity of 323/A3-800CW after conjugation. A significant (p < 0.01) 
difference was observed between 323/A3-800CW and MOPC21-800CW signals on MCF-7, 
HT29, OSC-19 and FaDu cells, but not on the low EpCAM expressing COLO320 and MB- 
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800CW on various cell types, corrected for cell number using the 800/700nm ratio (B). Experiments were done in 
human colon (HT29-luc2, COLO320), breast (MCF-7-luc2-cGFP, MDA-MB231) and head & neck (OSC-19-luc2-
cGFP, FaDu-luc2) cancer. Cells were incubated with different concentrations of 323/A3-800CW or an isotype normal 
mouse IgG (MOPC21) conjugated to 800CW. To correct for the number of cells, the ratio of NIR fluorescence and 
the fluorescence intensity of TO-PRO-3 was plotted. 323/A3-800CW showed to be stable in human serum with more 
than 60% of the conjugate still free to bind EpCAM after 96 hours with the remaining 40% aggregated or bound to 
albumin (C). 
 
MDA-231 cells (Figure 2B). The fluorescence intensity of MOPC21-800CW showed a slight 
concentration dependent increase as a result of non-specific binding. The results are in 
accordance to the EpCAM expression found using flow cytometry results of the antibodies 
without 800CW label, as shown in Figure 1. The increase in concentration resulted in a plateau in 
fluorescence intensity in MDA-MB-231, OSC-19 and FaDu cells. A further increase in 
concentration did not increase signal intensity. This phenomenon was not seen in MCF-7 and 
 
HT29 cells, possibly due to the high EpCAM expression. The EpCAM specific conjugate 
showed to be stable in human serum with more than 60% of the conjugate still free to bind 
EpCAM after 96 hours with the remaining 40% aggregated or bound to albumin (Figure 2C).  
 
Intra-operative NIR fluorescence tumour delineation and resection 
In vivo specificity of 323/A3-800CW was shown by competition with unconjugated antibody. 
Pre-injection of 1 mg unconjugated 323/A3, resulted in a decrease of the percentage of injected 
dose per gram of tumour from 3.2±0.9 % ID/g to 1.0±0.1 % ID/g (p< 0.01, n=3 in both 
groups), see figure 3A. 
 
Figure 3 – EpCAM specificity and intra-operative tumour-to-background ratios (TBR’s): Competition with 1 
mg of cold 323/A3 antibody significantly decreased the percentage of injected dose 323/A3-800CW per gram tumour 
(%ID/gram) indicating in vivo tumour specificity (A). After development of subcutaneous HT29-luc2 tumours, 1 nmol 
(150ug) of 323/A3-800CW, MOPC21-800CW and IRDye 800CW was injected intravenously. TBR’s were calculated 
from 4 hours to 120 hours after injection (B). Subsequently, 1 nmol (150ug) 323/A3-800CW and MOPC21-800CW 
was intravenously injected in mice bearing orthotopic colon (HT29-luc2), breast (MCF-7-luc2-cGFP) and tongue 
(OSC-19-luc2-cGFP) tumours (C). TBR’s were calculated 72 hours post injection. TBR’s of EpCAM specific antibody 
323/A3-800CW in colon, breast and head & neck cancer are significantly higher compared to those of the control 
antibody MOPC21-800CW. 
 
The HT29 subcutaneous tumour model was used to assess the feasibility of  intraoperative 
fluorescence delineation using 1 nmol (150ug) intravenous 323/A3-800CW  combined with the 
Artemis imaging system. Tumours could be clearly delineated from 4 hours post injection and an 
increase in TBR was seen with highest values at 72 hours post-injection (5.2 ± 0.7, Figure 3B). 
After 72 hours the TBR slightly decreased. Significant differences in TBR (p< 0.01) between 
EpCAM specific (323/A3-800CW) and non-specific control (MOPC21-800CW) could be 
observed from 24 hours post injection (TBR 3.2 ± 0.1 and 1.7 ± 0.2 respectively). MOPC21-
800CW and IRDye 800CW showed a significantly lower TBR at all time points (p < 0.01). Based 
on the results from the subcutaneous tumour model an optimal incubation time of 72 hours was 
used to evaluate NIR fluorescence in clinically more realistic orthotopic mouse models for colon, 
breast and head-and-neck cancer. After exploration of the tumour, we assessed the feasibility of 
fluorescence-guided resection and chose suitable resection margins with the real-time NIR 
118 Chapter 5
 
fluorescence feedback of 323/A3-800CW and the Artemis imaging system. All tumours were 
radically resected as confirmed by BLI evaluation. Significant differences (p < 0.01) in TBRs 
were observed between the orthotopic colon (HT29) mice injected with 323/A3-800CW (TBR 
13.5 ± 3.6) and MOPC21-800CW (TBR 1.8 ± 0.4) (Figure 3C). For the breast (MCF-7) and 
head-and-neck (OSC-19) cancer models, 323/A3-800CW showed TBRs of 6.7 ± 1.9 and 4.9 ± 
0.7 respectively (Figure 3C). Significantly lower TBR values of 1.9 ± 0.1 and 1.6 ± 0.2 were 
observed for MOPC21-800CW in breast and head-and-neck cancer respectively (p < 0.01). 
Examples of in vivo and ex vivo images that were acquired with the Artemis imaging system after 
injection of 323/A3-800CW or MOPC21-800CW are shown for the orthotopic colon (Figure 4A 
& 4B), breast (Figure 4C) and head-and-neck cancer model (Figure 4D). Camera exposure time 
and gain were intra-operatively adjusted to obtain optimal image contrast. The most important 
factors influencing measured fluorescent intensities were sample fluorescence intensity, camera 
settings and the coupled distance to sample of both illumination source and camera. The Artemis 
camera is not calibrated for absolute intensity measurements (e.g. in lumen), hampering absolute 
intensity comparisons between images.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Intra-operative NIR fluorescence delineation of colon, breast and Head & Neck cancer: Colon (A, 
B), breast (C) and head & neck tumours (D) could clearly be visualized during operation using EpCAM specific 
323/A3-800CW (TBR colon 13.5, breast 6.7 and Head-and-neck 4.9) and the Artemis imaging system. 323/A3-
800CW (A, C, D, 1 nmol) and the non-specific antibody MOPC21-800CW (B, 1 nmol) were intravenously injected.  
After an incubation of 72 hours NIR fluorescence imaging was performed. Depicted images are: bright light, 
fluorescence, overlay (fluorescence and bright light), ex vivo fluorescence and ex vivo overlay. Scale bars are 5 mm . 
Artemis fluorescence intensities were intra-operatively optimized for optimal contrast. Intensities can only be 
compared within images. 
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fluorescence feedback of 323/A3-800CW and the Artemis imaging system. All tumours were 
radically resected as confirmed by BLI evaluation. Significant differences (p < 0.01) in TBRs 
were observed between the orthotopic colon (HT29) mice injected with 323/A3-800CW (TBR 
13.5 ± 3.6) and MOPC21-800CW (TBR 1.8 ± 0.4) (Figure 3C). For the breast (MCF-7) and 
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Figure 4 – Intra-operative NIR fluorescence delineation of colon, breast and Head & Neck cancer: Colon (A, 
B), breast (C) and head & neck tumours (D) could clearly be visualized during operation using EpCAM specific 
323/A3-800CW (TBR colon 13.5, breast 6.7 and Head-and-neck 4.9) and the Artemis imaging system. 323/A3-
800CW (A, C, D, 1 nmol) and the non-specific antibody MOPC21-800CW (B, 1 nmol) were intravenously injected.  
After an incubation of 72 hours NIR fluorescence imaging was performed. Depicted images are: bright light, 
fluorescence, overlay (fluorescence and bright light), ex vivo fluorescence and ex vivo overlay. Scale bars are 5 mm . 
Artemis fluorescence intensities were intra-operatively optimized for optimal contrast. Intensities can only be 
compared within images. 
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Detection of small tumour sizes  
Four weeks after the intra-peritoneal injection of MCF-7-luc2-cGFP cells multiple tumours were 
observed by BLI imaging. Millimetre size tumour nodules located on the peritoneum, which were 
not visual by the naked eye, could be observed by NIR fluorescence imaging after injection of 1 
nmol (150ug) 323/A3-800CW, using both the Pearl and Artemis imaging system (Figure 5). After 
the peritoneum was resected, BLI confirmed that intra-peritoneal metastases could be detected 
by NIR fluorescence imaging (Figure 5). As in Figure 4, camera exposure time and gain were 
adjusted to obtain optimal contrast. ROC curve analysis (Figure 5) showed an accuracy of 98% 
(area under the curve, p < 0.0001) for detecting micro metastases with a sensitivity of 93% and 
specificity of 92% at the curve’s optimal TBR cutoff value. A cutoff value obtaining the highest 
sensitivity of 100% correlates with a specificity of 73%. A specificity of 100% on the other hand 
correlates with a sensitivity of 84%.  
 
 
Figure 5 – tumour detection limit: Submillimeter sized intra-peritoneal metastases could clearly be visualized using 
EpCAM specific 323/A3-800CW and the Artemis system. MCF-7-luc2-cGFP cells were injected intraperitoneal. After 
the development of multiple tumours, 1 nmol (150ug) 323/A3-800CW was injected intravenously. NIR fluorescence 
imaging was performed after 72 hours of incubation using the Pearl and Artemis system. Confirmation of tumour 
tissue was performed by Green Fluorescent Protein (GFP) fluorescence imaging or Bioluminescence Imaging (BLI) 
using the IVIS spectrum. Micrometastases (arrow) of the colon could be discovered by NIR fluorescence imaging after 
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Figure 6 – Histology: 323/A3-800CW is specifically located in head-and-neck (A, B), breast (C), and colon (D) 
tumours. Tumour tissue was sectioned 72 hours after injection of 323/A3-800CW, MOPC21-800CW or IRDye 
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islands (*) are NIR fluorescent. A low, non specific fluorescence signal was observed in sections with MOPC21-
800CW and IRDye 800CW (B). T = tumour; N = normal tissue; C = center tumour; B = tumour border. A and B 1x 
zoom; C and D 10x zoom 
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Detection of small tumour sizes  
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specificity of 92% at the curve’s optimal TBR cutoff value. A cutoff value obtaining the highest 
sensitivity of 100% correlates with a specificity of 73%. A specificity of 100% on the other hand 
correlates with a sensitivity of 84%.  
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tissue was performed by Green Fluorescent Protein (GFP) fluorescence imaging or Bioluminescence Imaging (BLI) 
using the IVIS spectrum. Micrometastases (arrow) of the colon could be discovered by NIR fluorescence imaging after 
resection of the peritoneum. ROC curve analysis of TBR of fluorescent spots in the peritoneum. True positive rate was 
plotted versus false-positive rate using ascending positive cutoff values.  B = bladder. Scale bars are 5 mm. Artemis 
fluorescence intensities were intra-operatively optimized for optimal contrast. Intensities can only be compared within 
images. 
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intensity and localization of 323/A3-800CW, MOPC-800CW and IRDye 800CW in tissue 
sections of tongue tumours, surrounded by normal tissue of the tongue. Fluorescence of 
323/A3-800CW co-localized with the outer part of the tumour bulk and with small peninsulas of 
tumour cells (Figure 6A). Fluorescence intensity of MOPC21-800CW and IRDye 800CW was 
hardly visible and did not show association with tumour tissue (Figure 6B). In both, breast and 
colon cancer tissue sections NIR fluorescence appeared in the outer rim of tumour tissue. (Figure 
6C and D). In colon cancer clear co-localization of small tumour islands and NIR fluorescence 
(indicated in red) was observed with 323/A3-800CW (Figure 6D). Cytokeratin staining (brown) 
was performed to confirm the presence of colonic tumour cells in sections of orthotopic colon 
tumours (Figure 6D). 
  
 
Discussion 
 
In this study we investigated an EpCAM-specific NIR-fluorescent agent using a state-of-the-art 
next generation clinical NIR imaging system. The recent technical developments stimulate the 
use of advanced but affordable imaging systems in the clinic. The Artemis imaging system 
simultaneously acquires NIR-fluorescent and visible light, generating a merged image in real-time. 
Systems like this will boost the demand for specific tumour probes dramatically. 
 
The EpCAM directed antibody in this study has been extensively evaluated for imaging of 
various tumour models using radionuclides Technetium, Zirconium, Iodium and Rhenium [30, 
31, 39]. Typically, in these experiments 15-20 µg of conjugate was used per mouse to obtain clear 
tumour signals in subcutaneous breast, colon and ovarian tumours. Using the same antibody but 
conjugated to a NIR dye and in combination with a state of the art NIR-fluorescence imager, we 
showed that 1 nmol (=150µg) clearly identified breast, colon and head-and-neck cancers, as well 
as micro-metastases in human orthotopic xenograft mouse models. The probe/system 
combination allowed an accurate demarcation of the tumours, the recognition of tumour 
margins, examination of malignant spread, and identification of micrometre sized metastasis or 
remnant disease.  
 
A probe against a ‘universal’ target facilitates clinical usability, and prevents time consuming and 
costly development of multiple agents. Although EpCAM is considered to be a potential target 
for epithelial derived cancers, not all epithelial cancers over-express EpCAM enough to outflank 
adjacent normal tissue. But on the other hand not all tumours of mesenchymal origin are 
EpCAM negative. Over-expression of EpCAM was recently observed in all osteosarcomas, half 
of the angiosarcomas and 62.5% of the leiomyosarcomas, indicating the broad spectrum of 
tumours that might be targeted [40]. 
 
In breast cancer, 20% of tumours that seem radically resected during surgery turn out to be 
irradically removed in histologic analyses. Consequently, FGS in breast cancer could enhance the 
number of radical resections without increasing margins, thus improving patient’s prognoses and 
cosmetic outcomes after lumpectomies and oncoplastic surgery [5, 41]. As pointed out earlier, in 
copies per cell EpCAM can probably not compete with Her2/Neu in the subpopulation of Her2 
positive breast cancers, but in percentage of positive breast tumours EpCAM is clearly the more 
prevalent target. For head-and-neck cancer a relatively low percentage of tumours is irradically 
resected (16%). Due to the many vital structures in the surrounding tissue, resection margins 
should be small and FGS targeting would be of great clinical benefit. EpCAM overexpression is 
seen in 62.5% of tongue tumours [25, 42]. In colorectal cancers 80-100% overexpression of 
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EpCAM is found. Although irradical resections occur, the main problem is damage to vital 
structures in the lower abdomen. Ureteral injury is a rare but serious complication of lower 
abdominal surgery, with a reported incidence varying from 0.7 up to 10% [43]. EpCAM-based 
FGS of colorectal tumours in combination with FGS of the ureters could enhance the number of 
radical resections while preserving vital structures. 
 
In our study, we performed a single injection of 1 nmol (150ug) of 323/A3-800CW to visualize 
tumours. This is the equivalent of 0.5 mg/kg for humans when converted using the body-
surface-area method [44]. Using this dose, subcutaneously located colon tumours were clearly 
recognized from 4 hours after injection with optimal TBRs at 72 hours, showing the feasibility of 
the agent. The 72-hour time-point was utilized to perform surgery at the orthotopic colon, 
breast, and head-and-neck cancer models validating the results from the subcutaneous model in 
clinically more relevant models. At this time point the agent-imaging system combination was 
able to indicate small tumour nodules on the peritoneum or in the abdominal cavity that were 
otherwise only detectable by bioluminescence of these cells. Although we did not study the lower 
boundary of tumour size that could be detected, tumour nodules of 1 mm3 could clearly be 
visualized. Based on the number of cells in spheroids of that size, we estimate the minimal 
number of cells to be detectable above 50,000. Obviously this detection limit is depending on 
multiple factors like the imaging system, optical properties of overlying tissue and the probe. The 
ROC analysis for the detection of micrometastases showed an excellent sensitivity and specificity 
at the optimal TBR cutoff. Nevertheless, a remark has to be added that the ex vivo detection of 
micrometastases in the peritoneum is very opportune because almost no background 
fluorescence is observed in the peritoneum and the detection of metastases is not compromised 
by any tissue depth. Due to the lack of performance standards for clinically applicable imaging 
systems as well as imaging agents, at present, the combination of both is of major importance for 
a successful outcome [45, 46]. 
 
Although the anti-EpCAM/800CW conjugate performed well in various tumour types, this 
probe could still be optimized. The use of antibodies with relatively high affinity, like 323/A3, 
might culminate in heterogeneous tumour staining, concentrated around the tumour 
vascularization rather than homogeneous throughout the tumour. The use of an antibody with 
low or intermediate EpCAM affinity for EpCAM might promote a more homogenous 
distribution and avoid adverse effects at the cost of a lower total tumour uptake [31, 47]. An 
improvement in imaging accuracy without compromising the total tumour uptake could be 
expected by reducing Fc/FcγR interactions through deglycosylation of antibody-based imaging 
as recently demonstrated by Gao et al. [48]. Further, most EpCAM antibodies target actually the 
same EGF-like domain of EpCAM. Antibodies identifying other EpCAM domains, like the C- 
 
domains might improve detection efficiency [49]. The use of any mouse-derived antibody, like 
323/A3, will inevitably induce human anti-mouse antibodies. Although this is not disastrous for 
imaging purposes, where only one single dose is needed, a chimerized or humanized version with 
retained efficacy should be preferred [31]. Last but not least, fragments of antibodies like Fab or 
Fab2 could have higher penetration capabilities compared to full-size antibodies, as shown for 
several antibodies including anti-EpCAM [37, 39, 50]. Using antibody fragments would lead to 
shorter incubation times, making clinical translation more applicable. Moreover, recent 
developments have opened the way for hybrid molecules like immunoenzymosomes, consisting 
of liposomes equipped with 323/A3 Fab fragments for targeting [51]. Alternative probes for pre- 
and intraoperative imaging could also be generated by conjugation of the antibody with 2 
different labels, one for PET/SPECT and one for NIRF imaging like has been done recently[36, 
37, 52, 53]. 
 
In conclusion, FGS is a promising technique to ensure intra-operative fluorescence feedback of 
tumour margins. Clinical success is only achieved by using a dedicated camera system and 
tumour-specific agents. This study aimed to achieve complete preclinical validation of an 
EpCAM targeting fluorescence agent in combination with a next-generation Artemis imaging 
system. We showed the ability to visualize, primary tumours and millimetre sized tumour nodules 
and metastases that were otherwise invisible for the human eye. As a novel EpCAM specific 
optical agent can be used in a wide variety of tumours, together with the knowledge from 
previous clinical trials and the results from this study, this paves the way for a fast and cost 
effective clinical translation.  
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ABSTRACT 
 
Purpose 
Near-infrared (NIR) fluorescence imaging can provide the surgeon with real-time visualization 
of, e.g., tumour margins and lymph nodes. We describe and evaluate the Artemis, a novel, 
handheld NIR fluorescence camera. 
 
Procedures 
We evaluated minimal detectable cell numbers (FaDu-luc2, 7D12-IRDye 800CW), preclinical 
intraoperative detection of sentinel lymph nodes (SLN) using indocyanine green (ICG), and of 
orthotopic tongue tumours using 7D12-800CW. Results were compared with the Pearl imager. 
Clinically, three patients with liver metastases were imaged using ICG. 
 
Results 
Minimum detectable cell counts for Artemis and Pearl were 2×105 and 4×104 cells, respectively. 
In vivo, seven SLNs were detected in four mice with both cameras. Orthotopic OSC-19-luc2-
cGFP tongue tumours were clearly identifiable, and a minimum FaDu-luc2 tumour size of 1 
mm3 could be identified. Six human malignant lesions were identified during three liver surgery 
procedures. 
 
Conclusions 
Based on this study, the Artemis system has demonstrated its utility in fluorescence-guided 
cancer surgery.  
 
Introduction 
 
In surgery, many non-invasive imaging modalities, such as computed tomography (CT), magnetic 
resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron 
emission tomography (PET), are used in a preoperative setting for the detection of tumours and 
for surgical planning. Translating these techniques to the operating room is challenging due to 
altered body positions and tissue manipulation. Therefore, the surgeon still mainly relies on visual 
inspection and tactile information during surgery. New intraoperative imaging modalities that 
support the surgeon in identifying vital structures and discriminating healthy from diseased 
tissues in real-time are needed, which is especially important for laparoscopic procedures where 
the surgeon lacks tactile information. Near-infrared (NIR) fluorescence-guided surgery (FGS) is 
such a novel technique [1, 2]. Compared to SPECT or PET, NIR fluorescence provides high-
resolution images, can visualize microscopically tumour nodules, and can be tumourspecific due 
to targeted exogenous agents [3]. NIR light has the advantage of increased depth penetration and 
decreased autofluorescence compared to visible light [4, 5]. Furthermore, NIR light is invisible to 
the human eye and consequently does not alter the surgical field. The success of FGS in 
recognizing tumours and vital structures depends to a large extent on the imaging system used. In 
an excellent review, Gioux et al. [6] systematically described the required criteria to which a new 
clinically applicable NIR fluorescence camera system has to comply. These requirements are 
translated into a set of practical criteria. The most important criteria for practical application are 
the following: field of view, imaging distance to the patient, maneuverability, simultaneous 
imaging of near-infrared and visible light, real-time imaging, light intensity, sterility, and electrical 
safety. These criteria mainly affect the design choices of the following camera components: 
sensor, lens system, light source, and  filters/dichroic mirrors. Currently, a small number of 
camera systems that fit most of the criteria above are clinically available [7]. The intraoperative 
Artemis imaging system is recently developed within the Center for Translational Molecular 
Medicine (CTMM) consortium. The system is developed in close collaboration with the clinic, 
which resulted in an easily maneuverable system (Fig. 1a) that acquires (NIR) fluorescence and 
white light images simultaneously allowing for a depicted overlay. Furthermore, the Artemis has 
an option to assemble a laparoscope to the camera head, allowing for minimally invasive surgery. 
The goal of this work was to evaluate the Artemis camera in two oncological procedures in 
which real-time NIR fluorescence could be of added value: (a) radical tumour resection and (b) 
the detection of sentinel lymph nodes, the first draining nodes from the tumour. Irradical tumour 
resections are a major problem in cancer surgery. At present, although tumours clinically appear 
to be radically resected, high percentages of microscopically irradical resections have been 
reported at pathological analysis [8, 9]. Such patients require adjuvant treatment and have higher 
risk of tumour recurrence [10, 11]. When performed with an exogenous tumour-specific ligand, 
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NIR FGS enables intraoperative guidance of tumour resections. This potentially decreases the 
relatively high percentages of irradical tumour resections and locoregional recurrences, which 
may lead to increased survival rates and decreased morbidity [8, 9]. The detection of the SLN is 
of vital importance for cancer staging and consequently influences the choice of therapy and 
therefore the survival rates. In breast cancer and melanoma surgery, the SLN procedure is 
presently the standard of care [12]. Currently, two exogenous contrast agents are clinically 
available: indocyanine green (ICG) (800 nm) and methylene blue (700 nm). Both non-specific 
contrast agents are used for the visualization of SLNs, vital structures, and various tumours in the 
clinic [12]. In this study, we performed a preclinical assessment of the sensitivity and 
intraoperative utility of the Artemis in the detection of head-and-neck tumours and SLNs 
preclinically in xenograft mouse models. Images were simultaneously acquired with the Pearl 
Impulse Small Animal Imager (LI-COR), an existing commercially available and commonly used 
imaging system. The Pearl system is expected to be an order of magnitude more sensitive than 
the Artemis, and therefore, these images serve as a ground truth comparison. The Pearl camera 
does not allow real-time imaging. The sample is shed from outside light imaging in a closed box. 
Although benefitting the image quality, the latter two characteristics prevent application of the 
Pearl for intraoperative (pre-)clinical imaging. The Artemis imaging system allows real-time 
imaging and free access to the sample, but imaging takes place at less ideal circumstances than in 
the Pearl. We report the first in-human study performed with the Artemis imaging system where 
colorectal liver metastases were visualized using ICG. 
 
Figure 1 - Artemis NIR imaging system: a The NIR fluorescence imaging Artemis handheld system is positioned on a 
movable trolley. Ring light (1) and lens (2) have to be attached to the handheld camera (3) to obtain NIR fluorescence images.  
Instead of lens and ring light, a scope (4) can be attached to the handheld camera when minimal invasive surgery is applied. B 
Schematic representation of the Artemis camera with light path and filters. The sample is illuminated by a ring light around 
the camera lens. 
 
Materials and Methods 
 
Near-Infrared Camera Systems 
The Artemis camera system was developed by Quest Medical Imaging and the Leiden University 
Medical Center (Fig. 1). Images were acquired using custom-designed cameras in a portable, 
freely moveable camera head. A wide field lens for open surgery was used. Samples were 
illuminated from a ring containing optical fibers (Fig. 1a-1) attached to the lens (Fig. 1a-2) during 
open surgery imaging. A Lumencor light engine was used containing four solid-state light sources 
for visible light illumination with peak intensities in the blue, cyan, green, and red. For NIR 
fluorescence imaging, an NIR laser with a peak intensity at 785 nm was used for the preclinical 
and at 793 nm for the clinical system. The intensities of the light sources could be controlled 
from the Artemis software. A sterilizable optical fiber was used to connect the light engine to the 
illumination ring. Reflected light was captured in the camera head as depicted in Fig. 1b. 
Reflected excitation light is blocked by a 750–800-nm notch filter. Subsequently, the light passes 
through a lens that could be used for focusing. The light then enters a prism containing a 
dichroic coating (G785 mm) in order to separate visible and NIR light. The visible light passes 
through a low-pass filter (G640 nm) and the NIR light through a high-pass filter (9808 nm). Both 
light beams are captured by a Sony ICX618 sensor with Bayer configuration having a 640×494 
pixel grid. Exposure times and sensor gains were separately adjusted for both imaging channels, 
and acquisition was synchronized to the longest exposure time. The raw data of both sensors 
could be saved as individual snapshots or as a real-time movie. During procedures, the visible 
light channel, the NIR fluorescence channel, and an adjustable overlay are presented. The Pearl 
Impulse uses two lasers for excitation with a wavelength of 685 and 785 nm. In this work, only 
the 785-nm excitation light is used. The Pearl camera automatically optimizes exposure times. 
Imaging data is acquired with a thermoelectrically cooled CCD sensor. 
 
Near-Infrared Probe(s) 
The Artemis was evaluated in two imaging procedures in which fluorescence-guided surgery 
could be of added value. The clinically available ICG (Pulsion Medical Systems, Munich, 
Germany, λex= 780 nm, λem=820 nm) is frequently used in SLN mapping and for that the 
choice of dye in this study. IRDye 800CW (LI-COR, Lincoln, NE, USA, λex=774 nm, λem=789 
nm) was chosen because it is one of two novel fluorophores in the process of clinical translation 
[2]. Two imaging procedures were evaluated because of the differences in fluorophores and 
mainly because fluorophore concentration differs at the side of interest. The near-tumoural 
injected ICG is highly concentrated compared to the intravenously injected IRDye 800CW 
conjugated to a targeting moiety. Furthermore, ICG and IRDye 800CW differ in excitation and 
emission spectra and have different quantum yields. ICG was resuspended in Cealb (20 % human 
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light beams are captured by a Sony ICX618 sensor with Bayer configuration having a 640×494 
pixel grid. Exposure times and sensor gains were separately adjusted for both imaging channels, 
and acquisition was synchronized to the longest exposure time. The raw data of both sensors 
could be saved as individual snapshots or as a real-time movie. During procedures, the visible 
light channel, the NIR fluorescence channel, and an adjustable overlay are presented. The Pearl 
Impulse uses two lasers for excitation with a wavelength of 685 and 785 nm. In this work, only 
the 785-nm excitation light is used. The Pearl camera automatically optimizes exposure times. 
Imaging data is acquired with a thermoelectrically cooled CCD sensor. 
 
Near-Infrared Probe(s) 
The Artemis was evaluated in two imaging procedures in which fluorescence-guided surgery 
could be of added value. The clinically available ICG (Pulsion Medical Systems, Munich, 
Germany, λex= 780 nm, λem=820 nm) is frequently used in SLN mapping and for that the 
choice of dye in this study. IRDye 800CW (LI-COR, Lincoln, NE, USA, λex=774 nm, λem=789 
nm) was chosen because it is one of two novel fluorophores in the process of clinical translation 
[2]. Two imaging procedures were evaluated because of the differences in fluorophores and 
mainly because fluorophore concentration differs at the side of interest. The near-tumoural 
injected ICG is highly concentrated compared to the intravenously injected IRDye 800CW 
conjugated to a targeting moiety. Furthermore, ICG and IRDye 800CW differ in excitation and 
emission spectra and have different quantum yields. ICG was resuspended in Cealb (20 % human 
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serum albumin, Sanquin, Amsterdam, The Netherlands) to obtain a dilution from 1 mM to 100 
fM. Clinically, 25 mg ICG was resuspended in 10 ml of sterile water before injection obtaining a 
stock solution of 2.5 mg/ml (3.2 mM). Of this, 4 ml, corresponding to a dose of 10 mg, was 
administered intravenously. IRDye 800CW carboxylate was resuspended in phosphatebuffered 
saline to obtain a dilution from 1 μM to 100 fM. Tumourspecific imaging experiments were done 
using the epidermal growth factor receptor-specific nanobody 7D12 with the nonepidermal 
growth factor receptor (EGFR)-specific nanobody R2 as a control [13, 14]. The generation of the 
nanobodies 7D12 and R2 and the conjugation to the NIR fluorophore IRDye 800CW were done 
as described previously [15–17]. 
 
Cell Lines 
Two human cancer cell lines were used: FaDu-luc2 (human hypopharyngeal squamous cell 
carcinoma) and OSC-19-luc2-Cgfp (metastatic oral squamous cell carcinoma). Both were 
cultured as previously described [1, 14]. 
 
Camera Characterization In Vitro 
Calibration of Camera System 
Concentration series of both NIR fluorophores were used to estimate the concentration-
dependent sensitivity. ICG was dissolved in human serum albumin (HSA) in concentrations from 
1 mM to 100 fM. HSA without ICG served as a control. IRDye 800CW was dissolved in PBS in 
concentrations of 1 μM to 100 fM. PBS without IRDye 800CW served as a control. One 
hundred microliters of each concentration was added to a 96-well plate and experiments were 
performed in duplicate. All series were imaged using both Pearl and the Artemis (with exposure 
times of 60 ms, to ensure real-time imaging).  
 
Cell Experiments 
FaDu-luc2 cells were cultured in T75 culture flasks until subconfluence. After washing with 
binding medium (MEM supplemented with 25 mM Hepes and 1 % BSA, at pH 7.2), 20 ml of 
binding medium with 50 nM 7D12-800CW was added. Cells were incubated in the dark, for 2 
hours in a humidified incubator at 37 °C and 5 % CO2. Cells were harvested with a solution of 
10 % trypsin in PBS. Subsequently, cells were washed in medium and adjusted to a suspension 
containing 2×106 cells. This suspension was diluted ten times in a 1:2 ratio in medium and 
aliquoted in 500-μl tubes. Tubes were centrifuged with 13,000 rates per minute, and after the 
aspiration of medium, cell pellets were imaged with the Pearl and Artemis camera system. After 
imaging, cells were resuspended in 50 μl of PBS containing 2 μl of Dluciferin solution (Syncem, 
Inc. Elk Grove Village, IL) followed by bioluminescence imaging (BLI) using the IVIS Spectrum 
imaging system (Caliper Life Sciences). Quantification of the BLI signal was performed through 
 
standardized regions of interest using Living Image software (Caliper Life Sciences). The 
experiment was performed in duplicate and cells incubated with medium served as a negative 
control [18]. The same dilutions of cells were made without incubation of 7D12-800CW to 
correlate the BLI signal to the number of cells (Fig. 2e). 
 
Camera Characterization In Vivo 
Animal Models 
Animal experiments were performed in female nude Balb/c mice (Charles River laboratories, 
l’Arbresle, France) aged 4–6 weeks. Mice were housed in individually ventilated cages and 
provided with food and sterilized water ad libitum. During the experiments, general health was 
monitored by weight measurements and tongue inspections. Imaging procedures were performed 
under isoflurane gas anesthesia (5 % induction and 2 % maintenance). The local animal welfare 
committee of the Leiden University Medical Center approved the animal experiments. In order 
to induce subcutaneous xenografts of hypopharyngeal squamous cell carcinomas, mice were 
inoculated at four spots on the back with 1, 2, 3, and 4×106 FaDu-luc2 cells, diluted in 50 μl 
PBS. Tumour growth was monitored twice a week with BLI. At day 10, mice were randomly 
allocated to injection with 7D12-800CW or R2-800CW. Orthotopic tongue tumours were 
induced in the tip of the tongue through a submucosal injection of 40,000 OSC-19-luc2-cGFP 
cells, diluted in 10 μl phosphate-buffered saline. Twice a week, mice body weight was monitored, 
tongues were inspected, and BLI was measured. At day 20, mice were randomly allocated to 
injection of 7D12-800CW or R2-800CW. BLI signals served as a control for the tumour 
specificity of the probe.  
 
Sentinel Lymph Node Detection Using ICG 
Precontrast images were taken with the Artemis and Pearl imaging systems to obtain background 
signal intensities of the tissue of interest. The Artemis was configured to image in real time 
(exposure time of 40 ms). After positioning of the mice (n=4), 10 μl of 100 μM ICG and HSA 
was injected submucosally in the tip of the tongue. NIR fluorescence imaging of ICG was 
performed at 0, 5, 10, 15, and 20 min after injection with both the Pearl and Artemis imaging 
systems. After 20 min, the skin of the cervical region was removed and images were taken. 
Subsequently, cervical lymph nodes were removed under NIR fluorescence guidance of the 
Artemis imaging system.  
 
Tumour-Specific Imaging Using 7D12-800CW  
FaDu-luc2 mice were randomly allocated to the intravenous injection of 7D12-800CW (3.2 nmol, 
n=4) or R2-800CW (3.0 nmol, n=3). After an incubation of 24 h, imaging was performed using 
both imaging systems. Tumours of mice injected with 7D12-800CW were excised with direct 
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signal intensities of the tissue of interest. The Artemis was configured to image in real time 
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Tumour-Specific Imaging Using 7D12-800CW  
FaDu-luc2 mice were randomly allocated to the intravenous injection of 7D12-800CW (3.2 nmol, 
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both imaging systems. Tumours of mice injected with 7D12-800CW were excised with direct 
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guidance of the real-time fluorescence signal of the Artemis (exposure time 60 ms). All excised 
tumours were imaged ex vivo with both imaging systems, and tumour volume was determined by 
measuring the width (W), length (L), and height (H) of each tumour using a digital caliper. 
Tumour volume was calculated by using the ellipsoid volume formula π/6×L×W×H [19]. Four 
tumours of mice injected with 7D12-800CW were cut in half and subsequently divided into 
halves until submillimeter tumour parts were obtained after which NIR fluorescence images were 
acquired. Muscle tissue was used as a control. When OSC-19-luc2-cGFP tumours were visible by 
the human eye and BLI signal ranged between 5×109 and 1×1010 relative light units (RLU), 
7D12-800CW (3.2 nmol, n=3) or R2-800CW (3.0 nmol, n=3) was intravenously injected. Whole 
body fluorescence imaging with the Pearl and Artemis was performed after 24 h of incubation. 
Subsequently, all tongue tumours were resected under direct fluorescence guidance of the 
Artemis camera system.  
 
Histology and Fluorescence Microscopy 
The resected hypopharyngeal squamous cell carcinomas and tongue tumours were cut in two, 
one half was snap frozen in isopentane and stored at −80 °C. The other half was fixed in 
formalin overnight and embedded in paraffin. Frozen or paraffin tissue sections of 10μm were 
air-dried, and fluorescence imaging was performed using the Odyssey (LI-COR) to confirm 
tumour specificity of 7D12-800CW. Histologic sections were stained with standard hematoxylin– 
eosin stain (HE). The presence of OSC-19-luc2-cGFP and FaDu-luc2 cells was confirmed by 
staining the sections with antihuman wide spectrum cytokeratin staining (Abcam Inc.,  
Cambridge, MA, USA). 
 
Human Liver Metastases 
Three patients with suspected colorectal liver metastases, based on a preoperative four-phase CT 
scan (Aquilion 64; Toshiba, Tokyo, Japan) of the thorax and abdomen, who were planned to 
undergo surgery with curative intent, were included. Exclusion criteria were pregnancy, lactation, 
or an allergy to iodine, shellfish, or ICG. Patients received 10 mg of ICG, diluted in 4 ml sterile 
water, as an intravenous bolus at 24 h prior to surgery. After exploration, the liver was first 
visually inspected and palpated then intraoperative ultrasound imaging was performed to locate 
the liver metastases. Subsequently, all liver segments were imaged using the Artemis imaging 
system. Patients were provided with informed consent, and the study was approved by the Local 
Medical Ethics Committee of the Leiden University Medical Center, Leiden, The Netherlands 
and was performed in accordance with the ethical standards of the Helsinki Declaration of 1975.  
 
  
 
Statistical Analysis 
All acquired images were analyzed by annotating regions of interest (ROI). During in vitro 
acquisitions, the background ROI was positioned at a location of homogeneous intensity without 
tissue. For the in vivo acquisitions, one background ROI was taken on the animal, next to the 
structures of interest. Furthermore, a ROI was drawn on a dark area outside the animal or sample 
for camera background correction. In each acquisition, mean foreground μf and background μb 
signals were measured within the ROIs. The camera noise σn was estimated as the standard 
deviation with the annotated homogeneous areas. Each acquisition is characterized by three 
measures: 1. Signal-to-noise ratio (SNR): μf /σn. This indicates how well signals of a particular 
intensity can be detected. 2. Contrast-to-noise ratio (CNR): (μf−μb)/σn. This indicates how well 
different regions can be identified. 3. Signal-to-background ratio (SBR): μf/μb. This measure is 
often reported in the literature to evaluate (tumour) marker specificity. In this work, CNR is 
mainly used to evaluate the Artemis camera system. This is different than the SBR used in many 
probebinding studies. While SBR is essentially a measure for the uptake of a probe, it does not 
measure how well a camera system is capable of capturing the contrast between tissues with 
different probe uptake. For the latter, it is essential to take the camera noise into account. A 
tumour with a high SBR may be almost invisible when imaged with a camera with high noise 
levels, while a very low SBR may be discernible very well when camera noise is low. 
Measurements with minimal CNR=2 were considered reliable. This corresponds to a limit of 
detection (LOD) defined as the control or background intensity plus two times the noise level. 
The SNR, CNR, and SBR for Pearl and Artemis were subjected to a Wilcoxon rank-sum test or 
U-test for non-normally distributed data. 
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Results 
 
Camera Characterization In Vitro 
 
Calibration of Camera System  
Acquisitions of 96-well plates with concentration series of ICG and 800CW were compared 
between the Artemis and Pearl camera systems based on SNR (Fig. 2a, c) and SBR (Fig. 2b, d). 
CNR is in this experiment very similar to SNR. The SNR and SBR curves for ICG from the 
Pearl show an increase in SNR and SBR for increasing concentrations up to 10 μM. After this, 
peak quenching takes place, causing a decrease in intensity. The SNR and SBR for the Artemis 
peak earlier. This is, however, due to sensor saturation (i.e., values of 255, the high end of the 
dynamic range) for the fixed exposure time of 60 ms. For shorter exposure times, higher 
concentrations could be imaged within the dynamic range. For the lower concentrations, the 
SNR and SBR curves flatten off at a higher concentration than for the Pearl, indicating 10−2 μM 
as the lower boundary for reliable ICG detection. The SBR for low concentrations of ICG for 
the Artemis is about 100 instead of 1. This is due to bright reflections of the excitation light in 
the well plates that penetrates through the emission filter. These reflections were visible in wells 
with low concentrations of fluorophore as well as the control well and showed the eight bright 
spots that corresponded to the fiber ends in the illumination ring. The plot in Fig. 2a shows that 
within the dynamic range of the Artemis at 60 ms exposure time, SNRs are comparable between 
Artemis and Pearl. Pvalues for the U-test were P=0.75 and P=0.09, respectively. Figure 2c, d 
shows similar results for the 800CW concentration series as for the ICG concentration series. 
Bright reflections of the excitation light again cause high SNRs and SBRs for low 800CW 
concentrations, while the sensor was saturated for 10 μM of 800CW. The minimum detectable 
concentration of 800CW is again 10−2 μM. However, as for the ICG, the excitation light 
reflections may prevent detection of lower concentrations. P-values for the U-test were P=0.04 
(SNR) and P=0.01 (SBR). These significant differences can be attributed to both a smaller 
dynamic range of the Artemis, as well as a higher minimally detectable concentration.  
 
 
 
Figure 2 - Calibration of the Artemis system and minimal detection limit of hypopharyngeal tumour cells: a, c 
Signal-to-noise (SNR) and b, d signal-to-background (SBR) ratios of concentration ranges of a, b ICG and c, d CW800 
imaged in 96-well plates. Measurements from control wells with 0 μM ICG and CW800 are shown as red horizontal 
lines. e Bioluminescence was correlated to the number of FaDu-luc2 cells. f FaDu-luc2 cells were incubated with the 
EGFR-specific nanobody 7D12-800CW and g non-specific nanobody R2-800CW for 2 hours. After incubation, cells 
were washed twice and cell pellets containing different amount of cells were imaged using the Artemis and Pearl 
imaging system. 
 
Cell Line Experiments  
Flow cytometry showed EGFR expression of FaDu-luc2 cells (data not shown). The experiment 
to determine the minimal detection limit of FaDu-luc2 cells was performed using the EGFR-
specific nanobody 7D12-800CW and the non-EGFR-specific R2- 800CW as a control. The total 
intensities of fluorescence measured for 7D12-800CW show agreement between Artemis and 
Pearl (Fig. 2f). Also, although clearly not a linear relationship, both cameras measure an increased 
amount of total fluorescence for a larger number of cells, as indicated by a higher bioluminescent 
signal. For the nonspecific R2-800CW, both cameras show no relation between bioluminescence 
and total intensity (Fig. 2g). The Artemis total intensities were higher for the R2-800CW 
experiment than for the low bioluminescent cell pellets with 7D12-800CW, while Pearl total 
intensities are comparable. We attribute this (small) variation to variations in sample placement 
under the Artemis. The minimum amount of cells that could be detected with the Artemis was 
extrapolated from the bioluminescence signal (Fig. 2e) and proved to be approximately 2×105 
cells and 4×104 cells using the Artemis and Pearl, respectively. 
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Camera Characterization In Vivo 
 
Sentinel Lymph Node Detection  
Using ICG Using both the Artemis and Pearl camera, seven SLNs were detected in vivo in four 
mice. All lymph nodes were visible within 10 min after injection. Massaging the injection spot 
could have expedited this process. After removal of the skin, all eight lymph nodes were visible. 
The initially invisible lymph node was covered by strongly absorbing tissue and was visible after 
removal of skin. Figure 3 shows NIR fluorescence images acquired with Artemis and Pearl after 
ICG injection in the tongue, as well as overlays with reflectance images. The distribution of ICG 
in the lymph node, as well as the lymphatic ducts, is clearly visible using both camera systems. 
CNRs are computed for each lymph node, where the background ROI is positioned between the 
front paws of the mouse. The mean CNR (Pearl 833, Artemis 225) and standard deviations (Pearl 
584, Artemis 96) for the seven detected lymph nodes with closed skin are shown in Fig. 3. Signal-
to-background ratios were 126 (standard deviation (SD) 59) for the Pearl and 1,260 (SD 691) for 
the Artemis. This difference was mainly due to low background signals, where the Pearl 
background was relatively higher. SBR is an unreliable measure when the background signal is 
low. The U-test P-values showed significant differences for both CNR (P=0.010) and SBR 
(PG0.001).  
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Tumour-Specific Imaging Using 7D12-800CW, Tongue Tumour Model  
Orthotopic EGFR-overexpressing (data not shown) OSC-19-luc2-cGFP tongue tumours were 
clearly identifiable using both Artemis and Pearl after injection of 7D12-800CW (Fig. 4). 
Bioluminescence confirmed the location of the tumour, and there was colocalization between 
fluorescence and bioluminescence signals. No fluorescence was observed with the control 
nanobody R2-800CW. CNRs for both Artemis and Pearl are 101 (SD 55) and 143 (SD 15) for 
7D12-800CW, while a low fluorescence signal was detected for R2-800CW with CNRs 12 (18) 
and 18 (25) for Artemis and Pearl, respectively. The larger standard deviation in CNR of 7D12-
800CW for the Artemis than for the Pearl could be attributed to inhomogeneous lighting 
conditions in the Artemis camera setup. In an open camera setting, a lower amount of excitation 
light tends to reach the tissue of interest, leading to excitation of a lower amount of fluorophore 
resulting in a lower excitation fluorescence signal that can be detected [5]. The large standard 
deviation is reflected in the differences in CNR of 7D12-800CW and R2-800CW between the 
Artemis and Pearl with P=0.7 and P=0.4, respectively. The CNR between 7D12-800CW and R2-
800CW was statistically significantly different for the Pearl (P=0.017) but not for the Artemis 
(P=0.13). The larger standard deviation in CNR of 7D12-800CW for the Artemis could partly be 
attributed to inhomogeneous lighting conditions in the Artemis camera setup. Furthermore, due 
to short acquisition times in an intraoperative imaging setting, a smaller amount of fluorescent 
photons are captured per acquired frame, leading to noisier images. Lastly, the Artemis system 
does not have a cooled camera, 
increasing sensitivity to thermal noise.  
 
 
Figure 4 - Near-infrared fluorescence delineation of orthotopic tongue tumours: OSC-19-luc2-cGFP tongue 
tumours could clearly be identified after injection of the epidermal growth factor receptor-specific nanobody 7D12-
800CW (50 μg) using both the Artemis and Pearl. No fluorescence could be observed after injection of 50 μg of 
control nanobody R2-800CW. Contrast-to-noise ratios (CNR) calculated by using the Artemis and Pearl are shown. A 
= Artemis; P = Pearl. 
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Camera Characterization In Vivo 
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Tumour-Specific Imaging Using 7D12-800CW, Hypopharyngeal Tumour Model  
Subcutaneous FaDu-luc2 tumours could be clearly imaged with both the Artemis and Pearl 
camera after injection of 7D12-800CW. Histology confirmed tumour specificity of 7D12-800CW 
(Supplementary Fig. 1). Figure 5 shows the bioluminescent signal (a) that confirms the tumour 
presence and overlays from the Artemis (b) and Pearl (c). The Artemis overlay shows a high 
signal between the kidneys, while the Pearl overlay does not show this signal. In contrast to the 
Artemis, for the Pearl, the overlay can be adjusted to show that the tumours fluoresce stronger 
than the center of the back of the mouse where scattering increases fluorescence signal next to 
the kidneys.  
 
 
Figure 5 - Tumour detection limit: Hypopharyngeal FaDu-luc2 tumours of different sizes visualized using 
bioluminescence imaged by a the IVIS Spectrum system could clearly be delineated in vivo using both b the Artemis 
and c Pearl. fIn vivo tumour signal-tobackground ratios (SBR) were calculated. Twenty-four hours after injection of 
7D12-800CW and R2-800CW, all tumours were repeatedly halved until submillimeter size. Tumour pieces were 
measured using the d Artemis and e Pearl. g Contrast-to-noise ratios (CNR) were plotted against the volume of the 
tumour pieces. Ruler lines denote millimeters. K = kidney; T = tumour; M = muscle; A = Artemis; P = Pearl. 
 
For the Artemis, the large spatial variation in illumination intensity caused a non-significant 
difference between SBRs for tumours with 7D12-800CW and R2-800CW (P=0.09), while the 
difference for the Pearl was significant (PG0.001) (Fig. 5f). Figure 5d, e show an example of a 
 
halved tumour with 7D12-800CW imaged with both Artemis (d) and Pearl (e). In the Artemis 
overlay, part of a ruler is visible. For each tumour piece, the volume is estimated and the relation 
between CNR and volume is shown in Fig. 5g. Muscle tissue was included as an additional 
control. A clear relation between tumour volume and CNR is visible for 7D12-800CW for both 
Artemis and Pearl, where the Pearl in general showed a higher CNR and the Artemis a larger 
spread. The CNRs were significantly different for both 7D12-800CW (PG0.001) and R2-800CW 
(PG0.001). Fluorescence of tumour pieces with a CNR below 2 is practically invisible by eye 
(depicted by the gray horizontal line). Five tumour pieces were below this line for the Artemis, 
while these tumour pieces were hardly visible with the Pearl. The tumour pieces missed by the 
Artemis had an average size in the order ≤1 mm3 . Although smaller pieces in general had a 
lower CNR, a size of 1 mm3 should be considered as the lower boundary, as the majority of 
tumour pieces of this size were visible by both cameras. Contrast-to-noise ratios are significantly 
different between specific and non-specific probes for both Artemis (PG0.001) and Pearl 
(PG0.001). 
 
Human Liver Imaging 
Three patients with liver metastases were imaged using the Artemis camera system during 
surgery. All three patients had metastases from colon tumours near or at the liver surface. Figure 
6 illustrates the combination of images such as presented to the surgeon: visible light (Fig. 6a), 
NIR fluorescence signal (Fig. 6b), and a real-time overlay (Fig. 6c). The metastases in this 
example are recognizable due to their fluorescent rim. Benign lesions could be differentiated 
from malignant lesions by a lack of this fluorescent rim around the tumour, as was confirmed by 
pathologic analysis [20]. A total of six lesions with fluorescent rim were identified during surgery 
with NIR fluorescence, and all showed to be malignant after pathologic evaluation. No false-
negative nodules were found. One lesion in segment 6 of the liver was initially missed by eye but 
was clearly visualized using the Artemis system. 
 
 
 
 
 
 
 
 
Figure 6 - Near-infrared fluorescence imaging of colorectal liver metastases: 24 h after injection of 10 mg 
indocyanine green, colorectal liver metastases could clearly be identified by a rim around the tumour (I and II). Benign 
lesion (III) could be identified by fluorescence without the rim. Images are depicted in a visible light, b NIR 
fluorescence signal, and c a real-time overlay. 
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Figure 6 - Near-infrared fluorescence imaging of colorectal liver metastases: 24 h after injection of 10 mg 
indocyanine green, colorectal liver metastases could clearly be identified by a rim around the tumour (I and II). Benign 
lesion (III) could be identified by fluorescence without the rim. Images are depicted in a visible light, b NIR 
fluorescence signal, and c a real-time overlay. 
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Discussion 
 
Fluorescence-guided surgery is a high potential imaging technique that provides surgeons with 
real-time information about vital structures, tumour margins, and regional disseminated disease. 
By real-time feedback of tumour margins and vital structures, tumours could be radically resected 
while healthy tissue can be preserved. A dedicated NIR fluorescence camera is vital as NIR light 
is invisible to the human eye. In this study, we evaluated the Artemis NIR fluorescence camera 
system. Its performance in detecting ICG and IRDye 800CW was assessed and was put in 
perspective by comparison with the preclinical Pearl imaging system. Furthermore, we 
demonstrated its utility in detecting and guiding resection of cervical SLNs using ICG, as well as 
primary tongue tumours and hypopharyngeal tumours using an EGFR-targeting nanobody 
conjugated to IRDye 800CW. Next, first in-human clinical data using the Artemis was shown by 
the detection of liver metastases using ICG. The efficacy of NIRF camera systems and the final 
realtime fluorescence imaging results are dependent on multiple factors. These factors include the 
interplay between the type of probe or fluorophore used, probe concentration injected, 
concentration of probe at the location of interest, tumour size, optical properties, and the camera 
system. The Artemis was evaluated for the use in two frequently used FGS procedures because 
there is a major difference in dye and in concentration of dye at the site of interest between both 
procedures. The near-tumoural injected ICG in SLN mapping is highly concentrated compared 
to the intravenously injected conjugate of IRDye 800CW and a targeting moiety in 
tumourspecific imaging. Furthermore, ICG and IRDye 800CW differ in excitation spectra, 
emission spectra, and quantum yield. In general, imaging results are more adequate when a 
fluorophore has a high quantum yield and there is a high concentration at the site of interest. The 
second variable that intervenes with the efficacy of a NIRF camera is the injected concentration 
of probes. For the experiments in vivo, the optimal concentration was chosen. The optimal 
concentration of ICG was extrapolated from the ICG dilution series in vitro. In the choice of the 
injected dose in vivo (100 μM), dilution of ICG after intratumoural injection was taken into 
consideration. Concentrations of 7D12-800CW (50 μM) and R2-800CW (μM) were chosen from 
earlier studies [14]. Next, the size of the tumour determines the imaging results. We assessed the 
detection limit of a FaDu-luc2 tumour nodule size that could be detected using the nanobody 
7D12-800CW. For that, tumour pieces were subdivided into halves until submillimeter size. Since 
7D12-800CW is homogenously distributed throughout the tumour [13, 14] (Supplementary Fig. 
1), subdivision was justified. A size of 1 mm3 could be considered as the lower boundary of 
detection, as the majority of tumour pieces of this size were visible. A tumour size of 1 mm3 is 
considered to contain around three million tumour cells. Using this setup, lower amount of cells 
that could be clinically significant would not be detected. Obviously, a detection limit is 
dependent on multiple factors like the probe that is used, the observer, the concentration and 
 
pharmacokinetics of the probe, the target that is chosen, and the amount of receptors in the 
tissue of interest. Furthermore, in vivo, the optical properties of the tissue of interest and 
overlaying tissue determine in a great extent what size of tumour tissue can be detected. Again, 
results were compared to the Pearl to validate the Artemis data. Despite successful utility of the 
Artemis in our preclinical experiments and the successful utility of the Artemis in a clinical 
setting, several improvements can be made to increase the applicability and imaging reliability. 
First, the illumination intensity as projected by the Artemis sharply decreases near the edge of the 
imaged field. This causes the apparent fluorescence intensity to have a strong dependence on the 
location in the image. In the experiment using cell lines in vitro, we showed that both the 
Artemis and Pearl were able to image the same relationship between number of cells and 
intensity for the tumour-specific 7D12-800CW probe. For the non-specific R2-800CW, both 
cameras showed a flat profile. The Artemis signal was less consistent than that of the Pearl for 
low cell counts with 7D12-800CW and for the cells with R2-800CW. This can be attributed to a 
less inhomogeneous illumination of the sample than for the Pearl. Precise positioning of the 
sample when comparing fluorescence intensities is thus essential for the Artemis while less 
critical for the Pearl. This spatial illumination variation is also visible in Fig. 5f, as a large standard 
deviation on the SBRs for the in vivo tumours resulting in a non-significant difference between 
SBRs for tumours with 7D12-800CW and R2-800CW (P=0.09). Second, a possible improvement 
lies in filtering the excitation light. The filters that are intended to block the excitation light do 
not block most specular reflections. If available, filters with a higher optical density would solve 
this problem or cross-polarization could be used. Results of the impairment in blocking 
reflections can be seen in the baseline experiment for evaluating the sensitivity of the Artemis 
system that consisted of measuring the signal from fluorophores in concentration series. For the 
real-time setting of 60 ms exposure time per image, the Artemis was able to measure 
concentrations of both ICG and 800CW of 10−2 μM and higher. The control Pearl camera 
showed that fluorophores were present in wells with lower concentrations. This lower boundary 
was not solely due to sensitivity limits of the Artemis camera but also due to reflected excitation 
light that was not sufficiently filtered out. For concentrations smaller than 10−2 μM, these 
reflections were stronger than the fluorescence signal. Third, the current camera has a rather low 
depth of field. Since the camera does not have an autofocus mechanism, this requires frequent 
adjustment of the focus. An additional problem with the current Artemis camera systems is a 
focal length difference between the visible light and near-infrared channels. This requires 
changing the focus between a sharp visible light and near-infrared fluorescence image at close 
imaging distances (G15 cm). A last possible improvement is the dynamic range of the camera. 
This lack of range is visible in the images with concentration ranges; only a few concentrations 
are between the lower detection boundary and the saturation boundary. Although such a wide 
variation in concentrations is not to be expected in clinical applications and overexposure is not a 
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adjustment of the focus. An additional problem with the current Artemis camera systems is a 
focal length difference between the visible light and near-infrared channels. This requires 
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This lack of range is visible in the images with concentration ranges; only a few concentrations 
are between the lower detection boundary and the saturation boundary. Although such a wide 
variation in concentrations is not to be expected in clinical applications and overexposure is not a 
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big issue, large variations in working distance during surgery also lead to large intensity variations 
of the fluorescence signal. The visible light channel also tended to be overexposed, even at the 
least sensitive camera settings. 
 
  
 
Conclusion 
 
NIR fluorescence-guided surgery could aid surgeons in real-time visualization of tumours, SLNs, 
and vital structures to ensure a radical resection, adequate staging, and minimize damage to 
normal tissue. In this study, we evaluated the Artemis system and assessed the minimal detection 
limit of tumour-specific imaging using an EGFR-targeting nanobody. Furthermore, we 
demonstrated the possibility of fluorescence-guided resection of head and neck tumours and 
sentinel lymph nodes. At last, we demonstrated the use of the Artemis system for the detection 
and fluorescence-guided resection of liver metastases in a first in-human clinical trial. Based on 
this study, although improvements can be made, we think the Artemis system has demonstrated 
its utility in fluorescence-guided cancer surgery. 
  
Artemis camera in fluorescence-guided surgery 151
6
 
big issue, large variations in working distance during surgery also lead to large intensity variations 
of the fluorescence signal. The visible light channel also tended to be overexposed, even at the 
least sensitive camera settings. 
 
  
 
Conclusion 
 
NIR fluorescence-guided surgery could aid surgeons in real-time visualization of tumours, SLNs, 
and vital structures to ensure a radical resection, adequate staging, and minimize damage to 
normal tissue. In this study, we evaluated the Artemis system and assessed the minimal detection 
limit of tumour-specific imaging using an EGFR-targeting nanobody. Furthermore, we 
demonstrated the possibility of fluorescence-guided resection of head and neck tumours and 
sentinel lymph nodes. At last, we demonstrated the use of the Artemis system for the detection 
and fluorescence-guided resection of liver metastases in a first in-human clinical trial. Based on 
this study, although improvements can be made, we think the Artemis system has demonstrated 
its utility in fluorescence-guided cancer surgery. 
  
152 Chapter 6
 
Acknowledgments.  
 
We would like to thank Mr. C.T.M. van Gaalen, MSc, for his contribution to the text and the 
interesting discussions. This study was performed within the framework of CTMM, the Center 
for Translational Molecular Medicine (MUSIS project, grant 03O-202 and MAMMOTH 
project, grant 030-201). 
  
 
Conflict of Interest.  
 
The authors report no conflicts of interest 
  
Artemis camera in fluorescence-guided surgery 153
6
 
Acknowledgments.  
 
We would like to thank Mr. C.T.M. van Gaalen, MSc, for his contribution to the text and the 
interesting discussions. This study was performed within the framework of CTMM, the Center 
for Translational Molecular Medicine (MUSIS project, grant 03O-202 and MAMMOTH 
project, grant 030-201). 
  
 
Conflict of Interest.  
 
The authors report no conflicts of interest 
  
154 Chapter 6
 
References 
 
1. Keereweer S, Mol IM, Vahrmeijer AL et al (2012) Dual wavelength tumour targeting for 
detection of hypopharyngeal cancer using nearinfrared optical imaging in an animal 
model. Intl J Cancer 131:1633–1640 
2. Vahrmeijer AL, Hutteman M, Van Der Vorst JR et al (2013) Imageguided cancer surgery 
using near-infrared fluorescence. Nat Rev Clin Oncol 10:507–518 
3. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012–
4021 
4. Adams KE, Ke SK et al (2007) Comparison of visible and near-infrared wavelength-
excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12:024017 
5. Keereweer S, Van Driel PB, Snoeks TJ et al (2013) Optical imageguided cancer surgery: 
challenges and limitations. Clin Cancer Res 19:3745–3754 
6. Gioux S, Choi HS, Frangioni JV (2010) Image-guided surgery using invisible near-
infrared light: fundamentals of clinical translation. Mol Imaging 9:237–255 
7. Schaafsma BE, Mieog JS, Hutteman M et al (2011) The clinical use of indocyanine green 
as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg 
Oncol 104:323–332 
8. Mcmahon J, O’Brien CJ, Pathak I et al (2003) Influence of condition of surgical margins 
on local recurrence and disease-specific survival in oral and oropharyngeal cancer. Brit J 
Oral Maxillofac Surg 41:224–231 
9. Huston TL, Simmons RM (2005) Locally recurrent breast cancer after conservation 
therapy. Am J Surg 189:229–235  
1. Meric F, Mirza NQ, Vlastos G et al (2003) Positive surgical margins and ipsilateral breast 
tumour recurrence predict diseasespecific survival after breast-conserving therapy. 
Cancer 97:926–933 
10. Rusthoven KE, Raben D, Song JI et al (2010) Survival and patterns of relapse in patients 
with oral tongue cancer. J Oral Maxillofac Surg 68:584–589 
11. Schulze T, Bembenek A, Schlag PM (2004) Sentinel lymph node biopsy progress in 
surgical treatment of cancer. Arch Surg 389:532–550 
12. Oliveira S, Van Dongen GA, Stigter-Van Walsum M et al (2012) Rapid visualization of 
human tumour xenografts through optical imaging with a near-infrared fluorescent anti-
epidermal growth factor receptor nanobody. Mol Imaging 11:33–46 
13. Van Driel PB, Van Der Vorst JR, Verbeek FP et al (2013) Intraoperative fluorescence 
delineation of head and neck cancer with a fluorescent anti-epidermal growth factor 
receptor nanobody. Intl J Canc 
 
14. Dolk E, Van Vliet C, Perez JM et al (2005) Induced refolding of a temperature 
denatured llama heavy-chain antibody fragment by its antigen. Proteins 59:555–564 
15. Gainkam LO, Huang L, Caveliers V et al (2008) Comparison of the biodistribution and 
tumour targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole 
SPECT/micro-CT. J Nucl Med: Off Publ Soc Nucl Med 49:788–795 
16. Roovers RC, Laeremans T, Huang L et al (2007) Efficient inhibition of EGFR signaling 
and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol 
Immunother: CII 56:303–317 
17. Mieog JS, Vahrmeijer AL, Hutteman M et al (2010) Novel intraoperative near-infrared 
fluorescence camera system for optical imageguided cancer surgery. Mol Imaging 9:223–
231 
18. TomaykoMM, Reynolds CP (1989) Determination of subcutaneous tumour size in 
athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154 
19. Van Der Vorst JR, Schaafsma BE, Hutteman M et al (2013) Nearinfrared fluorescence-
guided resection of colorectal liver metastases. Cancer 119:3411–3418  
Artemis camera in fluorescence-guided surgery 155
6
 
References 
 
1. Keereweer S, Mol IM, Vahrmeijer AL et al (2012) Dual wavelength tumour targeting for 
detection of hypopharyngeal cancer using nearinfrared optical imaging in an animal 
model. Intl J Cancer 131:1633–1640 
2. Vahrmeijer AL, Hutteman M, Van Der Vorst JR et al (2013) Imageguided cancer surgery 
using near-infrared fluorescence. Nat Rev Clin Oncol 10:507–518 
3. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012–
4021 
4. Adams KE, Ke SK et al (2007) Comparison of visible and near-infrared wavelength-
excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12:024017 
5. Keereweer S, Van Driel PB, Snoeks TJ et al (2013) Optical imageguided cancer surgery: 
challenges and limitations. Clin Cancer Res 19:3745–3754 
6. Gioux S, Choi HS, Frangioni JV (2010) Image-guided surgery using invisible near-
infrared light: fundamentals of clinical translation. Mol Imaging 9:237–255 
7. Schaafsma BE, Mieog JS, Hutteman M et al (2011) The clinical use of indocyanine green 
as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg 
Oncol 104:323–332 
8. Mcmahon J, O’Brien CJ, Pathak I et al (2003) Influence of condition of surgical margins 
on local recurrence and disease-specific survival in oral and oropharyngeal cancer. Brit J 
Oral Maxillofac Surg 41:224–231 
9. Huston TL, Simmons RM (2005) Locally recurrent breast cancer after conservation 
therapy. Am J Surg 189:229–235  
1. Meric F, Mirza NQ, Vlastos G et al (2003) Positive surgical margins and ipsilateral breast 
tumour recurrence predict diseasespecific survival after breast-conserving therapy. 
Cancer 97:926–933 
10. Rusthoven KE, Raben D, Song JI et al (2010) Survival and patterns of relapse in patients 
with oral tongue cancer. J Oral Maxillofac Surg 68:584–589 
11. Schulze T, Bembenek A, Schlag PM (2004) Sentinel lymph node biopsy progress in 
surgical treatment of cancer. Arch Surg 389:532–550 
12. Oliveira S, Van Dongen GA, Stigter-Van Walsum M et al (2012) Rapid visualization of 
human tumour xenografts through optical imaging with a near-infrared fluorescent anti-
epidermal growth factor receptor nanobody. Mol Imaging 11:33–46 
13. Van Driel PB, Van Der Vorst JR, Verbeek FP et al (2013) Intraoperative fluorescence 
delineation of head and neck cancer with a fluorescent anti-epidermal growth factor 
receptor nanobody. Intl J Canc 
 
14. Dolk E, Van Vliet C, Perez JM et al (2005) Induced refolding of a temperature 
denatured llama heavy-chain antibody fragment by its antigen. Proteins 59:555–564 
15. Gainkam LO, Huang L, Caveliers V et al (2008) Comparison of the biodistribution and 
tumour targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole 
SPECT/micro-CT. J Nucl Med: Off Publ Soc Nucl Med 49:788–795 
16. Roovers RC, Laeremans T, Huang L et al (2007) Efficient inhibition of EGFR signaling 
and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol 
Immunother: CII 56:303–317 
17. Mieog JS, Vahrmeijer AL, Hutteman M et al (2010) Novel intraoperative near-infrared 
fluorescence camera system for optical imageguided cancer surgery. Mol Imaging 9:223–
231 
18. TomaykoMM, Reynolds CP (1989) Determination of subcutaneous tumour size in 
athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154 
19. Van Der Vorst JR, Schaafsma BE, Hutteman M et al (2013) Nearinfrared fluorescence-
guided resection of colorectal liver metastases. Cancer 119:3411–3418  
  
III 
Future of fluorescence-guided therapy in 
oncology, theranostics 
  
  
III 
Future of fluorescence-guided therapy in 
oncology, theranostics 
  
 Chapter 7.  
 
Shifting focus in fluorescence-guided surgery 
  
 
Shifting focus in fluorescence-guided surgery 
 
Stijn Keereweer1,2, Pieter B.A.A. van Driel2, Dominic J. Robinson3, Clemens W.G.M. 
Löwik1 
 
 
1. Department of Molecular Imaging, Leiden University Medical Center, Leiden, The 
Netherlands. 
2. Department of Otorhinolaryngology Head and Neck Surgery, Erasmus Medical Center, 
Rotterdam, The Netherlands. 
3. Center for Optical Diagnostics and Therapy, Postgraduate School of Molecular Medicine, 
Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands 
 
Published in Molecular Imaing and Biology 
September 2013, 16:1-9 
  
CHAPTER 7
 
Chapter 7.  
 
Shifting focus in fluorescence-guided surgery 
  
 
Shifting focus in fluorescence-guided surgery 
 
Stijn Keereweer1,2, Pieter B.A.A. van Driel2, Dominic J. Robinson3, Clemens W.G.M. 
Löwik1 
 
 
1. Department of Molecular Imaging, Leiden University Medical Center, Leiden, The 
Netherlands. 
2. Department of Otorhinolaryngology Head and Neck Surgery, Erasmus Medical Center, 
Rotterdam, The Netherlands. 
3. Center for Optical Diagnostics and Therapy, Postgraduate School of Molecular Medicine, 
Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands 
 
Published in Molecular Imaing and Biology 
September 2013, 16:1-9 
  
160 Chapter 7
 
ABSTRACT 
 
Cancer patients could benefit from a surgical procedure that helps the surgeon to determine 
adequate tumour resection margins. Systemic injection of tumour-specific fluorescence agents 
with subsequent intraoperative optical imaging can guide the surgeon in this process. However, 
tumour heterogeneity hampers tumour-specific targeting. In addition, determination of adequate 
resection margins can be very challenging due to invasive tumour strands that are difficult to 
resolve and because of the confounding effect of variations in tissue optical properties in the 
surgical margin. We provide an overview of the “classic approach” of imaging tumour-specific 
targets or tumour-associated pathophysiological processes, and explain the limitations of these 
targeting strategies. It is proposed that problems of tumour heterogeneity can theoretically be 
circumvented by shifting focus of tumour targeting towards the follicle-stimulating hormone 
receptor (FSHR). Furthermore, we discuss why objective determination of resection margins is 
required to improve resection of the invasive strands, a goal that may be achieved by targeting 
the FSHR. When invasive strands would nevertheless extend beyond such a standardized 
resection margin, we suggest that adjuvant photodynamic therapy would be a very suitable 
therapeutic regimen. Finally, we describe how point optical spectroscopy can be used to 
scrutinize suspect tissue that is difficult to differentiate from normal tissue by measuring the local 
tissue optical properties to recover a local intrinsic fluorescence measurement.  
 
Introduction 
 
Despite the technological advancements of preoperative imaging techniques, clinical outcome of 
cancer surgery for most cancer types has only gradually improved over the last 3 decades. 
Introduction of real-time optical imaging could revolutionize the intraoperative approach to cure 
cancer by providing the surgeon with direct feedback on histopathologic markers. This 
intraoperative tissue characterization could improve surgical outcome, local control, and disease-
free survival. In addition, it enables better preservation of healthy tissue, which is critical to 
postoperative functionality and quality of life. In optical imaging, tumour-specific fluorescent 
agents can be systemically injected to guide the surgeon in adequately determining resection 
margins. Although feasibility of intraoperative tumour-specific nearinfrared (NIR) fluorescence 
imaging was demonstrated in humans [1], cancer targeting with high sensitivity and specificity 
remains challenging. The continuous quest for a universal tumour-specific target has not yet been 
successful and the growing insight in cancer invasion is increasingly pointing toward 
multifactorial processes [2, 3]. There are many general aspects involved in making a tumour-
specific targeting agent suitable for in vivo use, including high affinity of the agent with low non-
specific binding, abundance of the target receptors or epitopes [4], biodistribution of the agent to 
the target, sufficient contact time with the target for binding to occur, retaining of the agent while 
non-bound agents are cleared from the circulation and toxicity issues [5]. These aspects have 
been extensively reviewed elsewhere [5–8]. Although an extensive amount of work is still needed 
to consider these issues, we anticipate that the next generations of fluorescent agent design will 
continue to improve these aspects. However, we have identified the three fundamental challenges 
that will remain to contribute to the conundrum of optical image-guided cancer surgery: dealing 
with tumour heterogeneity, obtaining adequate resection margins that include invasive tumour 
strands, and managing the confounding effects of differences and variations in optical tissue 
properties (Fig. 1). This review aims to explain the limitations of the “classic approach” of 
(combined) imaging of tumour-specific cell-surface receptors and tumour-associated 
pathophysiological processes. Next, we suggest that shifting focus to the follicle-stimulating 
hormone receptor (FSHR) could theoretically circumvent the problems of tumour heterogeneity. 
Furthermore, we advocate the need for objective intraoperative determination of resection 
margins to improve resection of the invasive strands and explain how this may be achieved by 
targeting the FSHR. If invasive strands would extend beyond the resection margin, we propose 
that photodynamic therapy (PDT) is the ideal adjuvant therapeutic regimen that is likely to play 
an increasingly important role in optical image-guided cancer therapy. Finally, the confounding 
effects of differences in tissue optical properties impede the ability to differentiate between areas 
of healthy and tumour tissue, particularly in the surgical margin where fluorescent signals can be 
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lower. We describe how point reflectance and fluorescence spectroscopy using fiber optic probes 
can be used to overcome these effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1; Schematic illustration of the three fundamental problems in optical image-guided cancer surgery. a How to 
deal with differences in optical properties that influence propagation of light in tissue (1–3): Absorption by tissue 
components that influences the optical path length (1), scattering by tissue components that influences the spatial 
distribution of light (2), and specular reflection at the tissue surface (3). b How to obtain adequate resection margins 
that include invasive tumour strands that extend beyond the (visible) tumour border. c How to cope with tumour 
heterogeneity that results in variability in expression of surface receptors, hampering target-specific imaging. 
 
Challenges of Tumour-Specific imaging 
 
Imaging Tumour Heterogeneity 
The first problem that is currently challenging tumour-specific imaging is tumour heterogeneity. 
Different populations of tumour cells within a tumour display variable phenotypes such as the 
ability to metastasize or to survive chemo- or radiotherapy. This intra-tumour phenotypic 
diversity results from genetic and epigenetic heterogeneity, a consequence of genomic instability 
combined with high cell turnover, aswell as fromdifferences in the tumour microenvironment [9]. 
Improved molecular understanding of cancers has resulted in identification of targets for 
diagnostic and therapeutic interventions. However, the concept of tumour heterogeneity explains 
why tumour-specific imaging based on these targets is limited in many cases [9, 10]. 
 
 
Invasive Tumour Strands 
The second factor that fluorescence-guided tumour resection has to deal with is the problem on 
how to include invasive tumour strands into the resection margin. Invasive tumour strands are 
crucial for the development of regional and distant metastasis. Moreover, invasive strands are less 
sensitive to adjuvant therapy due to adaptive responses to different types of therapy-induced 
stress inducing tumour cell survival [2]. This reactive resistance to adjuvant therapy emphasizes 
the importance of radical surgical resection that includes invasive strands [2, 3]. In addition, the 
pattern of tumour invasion at the invasive front may be indicative for tumour behavior [11]. 
However, it remains to be determined whether high-risk tumours require greater margin 
distances than low-risk tumours [12].  In conventional surgery, an extra resection margin around 
the tumour mass is removed in order to include potential invasive strands and to compensate for 
inaccurate determination of the tumour border. Because it is practically infeasible to objectively 
determine a consistent margin, for instance of 1 cm, using a caliper in all dimensions around the 
tumour, the resection margin is subjectively assessed by the surgeon, resulting in intersurgeon 
variability [13]. This interferes with standardized oncologic care and hampers complete surgical 
resection in some cases. Although optical imaging techniques can provide the surgeon with direct 
feedback on histopathological markers, it is impossible to image individual invasive strands under 
many circumstances. To detect invasive strands, fluorescent agents would require very high 
affinity for these thin layers of cancer cells. However, as will be explained below, the influence of 
differences in background optical properties of tissue and their spatial heterogeneity would 
regularly prevent detection or detailed imaging. The inability to identify individual invasive 
strands dictates a new approach to consistently include an objective resection margin into the 
surgical resection.  
 
Optical Tissue Properties 
Finally, tumour-specific imaging and subsequent imageguided surgical resection is strongly 
influenced by the background tissue optical properties. The basic geometry of optical imaging 
requires excitation light from an external light source that travels through the imaged tissue and 
excites the fluorophore inside the tissues [5, 7]. After excitation, the fluorescent light travels back 
through the tissues and is detected outside the body by a dedicated camera system. The path that 
these photons travel is influenced by the optical properties of the tissues at the excitation and 
emission wavelength. Scattering can change the direction of part of the photons and multiple 
consecutive scatter events will result in diffuse light; a gradual randomization of the propagation 
direction [5, 7, 14, 15]. Additionally, photons can be absorbed by various components in the 
tissue. Consequently, fluorescence images will display intensities that are strongly influenced by 
varying absorption properties of the tissue and the images may be blurred due to the scattering of 
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light. The problem with targeting invasive tumour strands could be as follows: invasive strands 
can be very thin, limiting the amount of tumour-specific fluorescent agent that is bound or 
activated. This results in a relatively low amount of fluorescent photons that are subsequently 
influenced by scattering and absorption. Imaging of strands that are invading the surrounding 
tissues will result in blurry images with very low intensity. Various groups have developed 
imaging systems that incorporate tissue attenuation correction algorithms that have been 
validated using phantoms [16–18]. Although improved margin delineation and quantification is 
reported, it is unlikely that such estimations or more sensitive detectors will be able to completely 
resolve the effects caused by optical properties and autofluorescence in vivo, because of the 
heterogeneous composition of the tissue and differences in autofluorescence intensity in location 
and over time [7].  
 
 
Current Strategies of Tumour-Specific imaging 
 
Imaging The “Classic Approach”: Targeting of Tumour-Specific Cell Surface Receptors 
Themost often approach employed for tumour-specific targeting is to conjugate a fluorophore to 
a tumour-specific antibody or peptide targeting a receptor. The limitless replicative potential of 
tumour cells, a key feature of carcinogenesis, offers useful targets because it is facilitated by 
increased metabolism, high expression of growth-signalling receptors, and increased tumour 
angiogenesis to supply sufficient oxygen and nutrients [19]. Many of these hallmarks of cancer 
have been a target for antibody-derivatives, peptides, or small molecules conjugated to a 
fluorophore [20]. For instance, promising results have been reported in preclinical experiments 
that target growth-signalling receptors [1, 21–23]. However, these preclinical models mostly 
include homogeneous tumours, and antibody-specific targeting is likely to be limited when 
tumours become increasingly heterogeneous. Moreover, these models are often formed using 
human xenografts that are targeted by human antibody derivatives, resulting in zero background 
signal. Sustained angiogenesis has been imaged by targeting integrins; specific cell-surface 
markers of tumour angiogenesis [24, 25], which results in the imaging of tumour vasculature. 
Although this strategy could strongly reduce the problem of tumour heterogeneity, studies have 
shown that these agents are taken up by cancer cells in vitro, improving their tumour-specific 
fluorescence signal but increasing variability of this signal due to tumour heterogeneity [25]. 
Moreover, this targeting strategy does not include an objective standardized resection margin, 
which is required because targeting of angiogenesis will not image strands that are not (yet) 
supported by new sprouting vessels, such as solid strands that can be found in basal and 
squamous cell carcinomas [3]. 
 
 
Targeting Tumour-Associated Pathophysiological Processes 
To reduce the problem of tumour heterogeneity and find a more universal tumour-specific 
target, the approach changed from targeting cell surface receptors to targeting tumour-associated 
pathophysiological processes. The best-known example of such a process is the degradation of 
the extracellular matrix, which is required for tumour growth andmetastasis. By targeting 
enzymes that are involved in these general processes, the tumour border is imaged, independent 
from the type of receptors that are expressed by the cancer cells [19, 21, 26, 27]. Targeting of 
proteolytic enzymes results in imaging of the invasive tumour front where these enzymes are 
abundant. Therefore, surgical resection guided by the enzyme-specific fluorescence signal could 
be sufficient for radical resection including invasive tumour strands. To further improve 
sensitivity, different tumour-specific characteristics have been targeted simultaneously. These 
different targets can be imaged at different wavelengths, allowing separate analysis of different 
cancer features [21]. The use of a “cocktail” of fluorescent agents that target different tumour 
markers could reduce the effect of tumour heterogeneity. Although this may seem a feasible 
approach, it is difficult to assess in advance what percentage of the tumour would be “covered” 
by this mixture of tumour targets. As an alternative, the biologic tumour markers for each 
individual tumour could be determined preoperatively, which would require representative 
samples and complex biochemical analyses. Both approacheswillmost likely not be cost-effective 
compared to the use of a single universal targeting agent. Moreover, although targeting of cancer 
cell surface receptors, either or not in combination with simultaneous imaging of tumour-specific 
pathophysiological processes, seem to solve most of the aforementioned limitations while 
imaging with high specificity, a closer look into its basic principles reveal that fundamental 
limitations remain equally existent. First, targeting tumour-associated pathophysiological 
processes goes at the expense of sensitivity and specificity of the imaging technique. Although 
imaging of tumour-associated pathophysiological processes is not affected by phenotypic 
heterogeneity of cell-surface receptors, there is still heterogeneity in the behavioral features of the 
tumour that influences sensitivity. For example, proteolytic activity may be reduced at the 
invasive front in less invasive tumours with fewer tendencies towards metastasis, or in cases of 
encapsulated tumours, reducing the sensitivity of this target. On the other hand, specificity of the 
target is limited due to the regular expression of these enzymes in healthy tissues and increased 
expression in inflammatory tissues [26, 28]. Second, a resection margin as indicated by 
fluorescent agents that target tumour-associated pathophysiological processes would be 
inconsistent as a result of the variability of proteolytic activity due to phenotypic heterogeneity 
and regular expression in inflammatory tissues. Although it is expected that proteolytic activity 
would be increased in regions where invasive strands are found, this approach does not 
incorporate a standardized objective resection margin. Consequently, the resection margin could 
be too small in slow-growing tumours or too large in tumours that are surrounded by 
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target, the approach changed from targeting cell surface receptors to targeting tumour-associated 
pathophysiological processes. The best-known example of such a process is the degradation of 
the extracellular matrix, which is required for tumour growth andmetastasis. By targeting 
enzymes that are involved in these general processes, the tumour border is imaged, independent 
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invasive front in less invasive tumours with fewer tendencies towards metastasis, or in cases of 
encapsulated tumours, reducing the sensitivity of this target. On the other hand, specificity of the 
target is limited due to the regular expression of these enzymes in healthy tissues and increased 
expression in inflammatory tissues [26, 28]. Second, a resection margin as indicated by 
fluorescent agents that target tumour-associated pathophysiological processes would be 
inconsistent as a result of the variability of proteolytic activity due to phenotypic heterogeneity 
and regular expression in inflammatory tissues. Although it is expected that proteolytic activity 
would be increased in regions where invasive strands are found, this approach does not 
incorporate a standardized objective resection margin. Consequently, the resection margin could 
be too small in slow-growing tumours or too large in tumours that are surrounded by 
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inflammatory tissue. Third, with either of the two targeting strategies, it is even more important 
to consider the influence of the tissue optical properties (absorption and scattering) in the 
tumour margin which are themselves likely to be altered differently by the presence of an 
invasive front or at the boundary of an encapsulated tumour. Consequently, smaller lesions and 
invasive strands may be very difficult to detect, and a basic understanding of the optical physics is 
required for the surgeon to adequately interpret the acquired images.  
 
 
Shifting Focus in Optical Image-Guided Therapy 
 
To establish a definite role for optical image-guided therapy into clinical practice, it is necessary 
to be able to identify the tumour with high sensitivity and specificity, and to remove the complete 
tumour mass including invasive tumour strands. In the following section, we propose that a shift 
in focus is required to deal with the three challenges that were identified: tumour heterogeneity, 
obtaining adequate resection margins that include invasive tumour strands, and managing and 
ultimately correcting for the effects of tissue optical properties during the surgical resection. 
 
Circumventing the Problems of Tumour Heterogeneity 
Recently, a new potential target was identified with the finding of expression of FSHR in tumour 
blood vessels of a wide range of different cancer types [29]. Expression was found from 5 mm 
within the tumour to 9 mm outside of the tumour and was not located in healthy tissue more 
than 10 mm from the tumour (Fig. 2). Although the exact pathogenic mechanism of expression 
of FSHR is yet unknown, this finding introduces new opportunities for image-guided cancer 
surgery: resection of tumour margin guided by an FSHR-specific signal may prove to be 
sufficient to completely remove the tumour. Because expression of the FSHR was found in a 
wide range of different cancer types that have different cellsurface receptors and variable 
malignant behavior, sensitivity is not influenced by tumour phenotypic or behavioural 
heterogeneity. Moreover, expression of the FSHR was found in tumour blood vessels and not in 
cancer cells. The specificity of this target is very high, as the FSHR is expressed only in the 
granulosa cells of the ovary and the Sertoli cells of the testis in adult humans. Hence, targeting of 
the FSHR would result in very low non-specific binding. Although the amount of FSHRs might 
be lower in smaller tumours, Radu et al. calculated that the volume that consists of blood vessels 
that have FSHR-expressing endothelial cells represents a substantial fraction of the tumour 
volume (e.g., in a tumour with a 2-cm diameter, a 3- mm-thick peripheral layer inside the tumour 
accounts for 66 % of its volume) [29]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2; FSHR expression according to vessel location. The blood vessels were visualized with the use of anti-von 
Willebrand factor antibodies followed by Alexa-488 dye secondary antibodies, and FSHR-stained vessels were 
visualized by the FSHR323 antibody followed by Alexa-555 dye-labeled secondary antibodies. The vessels were 
counted on 148 microscopical digital images of tumours obtained from five patients. Zero (0) indicates the border of 
the tumour, the negative numbers indicate the interior of the tumour, and the positive numbers indicate the exterior of 
the tumour. The red circles and dashed line represent the percentage of FSHRexpressing vessels. The blue squares 
indicate the total number of vessels per square millimeter; the mean number was higher in the interior of the tumour 
than in the exterior (37±2 vs. 25±1 vessels/mm2, PG0.001 with the use of a twotailed t test). I bars denote standard 
errors. Reproduced with permission from Radu et al., [29], Copyright Clearance Center Rightslink. 
 
This example excludes the additional number of FSHR-expressing vessels that co-exist up to 10 
mm outside the tumour border. Expression has been described even in early T1 tumours and in 
tumour metastases, illustrating the full potential of this target for image-guided cancer therapy. 
Development of a fluorescently labeled FSHR target is currently still in the experimental phase 
and future studies on pharmacodynamics, pharmacokinetics, and toxicity (including side effects 
on the reproductive system) are required for FDA approval. A possible drawback of this target 
could be that identification of tumours by targeting the FSHR is only feasible after formation of 
tumour blood vessels. In the prevascular phase, tumour volume is limited to 2–3 mm3 , a size 
that is usually clinically undetectable [30]. After the angiogenic switch has occurred, 
neovascularization permits tumours to grow and metastasize, which heralds the onset of 
symptoms [30, 31]. Because surgery is performed only on clinically detectable lesions that have 
given symptoms in most cases, neovascularization will always be present and expression of the 
FSHR can be used as an imaging target for optical image-guided surgery. In addition, most 
injectable agents have additional “tumour binding” through the nonspecific effect of enhanced 
permeability and retention (EPR) that is present in many tumours [32, 33]. Non-specific 
retention of the agent in the tumour (periphery) could have a positive effect by increasing the 
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This example excludes the additional number of FSHR-expressing vessels that co-exist up to 10 
mm outside the tumour border. Expression has been described even in early T1 tumours and in 
tumour metastases, illustrating the full potential of this target for image-guided cancer therapy. 
Development of a fluorescently labeled FSHR target is currently still in the experimental phase 
and future studies on pharmacodynamics, pharmacokinetics, and toxicity (including side effects 
on the reproductive system) are required for FDA approval. A possible drawback of this target 
could be that identification of tumours by targeting the FSHR is only feasible after formation of 
tumour blood vessels. In the prevascular phase, tumour volume is limited to 2–3 mm3 , a size 
that is usually clinically undetectable [30]. After the angiogenic switch has occurred, 
neovascularization permits tumours to grow and metastasize, which heralds the onset of 
symptoms [30, 31]. Because surgery is performed only on clinically detectable lesions that have 
given symptoms in most cases, neovascularization will always be present and expression of the 
FSHR can be used as an imaging target for optical image-guided surgery. In addition, most 
injectable agents have additional “tumour binding” through the nonspecific effect of enhanced 
permeability and retention (EPR) that is present in many tumours [32, 33]. Non-specific 
retention of the agent in the tumour (periphery) could have a positive effect by increasing the 
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fluorescent signal, but on the other hand could reduce the exact specificity of margin delineation 
by the tumour-specific agent. Preclinical studies have demonstrated clear differences in tumour-
specific binding localization [25] and intensity [17] between non-specific EPR and tumour-
specific targeting. Finally, similar to targeting of growth factor receptors, injection of contrast 
agents that target hormone receptors heralds a risk of potentially harmful effects such as tumour 
proliferation. In longitudinal animal studies on fluorescent agents targeting the epidermal growth 
factor receptor (EGFR) in prostate cancer, no tumour-promoting effects were found [34]. In 
contrast to prostate cancer cells that express EGFR, FSHR-expression was only found in the 
tumour vasculature and not in cancer cells [29], but it is currently unknown if stimulation of the 
FSHR has effects on tumour growth. As long as these agents are used solely for guidance of 
tumour resection, the agents would be injected preoperatively and such potentially proliferative 
effects would be limited to the tumour that is directly removed, provided that regional or distant 
metastasis are non-existent. Nevertheless, this aspect requires attention in the evaluation of the 
clinical feasibility of an FSHR-specific fluorescent agent.  
 
Dealing with Undetectable Invasive Tumour Strands 
The high recurrence rates in many cancer types warrant a new approach to the inability to 
identify individual invasive tumour strands. Optical imaging would allow consistent inclusion of 
an objective resection margin into the surgical resection by targeting of the FSHR. Because 
FSHR expression was found up to 9 mm outside the tumour border, a resection guided by an 
FSHR-specific fluorescence signal would include a consistent resection margin and would 
theoretically include invasive tumour strands in the vast majority of resectable tumours. Even 
with a highly specific targeting agent available, the fundamental problems associated with 
detecting weak fluorescence signals in an environment dominated by heterogeneous optical 
absorption may sometimes prevent undisputable identification of the border of the fluorescent 
resection margin [7, 8, 15, 35]. Furthermore, high-risk pathological characteristics could imply 
that adjuvant therapy may still be required to completely treat the cancer [11]. In these selected 
cases, PDT may be very suitable for adjuvant therapy after optical imageguided cancer surgery 
for various important reasons. In PDT, photosensitizers are used that produce cytotoxic reactive 
oxygen species after excitation by light with a specific wavelength. As a result, cancer cells are 
killed by apoptosis and/or necrosis, and tumour microvasculature is obliterated [36, 37]. Specific 
damage of the tissue of interest is obtained by local illumination. Furthermore, the very short 
half-life of cytotoxic reactive oxygen species ensures that damage only occurs in the immediate 
vicinity of its formation. Although conventional adjuvant treatments (i.e., radiotherapy, 
chemotherapy, or a combination) can induce immunosuppression, PDT-induced immunogenic 
cell death induces a local inflammatory reaction and stimulates the host immune system [37]. In 
addition, formation of a tumourspecific immune response (e.g., production of tumour-specific 
 
cytotoxic T-cells) offers opportunities to treat distant metastases [37]. Preclinical studies showed 
possibilities of boosting the immune response by the adjuvant use of an oncolytic vaccine virus 
resulting in effective inhibition of distant metastatic spread [38]. Compared to other adjuvant 
therapeutic modalities, PDT has the potential to induce low toxicity in normal tissue, produce 
negligible systemic effects, and reduce acute and long-term morbidity [36]. Furthermore, PDT 
does not compromise future treatment options for patients with residual or recurrent disease and 
can be repeated with perpetual efficacy. However, due to limited light penetration depth (G1 
cm), PDT is only applicable for superficial lesions, unless the tumour is accessible for insertion of 
fibers into the tumour to deliver the light. In larger tumours that are inaccessible, debulking of 
the tumour mass is therefore preferred before adjuvant PDT could be performed [39]. 
Wavelength-specific excitation of photosensitizers could technically be performed using the same 
imaging systems as those used for optical image-guided surgery, emphasizing its practical 
advantages as an adjuvant therapeutic modality in the surgical theatre. In order to fully exploit the 
advantages of both modalities, a tumour-specific NIR fluorescent photosensitizer is required [40, 
41]. A tumour-specific photosensitizer has the potential to be much more efficient and cause less 
damage to surrounding normal tissue than a non-specific photosensitizer [40, 41]. The increasing 
amount of photosensitizer that is expected to accumulate in the tissue of interest ensures that less 
light is required to induce a cytotoxic reaction. Consequently, even light that penetrates deeper 
into tissue (>1 cm) will result in specific damage of tumour cells that are deeper located. 
Moreover, such an agent could be used for both NIR fluorescence image-guided surgery and 
adjuvant PDT (i.e., a “theranostic”). Thereby, a targeting moiety and photosensitizer conjugate 
can be chosen that accumulates at a location in the cell that is favourable for eliciting a specific 
cellular or host response (e.g., apoptosis or an immune response)[36]. Recent studies report of 
tumour-specific PDT that could potentially be performed using heptamethine cyanine dyes that 
have been shown to specifically target cancer cells in vivo through internalization into the cell by 
the organic anion transporting polypeptide [42]. Because these agents have shown 
photosensitizing properties, they are nominated as promising theranostics for future NIR 
fluorescence imageguided surgery with adjuvant PDT [43]. A second approach could be to 
design a construct that is a combination of a fluorophore and photosensitizer conjugated with a 
tumourspecific target. The use of  nanotechnology may circumvent some of the negative physio-
chemical properties of photosensitizer conjugates [44] and a photosensitizer.  
 
Managing and Correcting for the Effects of Optical Tissue Properties  
As we have described above, a current approach to tumourspecific imaging results in 
fluorescence signals that are strongly influenced by the background tissue optical properties of 
the tissue under investigation. Given the nature of the fluorescence signals, we propose a shift of 
focus in optical image-guided cancer therapy towards intraoperative quantitative intrinsic 
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FSHR has effects on tumour growth. As long as these agents are used solely for guidance of 
tumour resection, the agents would be injected preoperatively and such potentially proliferative 
effects would be limited to the tumour that is directly removed, provided that regional or distant 
metastasis are non-existent. Nevertheless, this aspect requires attention in the evaluation of the 
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Dealing with Undetectable Invasive Tumour Strands 
The high recurrence rates in many cancer types warrant a new approach to the inability to 
identify individual invasive tumour strands. Optical imaging would allow consistent inclusion of 
an objective resection margin into the surgical resection by targeting of the FSHR. Because 
FSHR expression was found up to 9 mm outside the tumour border, a resection guided by an 
FSHR-specific fluorescence signal would include a consistent resection margin and would 
theoretically include invasive tumour strands in the vast majority of resectable tumours. Even 
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resection margin [7, 8, 15, 35]. Furthermore, high-risk pathological characteristics could imply 
that adjuvant therapy may still be required to completely treat the cancer [11]. In these selected 
cases, PDT may be very suitable for adjuvant therapy after optical imageguided cancer surgery 
for various important reasons. In PDT, photosensitizers are used that produce cytotoxic reactive 
oxygen species after excitation by light with a specific wavelength. As a result, cancer cells are 
killed by apoptosis and/or necrosis, and tumour microvasculature is obliterated [36, 37]. Specific 
damage of the tissue of interest is obtained by local illumination. Furthermore, the very short 
half-life of cytotoxic reactive oxygen species ensures that damage only occurs in the immediate 
vicinity of its formation. Although conventional adjuvant treatments (i.e., radiotherapy, 
chemotherapy, or a combination) can induce immunosuppression, PDT-induced immunogenic 
cell death induces a local inflammatory reaction and stimulates the host immune system [37]. In 
addition, formation of a tumourspecific immune response (e.g., production of tumour-specific 
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design a construct that is a combination of a fluorophore and photosensitizer conjugated with a 
tumourspecific target. The use of  nanotechnology may circumvent some of the negative physio-
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Managing and Correcting for the Effects of Optical Tissue Properties  
As we have described above, a current approach to tumourspecific imaging results in 
fluorescence signals that are strongly influenced by the background tissue optical properties of 
the tissue under investigation. Given the nature of the fluorescence signals, we propose a shift of 
focus in optical image-guided cancer therapy towards intraoperative quantitative intrinsic 
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fluorescence measurements. While various groups have developed imaging systems that 
incorporate tissue attenuation correction algorithms [16–18], other approaches are aimed at 
performing truly quantitative in vivo fluorescence measurements [45]. To perform truly 
quantitative intrinsic fluorescence measurements, the research field of biomedical optics has 
mainly focused on the use of optical techniques in which the path length of light in tissue can be 
controlled. This generally involves placing a fiber optic probe on the surface of the tissue, 
through which light enters the tissue and is subsequently collected from a known distance inside 
the tissue. The use of a known distance between light source and light detection is important for 
two reasons. First, it determines the volume over which optical signals are averaged, which is an 
important consideration for the interrogation of tumour, tumour margin, and the surrounding 
normal tissue. Second, using a known separation distance between the light source and the light 
detection, theoretical models can be built to describe the complex interaction of light with tissue 
over this distance. By applying these theoretical models to the light measured by the fiber optic 
probe, the tissue optical properties can be quantified. The use of a fiber optic probe also 
facilitates the acquisition of spectrally resolved fluorescence with a high signal-to-background 
ratio. Spectral deconvolution allows intrinsic fluorophore fluorescence to be distinguished from 
the tissue autofluorescence and residual excitation light. Recently, the use of a single fiber optic 
probe for the delivery and collection of light has been described; single fiber reflectance 
spectroscopy (SFR) [46]. Mathematical models have been developed to describe the underlying 
interaction of light with tissue [47, 48]. The sampling volume can be tailored to a specific clinical 
application or suited to the intraoperative need by varying the diameter of the optical fiber(s) that 
are used (range in sampling depth 0.1–1 mm). Using knowledge of the sampling volume, 
algorithms have been developed that can be used to perform quantitative reflectance and 
fluorescence spectroscopy [45, 49]. By utilizing two or more fiber diameters in a single fiber optic 
probe, SFR spectroscopy enables a complete determination of tissue optical properties [49, 50]. 
This technique, termed multi-diameter single fiber reflectance spectroscopy (MDSFR), can then 
be used to recover a fully quantitative measure of intrinsic fluorescence [51]. In MDSFR 
spectroscopy, an overlap exists in delivery and collection of light, which provides information on 
the distribution of angles at which the light scatters [52, 53]. Preclinical studies have suggested 
that measuring these types of scattering properties may have diagnostic value [54]. This approach 
yields the quantification of intrinsic fluorescence, given as the product of the tissue fluorophore 
absorption coefficient at the excitation wavelength. Recently, the first promising results were 
reported in neurosurgical and gastrointestinal applications using similar approaches [55, 56]. The 
use of a fiber optic probe has some disadvantages; the point measurement technique needs to be 
incorporated into the procedure of image-guided surgery and it is not ideal for covering a large 
proportion of the tumour margin. In addition, true real-time acquisition is not possible, because 
the measurements take a few seconds to produce at each measurement location. Future 
 
developments in the clinical implementation of MDSFR such as the use of larger coherent fiber 
bundles [57] could allow this fiber-based technique to approach the resolution and speed of 
optical imaging. It is also important to consider how point spectroscopic information and optical 
imaging might be registered most optimally. The acquisition of point measurements as an 
adjuvant intraoperative optical imaging technique to fluorescenceguided surgery is clearly not 
limited to the use of reflectance and fluorescence spectroscopy. Other spectroscopic approaches 
such as Raman spectroscopy have significant potentials [58] but spectral analysis of a tumour 
margin during fluorescence-guided surgery may be hampered by the presence of the exogenous 
fluorophores. In addition, although these techniques are rapidly improving, the acquisition time 
of a representative Raman spectrum is currently too long to be used intraoperatively. Given the 
potential of the approaches that we have presented, we advocate the use of fluorescence-guided 
surgery for resection of the gross tumour mass, followed by point spectroscopic fluorescence 
measurements of suspect tumour margins. 
 
The Paradigm of Field Cancerization 
An interesting problem for optical image-guided cancer therapy is introduced with the concept of 
field cancerization that suggests that achieving histological adequate margins may not be 
sufficient in some cases [59]. Squamous cell carcinomas develop within preneoplastic fields of 
mucosal epithelium made up of genetically altered cells. However, these precursor changes in the 
mucosa may have a macroscopically normal appearance. Therefore, preneoplastic lesions can be 
found in parts of the surrounding mucosal epithelium [59] and can extend into the surgical 
margins when tumours are excised [60] causing local recurrences and second primary tumours. 
The relation between dysplastic changes surrounding tumours and the rate of local recurrences 
and multiple primary tumours in cancer has been reviewed extensively [59, 60]. An important 
aspect of the genetic basis of multi-step progression from normal mucosa to squamous cell 
carcinoma is found in the role of p53 [61] and loss of heterozygosity of specific chromosomes 
[59, 60, 62]. Although the cancerization process can be clearly identified genetically, no specific 
targeting agents have thus far been found for identification of preneoplastic lesions. An 
important reason is that preneoplastic fields have much more biological similarities with normal 
mucosa than with tumour, making array and proteomic studies very difficult. The paradigm of 
field cancerization poses a problem for identification of tumour-free margins using optical 
imaging. Considering the surrounding preneoplastic lesions and their relevance for local 
recurrence rates, it might not be sufficient to completely remove the tumour at its borders. At 
present, no literature exists that is able to guide a surgeon towards adequate margins in the setting 
of field cancerization [12]. However, the potential extent of this problem emphasizes the 
necessity to include a consistent objective resection margin as would be indicated by targeting of 
the FSHR. 
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use of a fiber optic probe has some disadvantages; the point measurement technique needs to be 
incorporated into the procedure of image-guided surgery and it is not ideal for covering a large 
proportion of the tumour margin. In addition, true real-time acquisition is not possible, because 
the measurements take a few seconds to produce at each measurement location. Future 
 
developments in the clinical implementation of MDSFR such as the use of larger coherent fiber 
bundles [57] could allow this fiber-based technique to approach the resolution and speed of 
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imaging might be registered most optimally. The acquisition of point measurements as an 
adjuvant intraoperative optical imaging technique to fluorescenceguided surgery is clearly not 
limited to the use of reflectance and fluorescence spectroscopy. Other spectroscopic approaches 
such as Raman spectroscopy have significant potentials [58] but spectral analysis of a tumour 
margin during fluorescence-guided surgery may be hampered by the presence of the exogenous 
fluorophores. In addition, although these techniques are rapidly improving, the acquisition time 
of a representative Raman spectrum is currently too long to be used intraoperatively. Given the 
potential of the approaches that we have presented, we advocate the use of fluorescence-guided 
surgery for resection of the gross tumour mass, followed by point spectroscopic fluorescence 
measurements of suspect tumour margins. 
 
The Paradigm of Field Cancerization 
An interesting problem for optical image-guided cancer therapy is introduced with the concept of 
field cancerization that suggests that achieving histological adequate margins may not be 
sufficient in some cases [59]. Squamous cell carcinomas develop within preneoplastic fields of 
mucosal epithelium made up of genetically altered cells. However, these precursor changes in the 
mucosa may have a macroscopically normal appearance. Therefore, preneoplastic lesions can be 
found in parts of the surrounding mucosal epithelium [59] and can extend into the surgical 
margins when tumours are excised [60] causing local recurrences and second primary tumours. 
The relation between dysplastic changes surrounding tumours and the rate of local recurrences 
and multiple primary tumours in cancer has been reviewed extensively [59, 60]. An important 
aspect of the genetic basis of multi-step progression from normal mucosa to squamous cell 
carcinoma is found in the role of p53 [61] and loss of heterozygosity of specific chromosomes 
[59, 60, 62]. Although the cancerization process can be clearly identified genetically, no specific 
targeting agents have thus far been found for identification of preneoplastic lesions. An 
important reason is that preneoplastic fields have much more biological similarities with normal 
mucosa than with tumour, making array and proteomic studies very difficult. The paradigm of 
field cancerization poses a problem for identification of tumour-free margins using optical 
imaging. Considering the surrounding preneoplastic lesions and their relevance for local 
recurrence rates, it might not be sufficient to completely remove the tumour at its borders. At 
present, no literature exists that is able to guide a surgeon towards adequate margins in the setting 
of field cancerization [12]. However, the potential extent of this problem emphasizes the 
necessity to include a consistent objective resection margin as would be indicated by targeting of 
the FSHR. 
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Conclusion 
 
Although the introduction of optical imaging techniques for intraoperative applications has great 
potential to improve assessment of tumour margins during surgery, optimizing sensitivity and 
specificity remain challenging because of tumour heterogeneity. In addition, results of optical 
imageguided surgery are potentially limited due to difficulty in including invasive tumour strands 
in the resection margin and dealing with the influences that optical tissue properties have on the 
image. We review three new concepts that could deal with these challenges. First, expression of 
the FSHR provides an ideal target for cancer imaging and could theoretically circumvent the 
problems of tumour heterogeneity. Next, the inability to identify individual invasive strands 
dictates a new approach to consistently include an objective resection margin into the surgical 
resection. The FSHR positive margin would provide such a consistent objective resection 
margin. Extension of invasive strands beyond such a standardized resection margin could ideally 
be treated with adjuvant photodynamic therapy. And finally, the confounding effects of variable 
background tissue optical properties can be overcome by combining fluorescence-guided surgery 
with quantitative optical spectroscopy of the tumour margin. We anticipate that these promising 
concepts will play an elementary role in the next generation of optical image-guided cancer 
therapy.  
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ABSTRACT 
 
Photodynamic therapy (PDT) induces cell death through local light activation of a 
photosensitizer (PS) and has been used to treat head and neck cancers. Yet, common PS lack 
tumour specificity,which leads to collateral damage to normal tissues. Targeted delivery of PS via 
antibodies has pre-clinically improved tumour selectivity.However, antibodies have long half-
lives and relatively poor tissue penetration, which could limit therapeutic efficacy and lead to long 
photosensitivity. Here, in this feasibility study, we evaluate at the pre-clinical level a recently 
introduced format of targeted PDT,which employs nanobodies as targeting agents and awater-
soluble PS (IRDye700DX) that is traceable through optical imaging. In vitro, the PS solely binds 
to cells and induces phototoxicity on cells overexpressing the epidermal growth factor receptor 
(EGFR), when conjugated to the EGFR targeted nanobodies. To investigatewhether this new 
format of targeted PDT is capable of inducing selective tumour cell death in vivo, PDTwas 
applied on an orthotopic mouse tumour model with illumination at 1 h post-injection of the 
nanobody–PS conjugates, as selected from quantitative fluorescence spectroscopymeasurements. 
In parallel, and as a reference, PDTwas appliedwith an antibody–PS conjugate, with illumination 
performed 24 h post-injection. Importantly, EGFR targeted nanobody–PS conjugates led to 
extensive tumour necrosis (approx. 90%) and almost no toxicity in healthy tissues, as observed 
through histology 24 h after PDT. Overall, results showthat these EGFR targeted nanobody–PS 
conjugates are selective and able to induce tumour cell death in vivo. Additional studies are now 
needed to assess the full potential of this approach to improving PDT.  
 
Introduction 
 
Cancers of the head and neck region are the sixth most common cancers in the world [1]. In 
spite of recent advances in surgery and radiotherapy, increasing incidences and moderate survival 
rates are reported [2]. Photodynamic therapy (PDT) is a promising minimally invasive approach 
that is being used for the local treatment of premalignant and malignant lesions in the head and 
neck region [3,4]. Despite the potential advantages of PDT, collateral damage to normal tissue 
remains a significant side effect, particularly in the treatment of large tumours [5]. Targeted PDT, 
in which photosensitizers (PS) are selectively delivered to the tumour, could greatly enhance the 
results of PDT in head and neck cancer. PDT makes use of three essential elements to induce 
localized (tumour) cell death: a PS, light of a particular wavelength, and oxygen [3]. Although 
each of these individual components is not toxic, together they induce local toxicity through the 
formation of toxic reactive oxygen species, notably singlet oxygen (1O2), damaging proteins, 
lipids and/or nucleic acids. The lifetime and diffusion distance of 1O2 are very short [6], 
consequently, the localization of PS at the time of the illumination is a critical factor in the 
selectivity of PDT. The overall localization of the PS at the tumour and the surrounding normal 
tissues is determined by the pharmacokinetics of the PS (i.e. its absorption, distribution, 
metabolism, and excretion). The generation of 1O2 in the target tissue results in cell death 
through apoptosis and/or necrosis. Necrotic cell death can be induced either by a direct effect on 
tumour cells or indirectly through a shutdown of tumour vasculature. An important additional 
mechanism of action in PDT is derived from a robust inflammatory response that can lead to 
development of systemic immunity [3]. Clinically available PSs can be categorized as derivatives 
of three major families: porphyrins (e.g. Photofrin), chlorins (e.g. Foscan) and phthalocyanines 
(e.g. Photosense) [7]. In general, most PSs are rather hydrophobic which promotes cell binding, 
but provides no specificity. As a result, 2 to 4 days are generally necessary between injection of 
the PS and illumination, in order to favor clearance of PS from normal tissues and to promote 
some tumour specificity [7]. Alternatively, light can be applied earlier after PS administration, 
with the particular intention to induce vascular damage [3]. In addition, patients generally show 
skin photosensitivity for long periods of time (2–6 weeks) [3,8]. Therefore, efforts have been 
made to render PS more hydrophilic and to target these molecules more selectively to tumours, 
through chemical modifications, delivery systems, and/or targeting molecules [9–13]. The 
targeting of PS through the use of monoclonal antibodies (mAbs), which is termed 
photoimmunotherapy [11], has shown promising results [14,15]. Nevertheless, due to their large 
molecular weight (150 kDa), mAb–PS conjugates have a limited capability of penetrating into the 
interior of large tumours [16,17]. Moreover, the larger size of mAbs–PS conjugates (~15 nm) 
may impede the generation of 1O2 within the outer cell membrane of targeted cells and affect 
the therapeutic efficacy. The location of lipophilic photosensitisers within the plasma membrane 
EGFR-targeted photodynamic therapy 181
8
 
ABSTRACT 
 
Photodynamic therapy (PDT) induces cell death through local light activation of a 
photosensitizer (PS) and has been used to treat head and neck cancers. Yet, common PS lack 
tumour specificity,which leads to collateral damage to normal tissues. Targeted delivery of PS via 
antibodies has pre-clinically improved tumour selectivity.However, antibodies have long half-
lives and relatively poor tissue penetration, which could limit therapeutic efficacy and lead to long 
photosensitivity. Here, in this feasibility study, we evaluate at the pre-clinical level a recently 
introduced format of targeted PDT,which employs nanobodies as targeting agents and awater-
soluble PS (IRDye700DX) that is traceable through optical imaging. In vitro, the PS solely binds 
to cells and induces phototoxicity on cells overexpressing the epidermal growth factor receptor 
(EGFR), when conjugated to the EGFR targeted nanobodies. To investigatewhether this new 
format of targeted PDT is capable of inducing selective tumour cell death in vivo, PDTwas 
applied on an orthotopic mouse tumour model with illumination at 1 h post-injection of the 
nanobody–PS conjugates, as selected from quantitative fluorescence spectroscopymeasurements. 
In parallel, and as a reference, PDTwas appliedwith an antibody–PS conjugate, with illumination 
performed 24 h post-injection. Importantly, EGFR targeted nanobody–PS conjugates led to 
extensive tumour necrosis (approx. 90%) and almost no toxicity in healthy tissues, as observed 
through histology 24 h after PDT. Overall, results showthat these EGFR targeted nanobody–PS 
conjugates are selective and able to induce tumour cell death in vivo. Additional studies are now 
needed to assess the full potential of this approach to improving PDT.  
 
Introduction 
 
Cancers of the head and neck region are the sixth most common cancers in the world [1]. In 
spite of recent advances in surgery and radiotherapy, increasing incidences and moderate survival 
rates are reported [2]. Photodynamic therapy (PDT) is a promising minimally invasive approach 
that is being used for the local treatment of premalignant and malignant lesions in the head and 
neck region [3,4]. Despite the potential advantages of PDT, collateral damage to normal tissue 
remains a significant side effect, particularly in the treatment of large tumours [5]. Targeted PDT, 
in which photosensitizers (PS) are selectively delivered to the tumour, could greatly enhance the 
results of PDT in head and neck cancer. PDT makes use of three essential elements to induce 
localized (tumour) cell death: a PS, light of a particular wavelength, and oxygen [3]. Although 
each of these individual components is not toxic, together they induce local toxicity through the 
formation of toxic reactive oxygen species, notably singlet oxygen (1O2), damaging proteins, 
lipids and/or nucleic acids. The lifetime and diffusion distance of 1O2 are very short [6], 
consequently, the localization of PS at the time of the illumination is a critical factor in the 
selectivity of PDT. The overall localization of the PS at the tumour and the surrounding normal 
tissues is determined by the pharmacokinetics of the PS (i.e. its absorption, distribution, 
metabolism, and excretion). The generation of 1O2 in the target tissue results in cell death 
through apoptosis and/or necrosis. Necrotic cell death can be induced either by a direct effect on 
tumour cells or indirectly through a shutdown of tumour vasculature. An important additional 
mechanism of action in PDT is derived from a robust inflammatory response that can lead to 
development of systemic immunity [3]. Clinically available PSs can be categorized as derivatives 
of three major families: porphyrins (e.g. Photofrin), chlorins (e.g. Foscan) and phthalocyanines 
(e.g. Photosense) [7]. In general, most PSs are rather hydrophobic which promotes cell binding, 
but provides no specificity. As a result, 2 to 4 days are generally necessary between injection of 
the PS and illumination, in order to favor clearance of PS from normal tissues and to promote 
some tumour specificity [7]. Alternatively, light can be applied earlier after PS administration, 
with the particular intention to induce vascular damage [3]. In addition, patients generally show 
skin photosensitivity for long periods of time (2–6 weeks) [3,8]. Therefore, efforts have been 
made to render PS more hydrophilic and to target these molecules more selectively to tumours, 
through chemical modifications, delivery systems, and/or targeting molecules [9–13]. The 
targeting of PS through the use of monoclonal antibodies (mAbs), which is termed 
photoimmunotherapy [11], has shown promising results [14,15]. Nevertheless, due to their large 
molecular weight (150 kDa), mAb–PS conjugates have a limited capability of penetrating into the 
interior of large tumours [16,17]. Moreover, the larger size of mAbs–PS conjugates (~15 nm) 
may impede the generation of 1O2 within the outer cell membrane of targeted cells and affect 
the therapeutic efficacy. The location of lipophilic photosensitisers within the plasma membrane 
182 Chapter 8
 
has previously been shown to influence in vitro and in vivo efficacy [18]. Furthermore, because 
of long half-lives of mAbs in the bloodstream, time is needed for tumour accumulation and 
development of sufficient tumour-to-background ratios (TBR) to protect healthy tissues. As 
many of these disadvantages are related to the size of mAbs, some studies reported the use of 
smaller mAb fragments such as F(ab′)2 and scFv conjugated to a PS [19–24]. Recently, we have 
introduced an alternative approach for targeted PDT employing nanobodies conjugated to 
awater-soluble and traceable PS, leading to encouraging results in vitro [25]. Nanobodies are the 
smallest naturally derived antigen-binding fragments that consist of the variable domain of heavy 
chain antibodies, whichwere first discovered in dromedaries in 1993 [26]. Nanobodies bind 
specifically and with high affinities to their antigens [26,27], they are stable and soluble in 
aqueous solutions, can be chemically modified, and have low immunogenic potential [28]. 
Importantly, with a molecular weight ten times smaller than conventional antibodies (15 kDa vs 
150 kDa) [29] and high binding affinities, tumour penetration of nanobodies is greatly enhanced, 
and occurs more rapidly [27,30,31] (this is in line with the modeling of Schmidt and Wittrup 
[32]). In addition, the rapid clearance through the kidneys accelerates the acquisition of 
imageswith sufficient TBR, as demonstrated in our previous studies in which a nanobody was 
compared to an antibody for optical molecular imaging [30,31]. The nanobodies that we used for 
PDT, i.e. the monovalent 7D12 [31,33] and the biparatopic 7D12-9G8 [34], specifically targeted 
the epidermal growth factor receptor (EGFR). With more than 83% of all head and neck 
squamous cell carcinomas overexpressing EGFR [35], it serves as a promising target in head and 
neck cancer patients. In fact, increased levels of EGFR are associated with poor prognosis by 
locoregional failure and decreased survival [36]. The PS that we conjugated to the nanobodies 
was IRDye700DX, which is a water-soluble silicon-phthalocyanine derivative, that has a strong 
absorption band in the near-infrared region of the spectrum (690 nm) and is also traceable 
through optical imaging [15,37]. Our previous studies showed that, in vitro, the nanobody–PS 
conjugates (i.e. 7D12–PS and 7D12-9G8–PS) bound specifically to EGFR, allowing the 
distinction of cell lines with different expression levels of EGFR. Notably, the conjugates 
specifically induced cell death of EGFR overexpressing cells in low nanomolar concentrations. 
Importantly, the biparatopic conjugate (i.e. 7D12-9G8–PS) was more toxic, as it could deliver 
more PS intracellularly [25], via the clustering induced endocytosis of EGFR [38]. These 
encouraging results have stimulated further investigation of these conjugates in an in vivo setting. 
The aim of the present study is to investigate the therapeutic potential of nanobody–PS 
conjugates for targeted PDT, i.e. to determine whether these conjugates are capable of inducing 
selective tumour cell death in vivo, in a pre-clinical head and neck tumour model. First, the 
nanobody–PS conjugates are characterized for their specificity and phototoxicity in vitro 
employing the EGFR overexpressing oral squamous cell carcinoma cell line OSC-19-luc2-cGFP 
(OSC). Subsequently, this cell line is grown as an orthotopic model in the tongue of mice to 
 
allow pre-clinical evaluation through histological analysis post-PDT. As a reference or positive 
control, and for validation of themodel and analysis procedure employed in this feasibility study, 
Cetuximab–PS was employed as Mitsunaga et al. [15] have described the use of their mAb–PS 
conjugates. To determine the best time point for illumination after intravenous injection of the 
nanobody–PS conjugates, quantitative fluorescence spectroscopy is employed. This is a method 
that has been developedwithin our group and is currently being evaluated in the clinic for guiding 
PDT applications, as it provides insights in the pharmacokinetics (through local distribution) of 
the PS. Thereafter, PDT is applied in this orthotopic tumour model and the efficacy is evaluated 
in vivo by histological analysis. Our data show that nanobody–PS conjugates are selective and 
able to induce specific tumour cell death in a pre-clinical model of head and neck cancer. 
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Materials and Methods 
 
2.1. Nanobodies and PS conjugation 
Nanobodies 7D12, R2, and 7D12-9G8 were produced as described previously, i.e. His-tagged 
nanobodies were produced in E. coli and purified from the periplasmic space by TALON affinity 
purification [31, 34]. The nanobody 7D12 binds to the domain III of the EGFR, preventing 
EGF binding to the receptor [39]. The biparatopic nanobody 7D12-9G8 is composed of two 
nanobodies that bind to different epitopes on EGFR and that cannot bind simultaneously to the 
same receptor, therefore being able to create clusters of receptors [39]. The irrelevant nanobody 
R2 is employed as a control and was specifically selected to bind to the azo dye Reactive Red 6 
[40,41]. The photosensitizer IRDye700DX (here named PS) was purchased from LI-COR (LI-
COR Biosciences, Lincoln, Nebraska) as an N-hydroxysuccinimidine (NHS) ester. Conjugation 
of the PS to the nanobodies was performed as described in Heukers et al. [25], except that the 
molar ratio for conjugation was 1 to 4 for 7D12–PS and 1 to 2 for R2–PS and 7D12-9G8–PS. 
After 2 h at room temperature, the conjugates were separated from free PS by size exclusion 
chromatography using Zebra Spin Desalting columns (Thermo Fisher Scientific, Perbio Science 
Nederland, Etten-Leur, The Netherlands), in three sequential steps. The degree of conjugation 
(DOC) was determined as recommended by the provider, by measuring the absorbance at 280 
nmand 689nmusing a NanoDrop spectrophotometer (NanoDrop Technologies,Wilmington, 
Delaware, USA). Purity and integrity of the nanobody–PS conjugates were determined by 
molecular size separation through SDS-PAGE using 15% gels. Immediately after running the 
gels, these were imaged on an Odyssey Infrared scanner (LI-COR Biosciences) using the 700 nm 
channel to detect PS fluorescence. Thereafter, Coomassie Blue staining was performed and 
detected in the same way as the PS. Cetuximab–PSwas used as a reference or positive control in 
this study andwas obtained as described byMitsunaga et al. [15] for panitumumab. 
 
2.2. Cell lines 
Three human cell lines with different EGFR expressions were used. The well differentiated 
squamous cell carcinoma of the tongue OSC-19-luc2-cGFP (high EGFR overexpression) was 
cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 
4.5 g D-glucose/L, 110 mg sodium pyruvate/L, 580 mg L-glutamine/L supplemented with 10% 
fetal bovine serum (FCS; Lonza, Basel, Swiss), 400 IU/mL penicillin, 100 μg/mL streptomycin 
(Invitrogen) 1× Minimal Essential Medium (MEM) non-essential amino acids solution and 1× 
MEM vitamin solution (Invitrogen) [42]. The human cervical cancer cell line HeLa (intermediate 
EGFR expression) was cultured in DMEM (Gibco, Invitrogen, United Kingdom) supplemented 
with 8% FCS (v/v), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (PAA, 
Germany) [25]. The human colorectal cancer cell line SW620 (low EGFR) was cultured in 
 
Leibovitz's L-15 medium (Invitrogen) containing 300 mg L-tlutamine/L supplemented with 10% 
FetalClone II (Hyclone, Logan, UT), 100 IU/mL penicillin, 100 μg/mL streptomycin 
(Invitrogen) and 20 mM HEPES (Invitrogen) [42]. All cell lines were grown in ahumidified 
incubator at 37 °C and 5% CO2 andwere regularly checked for Mycoplasma infection by 
polymerase chain reaction. 
 
2.3. Cell binding assay 
A total of 8000 cells were seeded per well of a 96-wells plate (Nunc, Roskilde, Denmark) and 
allowed to adhere overnight. For the affinity determination, plates were placed at 4 °C and cells 
were washed with cold binding medium (1% BSA and 25 mM HEPES in DMEM without 
phenol red, pH 7.2). Subsequently, cells were incubated with a concentration range of nanobody–
PS conjugates in binding medium for 2 h at 4 °C. Thereafter, cells were washed twice with cold 
binding medium and bound conjugates were detected though fluorescence imaging of the PS 
with the Odyssey Infrared scanner, using the 700 nm channel. Fluorescence intensities were 
plotted (in triplicate ± SEM) versus the concentrations. The resulting saturation curveswere used 
to determine the apparent affinity (kD) of the nanobody–PS conjugates, using the GraphPad 
Prism 5.02 software for Windows (GraphPad Software, San Diego, CA), and one-site specific 
binding, non-linear regression protocol. Experiments were repeated at least twice. For evaluation 
of the binding specificity by fluorescence microsocpy, cells were incubated with 25 nMof 
nanobody–PS as described above, followed by twowashing steps and incubation with calcein 
AM(0.5 μg/ml, Invitrogen) for detection of cells. This calcein incubation was not performed 
with OSC cell line as this one is GFP positive and thus already detectable through fluorescence 
microscopy. Imagingwas performedwith an EVOS Microscope (Advanced Microscopy Group, 
AMG, Thermo Fischer Scientific) equipped with 10× objective (Plan Fluor, 10×, NA 0.3, Air 
and working distance 8.3 mm, AMG) and the following LED-based fluorescence light cubes: 
GFP (Cat. no. 12-563-470) and Cy5 (for PS detection, Cat. no. 12-563-475) (fromWestover 
Scientific Inc., AMG). Overlays of the separate imageswere also generatedwith the EVOS 
Microscope software (AMG).  
 
2.4. Steady-state fluorescence and absorption measurements  
The fluorescence quantum yields (ΦF) of the nanobody/antibody conjugates were determined 
using a relative method in PBS (pH 7.4) [43] using Chlorin e6 (Ce6) in the same buffer as a 
reference. At pH 7.4 the fluorescence quantum yield of Ce6 is 0.18 [44,45]. The absorption 
spectrum of Ce6 and conjugates (concentration 1 × 10−6 M) was recorded in Shimadzu 
spectrophotometer (UV-2101 PC, Duisburg, Germany). The fluorescence emission of PS was 
recorded in a Perkin-Elmer spectrofluorometer (LS 50B, Massachusetts, USA). Ce6 and 
conjugates fluorescence spectra were acquired under 630 nm and 660 nm excitation respectively 
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spectrum of Ce6 and conjugates (concentration 1 × 10−6 M) was recorded in Shimadzu 
spectrophotometer (UV-2101 PC, Duisburg, Germany). The fluorescence emission of PS was 
recorded in a Perkin-Elmer spectrofluorometer (LS 50B, Massachusetts, USA). Ce6 and 
conjugates fluorescence spectra were acquired under 630 nm and 660 nm excitation respectively 
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at an OD lower than 0.1. Calculations ofΦF was accompanied by careful consideration of the 
differences in photon number at different wavelengths. 
 
2.5. Singlet oxygen quantum yield measurements 
Photo-oxidation of Singlet Oxygen Sensor Green Reagent (SOSGR) (Molecular Probes, NL) was 
used to determine the singlet oxygen formation by the nanobody–PS conjugates. This reagent 
was used because of its high selectivity for singlet oxygen and lowsensitivity to hydroxyl 
radicals/superoxides [46]. Stock solution of SOSGR (5 mM) was prepared in methanol. The final 
concentration of SOSGR within the PS solution in PBS pH 7.4 was 1 μM. Solutions of PS and 
nanobody–PS or antibody–PS conjugates were prepared in PBS pH 7.4. The concentration of PS 
were adjusted so that all absorb the same number of photonswithin the irradiated region 
(O.D.=0.014 at the λirr.=660nm(Spectra Physics, NL). Data was acquired in quartz cuvettes in 
aerobic conditions using stirring under uniform,measured fluence rate at 5 mW/cm2. At 
intervals, the cuvette was removed from magnetic stirrer and absorption and fluorescence 
emission spectrum (λexc = 405 nm) acquired. The singlet oxygen quantum yields (ΦD) of 
conjugates in PBS were determined in duplicate by a relative method [47] with a ΦD = 0.64 of 
Ce6 in the PBS at pH 7.4 as reference [48]. 
 
2.6. In vitro PDT 
One day after seeding 8000 cells per well of 96-wells plates (Greiner Bio-One, Alphen a/d Rijn, 
The Netherlands), cells are washed once with PDT medium (DMEM without phenol red 
supplemented with 8% FCS (v/v), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-
glutamine). Then, a dilution range of nanobody–PS conjugates was added to the cells and 
incubated for 30 min at 37 °C. After the incubation (also referred to as pulse), cells were washed 
twice with PDT medium. Immediately after, the fluorescence intensity of the conjugates bound 
to and/or internalized by the cells was detected with the Odyssey scanner and the cells were 
illuminated immediately after. Plates were illuminated with ~4 mW/cm2 fluence rate (measured 
with an Orion Laser power/energy monitor, Ophir Optronics LTD, Jerusalem, Israel), for a total 
dose of 10 J/cm2, using a device consisting of 96 LED lamps (670 ± 10 nm, 1 LED per well) 
described in [49,50]. After illumination, cells were placed back into the incubator, unless 
mentioned otherwise. In all experiments, a number of wells were covered during  llumination as 
internal negative control. Experiments were repeated at least twice. 
 
  
 
2.7. Cell viability assays 
After overnight incubation of the cells treated as described above, cells were incubated with the 
Alamar Blue reagent, according to the manufacturer's protocol (AbD Serotec, Oxford, United 
Kingdom), i.e. 10 μl of Alamar Blue was added into each well and mixed with the 100 μl of 
medium present in the wells. After an incubation of 1 h at 37 °C, fluorescence intensity was 
measured on a FluoStar Optima fluorescent plate reader (BMG Labtech GmbH, Ortenberg, 
Germany). Values of fluorescence intensities obtained fromwells only containing medium and 
Alamar bluewere taken as background,whilewells containing cells that were covered during 
illumination and that were not treated with nanobody–PS conjugates were set to 100% cell 
viability. Results are expressed as cell viability in percentage (%), thus relatively to the untreated 
cells, and the half maximal inhibitory concentration (IC50) are determined using the GraphPad 
Prism 5.02 software.  
 
2.8. Co-culture assay 
A mixture consisting of 50% of HeLa and 50% of OSC cell lines was seeded in 96-wells plates 
(Greiner), pulsed with 25 nM of nanobody– PS and followed by 10 J/cm2 of light dose. After 
overnight incubation (~16 h), dead cellswere distinguished fromliving cells by propidiumiodide 
(1 μg/ml, Invitrogen) and calcein AM(0.5 μg/ml, Invitrogen) staining, according to the 
manufacturers' protocol. Cells were imaged with an EVOS Microscope equipped with 10× 
objective and the following LED-based fluorescence light cubes: GFP for calcein AM and RFP 
(Cat. no. 12-563-471) for propidium iodide. Phase contrast images were also taken. Overlays of 
the separate images were generated with the EVOS Microscope software. 
 
2.9. Animal model 
Nude Balb/c female mice (Charles River laboratories, l'Arbresle, France), aged 4–6 weeks, were 
housed in individually ventilated cages and provided with food and sterilized water ad libitum. 
Animal experiments were approved by the local animal welfare committee of the Leiden 
University Medical Center. Orthotopic tongue tumours were submucosally induced in the tip of 
the tongue through injection of 40,000 OSC-19-luc2-cGFP cells, in suspension in 20 μl PBS. 
General health was monitored twice a week by weight measurements and inspection of the 
tongue. Tumour growth was monitored twice a week by bioluminescence (BLI) measurements 
and visual inspection of the tongue. Mice were sacrificed by injection of high-doses 
ketamine/xylazine. 
 
2.10. Quantitative fluorescence spectroscopy 
Quantitative fluorescence spectroscopy, which fully corrects for the differences in tissue optical 
properties, was performed as described previously [51]. White light reflectance and fluorescence 
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spectra were acquired using a single probe that contained two fibers of 0.4 and 0.8 mm. The 0.8 
mm fiber was used for both fluorescence and reflectance spectroscopy while the 0.4 mm fiber 
was used to perform reflectance spectroscopy. The end of the fiber probe in contactwith the 
tissue was polished to an angle of 15° tominimize the collection of specular reflection. To obtain 
a reflectance spectrum, light froma tungsten halogen lamp was directed on the tissue through a 
probe containing 2 single fibers with diameters of 0.4 and 0.8 mm. This choice of fiber diameters 
was dictated by the intention to optically sample a representative proportion of the tumour and 
normal tissue under interrogation. The photon path length and therefore the sampling volume is 
on the order of the fiber diameter which means that approximately 1/3 of the tumour volume is 
interrogated by the smallest fiber diameter. After these sequential reflectance measurements, a 
single fiber fluorescence spectroscopy (SFF) spectrum was acquired using the 0.8 mm fiber and 
660 nm laser light. This wavelength was chosen to optimally separate IRDye700DX (PS) 
fluorescence from background autofluorescence. The reflectance and fluorescence spectra were 
detected by three spectrometers, one for each fiber to measure reflectance and one to measure 
fluorescence where a 675 nm notch filter was used to block scattered excitation light. The 
spectrometers, light sources and shutters were controlled by a custom made LabView program 
(National Instruments LabView 7.1) on a notebook computer. A single combined multi-diameter 
optical fiber (MDSFR)/SFF measurement took approximately 3 s. The fiber probe was removed 
from the tissue and replaced to perform repeated measurements. Three spectra were acquired 
from each tissue type, and the average and standard deviation of these measurements were 
reported. 
 
2.10.1. Data analysis 
To calculate the intrinsic fluorescence, the raw fluorescence signals were corrected for the effects 
of absorption and scattering using the optical properties obtained from the MDSFR reflectance 
spectra. A detailed mathematical description of the recovery of the tissue optical properties from 
an MDSFR spectrum and their use in determining the intrinsic SFF from a raw fluorescence 
spectrum has been described previously [52]. The result of this analysis is a calibrated, corrected 
fluorescence spectrum expressed as the wavelength-dependent intrinsic fluorescence, where 
Q(l)μf is the quantum efficiency of the fluorophore at each emission wavelength. This spectrum 
is then integrated over the emission bandwidth of the fluorophore IRDye700DX (PS) to yield 
the intrinsic fluorescence Q · μ f a,x where Q is now the fluorescence quantum yield of the PS. 
 
2.10.2. Fluorescence spectral analysis 
The fluorescence spectra, corrected for the influence of tissue optical properties, were then 
analyzed to determine the contribution from the tissue autofluorescence, and that from PS. A 
skewed Gaussian was used to fit the autofluorescence while the basis spectra for PS conjugated 
 
to each antibody/nanobody were isolated from an average of representative in-vivo spectra after 
subtraction of the autofluorescence [53]. We note that the width and peak of PS fluorescence was 
slightly different for each antibody/nanobody conjugate. 
 
2.10.3. Calibration of the MDSFR/SFF system 
Before each set ofmeasurements a careful calibration procedurewas performed as described 
previously [54] consisting of an integrating sphere calibration, a measurement of a calibrated light 
source, and measurements in water in a dark container and in a liquid phantom containing 1.32% 
Intralipid with a known reduced scattering coefficient (μs′ at 800 nm=1.2 mm−1). This 
procedure accounts for variations in the output powers of the light sources and the spectral 
transmission and sensitivity of the system.  
 
2.10.4. Quantitative fluorescence spectroscopy in vivo 
When OSC tumours were visible by the human eye and the BLI signal ranged between 5 × 109 
and 1 × 1010 relative light units (RLU), mice were randomly divided into three groups and 
received an intraveneous injection of 200 μg of 7D12–PS, 7D12-9G8–PS, or R2–PS, eachmouse 
receiving approximately 6 nmol of PS to allow comparison. Quantitative fluorescence 
spectroscopy measurements were performed 0.5, 1, 2, 4, 6, 8 and 24 h after injection of the 
conjugates. Cetuximab–PS was employed as other mAb–PS were described in [15] (i.e. 300 μg 
and also approximately 6 nmol of PS per mouse) and measurements were only performed at 24 h 
p.i., which corresponded to the selected illumination time point. 
 
2.11. Tumour specificity and distribution 
Tumour specificity of 7D12–PS and 7D12-9G8–PS was explored by optical imaging in vivo and 
fluorescence imaging of tissue sections. At 1 h after injection of 7D12–PS, 7D12-9G8–PS and 
R2–PS (200 μg), mice were imaged (n = 2) with the Pearl imaging system (LI-COR), while kept 
under isoflurane anesthesia. In parallel, other mice injectedwith each of the nanobody–PS 
conjugates (n=1) had their tongues resected, fixed overnight in 4% formalin and embedded in 
paraffin blocks. Tissue was sectioned at 10 μm and fluorescence imaging was performed using 
the Odyssey. All images were acquired using the same settings. Further, sectionswere processed 
for hematoxylin and eosin (H&E) staining. 
 
2.12. Photodynamic therapy 
When OSC-19-luc2-cGFP tumourswere visible by the human eye and the BLI signal ranged 
between 5 × 109 and 1 × 1010 relative light units (RLU), mice (n=4 per group)were randomly 
divided into three groups and received an intraveneous injection of 200 μg 7D12–PS, 7D12-
9G8–PS, R2–PS, or 300 μg cetuximab–PS. Based on the quantitative fluorescence spectroscopy 
EGFR-targeted photodynamic therapy 189
8
 
spectra were acquired using a single probe that contained two fibers of 0.4 and 0.8 mm. The 0.8 
mm fiber was used for both fluorescence and reflectance spectroscopy while the 0.4 mm fiber 
was used to perform reflectance spectroscopy. The end of the fiber probe in contactwith the 
tissue was polished to an angle of 15° tominimize the collection of specular reflection. To obtain 
a reflectance spectrum, light froma tungsten halogen lamp was directed on the tissue through a 
probe containing 2 single fibers with diameters of 0.4 and 0.8 mm. This choice of fiber diameters 
was dictated by the intention to optically sample a representative proportion of the tumour and 
normal tissue under interrogation. The photon path length and therefore the sampling volume is 
on the order of the fiber diameter which means that approximately 1/3 of the tumour volume is 
interrogated by the smallest fiber diameter. After these sequential reflectance measurements, a 
single fiber fluorescence spectroscopy (SFF) spectrum was acquired using the 0.8 mm fiber and 
660 nm laser light. This wavelength was chosen to optimally separate IRDye700DX (PS) 
fluorescence from background autofluorescence. The reflectance and fluorescence spectra were 
detected by three spectrometers, one for each fiber to measure reflectance and one to measure 
fluorescence where a 675 nm notch filter was used to block scattered excitation light. The 
spectrometers, light sources and shutters were controlled by a custom made LabView program 
(National Instruments LabView 7.1) on a notebook computer. A single combined multi-diameter 
optical fiber (MDSFR)/SFF measurement took approximately 3 s. The fiber probe was removed 
from the tissue and replaced to perform repeated measurements. Three spectra were acquired 
from each tissue type, and the average and standard deviation of these measurements were 
reported. 
 
2.10.1. Data analysis 
To calculate the intrinsic fluorescence, the raw fluorescence signals were corrected for the effects 
of absorption and scattering using the optical properties obtained from the MDSFR reflectance 
spectra. A detailed mathematical description of the recovery of the tissue optical properties from 
an MDSFR spectrum and their use in determining the intrinsic SFF from a raw fluorescence 
spectrum has been described previously [52]. The result of this analysis is a calibrated, corrected 
fluorescence spectrum expressed as the wavelength-dependent intrinsic fluorescence, where 
Q(l)μf is the quantum efficiency of the fluorophore at each emission wavelength. This spectrum 
is then integrated over the emission bandwidth of the fluorophore IRDye700DX (PS) to yield 
the intrinsic fluorescence Q · μ f a,x where Q is now the fluorescence quantum yield of the PS. 
 
2.10.2. Fluorescence spectral analysis 
The fluorescence spectra, corrected for the influence of tissue optical properties, were then 
analyzed to determine the contribution from the tissue autofluorescence, and that from PS. A 
skewed Gaussian was used to fit the autofluorescence while the basis spectra for PS conjugated 
 
to each antibody/nanobody were isolated from an average of representative in-vivo spectra after 
subtraction of the autofluorescence [53]. We note that the width and peak of PS fluorescence was 
slightly different for each antibody/nanobody conjugate. 
 
2.10.3. Calibration of the MDSFR/SFF system 
Before each set ofmeasurements a careful calibration procedurewas performed as described 
previously [54] consisting of an integrating sphere calibration, a measurement of a calibrated light 
source, and measurements in water in a dark container and in a liquid phantom containing 1.32% 
Intralipid with a known reduced scattering coefficient (μs′ at 800 nm=1.2 mm−1). This 
procedure accounts for variations in the output powers of the light sources and the spectral 
transmission and sensitivity of the system.  
 
2.10.4. Quantitative fluorescence spectroscopy in vivo 
When OSC tumours were visible by the human eye and the BLI signal ranged between 5 × 109 
and 1 × 1010 relative light units (RLU), mice were randomly divided into three groups and 
received an intraveneous injection of 200 μg of 7D12–PS, 7D12-9G8–PS, or R2–PS, eachmouse 
receiving approximately 6 nmol of PS to allow comparison. Quantitative fluorescence 
spectroscopy measurements were performed 0.5, 1, 2, 4, 6, 8 and 24 h after injection of the 
conjugates. Cetuximab–PS was employed as other mAb–PS were described in [15] (i.e. 300 μg 
and also approximately 6 nmol of PS per mouse) and measurements were only performed at 24 h 
p.i., which corresponded to the selected illumination time point. 
 
2.11. Tumour specificity and distribution 
Tumour specificity of 7D12–PS and 7D12-9G8–PS was explored by optical imaging in vivo and 
fluorescence imaging of tissue sections. At 1 h after injection of 7D12–PS, 7D12-9G8–PS and 
R2–PS (200 μg), mice were imaged (n = 2) with the Pearl imaging system (LI-COR), while kept 
under isoflurane anesthesia. In parallel, other mice injectedwith each of the nanobody–PS 
conjugates (n=1) had their tongues resected, fixed overnight in 4% formalin and embedded in 
paraffin blocks. Tissue was sectioned at 10 μm and fluorescence imaging was performed using 
the Odyssey. All images were acquired using the same settings. Further, sectionswere processed 
for hematoxylin and eosin (H&E) staining. 
 
2.12. Photodynamic therapy 
When OSC-19-luc2-cGFP tumourswere visible by the human eye and the BLI signal ranged 
between 5 × 109 and 1 × 1010 relative light units (RLU), mice (n=4 per group)were randomly 
divided into three groups and received an intraveneous injection of 200 μg 7D12–PS, 7D12-
9G8–PS, R2–PS, or 300 μg cetuximab–PS. Based on the quantitative fluorescence spectroscopy 
190 Chapter 8
 
measurements, 1 h post-injection (p.i.) was chosen to apply the light. Thus at this time after 
nanobody–PS administration, or 24 h p.i. of cetuximab–PS injection, mice received painkillers, 
were put under isoflurane anesthesia, and their tumours were then illuminated using a 690 nm 
diode laser (Modulight, Tampere, Finland). The power at the end of the optic fiber was calibrated 
with a power meter (Gigahertz optic, Turkenfeld, Germany). Light was delivered via a 600 
μmoptic fiberwith a fluence rate of 50mW/cm2 and a homogenous treatment area with the 
largest diameter of the tumour was used. The exposure time was adjusted to obtain a fluence of 
100 J/cm2. Mice were sacrificed 24 h after illumination, tongues were collected and frozen on 
dry ice for subsequent processing for histological analysis of tissue damage. 
 
2.13. Histological assessment post-PDT 
To assess whether nanobody-targeted PDT is capable of inducing selective tumour cell death in 
vivo, and using antibody-targeted PDT as a positive control, tongues of mice were collected 24 h 
after application of light for PDT. Thereafter, tongues were sectioned and processed for H&E 
staining and for CD31 staining of blood vessels. Briefly, for the CD31 staining, sections were 
subjected to 10 mM tris/EDTA at 96 °C for 20 min. Thereafter, endogene peroxidase was 
blocked with a solution of 3% hydrogen peroxide. Blocking of aspecific staining was performed 
with a solution of 5% low fat milk, for 30 min. Then, the primary antibody rabbit anti-CD31 
(Abcam, Cambridge, UK) and the secondary antibody goat-anti rabbit biotin (Dako, Heverlee, 
Belgium) were employed, followed by streptavidin-HRP (Southern Biotech, Birmingham, AL) 
and the final development of the brown color with DAB, and counterstained with hematoxylin. 
Pictures were taken with an Olympus microscope equipped with a 4×, 10× or 20× objectives. 
Two independent researchers scored the damage on H&E tissue sections in percentage (%) of 
necrosis and scored phototoxicity of normal epithelium, muscle cells, and endothelium (blood 
vessels), as well as edema, from 0 or 1+ to 3+ by observation of the tumour, and of the blood 
vessels or themuscle cells, either in close proximity or distant to the tumour. The CD31 staining 
was employed to score the damage of blood vessels in the tumour area by absence of the brown 
color. An experienced pathologist was the first observer and was responsible for the training of 
the second observer. At least 3 sections at different depths were analyzed per tumour. The 
second observer made use of the Image J software to determine % of necrosis, by drawing 
regions of necrosis and comparing to the overall region of the tumour. At the end, a consensus 
was reached on the final score. 
 
  
 
2.14. Statistical analysis 
Data was analyzed using the GraphPad Prism 5.02 software for Windows (GraphPad Software, 
San Diego, CA). To compare responses to PDT treatment in vitro, analysis of significance was 
performed through unpaired t-tests. Intrinsic fluorescence values are reported as mean and 
standard deviation.  Statistical analysis of spectroscopy was performed through a two way 
ANOVA with the Bonferroni correction. As for the effect in vivo, analysis of significance was 
performed through Mann–Whitney test because of the non-normal distribution of the data. In all 
cases, p b 0.05 was considered significant. 
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Results and discussion 
 
Targeted PDT aims to increase tumour specificity of the PS, in order to enhance the therapeutic 
effect and spare surrounding normal tissue. In this study, we evaluate the recently introduced 
nanobody–PS conjugates for their potential to induce specific tumour cell death in vivo. 
 
3.1 Characterization and  EGFR-specific binding of the nanobody–PS conjugates  
The nanobodies targeting EGFR used in this study are the monovalent 7D12 [31,33] and the 
internalizing, biparatopic 7D12-9G8 [34]. In addition, the irrelevant nanobody R2 [40,41] is used 
as a negative control. These nanobodies were conjugated to the PS (IRDye700DX) via random 
NHS-mediated coupling to lysine amino acids, similarly to the previous study [25]. After removal 
of unconjugated PS, SDS-PAGE was used to verify the conjugation. The molecularweights of 
the fluorescent nanobody–PS conjugates, as detected by fluorescence imaging (top gel, red 
bands, Fig. 1A), were similar to those of the nanobodies, as demonstrated by the post-Coomassie 
Blue stained SDS-PAGE gel (bottom gel, black bands, Fig. 1A). Furthermore, very little 
unconjugated PS was detectable at the front of the gel (Fig. 1A), which rendered the conjugates 
suitable for both in vitro and in vivo studies. The PS-to-protein molar ratios (or degree of 
conjugation, DOC) of 7D12–PS, 7D12-9G8–PS and R2–PS after random conjugation were on 
average 0.5, 1.0 and 0.5, respectively. Compared to our previous study, these are different ratios 
or DOC, except for 7D12–PS. In fact, 0.5 is the highest DOC this nanobody–PS can have while 
maintaining its low nanomolar binding affinity. For the negative control R2–PS, we chose to use 
the same DOC as for 7D12–PS (i.e. 0.5, instead of 1.0). To enable the comparison of the  
therapeutic potential in vivo, theDOCof7D12-9G8–PS was also decreased and used as twice the 
DOC of 7D12–PS (i.e. 1.0, instead of 1.5). This particular choice wasmade aiming at themost 
effective delivery of the drug, i.e. the PS, by the least amount of carrier needed, i.e. protein, in a 
manner that would allow normalization of PS dose administered in vivo. Thus,with the selected 
DOCs, the in vivo administration of equal amounts of protein (i.e. nanobody, in micrograms), 
result in the administration of equal molar amounts of PS, allowing a better comparison of the 
therapeutic potential. These two nanobody formats (i.e. 7D12–PS and 7D12-9G8–PS) are two 
independent carriers used for PS delivery,which are here investigated side-by-side, as it is difficult 
to anticipate which format is the most promising for in vivo application. Next, the specificity of 
7D12–PS and 7D12-9G8–PS for binding to EGFR was demonstrated. For that, besides the 
human oral squamous cell carcinoma cell line OSC (Fig. 1B), two human control cell lines were 
employed: the cervical cancer cell line HeLa and the colon cancer cell line SW620 (Fig. 1C). 
These three cell lines express high, intermediate (or normal), and very low levels of EGFR, 
respectively. Binding assays were performed at 4 °C to solely explore the binding of conjugates to 
 
EGFR. Fluorescence intensities of the bound conjugates correlated well with the level of EGFR 
expression, i.e. OSC N HeLa N SW620. Moreover, the approximately 2-fold difference in 
fluorescence intensity observed between the two EGFR targeted nanobody–PS conjugates 
correlated well with the difference in DOC. Binding affinities of 7D12–PS and 7D12-9G8–PS to 
high EGFR expressing OSC cells were 1.9 ± 0.4 nM and 1.0 ± 0.1 nM, respectively; and to 
intermediate EGFR expressing HeLa cellswere 0.7±0.3 nMand0.5±0.07nM, respectively.Hardly 
any fluorescence, and thus binding, was observed for 7D12–PS and 7D12-9G8–PS to low EGFR 
expressing SW620 cells, and for R2–PS and PS to any of the cell lines. To emphasize the specific 
binding of the nanobody–PS conjugates to EGFR, fluorescence microscopy was performed (Fig. 
1D). Among the three cell lines, binding of 7D12–PS and 7D12-9G8–PS was mainly observed in 
the high EGFR expressing OSC cells (Fig. 1D). As for R2–PS and PS, no fluorescence was 
observed in any of the three cell lines. Overall, comparable to our previous study, both 7D12–PS 
and 7D12-9G8–PS target EGFR specifically. Importantly, this water-soluble PS (IRDye700DX) 
has no cell binding capacity, unless it is conjugated to the EGFR targeted nanobodies. These 
facts together could guarantee tumour-specific PDT.  
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Figure 1; Purity and specificity of nanobody–PS conjugates. (A) Nanobodies and the respective nanobody–PS 
conjugates are separated by SDS-PAGE, with the following order (numbered 1–6): R2, R2–PS, 7D12, 7D12–PS, 
7D12-9G8, and 7D12-9G8–PS. Prior to the Coomassie stain, the fluorescence of the PS is detected (depicted in red, 
top gel); after the Coomassie stain, the proteins are visualized (depicted in black, bottom gel). (B) Fluorescence 
intensities of cell bound conjugates are plotted after incubation of OSC cells or (C) the control cell lines HeLa and 
SW620 with varying concentrations of the EGFR targeted conjugates 7D12–PS and 7D12-9G8–PS, or the controls 
R2–PS and PS. EGFR expression levels: OSC N HeLa N SW620. (D) Fluorescent microscopy depicting the 
fluorescence of the nanobody–PS bound to cells (in white, left panels) and that (in red, right panels) overlayed with 
either GFP (OSC cell line) or calcein staining (HeLa, SW620) for cell visualization (in green, right panels). 
  
 
3.2. Singlet oxygen quantum yield and in vitro efficacy of nanobody–PS conjugates 
To determine the relative potency of these nanobody–PS conjugates, singlet oxygen quantum 
yields (ϕΔ) were measured in test tubes. For that, first, fluorescence quantum yields were 
determined using a relative method in PBS and Chlorin e6 as a reference. The fluorescence 
quantum yields of PS, 7D12–PS and 7D12-9G8–PS were 0.15 ± 0.03, 0.14±0.03 and 0.16±0.03, 
respectively. Interestingly, the determined ϕΔ differed significantly between photosensitizer and 
conjugates: for PS it was determined to be 0.19 ± 0.06, for 7D12–PS 0.25 ± 0.06, and for 7D12-
9G8–PS 0.42±0.07. Previous studies have also documented variations in fluorescence and singlet 
oxygen quantum yields for free PS and conjugates with different DOC [55]. The differences in 
ϕΔ, for the two nanobody–PS conjugates, may be related to variations in amino acids to which 
the PS is conjugated, thus affecting the environment surrounding PS molecules. Although the 
efficient generation of singlet oxygen is an important factor in the induction of phototoxic 
effects, the localization of the PS, and variables determining this localization, also influence 
significantly the overall therapeutic effect. The phototoxicity of different concentrations of these 
conjugates was assessed in vitro following an incubation time of 30 min. This time period was 
based on previous work, in which we reported saturable binding of nanobody–PS conjugates 
after 30 min of incubation [25]. The EGFR targeted nanobody–PS conjugate 7D12-9G8–PS 
showed to be a very potent PDT agent on OSC cells with an IC50 value of 2.2 ± 0.97 nM (Fig. 
2A). As for 7D12–PS, cell viability was decreased by 32.3% at 50 nM, suggesting an IC50 higher 
than 50 nM, though likely belowthe micromolar range. No reduction of cell viabilitywas observed 
after illumination of cells incubated with R2–PS or PS alone, indicating the need of specific 
targeting to induce cell damage (Fig. 2A). The difference in phototoxicity between 7D12–PS and 
7D12-9G8–PS in vitro is larger than the difference in fluorescence intensity of the conjugates 
associatedwith the cells just before illumination (Supplementary Material, Fig. S1). This could 
partially be explained by the higher singlet oxygen quantum yield of 7D12-9G8–PS. Furthermore, 
several studies pointed to an intracellular localization of the PS as important to increase the 
phototoxicity of mAbs–PS [56–58]. In fact, aswe showed in our previous study, more 7D12-
9G8–PS is delivered intracellularly compared to 7D12–PS,which has been described to be via 
clustering induced endocytosis of EGFR [25]. Thus, both aspects are likely to explain the higher 
potency of 7D12-9G8–PS in vitro. Our previous study showed even lower IC50 values for 
7D12–PS and 7D12-9G8–PS, though that can be partly justified by a lower DOC for 7D12-
9G8–PS in the current study, and also by the different EGFR expression levels of the cell lines 
employed. In our previous study, A431 and 14C cell lineswere employedwhich have higher 
EGFR expression than the OSC cells. Here, to confirm that the phototoxicity is indeed 
dependent on the EGFR level, toxicity was also assessed on cell lines with different EGFR 
expression levels (Fig. 2B, i.e. HeLa and SW620), and indeed the phototoxicitywas lower than the 
values obtainedwith OSC cells,which related to the extent of conjugate bound to cells 
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showed to be a very potent PDT agent on OSC cells with an IC50 value of 2.2 ± 0.97 nM (Fig. 
2A). As for 7D12–PS, cell viability was decreased by 32.3% at 50 nM, suggesting an IC50 higher 
than 50 nM, though likely belowthe micromolar range. No reduction of cell viabilitywas observed 
after illumination of cells incubated with R2–PS or PS alone, indicating the need of specific 
targeting to induce cell damage (Fig. 2A). The difference in phototoxicity between 7D12–PS and 
7D12-9G8–PS in vitro is larger than the difference in fluorescence intensity of the conjugates 
associatedwith the cells just before illumination (Supplementary Material, Fig. S1). This could 
partially be explained by the higher singlet oxygen quantum yield of 7D12-9G8–PS. Furthermore, 
several studies pointed to an intracellular localization of the PS as important to increase the 
phototoxicity of mAbs–PS [56–58]. In fact, aswe showed in our previous study, more 7D12-
9G8–PS is delivered intracellularly compared to 7D12–PS,which has been described to be via 
clustering induced endocytosis of EGFR [25]. Thus, both aspects are likely to explain the higher 
potency of 7D12-9G8–PS in vitro. Our previous study showed even lower IC50 values for 
7D12–PS and 7D12-9G8–PS, though that can be partly justified by a lower DOC for 7D12-
9G8–PS in the current study, and also by the different EGFR expression levels of the cell lines 
employed. In our previous study, A431 and 14C cell lineswere employedwhich have higher 
EGFR expression than the OSC cells. Here, to confirm that the phototoxicity is indeed 
dependent on the EGFR level, toxicity was also assessed on cell lines with different EGFR 
expression levels (Fig. 2B, i.e. HeLa and SW620), and indeed the phototoxicitywas lower than the 
values obtainedwith OSC cells,which related to the extent of conjugate bound to cells 
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(Supplementary Material, Fig. S1), and correlated to the EGFR expression as demonstrated in 
Fig. 1B and C. The IC50 on HeLa cells was 33.5 ± 1.4 nM for 7D12- 9G8–PS, while 7D12–PS 
induced almost no effect in the concentration range here tested (i.e. highest concentration 50 
nM). These are significantly lower toxicities than observed in high EGFR expressing OSC 
cells.No IC50 could be calculated for SW620 cells indicating the absence of cell damage on low 
EGFR expressing cells (Fig. 2B). Co-culture experiments were performed to assess the selectivity 
of these nanobody–PS conjugates toward OSC cells overexpressing  EGFR, among intermediate 
EGFR expressing HeLa cells (Fig. 2C). In these cocultures, HeLa and OSC cells could be 
distinguished by the differences in morphology and GFP fluorescence imaging of cGFP 
transfected OSC cells (i.e. OSC-19-luc2-cGFP). 7D12–PS and 7D12-9G8–PS induced 
phototoxicity only to OSC cells, as indicated by the propidium iodide staining (indicative of dead 
cells, Fig. 2C) that coincides with GFP fluorescence. Also here, 7D12-9G8–PS showed to be 
more toxic than 7D12–PS, as illustrated by the higher number of dead cells. No PS nor 
phototoxicity was observed under the same conditions on HeLa cells (See Supplementary 
Material for similar treatment on these two cell lines separately, Fig. S2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2; Nanobody–PS are phototoxic to EGFR overexpressing cells. Phototoxicity of nanobody–PS conjugates and 
controls in (A) OSC, (B) HeLa andSW620 cells presented as percentage (%) of cell viability after a 10 J/cm2 light dose. 
Data depicted as means± SEM. (C) Fluorescence and phase contrast images of co-cultures of HeLa and OSC cells 
after PDT with nanobody–PS conjugates or the controls R2–PS and PS. Left panel depicts PS fluorescence,middle 
panel propidiumiodide (PI) to identify dead cells, and right panel the overlay of PI with both GFP and phase contrast 
to visualize cells. Cells can be differentiated by morphology and fluorescence of the GFP (green) positive OSC cells. 
  
 
3.3. Pharmacokinetics and macroscopic localization of nanobody–PS conjugates 
To investigate the selectivity and potency of these nanobody–PS conjugates in a pre-clinical 
model of head and neck cancer, the OSC cell line was inoculated and grown orthotopically in 
tongues of nude mice. Being the first pre-clinical study, we have decided to use a reference for 
validation of the procedure here employed: we used Cetuximab–PS as Mitsunaga et al. [15] have 
described the use of their mAb–PS conjugates, i.e. with a DOC of 3.0 and injecting a dose of 300 
μg permouse,which are equivalent to approximately 6 nmol of PS. With these particular 
conditions, we expected to induce tumour cell death and subsequently validate the procedure 
selected for analysis. Based on the selected DOC of the different nanobody–PS, the dose of 
protein to be injected was calculated so that it was normalized for the amount of drug carried, i.e. 
PS. For an effective PDT without damage to normal tissue, light should be applied locally at the 
most favorable time point post-injection (p.i.) of the nanobody–PS conjugates. This is when the 
highest dose of PS is located at the tumour, and the lowest dose in the surrounding tissues. In 
practice, this generally corresponds to a balance between the dose of PS at the tumour and a 
sufficient tumour-to-background ratio (TBR). As the nanobody–PS conjugates are traceable 
through optical imaging, wide field fluorescence imaging gives insights into their tumour 
specificity and distribution in vivo. However, the differences in optical properties of different 
tissues greatly influence the number of collected fluorescent photons. Alternatively, determining 
the intrinsic fluorescence enables a quantitative comparison of fluorescence's pharmacokinetics 
locally in tissues with different and/or varying optical properties (such as in tumour, normal 
tongue, and skin). Our group has been investigating the use of empiricalmodeling and point 
reflectance spectroscopy with multi-diameter optical fibers (MDSFR) combined with single fiber 
fluorescence spectroscopy (SFF) to measure the tissue optical properties μa, μ′s, and thereby 
recovering the intrinsic fluorescence fromthe interrogated volume [52]. This approach is 
particularly important when the optical properties of tumour and normal tissue are known to be 
significantly different [51]. Using this method, the quantitative fluorescence pharmacokinetics 
were assessed for the PS (IRDye700DX) in each conjugate. The intrinsic fluorescence reported in 
this study, defined as Qfμa f , is the product of the fluorescence quantum yield of the PS and its 
absorption coefficient at 660 nm.While reliable estimates of Qf and the in vivo extinction 
spectrum of the PS would allow for the quantitative determination of its concentration in vivo, 
we considered it sufficient for this study to determine the intrinsic fluorescence. No significant 
differenceswere observed in normal tongue tissue between all conjugates. At all time points, 
significantly less R2–PS was present in the tumour compared to 7D12–PS and 7D12-9G8–PS (p 
b 0.05 for all time point) (Fig. 3A). For 7D12–PS, more conjugate was present in the tumour 
compared to that in normal tongue tissue and skin, proving tumour specificity in vivo. 
Differences were statistically significant (p b 0,05) at time-point 0.5, 1, 6 and 24 h p.i. The 
maximum amount of 7D12–PS in the tumour was observed already at 30 min p.i., after which it 
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were assessed for the PS (IRDye700DX) in each conjugate. The intrinsic fluorescence reported in 
this study, defined as Qfμa f , is the product of the fluorescence quantum yield of the PS and its 
absorption coefficient at 660 nm.While reliable estimates of Qf and the in vivo extinction 
spectrum of the PS would allow for the quantitative determination of its concentration in vivo, 
we considered it sufficient for this study to determine the intrinsic fluorescence. No significant 
differenceswere observed in normal tongue tissue between all conjugates. At all time points, 
significantly less R2–PS was present in the tumour compared to 7D12–PS and 7D12-9G8–PS (p 
b 0.05 for all time point) (Fig. 3A). For 7D12–PS, more conjugate was present in the tumour 
compared to that in normal tongue tissue and skin, proving tumour specificity in vivo. 
Differences were statistically significant (p b 0,05) at time-point 0.5, 1, 6 and 24 h p.i. The 
maximum amount of 7D12–PS in the tumour was observed already at 30 min p.i., after which it 
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slowly decreased, correlating with our previous imaging study [31], and possibly related to the 
unbinding of non-internalized conjugates. However, a relatively high value of fluorescence was 
also present in normal tongue tissue at 30min p.i. At 1 h p.i. the fluorescence at the normal 
tongue tissue decreased slightly and a TBR of 1.8 ± 0.3 was obtained. Although at a later time 
point the TBR increased, such as to a value of 16.1 ± 4.5 at 24 h p.i. (Fig. 3B), the total 
fluorescence of 7D12–PS in the tumour at 24 h p.i. had already decreased 42% from the intrinsic 
fluorescence at 1 h p.i. Differences in TBR of 7D12–PS, compared to R2–PS, were statistically 
significant at 24 h p.i (p b 0.0001). Similar results were obtained for 7D12-9G8–PS, showing 
tumour specificity in vivo as significantly more conjugate was present in the tumour compared to 
that in normal tongue tissue and skin (p b 0.05 for all time points, except for 8 h p.i.). Unlike 
7D12–PS, the highest intrinsic fluorescence at the tumour was observed for a longer period, i.e. 
during the first 4 h p.i., which is possibly related to a more pronounced internalization and less 
unbinding of non-internalized conjugate. Already at 1 h p.i. a TBR of 3.8 ± 0.5 was obtained. 
Also in this case, higher TBR could be obtained at later time points, such as 30.8 ± 0.9 at 24 h 
p.i. The differences in TBR of 7D12-9G8–PS, compared to R2–PS, were statistically significantly 
at both 1 and 24 h p.i. (p = 0.0024 and p b 0.0001, respectively). However 24 h p.i. the intrinsic 
fluorescence had also in this case decreased 39%, compared to 1 h after the injection. One could 
expect that high TBRs are needed to spare normal tissue, and to enable accurate tumour 
detection with fluorescence imaging (in the setting of image-guided PDT). Nevertheless, in 
principle, the actual amount of PS in the tissue predominantly determines the actual phototoxic 
effect. Therefore, in order to maximize the concentration of PS while retaining a suitable TBR, 
we decided to subsequently apply the light locally at the tumour 1 h p.i. of the nanobody–PS 
conjugates. Clear differences were observed on the values of intrinsic fluorescence of the two 
EGFR targeted nanobody–PS conjugates, where higher values were obtained for 7D12-9G8–PS 
in the tumour at all times, compared to 7D12–PS. Thus, 7D12-9G8–PS seems to be the best 
nanobody format to carry PS to the tumour. Although additional experiments are needed to 
further clarify these differences, at this pointwe can speculate that these could be related to the 
different nanobody formats, i.e.monovalent versus biparatopic, and their different distribution 
and binding in tumours. In fact, the enhanced internalization documented for 7D12-9G8 in vitro 
[25] could play an important role. We have observed more internalization of 7D12-9G8–PS than 
7D12–PS, after 30 min incubation in vitro, thus at 1 h after i.v. injection it is well possible that 
the same trend can affect the results observed in vivo. In addition, differences are to some extent 
related to the different DOC of the nanobody–PS, as this was 0.5 for 7D12–PS and 1.0 for 
7D12-9G8–PS. Although, the equal dose of protein given (in micrograms) allowed the injection 
of equal amounts of PS molecules per mouse, approximately half of the 7D12 molecules were 
conjugated to PS, whereas all molecules of 7D12-9G8 injected contained a PS. As a consequence, 
competition of conjugated 7D12–PS and unconjugated 7D12 for binding to the EGFR, could  
 
 
Figure 3; Quantitative fluorescence spectroscopy for selecting the illumination time point. (A) Local assessment of the 
intrinsic fluorescence of the nanobody–PS conjugates at the tumour, normal tongue and skin, as an indication of their 
pharmacokinetics. Intrinsic fluorescence, Qfμa f , is the product of the fluorescence quantum yield of the PS and its 
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have contributed to the lower intrinsic fluorescence and TBRs of 7D12–PS, compared to 7D12-
9G8–PS. In order to further elucidate the mechanism(s) underlying the efficacy of our conjugates 
compared to that of a mAb–PS conjugate, we also performed quantitative spectroscopy in 
animals 24 h after the injection of cetuximab–PS (which was the time point employed in previous 
studies for mAb–PSs [15], with DOC of 3.0, equivalent PS injected as the other mice). At this 
time point the average value of Qfμa f was 0.0374 ± 0.0045, 0.0057 ± 0.0019 and 0.0036 ± 
0.0007, in tumour, normal tongue, and in skin, respectively, with a corresponding TBR of 6.5 ± 
0.9. These tumour values for Qfμa f are significantly greater (~7.5-fold) than the maximum 
fluorescence intensity early after the injection of 7D12-9G8–PS and the TBR exceeds the TBR 
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found for 7D12-9G8–PS at 1 h p.i. Despite the same dose of PS had been injected with this 
mAb–PS as with the nanobody–PS conjugates, these results suggest that the mAb–PS is the most 
effective carrier for higher accumulation of PS at the tumour. This is likely a consequence of a 
combination of the longer half-life of cetuximab–PS in the blood stream, which leads to later 
accumulation of the conjugate at the tumour (i.e. 24 h instead of 1 h p.i.), and the higher DOC of 
cetuximab–PS. It is important to note that quantitative spectroscopy provides a volume average 
signal (over ~1 mm3) and does not retain any information on themicroscopic distribution of the 
conjugates. Therefore, additional studies are required to compare themicroscopic localization of 
the different conjugates.  
 
To further validate the 1 h p.i. as being the optimal time point for illumination, a number ofmice 
(n=2)were subjected to in vivo optical imaging at that time point after injection of the different 
nanobody–PS conjugates. Clearly, very little fluorescence is observed at the tongue when R2–PS 
was injected, in contrast to the highly fluorescent tongues shown when mice were injected with 
either 7D12–PS or 7D12-9G8–PS (Fig. 4A). These images support the specificity documented 
earlier (Fig. 3). In parallel, tongues of mice were collected 1 h p.i. of the nanobody–PS conjugates 
and were processed for fluorescence imaging and histology. These analyses confirmed that both 
EGFR targeted conjugates are tumour specific. Already at 1 h p.i. of 7D12–PS and 7D12-9G8–
PS, a clear colocalization of fluorescence and tumour could be observed, confirming tumour 
specificity (Fig. 4B). No tumour accumulation was observed in sections of tongues of mice 
injected with the control R2–PS. Importantly, nanobody–PS conjugates showed a homogenous 
distribution through the solid tumour,which is in agreement with our previous optical imaging 
study [31] and is expected to contribute to treatment efficacy. 
 
  
 
 
 
Figure 4; EGFR-targeted nanobody–PS conjugates specifically localize in tumours. (A) Optical imaging of mice 1 h 
p.i. of the nanobody–PS conjugates. Images were obtained with a Pearl imaging system. Brightness of individual 
illustrations is manually adjusted to highlight the location of the fluorescence. Asterisks (*) indicate lymph nodes. (B) 
Fluorescence imaging of the PS (in dark) and H&E staining of sections of tongues obtained from mice 1 h p.i. of the 
nanobody–PS conjugates. OSC tumours are distinguished at the higher half of the tongues, by a characteristic dense 
mass of tumour cells, delimited by a dark line.  
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3.4. In vivo evaluation of nanobody-targeted PDT 
Besides the best time point for illumination (i.e. 1 h p.i.), an important consideration for 
optimizing the efficacy of the nanobody–PS conjugates in vivo is the choice of PDT illumination 
parameters: fluence and fluence rate. The latter was chosen to be 50 mW/cm2 to avoid any 
heating of the illuminated tissue and to maximize the ability of the tumour vasculature to supply 
oxygen during illumination. The former parameter, the therapeutic light fluence (or dose) was 
chosen to be 100 J/cm2 in order to maximize PDT efficacy, considering the penetration of the 
laser light (690 nm, which is the excitation maximum for this PS) in the tongue and the inevitable 
photobleaching of the PS during the illumination. It is important to note that this light fluence 
may be reduced, in the future, after a full optimization of the illumination parameters has been 
performed. Given the difficulty of light fluence (rate) treatment planning in mice, we chose to 
accept the potential overtreatment of the underlying normal tissue in the present study. Thus, 1 h 
p.i. of the nanobody–PS conjugates, illumination was performed superficially on the tongue of 
mice. As positive control for in vivo PDT,we injected micewith cetuximab–PS,whichwere then 
illuminated 24 h p.i., similar to the study ofMitsunaga et al. [15]. Thereafter, to determinewhether 
the conjugateswere capable of inducing selective tumour cell death in vivo, micewere sacrificed at 
24 h post-PDT and their tongues were processed for histological analyses. All the controls, i.e. 
light only and R2–PS, 7D12–PS and 7D12-9G8–PS without application of light, presented a 
viable and dense tumour (H&E), aswell as numerous blood vessels (CD31 staining), indicating 
that neither light alone, nor the nanobody–PS conjugates without light were capable of inducing 
damage (Fig. 5A). The antibody-targeted PDT led to tumour damage, which validates the model 
and procedure here employed, although with a broad variation of degree of necrosis, ranging 
from 25 to 70% (median 57.5%, Fig. 5A, B). Numerous blood vessels remained intact after this 
PDT, as observed in the corresponding CD31 staining. An unexpected mild to moderate tumour 
damage was obtained with R2–PS (median 42.5%, range 20–50% necrosis, Fig. 5B), likely a 
bystander effect due to vascular damage, as suggested by the heavily coagulated blood vessels 
observed just below the tip of the tongue and the absence of CD31 staining in the tumour area, 
though viable tumour is still observed (Fig. 5A, Table 1). Whether R2–PS is specifically 
associating with endothelial cells is not clear at this point in time, though this may be an 
explanation for these observations. On the contrary, for both nanobody formats targeting 
EGFR, a more homogenous damage to the tumour is observed, reaching even 90% of necrosis 
(Fig. 5A, B). In the case of 7D12–PS, a very localized and reproducible damage was induced at 
the tumour site (median 80%, range 80–90% necrosis), with minimal effect on the CD31 staining 
of blood vessels around the tumour (brown color present), whereas inside the tumour no CD31 
staining was observed (Fig. 5A, Table 1). With 7D12-9G8–PS, some variation between mice was 
observed in the extent of damage induced (median 80%, range 60–90% necrosis), and 
slightlymore coagulation was observed at the blood vessels surrounding the tumour (compared 
 
to 7D12–PS) (Fig. 5A, Table 1). Notably, the two EGFR targeted nanobodyphotosensitizer 
conjugates were the only format of conjugates capable of inducing 90% necrosis (Fig. 5B). 
7D12–PS induced significantly more necrosis compared to  both R2–PS (p = 0.0256) and 
cetuximab–PS (p = 0.0265) (Fig. 5B). Due to the variation in effect induced in mice with 7D12-
9G8–PS, the extent of necrosis was significantly higher compared to R2–PS (p = 0.0284), but 
not compared to cetuximab–PS (p = 0.1102) (Fig. 5B). Interestingly, although spectroscopy 
experiments showed a significantly higher concentration of cetuximab–PS at the time point of 
irradiation compared to 7D12-9G8–PS and 7D12–PS, significantly more necrosis was observed 
with the nanobody–PS conjugates. In fact, these in vivo results suggest that the most effective 
and reproducible treatment was obtained with the monovalent 7D12–PS  conjugate. Importantly, 
we realize that at this point conclusions should be very carefully drawn as these are in fact three 
different antibody formats and thus three independent carrier systems for PS, here investigated 
side-by-side in very particular conditions. Nevertheless, these results are remarkable, in light of 
the observations obtained with quantitative fluorescence spectroscopy revealing a lower 
concentration of PS and lower TBR obtained with the 7D12–PS conjugate, compared to 7D12-
9G8–PS or cetuximab–PS. Furthermore, while 7D12-9G8–PS was more toxic than 7D12–PS in 
vitro (Fig. 2), also in respect of induction of necrosis (Supplementary Material, Fig. S3), in vivo 
efficacy studies point to a higher phototoxicity induced by 7D12–PS. This increase in efficacy of 
themonovalent 7D12–PS could be due to its small size,which likely enables better penetration 
into the interior of tumours and a more homogenous distribution. It is well accepted that the 
diffusion of molecules from the blood vessels and their subsequent penetration through tissues is 
influenced by factors such as molecular weight, size, charge, affinity, and antigen expression 
among others [59,60]. Furthermore, using small nanobodies, the PS is in closer proximity to the 
cell membrane which could increase phototoxicity. More studies are certainly needed to better 
understand the differences observed in PDT efficacy between 7D12–PS and 7D12-9G8–PS in 
vivo, and future studies will also demonstratewhether the significant differences in necrosiswill 
result in differences in survival. However, at this point, it is clearly suggested that the overall 
amount of PS accumulated in the tumour is not per se the limiting factor for efficacy, but theway 
it is distributed is likely very critical. The more homogenous and reproducible degree of damage 
induced by 7D12–PS, as compared to cetuximab–PS, is in agreement with our former study 
showing differences in intratumoural distribution of 7D12 and cetuximab in A431 xenografts 
[31]. In a similar context, Watanabe et al. [24] have recently compared a mAb–PS (150 kDa) with 
a minibody–PS (80 kDa) and a diabody–PS (50 kDa), where the PS was IRDye700DX, and 
found that the use of the smallest fragment (in this case a diabody) resulted in the shortest time 
interval between injection and light exposure without compromising therapeutic efficacy. These 
results differ from ours, in that we found a difference in phototoxicity with our nanobody–PS 
conjugates (15 or 30 kDa), to the advantage of the smaller nanobody–PS conjugates compared to 
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the antibody–PS conjugate. The disparity between these results could be explained by the 
differences in format and/or size of diabody–PS and nanobody–PS conjugates. Besides the 
extent of damaged tumour, damage to the  epithelium and other features were also scored (Table 
1, with examples given in Fig. 5C). Overall, no significant damage to the epithelium was induced 
by any of the treatments, other than the damage likely associated with handling of the tongues 
with a pincette. Damage to muscle cells was common to all treatments on the cells nearest to the 
tumour, but absent inmuscle cells away fromthe tumour. Blood vessel damage varied for the 
different groups, although the trend was a more pronounced damaged in the tumour or in blood 
vessels surrounding the tumour and no damage further away from the tumour. Due to necrosis, 
the damage to muscle cells and blood vessels inside the tumour was not possible to score 
accurately from H&E sections. Edema was always present, while the extent of infiltration of 
neutrophils or mast cells varied, suggesting that PDT mediated by this PS (IRDye700DX) is also 
capable of recruiting immune cells. Future studies will have to prove how these inflammatory 
responses affect overall treatment efficacy. Vascular targeted PDT is very dependent on the time 
interval between PS administration and illumination. Here, we have selected 1 h p.i. for the 
nanobody–PS conjugates and 24 h p.i. for cetuximab–PS, to promote tumour targeted PDT. 
Shorter intervals could possibly lead to more vascular damage, also risking damage to normal 
tissues. Clearly, the time point selected was appropriate for 7D12–PS and 7D12-9G8–PS as this 
resulted in minimal damage of blood vessels and normal muscle cells around the tumour and no 
damage of blood vessel and normal muscle cells away from the tumour area. These details also 
indicate that high TBRs are not a requirement, in this particular formof PDT, to damage the 
tumour and spare normal tissue (TBRs obtained were 1.8 ± 0.3 for 7D12–PS and 3.8 ± 0.5 for 
7D12-9G8–PS). This is an interesting observation that could have important implications for the 
PDT field. Possibly, it is an effect of this particular PS, as this PS does not lead to any damage 
unless it is conjugated to a targeting molecule (nanobody) that binds to cells. Furthermore, the 
observation of minimal damage around the tumour also suggests appropriate selection of the 
fluence for the illumination. In fact, as much as the laser was pointed to the tumour, normal 
tissue surrounding itwas certainly also exposed to the illumination to some extent. Additionally, 
the light only control (Fig. 5A) also proved that the selected parameters are safe for normal 
tissues. Further in vivo research focused on varying nanobody–PS conjugate dose, illumination 
time point, and fluences for shorter treatment times, could optimize this protocol further. In 
such protocol optimization, quantitative fluorescence spectroscopy may be of substantial benefit, 
allowing patient- and tumour-specific planning for illuminations. The considerable efforts made 
in the field to render PDT tumour specific [14,61–63] have recently resulted in first-in-human 
trials, such as NCT02422979 (clinicaltrials.gov), which is testing an antibody–PS conjugate 
composed of cetuximab and IRDye700DX. This trialwill certainly have an impact in the field and 
hopefully stimulate additional trials that will encourage the use of targeted PDT as a standard 
 
treatment in the clinic. Even though antibody-targeted PDT has now entered a clinical trial, as 
demonstrated in this study, nanobody-targeted PDT has the potential to even further improve 
clinical PDT: through rapid accumulation and fast clearance of the conjugates, enabling light 
application very shortly after conjugate administration and minimizing possible photosensitivity. 
Thesewould likely bring benefits in respect of hospital management and costs involved per 
treatment. In fact, nanobodytargeted PDT has great potential to be translated to the clinic. First, 
because the PS investigated here is already being employed in a clinical trial, and second, because 
nanobodies have been in clinical trials for several years in areas other than oncology (e.g. 
antithrombotic nanobody [64]). The possibility for clinical translation surely should encourage 
additional research to further explore this approach of nanobody-targeted PDT.  
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tissues. Clearly, the time point selected was appropriate for 7D12–PS and 7D12-9G8–PS as this 
resulted in minimal damage of blood vessels and normal muscle cells around the tumour and no 
damage of blood vessel and normal muscle cells away from the tumour area. These details also 
indicate that high TBRs are not a requirement, in this particular formof PDT, to damage the 
tumour and spare normal tissue (TBRs obtained were 1.8 ± 0.3 for 7D12–PS and 3.8 ± 0.5 for 
7D12-9G8–PS). This is an interesting observation that could have important implications for the 
PDT field. Possibly, it is an effect of this particular PS, as this PS does not lead to any damage 
unless it is conjugated to a targeting molecule (nanobody) that binds to cells. Furthermore, the 
observation of minimal damage around the tumour also suggests appropriate selection of the 
fluence for the illumination. In fact, as much as the laser was pointed to the tumour, normal 
tissue surrounding itwas certainly also exposed to the illumination to some extent. Additionally, 
the light only control (Fig. 5A) also proved that the selected parameters are safe for normal 
tissues. Further in vivo research focused on varying nanobody–PS conjugate dose, illumination 
time point, and fluences for shorter treatment times, could optimize this protocol further. In 
such protocol optimization, quantitative fluorescence spectroscopy may be of substantial benefit, 
allowing patient- and tumour-specific planning for illuminations. The considerable efforts made 
in the field to render PDT tumour specific [14,61–63] have recently resulted in first-in-human 
trials, such as NCT02422979 (clinicaltrials.gov), which is testing an antibody–PS conjugate 
composed of cetuximab and IRDye700DX. This trialwill certainly have an impact in the field and 
hopefully stimulate additional trials that will encourage the use of targeted PDT as a standard 
 
treatment in the clinic. Even though antibody-targeted PDT has now entered a clinical trial, as 
demonstrated in this study, nanobody-targeted PDT has the potential to even further improve 
clinical PDT: through rapid accumulation and fast clearance of the conjugates, enabling light 
application very shortly after conjugate administration and minimizing possible photosensitivity. 
Thesewould likely bring benefits in respect of hospital management and costs involved per 
treatment. In fact, nanobodytargeted PDT has great potential to be translated to the clinic. First, 
because the PS investigated here is already being employed in a clinical trial, and second, because 
nanobodies have been in clinical trials for several years in areas other than oncology (e.g. 
antithrombotic nanobody [64]). The possibility for clinical translation surely should encourage 
additional research to further explore this approach of nanobody-targeted PDT.  
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Figure 5; In vivo tumour specific phototoxicity of nanobody–PS conjugates. (A) Sections of tongues of mice collected 
24 h post-PDT, processed for histology (H&E) and anti-CD31 staining to assess phototoxicity of the different 
treatments: intravenous administration of R2–PS, 7D12–PS or 7D12-9G8–PS followed by illumination 1 h p.i., or 
cetuximab–PS followed by illumination 24 h p.i. These are compared to the controls: light alone or each nanobody–PS 
conjugate without illumination. Each image is representative of the results obtained for that group. Areas of viable or 
necrotic tumour are indicated and blood vessels are highlighted by the anti-CD31 staining (in brown). (B) Percentages 
(%) of tumour necrosis obtained for each single treatment are depicted together with the median value. (C) 
Representative examples of damage to the epithelium, muscle cells, endothelium, and of edema and infiltration of 
neutrophils indicating recruitment of immune cells. 
 
Conclusions 
 
Overall, the EGFR targeted nanobody–PS conjugates 7D12–PS and 7D12-9G8–PS are selective 
and potent PDT agents that specifically accumulate in tumours in vivo. Upon local illumination 
within 1 h after administration, these conjugates lead to pronounced tumour necrosis and to the 
infiltration of immune cells. This study highlights the therapeutic potential of these novel 
nanomedicines and stimulates further research, contributing to the exploration of nanobody-
targeted PDT. 
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ABSTRACT 
 
During the European Molecular Imaging Meeting (EMIM) 2013, the fluorescence-guided surgery 
study group held its inaugural session to discuss the clinical implementation of fluorescence-
guided surgery. The general aim of this study group is to discuss and identify the steps required 
to successfully and safely bring intraoperative fluorescence imaging to the clinics. The focus 
group intends to use synergies between interested groups as a tool to address regulatory and 
implementation hurdles in Europe and operates within the intraoperative focus group of the 
World Molecular Imaging Society (WMIS) that promotes the same interests at the WMIS level. 
The major topics on the critical path of implementation identified within the study group were 
quality controls and standards for ensuring accurate imaging and the ability to compare results 
from different studies, regulatory affairs, and strategies to increase awareness among physicians, 
regulators, insurance companies, and a broader audience. These hurdles, and the possible actions 
discussed to overcome them, are summarized in this report. Furthermore, a number of 
recommendations for the future shape of the fluorescence-guided study group are discussed. A 
main driving conclusion remains that intraoperative imaging has great clinical potential and that 
many of the solutions required are best addressed with the community working together to 
optimally promote and accelerate the clinical implementation of fluorescence imaging towards 
improving surgical procedures. 
  
 
Introduction 
 
The inaugural fluorescence-guided surgery study groupmeeting was held during the European 
Molecular Imaging Meeting (EMIM) 2013, organized by the European Society for Molecular 
Imaging (ESMI) in Turin, Italy. The group focuses on the propagation of fluorescence imaging in 
surgery, in particular for accelerating clinical propagation while promoting safety and the use of 
standards for ensuring the development of accurate fluorescence imaging systems and clinical 
acceptance of the best agents. Fluorescence guidance can assist the surgeon to “see” beyond the 
limitations of human vision by imparting molecular contrast, improve the detection sensitivity 
over white-light color imaging, and enable subsurface visualization [1–3]. Correspondingly, there 
is an emerging drive to ensure that this technology is accepted widely for clinical use to improve 
the surgical healthcare offered to patients. The goal of the study group meeting was to serve as a 
forum to openly discuss aspects and hurdles faced by different investigators and stakeholders and 
to suggest solutions. The study group also intends to discuss European-specific issues and relay 
them to the corresponding World Molecular Imaging Society study group. Major discussion 
points during the session revolved around regulatory and safety issues for clinical  
implementation, quality controls and standards, strategies to increase awareness for a wider 
acceptance of the technology, and the future shape of the fluorescence-guided surgery study 
group. In this report, these topics are summarized together with proposed actions. A general 
consensus has been that information exchange and a common action on large-scale issues, in 
particular (1) the use of accurate and appropriate fluorescence imaging technology held at a high 
standard, (2) the action plan on informing regulatory bodies and obtaining regulatory approvals, 
and (3) the responsibility to act in a safe and ethical manner are important issues that should be 
addressed as a community to ensure a pragmatic propagation of this technology for the benefit 
of the patient.  
 
Ethics and Good Clinical Practice 
The first clinical trial of fluorescence-guided surgery using targeted agents has been performed 
[4], and new trials are presently ongoing. However, there are still numerous hurdles to be 
addressed before new imaging devices and optical probes can actually be implemented in 
standard clinical care. These hurdles include not only the obvious bottlenecks such as costs and 
regulatory approval but also the less visible but more important issue of good clinical practice 
and good scientific practice. We have seen in other scientific fields, such as gene therapy, how 
unfortunate events can have devastating effects on the progress of an entire area of research [5]. 
As a result, there is a significant responsibility of all investigators involved with the clinical 
propagation of intraoperative imaging to conduct preliminary clinical studies and lengthier 
clinical trials at the highest level of ethical conduct and safety precautions. 
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Regulatory Affairs 
The regulatory approval of an imaging agent and an imaging system presents complexities and 
has a direct effect on study design and data collection (and thus requires well-designed research 
protocols). The US Food and Drug Administration (FDA) and its European counterpart, the 
European Medicines Agency (EMA), have very similar guidelines for phases I and II clinical 
studies. A well-designed trial can thus be used in both the European and the US approval 
procedures. In Europe, however, approval is subject not only to European guidelines but also to 
additional regulatory bodies at a national level. All of these regional bodies come with their own 
specific set of regulations on top of the EMA framework. The trial design has a direct influence 
on the required toxicity tests, as these tests are dependent on variables like dosing, administration 
route, and number of administrations. Once these variables have been established, toxicity 
screening can be outsourced to dedicated commercial companies. Outsourcing prevents a lot of 
unnecessary work or delay and generates data in a format that is immediately ready for FDA and 
EMA filing. The execution of the clinical trial itself is complicated, as it requires close 
collaboration between multiple partners. This is especially the case for large multicentre trials 
performed in more than one country. It is during the setup of these trials that there is an 
important role for the European and worldwide intraoperative imaging study group in 
stimulating or even facilitating the exchange of knowledge on national regulatory issues and 
sharing experiences with trial design and approval procedures. Also, the study group can speed 
up the process of clinical implementation by making and distributing updated guidelines for good 
research practice, regulations, and study design. 
 
Quality Control for Agent Production 
The production of a fluorescence agent is also subject to extensive regulations. Minor chemical 
modifications such as coupling a dye to a targeting moiety are considered to be a manufacturing 
step and require approval as a new entity and corresponding production under good  
manufacturing practice (GMP) conditions, before clinical administration. Phase I clinical trials 
already require compounds produced to GMP standards. Currently, small GMP facilities are set 
up by research groups in order to produce probes for small inhouse trials. Running a GMP 
production facility is expensive and time-consuming, as it involves a lot of paperwork, 
regulations, and periodic inspections. However, it is advisable to start using GMP probes at a 
preclinical stage, as this can prevent problems introduced by changes in production procedures at 
a later point in time. Typical problems associated with switching to GMP production of  
compounds at a later time point include production and synthesis protocols in which one or 
more steps are not allowed under GMP regulations, insufficient purity of the manufactured 
agent, and difficulties in identifying the chemical characteristics of impurities. Increasing the 
 
production scale of a probe is essential during the transition from preliminary to large clinical 
trials. Often, the small in-house facilities are not suitable for largescale production. Moreover, 
probe production for one multicentre trial is ideally performed within one production facility to 
prevent quality variation. There are a number of issues when switching to large-scale probe 
production. First of all, most antibody and peptide-based probes are notoriously difficult to 
produce. Even for a dedicated facility, setting up a large-scale production line is expensive and 
very time-consuming. Second, the probe and its activity should be reevaluated after optimizing 
the production protocols. Third, as part of the GMP process, there should be a quality control 
system in place in order to ensure production stability in terms of probe quality and purity over 
time. Finally, the probe should be well characterized in terms of shelf life, stability, and possible 
aggregation, as running large multicentre trials will involve increased transport and storage time. 
Multicentre trials are ideally dependent on one dedicated centralized production facility. This 
requires extensive collaboration between scientific groups designing probes and their production 
protocols, clinical researchers leading these trials, pharmaceutical formulation experts, and probe 
manufacturers. The fluorescence-guided surgery study group should take a leading role in 
maintaining information flow in regard to experiences gained in this process and the pitfalls to 
avoid when setting up of a GMP production of a new agent. The study group can further aid in 
coordinating actions directed to the EMA in order to provide a common framework for all 
investigators involved in translating intraoperative imaging.  
 
Standardization of Fluorescence Cameras 
A discussion ensued on whether clinical approval will be granted for probes and imaging devices 
independently or whether certain fixed probe–camera combinations will become eligible for 
approval. This is a very relevant question as a good probe can lead to adverse clinical results if 
the performance of the imaging device used is inadequate. In essence, the question touches upon 
the need for standardization in the assessment of imaging device performance. Standardization 
and quality control is an important matter in all radiological modalities but is particularly 
important in fluorescence imaging since there is no established fluorescence imaging standard. In 
addition, the signals recorded by fluorescence “photographic” imaging depend nonlinearly on 
tissue optical properties, which may lead to insufficient or erroneous detection of fluorescence in 
tissues and result in false negatives or positives [6–9]. There is currently no objective way of 
determining the performance of an imaging device as a whole. One can easily compare the 
resolution and sensitivity of the cameras used, but not the overall performance of an imaging 
device, i.e., its performance in relation to tissue optical properties, light illumination 
homogeneity, and several other features that may impact performance. The insensitivity of the 
fluorescence signal intensity to the (variation of) tissue optical properties and corresponding 
methods for overall noise reduction is of great importance in understanding and characterizing 
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an intraoperative imaging device that has been developed for medical use, rather than just simple 
technical-only parameters such as camera sensitivity or resolution [10]. One step towards 
accurate fluorescence imaging is the development of a standardized fluorescent phantom. 
Phantoms can be imaged for assessing the performance and accreditation of a system for clinical 
use. Possibly, phantoms may also be necessary for system calibration, as they are common for 
other imaging modalities such as nuclear imaging [11]. Again, community involvement in 
understanding and addressing these issues is required for devising appropriate standards and 
recommending their use. 
 
Assessment of Imaging Agents 
Not only are the imaging devices in need of a standardized measure of performance but also 
probes and the even more fundamental measurements of biomarker expression levels are in need 
of standardization. An illustrative example is the vascular endothelial growth factor (VEGF). 
Each of seven different VEGF antibodies gives different results in terms of staining intensity 
when used for immunohistochemistry performed by one person within one laboratory due to 
slight variations in the execution of the staining procedure, such as buffer handling, incubation 
times, and antibody handling. Matters become even more complicated as one specific antibody 
can give rise to completely different results in different laboratories or when handled by different 
people [12]. Yet, immunohistochemical staining is one of the typical experiments used in 
scientific publications to show and measure biomarker expression levels and to prove probe 
specificity. Consequently, it is actually very difficult to compare biomarker expression and probe 
performance between different studies. In order to address the issue of comparing probe 
performance and biomarker expression levels between studies, there is a need for the 
standardization of the antibodies used, the methods and lab protocols, the measuring/imaging 
devices used, and the methods of signal quantification. These standards must be set for each 
individual biomarker. Another solution to the problem might lie in the use of techniques like 
mass spectrometry and liquid chromatography–mass spectrometry (LC–MS) for the  
quantification of expression levels [13]. Setting these standards on European and worldwide 
levels will create great opportunities when it comes to selecting the most promising probes to 
enter a clinical phase.  
 
Raising Wider Awareness 
The field of intraoperative imaging is moving forward towards clinical implementation. As we 
may be approaching a period of large multicentre clinical trials, the research field will require 
relatively large investments and research budgets in the near future. Similar to other areas of 
medical research, investments can come either from the industry or from public funding agencies 
and governments. A particular case for intraoperative imaging is that it does not have a dedicated 
 
“industry” space. It rather defines a new theranostic area that may generate its own industry. 
Many of the participants in the study group believe that this will be a sufficiently large field for 
imaging industries to enter; however, there is certain reluctance on their behalf, primarily due to 
the requirement for imaging agents, to enter a field where they do not have much experience. 
Intraoperative imaging is a field in great need of public funding. The benefits to the patient can 
be seen, but on the other hand, clinical translation is best handled today by clinical surgical 
departments with a clear view and understanding on how this field should move forward. This is 
a clear case of a “valley-of-death” scenario seen in clinical translation of promising technology 
that is best addressed by competitive publicly funded research to support clinical studies and to 
demonstrate the benefit of the technology. Such demonstration is then certain to attract 
industrial investment. The focus of research should lie on developing low-cost imaging systems 
and reagents in order to stimulate fast clinical translation of these systems. Furthermore, this field 
of development is consistent with the goals of the European community priority lists. Therefore, 
there is a further clear goal of the study group, and that is to promote a community approach to 
ensure sustainable funding that will enable the demonstration of promising agents and systems in 
the clinic, as an important remaining step towards wider clinical dissemination. Intraoperative 
imaging has great potential but requires support at a larger community level and beyond in 
reaching more widely the clinical communities and informing the general public and government 
regulatory and funding bodies of the opportunities and need for raising proper support. 
 
The Future of the ESMI Fluorescence-Guided Surgery Study Group 
Exchange of information and joint actions representing the community will be a major driving 
force during the implementation of intraoperative imaging. Therefore, the study group will foster 
synergies and scientific or regulationdriving alliances to focus on proper implementation of the 
technique in clinical practice. Through regular and ad hoc meetings, supported by ESMI and 
World Molecular Imaging Congress (WMIC) under the world focus group on intraoperative 
imaging, the European group aims to help investigators promote their interests in the field by 
addressing not only the common scientific challenges but also particular regulatory 
considerations associated with performing these studies in different European countries. It 
further aims to serve as a forum to compare “notes” and experiences in order to avoid the 
pitfalls and accelerate propagation of the technology. There is a need for a knowledge base where 
groups share relevant information on trial design, regulatory issues, and details of trials that are 
being performed. Sharing experiences on running trials, regulatory affairs, and possible pitfalls 
will prevent duplication of work and repetition of mistakes made by other groups. A field-wide 
collaboration on common challenges is the next logical step, especially as we stand on the brink 
of large multicentre trials of probes and imaging devices for certain specific indications. The 
study group can further play a key role in implementing standards for imaging devices, probe 
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performance, and biomarker expression, by synergizing, not only at a European level but also 
with all scientists under the WMIC focus group on intraoperative imaging to gain consensus on 
optimal guidelines. Setting these standards is of paramount importance, as it will create a 
reference frame within which data can be compared and this issue will remain on the agenda of 
future meetings with the aim of reaching a consensus on optimal imaging and targeting 
performance metrics. Finally, it is essential to develop means to communicate critical issues 
outside the research community. Awareness should be raised within three different target groups. 
First, surgeons, the future users of intraoperative imaging techniques, should be made aware of 
the technique and the possible implications for surgical oncology. This will create interest and 
possibilities for future cooperation within clinical trials and clinical implementation. Second, 
informing the general public via various media will increase the social support and understanding 
needed for the largescale public investments involved in the next stage of research. Finally, 
governments and funding bodies need to become aware of the particular benefits and challenges 
of the field, in order to offer valuable support in accelerating clinical propagation. 
 
  
 
General Conclusion 
 
Intraoperative imaging has great clinical potential. One investigator or group cannot address all 
the major challenges, neither it is reasonable that each interested party will have to overcome the 
same hurdles in a repetitive manner. Instead, there are grand challenges that need to be addressed 
at the community level, for example reaching out to regulatory bodies, raising awareness of the 
field, and in reaching a consensus on standards. The European study group will continue its role 
in offering a forum for discussion and coordinating actions with the ultimate goal of aiding in the 
establishment of guidelines and optimal practices and bringing the community together on 
critical issues. By creating an environment in which communication is stimulated and participants 
can engage in action groups with common benefits, the study group wishes to aid in the process 
of safe clinical implementation.  
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Summary 
 
 
Over the last century, pre- and postoperative imaging for early detection, staging and treatment 
evaluation have been a major part of oncological surgery.  Nevertheless, during surgery, surgeons 
mostly discriminate healthy tissue from cancerous tissue by means of visual inspection and 
palpation. Consequently, incomplete tumour resections are still encountered even though intra-
operatively these tumours seem radically resected. Providing the surgeon with intra-operative 
visual feedback on tumour margins may promise an improvement in radical resections of 
tumours, thus increasing patients’ survival rates. 
 
Fluorescence-guided surgery (FGS) is a technique based on near-infrared (NIR) light that 
provides the surgeon with real-time visualization of tissues of interest. Although initially not very 
appealing for clinical use, this radically changed with the discovery of NIR light. Using NIR light 
tissue penetration was higher and autofluorescence decreased significantly. The high potential of 
FGS for surgical oncology increased the amount of research in this relatively new field of optical 
imaging exponentially. Currently, FGS has been widely investigated for sentinel lymph node 
procedures, evaluation of perfusion of anastomosis and cholangiography during 
cholecystectomies. An increasing amount of clinical trials are performed studying targeted FGS 
to discriminate cancerous tissue from healthy surrounding tissue during surgery. Nevertheless, 
targeting cancer remains challenging, mostly because of a great extent of intra- and intertumoral 
heterogeneity of the targeted receptors. Further, optical properties of tissue hamper the detection 
of a single tumour cell potentially leaving residual tumour cells in situ after a NIR fluorescence-
guided resection.   
 
The aim of this thesis was to validate two probes and the newly designed Artemis camera for 
NIR FGS preclinically to pave the way for a clinical implementation. In the last part, the first 
steps were made to combine targeted NIR imaging and photodynamic therapy. A potential 
treatment combination to treat the last residual tumour cells.  
 
In part I the current modalities of fluorescence-guided surgery and the challenges in optical 
imaging were reviewed. Chapter 2 gives an extensive overview of the preclinical and clinical data 
in targeted fluorescence-guided oncologic surgery to reflect its current status. In particular, it 
focuses on specific targeting of primary tumours by organic fluorescent agents that target the 
alterations in cell physiology involved in cancer. Chapter 3 describes the fundamental basic 
principles of NIR fluorescence imaging. Here, the consequences of these principles on FGS and 
the influence on clinical decision-making are discussed in more detail. The technique can be a 
 
very powerful tool in guiding the surgeon to radical tumour resections, as long as the intrinsic 
limitations are taken into account.  
 
Preclinical studies were shown in part II. Here, two preclinical studies are performed using 
probes that target two important receptors in oncology. The first target that was explored is the 
epidermal growth factor receptor (EGFR) in chapter 4. The EGFR is a transmembrane 
glycoprotein that is involved in DNA synthesis and cell proliferation. Overexpression contributes 
to oncogenesis. Being widely overexpressed in oral squamous cell carcinomas (OSCC) we used 
an orthotopic OSCC of the tongue that metastasises to the cervical lymph nodes. Here, a 
nanobody was conjugated to the fluorophore IRDye-800CW. A nanobody is the smallest 
functional antigen-binding fragment derived from naturally occurring heavy-chain-only 
antibodies. They show very specific binding to their targets and their size ensures efficient 
distribution and tissue penetration, as well as rapid clearance from the body. All tumours could 
be clearly identified using the FLARE NIR fluorescence camera. From two hours after injection 
of 7D12-800CW a significantly higher tumour-to-background ratio (TBR) was observed 
compared to the control nanobody. A higher dose was needed to detect cervical lymph node 
metastases. Using an orthotopic tumour model and a clinically available NIR camera system this 
study showed the true potential of a nanobody based imaging agent in FGS.  In search for a 
more universal receptor we evaluated the epithelial cell adhesion molecule in chapter 5. EpCAM 
is a transmembrane glycoprotein involved in cell-cell interactions and cell-stroma adhesion. Its 
expression is restricted to epithelial cells and is highly up-regulated in virtually all epithelial 
carcinomas. To assess the value of this target in FGS we conjugated the monoclonal chimeric 
antibody 323/A3 to the IRDye 800CW.  The anti-EpCAM/800CW conjugate showed to be 
stable in serum and showed preserved binding capacity as evaluated on EpCAM positive and 
negative cell lines using flow cytometry and cell-based plate assays. Four clinically relevant 
orthotopic tumour models, i.e. colorectal cancer, breast cancer, head and neck cancer, and 
peritonitis carcinomatosa were used to evaluate the performance of the anti-EpCAM agent with 
the clinically validated Artemis imaging system. All tumour types could clearly be delineated and 
resected 72 hours after injection of the imaging agent. Millimetre sized tumour nodules were 
detected that were invisible for the naked eye. Fluorescence microscopy demonstrated the 
distribution and tumour specificity of the anti-EpCAM agent. This study showed the potential of 
EpCAM as a target in FGS in a versatile of orthotopic tumour models paving the way for clinical 
translation. Next, the use of the new Artemis NIR fluorescence camera was reported for the first 
time in literature. In chapter 6 we evaluated the performance of the new Artemis camera 
preclinically as well as clinically. The minimal detectable dose of pure ICG and IRDye 800CW 
was determined in vitro.  The lower limit of cells targeted by the EGFR targeting nanobody 7D12-
800CW that could be detected was 2 x 105 and 4 x 104 for the Artemis and preclinical camera 
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carcinomas. To assess the value of this target in FGS we conjugated the monoclonal chimeric 
antibody 323/A3 to the IRDye 800CW.  The anti-EpCAM/800CW conjugate showed to be 
stable in serum and showed preserved binding capacity as evaluated on EpCAM positive and 
negative cell lines using flow cytometry and cell-based plate assays. Four clinically relevant 
orthotopic tumour models, i.e. colorectal cancer, breast cancer, head and neck cancer, and 
peritonitis carcinomatosa were used to evaluate the performance of the anti-EpCAM agent with 
the clinically validated Artemis imaging system. All tumour types could clearly be delineated and 
resected 72 hours after injection of the imaging agent. Millimetre sized tumour nodules were 
detected that were invisible for the naked eye. Fluorescence microscopy demonstrated the 
distribution and tumour specificity of the anti-EpCAM agent. This study showed the potential of 
EpCAM as a target in FGS in a versatile of orthotopic tumour models paving the way for clinical 
translation. Next, the use of the new Artemis NIR fluorescence camera was reported for the first 
time in literature. In chapter 6 we evaluated the performance of the new Artemis camera 
preclinically as well as clinically. The minimal detectable dose of pure ICG and IRDye 800CW 
was determined in vitro.  The lower limit of cells targeted by the EGFR targeting nanobody 7D12-
800CW that could be detected was 2 x 105 and 4 x 104 for the Artemis and preclinical camera 
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(Pearl) respectively. In vivo, the camera was evaluated in two procedures namely sentinel lymph 
node imaging and tumour specific FGS. Two head and neck cancer cell lines were used in 
combination with 7D12-800CW. Orthotopic OSC-19-luc2-cGFP tongue tumours were clearly 
visible and a minimum FaDu-luc2 tumour size of 1 mm3 could be identified. Further, for the 
first time, clinical evaluation of cancer patients using the NIR Artemis camera was described. Six 
human malignant lesions were identified during three liver surgery procedures. 
 
In part III we focussed on the future of fluorescence-guided surgery. In chapter 7 three major 
challenges in FGS were described and subsequently possible solutions were postulated.  The 
challenges in FGS described here comprise imaging tumour heterogeneity, invasive tumour 
strands and dealing with the tissue optical properties. Tissue optical properties ensure that it is 
most unlikely that the last residual tumour cells will be visualized using FGS. Mainly in invasive 
tumour strands this could hamper radical tumour resections. To overcome the hurdle of optical 
properties, intrinsic fluorescence measurements can be performed intra-operatively. We 
described how point reflectance and fluorescence spectroscopy using fiber optic probes can be 
used to overcome the effects of tissue optical properties and detect residual fluorescent signal. A 
second promising solution to treat the remaining tumour cells is adjuvant photodynamic therapy. 
PDT is a promising minimally invasive approach that is being used for the local treatment of 
premalignant and malignant lesions. Compared to other adjuvant therapeutic modalities, PDT 
has the potential to induce low toxicity in normal tissue, produce negligible systemic effects, and 
reduce acute and long-term morbidity. Furthermore, PDT does not compromise future 
treatment options for patients with residual or recurrent disease and can be repeated with 
perpetual efficacy. More importantly PDT and NIR FGS can be combined in one theranostic 
probe. In chapter 8 we explored the feasibility of tumour specific photodynamic therapy and 
NIR fluorescence imaging. Despite the potential advantages of PDT, collateral damage to normal 
tissue remains a significant side effect, particularly in the treatment of large tumours. Targeted 
PDT, in which photosensitizers (PS) are selectively delivered to the tumour, could greatly 
enhance the efficacy of PDT and simultaneously reducing damage to normal tissue. Here, in this 
feasibility study, we conjugated the photosensitizer IRDye700DX to the EGFR targeting 
nanobody 7D12 and explored the selectivity and phototoxicity in an orthotopic head and neck 
cancer model. In vitro, the EGFR specific IRDye700DX conjugates solely binded to cells 
overexpressing the EGFR. Further, phototoxicity was only induced in cells that were bound by 
the conjugate. Importantly, EGFR targeted nanobody–PS conjugates led to extensive tumour 
necrosis (approx. 90%) in vivo and almost no toxicity in healthy tissues was observed through 
histology 24h after PDT. Overall, results showed that these EGFR targeted nanobody–PS 
conjugates are selective and able to induce tumour cell death in vivo. In chapter 9 we identified 
the steps required to successfully and safely bring intraoperative fluorescence imaging to the 
 
clinics. The major topics on the critical path of implementation were identified and the possible 
actions discussed to overcome them. A main overall conclusion remained that intraoperative 
fluorescence imaging has great clinical potential and that with the community working together 
the clinical implementation of FGS could be substantially accelerated.  
 
This thesis demonstrates the use of fluorescence-guided therapy in oncology. First it shows the 
preclinical validation of two different targets and probes for fluorescence-guided surgery, results 
that pave the way towards clinical implementation. Next, the utility of the NIR fluorescence 
Artemis camera is described. Lastly, the first steps are made towards fluorescence theranostics in 
oncology: NIR fluorescence-guided surgery and intra-operative targeted photodynamic therapy.    
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Discussion and Future perspectives 
 
 
Target 
Over the past decade, an important driver in the field of fluorescence-guided therapy was to 
identify a universal tumour-specific target with optimal tumour-to-background ratio. A probe 
against a ‘universal’ target facilitates clinical usability, and prevents time consuming and costly 
development of multiple agents. However, the continuous quest for a universal tumour-specific 
target has not yet been successful and the growing insight in cancer invasion is increasingly 
pointing towards multifactorial processes1,2. Next, cancer targeting with high sensitivity and 
specificity remains challenging, mostly related to issues with intra- and intertumoral 
heterogeneity. 
             
Figure 1 | Intertumoral and intratumor heterogeneity. 
 
Extensive genetic and phenotypic variation exist between tumours that originate from different 
tissues and cell types. They are even observed between tumours that originate from the same 
tissue and cell type (Figure 1). This intertumoral heterogeneity occurs probably because genetic 
events of transformation interact with cell-intrinsic biological properties3. Furthermore, genetic 
diversity in population of tumours cells is induced by genomic instability and the fact that a large 
number of proliferation cycles is needed for a macroscopic tumour to grow. Subsequently, 
subclones of cells within a tumour are formed by somatic evolution (Figure 1). The result is 
diversity in the expression of biomarkers in each tumour and even in subclones within a tumour. 
Therefore, complete imaging of the tumour border by a single target will be challenging.  This 
suggests that a personalized approach to individual patients may be required where multiple 
targets per patient are selected to completely image the tumour border during surgery. Costly 
developments of tumour specific agents hamper a rapid clinical implementation of multiple 
 
agents. Until surgeons will have access to a variety of agents, the first developments of agents will 
focus on the most universal targets or targets that can be used in a greater subset of tumours. An 
adequate target for NIR fluorescence imaging is defined by the exclusive upregulation on tumour 
cells compared to adjacent normal tissue cells, the localization on the cell membrane, the number 
of targeted proteins available per cell and the distribution of target expressing cells within the 
tumour4. The EGFR studied in chapter 4 is upregulated in most cancer types and serves as an 
interesting target that is used in therapeutic and imaging studies4. Being widely overexpressed in 
head and neck cancer the target served as a logical choice for our study. The second target 
studied in chapter 6 is the Epithelial Cell Adhesion Molecule (EpCAM). EpCAM is a 
transmembrane glycoprotein involved in cell-cell interactions and cell-stroma adhesion5. EpCAM 
certainly holds as an universal target for epithelial tumours as its expression is restricted to 
epithelial cells and is highly up-regulated in virtually all epithelial carcinomas6,7. Both targets 
proved their usability in preclinical experiments results from clinical trials have to be awaited. 
(NCT03282461, NCT03154411, NCT03134846, )  
 
 
Probe 
Research into the development of probes for optical imaging has been preceded by decades of 
research into therapeutic antibodies8. Many of the research done in therapeutic antibody 
(fragments) can be extrapolated to optical imaging. For instance, the challenge of 
immunogenicity of murine antibodies in patients and the development of humanized or fully 
human antibodies. Further research on antibody-drug conjugates brought attention to 
conjugation methods and site-specific conjugation9. Although antibodies became the mainstay of 
biotherapeutics, treatment of solid tumours remained difficult because of limited tumour 
penetration. One of the most important variables that determine penetration is the molecular 
radius.  Therefore, development of tumour targeting molecules focused on making smaller 
fragments including 7 kDa affibodies10, 12-15 kDa nanobodies11, 27kDa ScFvs12, 50 kDa Fabs 
and 80 kDa minibodies13. 
 
The desired requirements for therapeutic and optical agents differ significantly. Contrary to 
therapeutic antibodies where effector functions are desirable, optical agents have to be 
biologically inert to reduce the risk of unwanted side effects. Furthermore, therapeutic antibodies 
require significant concentrations in target tissue over time whereas optical imaging agents need 
to achieve high contrast at early times. Early imaging is practical and cost-effective in surgical 
practice because patients do not have to be admitted to the hospital days before surgery. In NIR 
FGS, where the tumour border is of main concern, it is still questionable whether penetration of 
solid tumours is of that much importance.  
Discussion and Future perspectives 233
10
 
Discussion and Future perspectives 
 
 
Target 
Over the past decade, an important driver in the field of fluorescence-guided therapy was to 
identify a universal tumour-specific target with optimal tumour-to-background ratio. A probe 
against a ‘universal’ target facilitates clinical usability, and prevents time consuming and costly 
development of multiple agents. However, the continuous quest for a universal tumour-specific 
target has not yet been successful and the growing insight in cancer invasion is increasingly 
pointing towards multifactorial processes1,2. Next, cancer targeting with high sensitivity and 
specificity remains challenging, mostly related to issues with intra- and intertumoral 
heterogeneity. 
             
Figure 1 | Intertumoral and intratumor heterogeneity. 
 
Extensive genetic and phenotypic variation exist between tumours that originate from different 
tissues and cell types. They are even observed between tumours that originate from the same 
tissue and cell type (Figure 1). This intertumoral heterogeneity occurs probably because genetic 
events of transformation interact with cell-intrinsic biological properties3. Furthermore, genetic 
diversity in population of tumours cells is induced by genomic instability and the fact that a large 
number of proliferation cycles is needed for a macroscopic tumour to grow. Subsequently, 
subclones of cells within a tumour are formed by somatic evolution (Figure 1). The result is 
diversity in the expression of biomarkers in each tumour and even in subclones within a tumour. 
Therefore, complete imaging of the tumour border by a single target will be challenging.  This 
suggests that a personalized approach to individual patients may be required where multiple 
targets per patient are selected to completely image the tumour border during surgery. Costly 
developments of tumour specific agents hamper a rapid clinical implementation of multiple 
 
agents. Until surgeons will have access to a variety of agents, the first developments of agents will 
focus on the most universal targets or targets that can be used in a greater subset of tumours. An 
adequate target for NIR fluorescence imaging is defined by the exclusive upregulation on tumour 
cells compared to adjacent normal tissue cells, the localization on the cell membrane, the number 
of targeted proteins available per cell and the distribution of target expressing cells within the 
tumour4. The EGFR studied in chapter 4 is upregulated in most cancer types and serves as an 
interesting target that is used in therapeutic and imaging studies4. Being widely overexpressed in 
head and neck cancer the target served as a logical choice for our study. The second target 
studied in chapter 6 is the Epithelial Cell Adhesion Molecule (EpCAM). EpCAM is a 
transmembrane glycoprotein involved in cell-cell interactions and cell-stroma adhesion5. EpCAM 
certainly holds as an universal target for epithelial tumours as its expression is restricted to 
epithelial cells and is highly up-regulated in virtually all epithelial carcinomas6,7. Both targets 
proved their usability in preclinical experiments results from clinical trials have to be awaited. 
(NCT03282461, NCT03154411, NCT03134846, )  
 
 
Probe 
Research into the development of probes for optical imaging has been preceded by decades of 
research into therapeutic antibodies8. Many of the research done in therapeutic antibody 
(fragments) can be extrapolated to optical imaging. For instance, the challenge of 
immunogenicity of murine antibodies in patients and the development of humanized or fully 
human antibodies. Further research on antibody-drug conjugates brought attention to 
conjugation methods and site-specific conjugation9. Although antibodies became the mainstay of 
biotherapeutics, treatment of solid tumours remained difficult because of limited tumour 
penetration. One of the most important variables that determine penetration is the molecular 
radius.  Therefore, development of tumour targeting molecules focused on making smaller 
fragments including 7 kDa affibodies10, 12-15 kDa nanobodies11, 27kDa ScFvs12, 50 kDa Fabs 
and 80 kDa minibodies13. 
 
The desired requirements for therapeutic and optical agents differ significantly. Contrary to 
therapeutic antibodies where effector functions are desirable, optical agents have to be 
biologically inert to reduce the risk of unwanted side effects. Furthermore, therapeutic antibodies 
require significant concentrations in target tissue over time whereas optical imaging agents need 
to achieve high contrast at early times. Early imaging is practical and cost-effective in surgical 
practice because patients do not have to be admitted to the hospital days before surgery. In NIR 
FGS, where the tumour border is of main concern, it is still questionable whether penetration of 
solid tumours is of that much importance.  
234 Chapter 10
 
In search of the optimal probe size we need to find out what the influence is of size on the 
targeting properties of the agent. In a study by Schmidt et al.14 a mechanistic model was 
developed that predicted the complex interplay between molecular size, affinity, and tumour 
uptake. In this study empirical relationships between molecular radius, capillary permeability, 
interstitial diffusivity, available volume fraction, and plasma clearance were obtained using data in 
the literature. Intermediate sized targeting agents (molecular weight approximately 25 kDa) 
seemed to have the lowest tumour uptake and similar peak tumour levels were predicted using 
small and large proteins. Contrary to large proteins, smaller proteins achieve high tumour levels 
rapidly but need a high affinity to be retained14. An increase in tumour penetration ensures a 
more homogenous distribution of smaller proteins in solid tumours.  
 
In this thesis two different sized tumour targeting agents were used: the 15kDa 7D12-800CW 
nanobody (chapter 4, 6 and 8) and the 150 kDa 323/A3-800CW antibody (chapter 5). 
Nanobodies are the smallest functional antigen-binding fragments derived from naturally 
occurring heavy-chain only antibodies. They bind specifically and with high affinities to their 
antigens15, 16, they are stable and soluble in aqueous solutions, can be chemically modified, and 
have low immunogenic potential17. Further, with a molecular weight ten times smaller than 
conventional antibodies (15 kDa vs 150 kDa) and high binding affinities, tumour penetration of 
nanobodies is greatly enhanced, and occurs more rapidly18. Therefore, nanobodies seem a logical 
choice for FGS. Nevertheless, the wide clinical experience and known safety of antibodies allows 
for a faster and safe clinical translation.  
 
Next to the targeting moiety, the fluorophore is one of the key factors in FGS. When all vairables 
(NIR wavelength, quantum yield, photobleaching, clearance, nonspecificity, solutibliy and 
toxicity)of the fluorophore are optimal, still tissue penetration will be relatively limited to a 
maximum of approximately 1 cm. Imaging in the NIR2 spectrum (1000 – 1700 nm)  is an 
interesting alternative option to increase tissue penetration because of reduced tissue scattering 
and negligible tissue autofluorescence19. A second, promising imaging tool to increase tissue 
penetration is photoacoustic imaging. Here, light of short laser pulses is absorbed by an 
exogenous contrast agent and converted into heat leading to ultrasonic emission. The 
photoacoustic waves can be detected by ultrasound transducers. Less scattering of soundwaves 
results in a high tissue penetration compared to NIR fluorescence imaging20. 
 
An interesting new area of imaging is multimodal imaging. Pre-operative tumour staging, intra-
operative imaging and post-operative pathologic examination can be achieved by one probe in 
multimodal imaging19. Here, preoperative imaging techniques (SPECT/PET) are combined with 
intraoperative fluorescence optical guidance. Postoperatively, fluorescence imaging guides the 
 
pathologic examination. Next to multimodal imaging, the theranostic concept (simultaneous 
diagnosis and treatment)  can be applied to FGS when it is combined with tumour targeted 
therapy. One of the promising fields in theranostics is the combination of NIR fluorescence 
imaging and photodynamic therapy20. Residual tumour cells located in the wound bed after FGS 
can be treated by intra-operative PDT, potentially reducing local recurrence21.  
 
 
Imaging systems 
The success of FGS in recognizing tumours and vital structures depends to a large extent on the 
imaging system used. The most important criteria for practical application of an imaging system 
are the field of view, imaging distance to the patient, manoeuvrability, simultaneous imaging of 
near-infrared and visible light, real-time imaging, light intensity, sterility, and electrical safety24. 
The criteria that mainly affect the design choices of the camera components are the sensor, lens 
system, light source, and  filters/dichroic mirrors. The last decade several research groups and 
industrial companies designed and developed NIR fluorescence imaging systems of which a small 
number fit most of the criteria above and are clinically available25. Further, for an adequate 
clinical translation and widespread clinical use it is of importance that the imaging systems are 
not overprized. The first NIR fluorescence intraoperative imaging systems were developed for 
open surgery and recently several became available for clinical trials25. Over the past decades, 
significant progression has been made towards minimally invasive surgery to reduce pain, 
haemorrhaging and to shorten recovery times. As fluorescence guided surgery could certainly be 
of major benefit in this emerging field of surgery, NIR imaging options were incorporated in 
laparoscopy, thoracoscopy and robotic systems25.  
 
A system that can be used for both open and laparoscopic surgery is the Artemis system. In 
Chapter 6 we evaluated the Artemis NIR imaging system in two oncological procedures in which 
real-time NIR fluorescence could be of added value: radical tumour resection and the detection 
of sentinel lymph nodes. Based on the results of this study, it was concluded that the Artemis 
system demonstrated its utility for fluorescence-guided cancer surgery preclinically and clinically 
but improvements had to be made. Many of the desired improvements that were suggested in 
chapter 6 have been implemented in the next generation Artemis system.  
 
Two major challenges in the development of imaging systems are the correction for the influence 
of optical properties and autofluorescence.  Signal to background ratios can be increased 
drastically if the influence of these factors can be reduced. As widely discussed in chapter 3, two 
possible solutions could be a correction scheme for light intensity variations in tissues26 and 
spectral unmixing27. For both, dedicated systems were developed26,27. Further, multiple imaging 
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systems have been developed for photoacoustic imaging that has the major advantage of an 
increased tissue penetration compared to NIR fluorescence imaging28. 
 
Nevertheless, the future of imaging systems predominantly lies in multimodal imaging and 
theranostics. If multiple targets are selected in personalized FGS, several excitation wavelengths 
need to be incorporated in one imaging system to detect multiple probes simultaneously. Further, 
hybrid tracers like ICG and 99mTc-nanocolloid need a hybrid modality that is capable of detecting 
both gamma and fluorescence signals29. Lastly, a logical development for the use in FGS 
combined with intra-operative targeted PDT is a multimodal system capable of imaging and 
treatment30. 
 
 
Adjuvant photodynamic therapy 
Although in 10 years even a single cell can be imaged on the surface using fluorescence imaging, 
optical properties will probably hamper detection of cancer cells situated under the surface. 
Consequently, tumor cells could be left in situ after the tumor seems radically resected by 
fluorescence navigation. This may require the need of adjuvant therapy. Here, intra-operative 
targeted PDT could be of great value.  
 
Like in FGS, intra- and intertumoral heterogeneity are important challenges in targeted PDT and 
a personalized approach to individual patients may be required. Next, the photosensitizer (PS) is 
a major challenge. Most PS’s are rather hydrophobic which promotes cell binding, but provides 
no specificity. Therefore, efforts have been made to render PS more hydrophilic and to target 
these molecules more selectively to tumors, through chemical modifications, delivery systems, 
and/or targeting molecules31-34. The PS that we conjugated to the nanobodies was IRDye700DX, 
which is a water-soluble silicon-phthalocyanine derivative that has a strong absorption band in 
the near-infrared region of the spectrum (690 nm) and is also traceable through optical imaging. 
Although a major advantage, the use of a single agent for both FGS and PDT holds some 
limitations. When a chromophore absorbs a photon it will result in fluorescence or the formation 
of reactive oxygen species. Thus, a single agent will not have an optimal fluorescence- and triplet 
state quantum yield. 
 
But several advantages favor the use of targeted PDT as an adjuvant treatment. Targeted PDT 
has the advantage of low toxicity in normal tissue, negligible systemic effects and it induces a 
local inflammatory reaction that stimulates the host immune system35,36. All are major advantages 
compared to other adjuvant therapeutic modalities like radiotherapy and/or chemotherapy. As 
demonstrated in chapter 8, a multimodal agent can be used for both FGS and intra-operative 
 
targeted PDT. In contrast to optical imaging where excitated and emitted photons encounter the 
challenge of optical properties, in targeted PDT only excitated photons are relevant. 
Consequently, tissue penetration increases. When PDT is used as adjuvant treatment after 
surgical resection, residual tumor will be situated directly under the surface of the tumor bed, 
lowering the need for a high tissue penetration of light. Furthermore, wavelength-specific 
excitation of photosensitizers (PS) could technically be performed using the same imaging 
systems as those used for FGS, emphasizing its practical advantages as an adjuvant therapeutic 
modality in the surgical theatre.  
 
Fluorescence guided therapy in oncology; one probe that allows NIR fluorescence guided 
resection of a tumor and intra-operative PDT of residual tumor cells.  
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of reactive oxygen species. Thus, a single agent will not have an optimal fluorescence- and triplet 
state quantum yield. 
 
But several advantages favor the use of targeted PDT as an adjuvant treatment. Targeted PDT 
has the advantage of low toxicity in normal tissue, negligible systemic effects and it induces a 
local inflammatory reaction that stimulates the host immune system35,36. All are major advantages 
compared to other adjuvant therapeutic modalities like radiotherapy and/or chemotherapy. As 
demonstrated in chapter 8, a multimodal agent can be used for both FGS and intra-operative 
 
targeted PDT. In contrast to optical imaging where excitated and emitted photons encounter the 
challenge of optical properties, in targeted PDT only excitated photons are relevant. 
Consequently, tissue penetration increases. When PDT is used as adjuvant treatment after 
surgical resection, residual tumor will be situated directly under the surface of the tumor bed, 
lowering the need for a high tissue penetration of light. Furthermore, wavelength-specific 
excitation of photosensitizers (PS) could technically be performed using the same imaging 
systems as those used for FGS, emphasizing its practical advantages as an adjuvant therapeutic 
modality in the surgical theatre.  
 
Fluorescence guided therapy in oncology; one probe that allows NIR fluorescence guided 
resection of a tumor and intra-operative PDT of residual tumor cells.  
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Nederlandse Samenvatting 
 
Pre- en postoperatieve beeldvorming is gedurende de afgelopen eeuw een belangrijk onderdeel 
van de oncologische chirurgie geworden. In de klinische praktijk worden verscheidene 
beeldvormende modaliteiten zoals echografie, röntgen, CT, MRI, PET en SPECT gebruikt voor 
de vroegtijdige opsporing van tumoren, adequate stadiering en evaluatie van de behandeling. 
Hoewel er vele mogelijkheden van beeldvorming beschikbaar zijn preoperatief, is de chirurg 
peroperatief afhankelijk van zijn handen en ogen om tumor weefsel te onderscheiden van gezond 
weefsel. Hoewel de chirurg macroscopisch het idee kan hebben dat de tumor radicaal is 
verwijderd, blijkt toch dat de patholoog microscopisch een hoog percentage irradicaal 
verwijderde tumoren ziet. Het onvermogen de rand van de tumor te kunnen zien peroperatief 
kan van invloed zijn op het hoge percentage irradicaal verwijderde tumoren. Intra-operatieve 
beeldvorming waarmee de tumor onderscheiden kan worden van het omliggende gezonde 
weefsel kan ervoor zorgen dat het percentage radicaal verwijderde tumoren en daarmee de 
overleving van de patiënt toeneemt.  
 
Fluorescentie geleide chirurgie (FGS) is een techniek die gebruik maakt van nabij-infrarood licht. 
Het geeft de chirurg peroperatieve visuele feedback over het weefsel van interesse. Nabij 
infrarood licht is noodzakelijk voor klinisch gebruik doordat dit licht het weefsel dieper 
penetreert en er bij deze golflengte geen verstoring is van autofluorescentie. FGS is uitgebreid 
onderzocht bij schildwachtklier procedures, anastomosen en cholecystectomiën. Het zou van 
grote waarde zijn als de chirurg door middel van fluorescentie tumor weefsel kan onderscheiden 
van gezond weefsel gedurende de operatie. De bewustwording van de potentie van FGS zorgde 
voor een exponentiele groei van het onderzoek dat vervolgens resulteerde in een groeiend aantal 
klinische trials. Echter blijft het targeten van tumoren een grote uitdaging, in het bijzonder 
vanwege de grote intra- en intertumorale heterogeniteit. Optische eigenschappen van weefsel 
maken daarnaast dat het detecteren van een enkele tumorcel een grote uitdaging zal blijven. Het 
doel van deze thesis is de preklinische validatie van twee nieuwe probes en de Artemis camera. 
Daarnaast zijn de eerste stappen gemaakt richting fluorescentie geleide peroperatieve 
fotodynamische therapie. Een behandeling waarmee gedurende de operatie eventuele 
overgebleven tumorcellen na chirurgische resectie kunnen worden behandeld.  
 
In deel 1 geven we een overzicht van de huidige status van FGS in de literatuur en kijken we 
naar de uitdagingen die het veld moet aangaan voor een succesvolle klinische introductie. In 
hoofdstuk 2 wordt een uitgebreide uiteenzetting gegeven van de literatuur over preklinische en 
klinische fluorescentiegeleide chirurgie. In het bijzonder richtten we ons hier op tumor specifieke 
targeting van primaire tumoren door organische fluorescente probes. Na de uiteenzetting van de 
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overgebleven tumorcellen na chirurgische resectie kunnen worden behandeld.  
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klinische fluorescentiegeleide chirurgie. In het bijzonder richtten we ons hier op tumor specifieke 
targeting van primaire tumoren door organische fluorescente probes. Na de uiteenzetting van de 
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huidige literatuur in hoofdstuk 2, gaat hoofdstuk 3 terug naar de fundamentele basis principes 
van de optische beeldvorming. Hier worden de consequenties van deze principes voor FGS 
bediscussieerd en bekijken we welke invloed ze hebben op de klinische besluitvorming. We laten 
zien dat er beperkingen zitten aan de techniek maar vooral ook dat het een krachtig instrument 
kan zijn om de chirurg bij te staan en het aantal radicale tumor resecties te verhogen.  
 
In deel 2 vervolgen we met de preklinische studies. In dit deel onderzoeken we een tweetal 
probes die aangrijpen op twee interessante receptoren binnen de oncologie. Het eerste target in 
hoofdstuk 4  is de epidermale groei factor receptor (EGFR). De EGFR is een transmembraan 
glycoproteine die is betrokken bij DNA synthese en cel proliferatie en waarbij overexpressie 
bijdraagt aan oncogenese. De EGFR komt veelal tot overexpressie bij orale 
plaveiselcelcarcinomen (OSCC). Om de EGFR specifieke probe te testen hebben we gekozen 
voor een orthotoop OSCC model van de tong die metastaseert naar de cervicale lymfklieren. In 
deze studie werd een nanobody geconjugeerd aan de fluorescente stof IRDye-800CW. Een 
nanobody is het kleinste antigen-bindende deel van een natuurlijk antilichaam met 1 zware keten. 
Ze binden zeer specifiek en de grootte van een nanobody zorgt voor een efficiënte distributie en 
weefsel penetratie, evenals een snelle klaring uit het lichaam. De FLARE NIR fluorescentie 
camera werd gebruikt in deze studie en vergeleken met preklinische camera’s. Twee uur na 
injectie van 7D12-800CW waren de tumoren duidelijk zichtbaar. De tumor tot achtergrond ratio 
was significant hoger dan die van de controle probe. Een hogere dosis was nodig om lymfklier 
metastasen te zien. In deze studie lieten we de potentie zien van een nanobody in fluorescentie 
geleide chirurgie door gebruik te maken van een orthotoop tumor model en een klinische 
camera. Het target dat misschien nog interessanter is vanwege de expressie die verhoogd is in een 
groter aantal tumoren, is de EPCAM receptor in hoofdstuk 5. EpCAM is een transmembraan 
glycoproteïne die betrokken is bij de cel-cel interacties en cel-stroma adhesie. De expressie is 
beperkt tot epitheliale cellen en is verhoogd in nagenoeg alle epitheliale tumoren. Om de waarde 
van dit target binnen de FGS te bekijken conjugeerden we het monoclonale antilichaam 323/A3 
aan IRDye 800CW. Dit conjugaat bleek stabiel in serum en specifiek te binden aan de EpCAM 
receptor, gemeten met flow cytometrie en plaat essays. Vier klinisch relevante orthotopische 
tumor modellen (peritonitis carcinomatosa en colorectale-, borst- en hoofd/hals- tumoren) 
werden gebruikt om deze probe samen met de Artemis camera te valideren. Alle tumoren waren 
goed te onderscheiden en konden met behulp van fluorescentie worden gereseceerd. Millimeter 
grootte tumoren werden gevonden die niet met het blote oog konden worden gezien. Tumor 
specificiteit werd bekeken met fluorescentie microscopie. In deze studie bewees EpCAM zich als 
universeel target binnen de FGS en werd een stap gezet naar klinische translatie. Uiteindelijk in 
deel twee, hoofdstuk 6, evalueren we de nieuwe Artemis camera in een preklinische en klinische 
setting. Als eerste in de literatuur wordt de Artemis camera klinisch gebruikt. We onderzoeken 
 
preklinisch wat de minimale dosis ICG en IRDye 800CW is die de Artemis nog kan detecteren. 
Het minimum aantal cellen, geïncubeerd met 7D12-800CW, dat nog detecteerbaar was met de 
Artemis camera is 2x 105 versus 4 x 104 met de preklinische Pearl camera. Verder onderzoeken 
we de prestatie van de Artemis camera in relatie met de poortwacht klier procedure en tumor 
specifieke FGS. Hiervoor gebruiken we twee hoofd-hals kanker tumoren in combinatie met de 
probe 7D12-800CW. FaDu-luc2 tumoren vanaf 1 mm3 konden gedetecteerd worden met de 
probe 7D12-800CW en de Artemis. De Artemis camera wordt in dit artikel klinisch gebruikt 
voor de detectie van levermetastases waarbij zes maligne tumoren werden ontdekt.  
 
In deel 3  ligt de focus op de toekomst van de fluorescentie geleide chirurgie. We onderzoeken 
hoe we tot een succesvolle klinische implementatie van FGS kunnen komen en of we ons doel 
van radicale tumor resecties behalen met een enkele tumor specifieke probe. Hoofdstuk 7 
beschrijft 3 grote uitdagingen binnen de FGS waarbij we vervolgens kijken naar de mogelijke 
oplossingen. De uitdagingen zijn tumor heterogeniteit, invasief groeiende tumoren en de optische 
eigenschappen van weefsel. De optische eigenschappen van weefsel zorgen ervoor dat het 
detecteren van een enkele tumor cel zeer onwaarschijnlijk zal zijn. Voornamelijk bij invasief 
groeiende tumoren kan dit ervoor zorgen dat tumoren irradicaal worden verwijderd. Het meten 
van de intrinsieke fluorescentie kan hiervoor een oplossing zijn. We beschrijven hoe punt 
reflectie en fluorescentie spectroscopie met het gebruik van fiber optische probes kan corrigeren 
voor het effect van de optische eigenschappen van weefsel. Zodoende zou een enkele tumorcel 
kunnen worden gedetecteerd. Een tweede oplossing is niet de detectie maar behandeling van de 
laatste tumorcellen met fotodynamische therapie (PDT). PDT wordt al gebruikt voor de 
behandeling van premaligne en maligne laesies. Vergeleken met andere adjuvante therapeutische 
modaliteiten, heeft PDT het voordeel dat er relatief weinig schade is aan normaal weefsel en er 
geen nadelige systemische effecten zijn. Verder beïnvloed PDT het effect van andere 
behandelingen niet en kan het herhaald worden indien nodig. Belangrijker echter is dat PDT 
gecombineerd kan worden met FGS waarbij er maar één probe gebruikt hoeft te worden. In 
hoofdstuk 8 Onderzoeken we de mogelijkheden van tumor specifieke PDT en FGS. Tumor 
specifieke PDT kan het effect van de PDT enorm vergroten en de schade aan normaal weefsel 
nog meer reduceren. In deze preklinische studie kijken we naar het effect van PDT met de 
EGFR specifieke nanobody 7D12 geconjugeerd aan de water oplosbare fotosensitizer IRDye 
700DX. Het construct is eveneens detecteerbaar met fluorescentie beeldvorming.  We kijken naar 
de selectiviteit en fototoxiteit gebruik makende van een orthotopisch hoofd-hals tumor model. 
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expressie van de EGFR. In hoofdstuk 9 bespreken we de stappen die nodig zijn om FGS 
succesvol en veilige naar de kliniek te brengen. De conclusie was dat FGS groot klinisch 
potentieel heeft en dat de klinische implementatie versneld kan worden als het veld samenwerkt.  
 
Dit proefschrift onderzoekt het gebruik van fluorescentie geleide therapie binnen de oncologie. 
Initieel beschrijven we de preklinische validatie van twee targets en stoffen voor fluorescentie 
geleide chirurgie. Resultaten die de weg vrij maken voor een klinische translatie. Verder 
onderzoeken we de werkzaamheid van de nieuwe Artemis camera in een preklinische en klinische 
setting. Als laatste zetten we de eerste stappen richting een peroperatieve, multimodale 
fluorescentie geleide behandeling binnen de chirurgische oncologie met behulp van tumor 
specifieke fotodynamische therapie. 
 
 
 
  
 
Een woord van dank 
 
 
Professor Lowik, beste Clemens, 
Een ontdekker puur sang. Het is absoluut een gave om buiten de kaders te denken en 
verschillende wetenschappelijke werelden bij elkaar te brengen. Jouw hunkering naar nieuwe 
ontdekkingen gecombineerd met je opportunisme en enthousiasme is wat mij betreft een enorme 
kwaliteit. Een korte vraag aan jou eindigde meestal in een college van 3 uur waarbij ik 
ondergedompeld werd in de wondere wereld van de moleculaire biologie. Ik ben zeer dankbaar 
dat je mij de kans hebt gegeven de wereld van de wetenschap te ontdekken. De avonden in het 
LUMC met wetenschap, pizza en bier zal ik nooit vergeten. We hebben de wetenschap kunnen 
combineren met vele borrels, congressen en ski-trips. Het heeft even geduurd, maar ik wil je 
bedanken voor een fenomenale tijd.  
 
Alexander Vahrmeijer, beste Lex, 
Het LUMC is een voorloper van de fluorescentie geleide chirurgie door jouw wetenschappelijke 
inspanning en ambitie. De klinische vertaalslag is inmiddels ruimschoots ingezet en hopelijk zal 
de fluorescentie geleide chirurgie zich de komende jaren klinisch bewijzen. Je weet continu een 
gezellige green light groep om je heen te verzamelen met een hoog wetenschappelijk niveau. Heel 
veel succes en bedankt voor een mooie samenwerking en de begeleiding gedurende mijn 
onderzoek.   
 
Stijn Keereweer, Stinjo 
Onderzoek doen met een goede vriend als jij was absoluut een zegen. Wij wisten als geen ander 
de wetenschap te combineren met plezier. Van bier en pizza in het LUMC tot wetenschappelijke 
discussies in de kroeg of in de sportschool. Juist deze discussies maakten de wetenschap levendig 
en vertaalden het preklinische onderzoek naar een klinische toepassing. “Denk in artikelen” is het 
eerste dat je me leerde, of in ieder geval dat ik heb onthouden. Je hebt de gave om rauwe 
natuurkundige en moleculair biologische materie op een heldere manier aan een breed klinisch 
publiek te presenteren. Een echte, kritische wetenschapper die ook nog eens enorm sociaal 
vaardig is, kan verbinden en onwaarschijnlijk scherp kan schrijven. De wetenschap samen was 
een mooi avontuur en ik hoop dat dit nog voort mag blijven duren. Je wordt een hele grote 
binnen de hoofd-hals chirurgie.  
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 Thomas Snoeks, 
Tijdens mijn wetenschapsstage en in het begin van dit promotieonderzoek was jij mijn houvast in 
de nieuwe wereld van de moleculaire biologie. Ik wil je bedanken voor een kritische blik en 
vooral mooie tijd.  
 
Sabrina Oliveira, 
De introductie met nanobodies die een belangrijk deel van mijn promotie vormden heb ik aan 
jou te danken. Als gedreven en zeer integere wetenschapper heb je mij naar een hoger niveau 
getild. Bedankt voor een vruchtbare samenwerking. 
 
Dominic Robinson, 
Met de introductie van fotodynamische therapie in mijn onderzoek kwam een mooie 
samenwerking tot stand met het Erasmus MC onder leiding van jou. Het was interessant en 
inspirerend om de natuurkundige kant van het onderzoek met licht te ontdekken. Ik heb enorm 
veel van je mogen leren. Succes met het vervolg onderzoek naar de combinatie van fluorescentie 
geleide chirurgie en fotodynamische therapie.  
 
Mark Boonstra, Bony 
De preklinische wetenschapper van de green light groep. De vele dagen in het muizen lab, in ons 
huis en avonden in de kroeg hebben de laatste jaren van mijn promotie zowel wetenschappelijk 
als persoonlijk veel moois gebracht. Ik heb enorm veel respect voor jouw discipline en 
doorzettingsvermogen. Dank voor een mooie en intense tijd.  
 
Christian van Gaalen, fluim 
Hoewel je bijnaam anders doet vermoeden bleek daar bij de hulp bij dit proefschrift niets van. 
Als ‘native’ heb je elke Engelse zin met veel interesse gelezen en met nog veel meer plezier 
gecorrigeerd als het naar jouw idee niet geheel correct was. Het was uitkijken naar het 
commentaar in de zijlijn dat ik elke keer lachend heb gelezen. Door de jaren heen ben je 
inmiddels ook medische inhoudelijk geschoold.. Dank voor een zeer waardevolle vriendschap die 
ik zal blijven koesteren. 
 
Pien van Vierssen Trip & Joost von Schmidt auf Altenstadt, Pien & Joost 
Een bijzondere eenheid en enorm (h)echte vriendschap. Zo waardevol en eentje die ik niet meer 
kan missen. Bedankt voor een onmisbare tijd en alvast voor alles wat gaat volgen de rest van ons 
leven.       
 
  
 
Steef, Thomas, Frank, Kaz, Mark  
We zijn een hecht jaar, zeer verschillend maar juist ook daarom is de vriendschap zo waardevol. 
Bedankt voor een hele mooie tijd, de steun tijdens mijn promotie en de herhaaldelijke vraag 
wanneer mijn verdediging eindelijk plaats zou vinden.  
 
Wout, Dalibor, Leon, Henri, Thomas 
Een vriendengroep als deze die bestaat sinds onze pubertijd en zo vanzelfsprekend is koester ik 
dierbaar.  
 
Bart, Edin, Tomek, Maks 
Wat was/is het een avontuur tijdens mijn opleiding en leven in Amsterdam. Een waardevolle en 
blijvende vriendschap. 
 
Mijn ouders 
Lieve pap en mam, wie ik ben heb ik in alles te danken aan jullie en de bagage die jullie me mee 
hebben gegeven. Ik ben enorm dankbaar voor jullie onvoorwaardelijke steun en interesse en kan 
me geen betere ouders wensen. Er komen nog veel mooie avonturen.  
 
Zussen en broertje 
Hoewel we aan de 4 uiteinden van het spectrum zitten is het een briljante eenheid. Lied, je bent 
zowel wetenschappelijk als persoonlijk een groot voorbeeld. Dierbare Charlot, door jouw 
tomeloze inzet is het een hechte eenheid. Art, broertje en beste vriend, je praatjes en intelligentie 
gaan je ver brengen.  
 
Lieve Sanne 
Ik ben dolblij dat jij in mijn leven bent gekomen en ben gek op je oprechtheid, temperament, 
eigenwijsheid, doortastendheid, moed en ambitie. Zonder je gaat niet meer.  
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